Novel full length cDNA
Novel full-length cDNAs are provided. 1970 cDNA derived from human have been isolated. The full-length nucleotide sequences of the cDNA and amino acid sequences encoded by the nucleotide sequences have been determined. Because the cDNA of the present invention are full-length and contain the translation start site, they provide information useful for analyzing the functions of the polypeptide.
Latest Patents:
- Instrument for endoscopic applications
- DRAM circuitry and method of forming DRAM circuitry
- Method for forming a semiconductor structure having second isolation structures located between adjacent active areas
- Semiconductor memory structure and the method for forming the same
- Electrical appliance arrangement having an electrical appliance which can be fastened to a support element, in particular a wall
The present invention relates to polynucleotides encoding novel polypeptides, polypeptides encoded by the polynucleotides, and new uses of these.
BACKGROUND OF THE INVENTIONCurrently, the sequencing projects, the determination and analysis of the genomic DNA of various living organisms have been in progress all over the world. The whole genomic sequences of more than 40 species of prokaryotes, a lower eukaryote, yeast, a multicellular eukaryote, C. elegans, and a higher plants, arabidopsis, etc. are already determined. For human genome, presumably having 3 billion base pairs, the analysis was advanced under global cooperative organization, and a draft sequence was disclosed in 2001. Moreover, all the structures are to be clear and to be disclosed in 2002-2003. The aim of the determination of genomic sequence is to reveal the functions of all genes and their regulation and to understand living organisms as a network of interactions between genes, proteins, cells or individuals through deducing the information in a genome, which is a blueprint of the highly complicated living organisms. To understand living organisms by utilizing the genomic information from various species is not only important as an academic subject, but also socially significant from the viewpoint of industrial application.
However, determination of genomic sequences itself cannot identify the functions of all genes. For example, as for yeast, only the function of approximately half of the 6000 genes, which is predicted based on the genomic sequence, was able to be deduced. On the other hand, the human genome has been estimated to contain about 30,000-40,000 genes. Further, 100,000 or more types of mRNAs are said to exist when variants produced by alternative splicing are taken into consideration. Therefore, it is desirable to establish “a high throughput analysis system of the gene functions” which allows us to identify rapidly and efficiently the functions of vast amounts of the genes obtained by the genomic sequencing.
Many genes in the eukaryotic genome are split by introns into multiple exons. Thus, it is difficult to predict correctly the structure of encoded protein solely based on genomic information. In contrast, cDNA, which is produced from mRNA that lacks introns, encodes a protein as a single continuous amino acid sequence and allows us to identify the primary structure of the protein easily. In human cDNA research, to date, more than three million ESTs (Expression Sequence Tags) are publicly available, and the ESTs presumably cover not less than 80% of all human genes.
The information of ESTs is utilized for analyzing the structure of human genome, or for predicting the exon-regions of genomic sequences or their expression profile. However, many human ESTs have been derived from proximal regions to the 3′-end of cDNA, and information around the 5′-end of mRNA is extremely little. Among human cDNAs, the number of the corresponding mRNAs whose encoding full-length protein sequences are deduced is approximately 13,000.
It is possible to identify the transcription start site of mRNA on the genomic sequence based on the 5′-end sequence of a full-length cDNA, and to analyze factors involved in the stability of mRNA that is contained in the cDNA, or in its regulation of expression at the translation stage. Also, since a full-length cDNA contains atg codon, the translation start site, in the 5′-region, it can be translated into a protein in a correct frame. Therefore, it is possible to produce a large amount of the protein encoded by the cDNA or to analyze biological activity of the expressed protein by utilizing an appropriate expression system. Thus, analysis of a full-length cDNA provides valuable information which complements the information from genome sequencing. Also, full-length cDNA clones that can be expressed are extremely valuable in empirical analysis of gene function and in industrial application.
Therefore, if a novel human full-length cDNA is isolated, it can be used for developing medicines for diseases in which the gene is involved. The protein encoded by the gene can be used as a drug by itself. Thus, it has great significance to obtain a full-length cDNA encoding a novel human protein.
In particular, human secretory proteins or membrane proteins would be useful by itself as a medicine like tissue plasminogen activator (TPA), or as a target of medicines like membrane receptors. In addition, genes for signal transduction-related proteins (protein kinases, etc.), glycoprotein-related proteins, transcription-related proteins, etc. are genes whose relationships to human diseases have been elucidated. Moreover, genes for disease-related proteins form a gene group rich in genes whose relationships to human diseases have been elucidated.
Therefore, it has great significance to isolate novel full-length cDNA clones of human, only few of which has been isolated. Especially, isolation of a novel cDNA clone encoding a secretory protein or membrane protein is desired since the protein itself would be useful as a medicine, and also the clones potentially include a gene involved in diseases. In addition, genes encoding proteins that are involved in signal transduction, glycoprotein, transcription, or diseases are expected to be useful as target molecules for therapy, or as medicines themselves. These genes form a gene group predicted to be strongly involved in diseases. Thus, identification of the full-length cDNA clones encoding those proteins has great significance.
SUMMARY OF THE INVENTIONAn objective of the present invention is to provide polynucleotides encoding novel polypeptides, polypeptides encoded by the polynucleotides, and novel usages of these.
The inventors have developed a method for efficiently cloning, from a cDNA library having very high fullness-ratio, a human full-length cDNA that is predicted to be a full-length cDNA clone, where the cDNA library is synthesized by an improved method (WO 01/04286) of the oligo-capping method (K. Maruyama and S. Sugano, Gene, 138: 171-174 (1994); Y. Suzuki et al., Gene, 200: 149-156 (1997)). Then, the nucleotide sequences of cDNA clones whose fullness ratio is high, obtained by this method, were determined mainly from their 5′-ends, and, if required, from 3′-ends.
Further, representative clones, which were estimated to be novel and full-length, among the clones obtained, were analyzed for their full-length nucleotide sequences. The determined full-length nucleotide sequences were analyzed by BLAST homology search of the databases shown below. Because the homology search of the present invention is carried out based on the information of full-length cDNAs including the entire coding regions, homology to every part of a polypeptide can be analyzed. Thus, in the present invention, the reliability of homology search has been greatly improved.
- [1] Swissprot (http://www.ebi.ac.uk/ebi_docsSwissProt_db/swisshome.html),
- [2] GenBank (http://www.ncbi.nlm.nih.gov/web/GenBank),
- [3] UniGene (Human) (http://www.ncbi.nlm.nih.gov/UniGene), and
- [4] nr (a protein database, which has been constructed by combining data of coding sequences (CDS) in nucleotide sequences deposited in GenBank, and data of SwissProt, PDB (http://www.rcsb.org/pdb/index.html), PIR (http://pir.georgetown.edu/pirwww/pirhome.shtml), and PRF (http://www.prf.or.jp/en/); overlapping sequences have been removed.)
Further, the gene expression profiles of cDNA clones whose full-length nucleotide sequence had been determined were studied by analyzing the large-scale cDNA database constructed based on the 5′-end nucleotide sequences of cDNAs obtained. In addition to the analysis for the expression profile by computer, the profiles of gene expression in living cells were also determined by PCR. The present inventors revealed the usefulness of the genes of the present invention based on these analysis results.
In the present invention, gene functions were revealed by the analysis of expression profiles in silico based on the information of full-length nucleotide sequences. The expression profiles used in the expression frequency analysis were studied based on the database containing sufficient amount of fragment sequence data. The expression frequency analysis was carried out by referring, for these expression profiles, to the full-length nucleotide sequences of many cDNA clones obtained in the present invention. Thus, a highly reliable analysis can be achieved by referring to the full-length nucleotide sequences of a wide variety of genes for the sufficiently large population for analysis (expression profiles). Namely, the results of expression frequency analysis using the full-length sequences of the present invention more precisely reflect the gene expression frequency in tissues and cells from which a certain cDNA library was derived. In other words, the information of full-length cDNA nucleotide sequence of the present invention made it possible to achieve the highly reliable expression frequency analysis.
The full-length cDNA clones of this invention were obtained by the method comprising the steps of [1] preparing libraries containing cDNAs with the high fullness ratio by oligo-capping, and [2] assembling 5′-end sequences and selecting one with the highest probability of completeness in length in the cluster formed (there are many clones longer in the 5′-end direction). However, the uses of primers designed based on the 5′- and 3′-end sequences of polynucleotides provided by the present invention enable readily obtaining full-length cDNAs without such a special technique. The primer, which is designed to be used for obtaining cDNAs capable of being expressed, is not limited to the 5′- and 3′-end sequences of polynucleotide.
Specifically, the present invention relates to a polynucleotide selected from the group consisting of the following (a) to (g):
-
- (a) a polynucleotide comprising a protein-coding region of the nucleotide sequence of any one of SEQ ID NOs shown in Table 1;
- (b) a polynucleotide encoding a polypeptide comprising the amino acid sequence of any one of SEQ ID NOs shown in Table 1;
- (c) a polynucleotide comprising a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of any one of SEQ ID NOs shown in Table 1, wherein, in said amino acid sequence, one or more amino acids have been substituted, deleted, inserted, and/or added, and wherein said nucleotide sequence encodes a polypeptide functionally equivalent to a polypeptide comprising the selected amino acid sequence;
- (d) a polynucleotide hybridizing under stringent conditions to a polynucleotide comprising the nucleotide sequence of any one of SEQ ID NOs shown in Table 1, wherein said nucleotide sequence encodes a polypeptide functionally equivalent to a polypeptide encoded by the selected nucleotide sequence;
- (e) a polynucleotide comprising a nucleotide sequence encoding a partial amino acid sequence of a polypeptide encoded by the polynucleotide according to any one of (a) to (d);
- (f) a polynucleotide comprising a nucleotide sequence having at least 70% identity to the nucleotide sequence of (a); and
- (g) a polynucleotide comprising a nucleotide sequence having at least 90% identity to the nucleotide sequence of (a).
The present invention also relates to a polypeptide encoded by the above-mentioned polynucleotide or a partial peptide thereof, an antibody binding to the polypeptide or the peptide, and a method for immunologically assaying the polypeptide or the peptide, which comprises the steps of contacting the polypeptide or the peptide with the antibody, and observing the binding between the two.
Furthermore, the present invention features a vector comprising the above-mentioned polynucleotide, a transformant carrying the polynucleotide or the vector, a transformant carrying the polynucleotide or the vector in an expressible manner, and a method for producing the polypeptide or the peptide, which comprises the steps of culturing the transformant and recovering an expression product.
Another feature of the present invention is an oligonucleotide comprising at least 15 nucleotides, said oligonucleotide comprising a nucleotide sequence complementary to the nucleotide sequence of any one of SEQ ID NOs: 1 to 1970 or to a complementary strand thereof. This oligonucleotide can be used as a primer for synthesizing the above-mentioned polynucleotide or used as a probe for detecting the polynucleotide. The present invention includes an antisense polynucleotide against the polynucleotide or a part thereof, and a method for detecting the polynucleotide, which comprises the following steps of:
- a) incubating a target polynucleotide with the oligonucleotide under hybridizable conditions, and
- b) detecting hybridization of the target polynucleotide with the oligonucleotide.
Still another feature of the present invention is a database of polynucleotides and/or polypeptides, said database comprising information on at least one of the nucleotide sequences of SEQ ID NOs: 1 to 1970 and/or on at least one of the amino acid sequences of SEQ ID NOs: 1971 to 3940.
Herein, “polynucleotide” is defined as a molecule, such as DNA and RNA, in which multiple nucleotides are polymerized. There are no limitations on the number of the polymerized nucleotides. In case that the polymer contains relatively low number of nucleotides, it is also described as an “oligonucleotide”, which is included in the “polynucleotide” of the present invention. The polynucleotide or the oligonucleotide of the present invention can be a natural or chemically synthesized product. Alternatively, it can be synthesized using a template polynucleotide by an enzymatic reaction such as PCR. Furthermore, the polynucleotide of the present invention may be modified chemically. Moreover, not only a single-strand polynucleotide but also a double-strand polynucleotide is included in the present invention. In this specification, especially in claims, when the polynucleotide is described merely as “polynucleotide”, it means not only a single-strand polynucleotide but also a double-strand polynucleotide. When it means double-strand polynucleotide, the nucleotide sequence of only one chain is indicated. However, based on the nucleotide sequence of a sense chain, the nucleotide sequence of the complementary strand thereof is essentially determined.
As used herein, an “isolated polynucleotide” is a polynucleotide the structure of which is not identical to that of any naturally occurring polynucleotide or to that of any fragment of a naturally occurring genomic polynucleotide spanning more than three separate genes. The term therefore includes, for example, (a) a DNA which has the sequence of part of a naturally occurring genomic DNA molecule in the genome of the organism in which it naturally occurs; (b) a polynucleotide incorporated into a vector or into the genomic DNA of a prokaryote or eukaryote in a manner such that the resulting molecule is not identical to any naturally occurring vector or genomic DNA; (c) a separate molecule such as a cDNA, a genomic fragment, a fragment produced by polymerase chain reaction (PCR) or a restriction fragment; and (d) a recombinant nucleotide sequence that is part of a hybrid gene, i.e., a gene encoding a fusion polypeptide. Specifically excluded from this definition are polynucleotides of DNA molecules present in mixtures of different (i) DNA molecules, (ii) transfected cells, or (iii) cell clones; e.g., as these occur in a DNA library such as a cDNA or genomic DNA library.
The term “substantially pure” as used herein in reference to a given protein or polypeptide means that the protein or polypeptide is substantially free from other biological macromolecules. For example, the substantially pure protein or polypeptide is at least 75%, 80%, 85%, 95%, or 99% pure by dry weight. Purity can be measured by any appropriate standard method known in the art, for example, by column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.
All the cDNAs provided by the present invention are full-length cDNAs. The “full-length cDNA” herein means that the cDNA contains the ATG codon, which is the start point of translation therein. The untranslated regions upstream and downstream of the protein-coding region, both of which are naturally contained in natural mRNAs, are not indispensable. It is preferable that the full-length cDNAs of the present invention contain the stop codon.
BRIEF DESCRIPTION OF THE DRAWINGS
All the clones (1970 clones) of the present invention are novel and encode the full-length polypeptides. Further, all the clones are cDNAs with the high fullness ratio, which were obtained by oligo-capping method, and also clones which are not identical to any of known human mRNAs (namely, novel clones) selected by searching, for the 5′-end sequences, mRNA sequences with the annotation of “complete cds” in the GenBank and UniGene databases by using the BLAST homology search [S. F. Altschul, W. Gish, W. Miller, E. W. Myers & D. J. Lipman, J. Mol. Biol., 215: 403-410 (1990); W. Gish & D. J. States, Nature Genet., 3: 266-272 (1993)]; they are also clones that were assumed to have higher fullness ratio among the members in the cluster formed by assembling. Most of the clones assessed to have high fullness ratio in the cluster had the nucleotide sequences longer in the 5′-end direction.
All the full-length cDNAs of the present invention can be synthesized by a method such as PCR (Current protocols in Molecular Biology edit. Ausubel et al. (1987) Publish. John Wiley & Sons Section 6.1-6.4) using primer sets designed based on the 5′-end and 3′-end sequences or using primer sets of primers designed based on the 5′-end sequences and a primer of oligo dT sequence corresponding to poly A sequence. Table 1 contains the clone names of full-length cDNA of 1970 clones of the present invention, SEQ ID NOs of the full-length nucleotide sequences, CDS portions deduced from the full-length nucleotide sequences, and SEQ ID NOs of the translated amino acids. The positions of CDS are shown according to the rule of “DDBJ/EMBL/GenBank Feature Table Definition” (http://www.ncbi.nlm.nih.gov/collab/FT/index.html). The start position number corresponds to the first letter of “ATG” that is the nucleotide triplet encoding methionine; the termination position number corresponds to the third letter of the stop codon. These are indicated being flanked with the mark “ . . . ”. However, with respect to the clones having no stop codon, the termination position is indicated by the mark “>” according to the above rule.
Namely, primers used to synthesize polynucleotides can be designed based on the nucleotide sequences of polynucleotides of the present invention shown in SEQ ID NOs in the above Table 1. When one intends to synthesize full-length cDNAs, an oligo dT primer can be used as the 3′-end primer. The length of the primers is usually 15-100 bp, and favorably between 15-35 bp. In case of LA PCR, which is described below, the primer length of 25-35 bp may provide a good result.
A method to design a primer that enables a specific amplification based on the aimed nucleotide sequence is known to those skilled in the art (Current Protocols in Molecular Biology, Ausubel et al. edit, (1987) John Wiley & Sons, Section 6.1-6.4). In designing a primer based on the 5′-end sequence, the primer is designed so as that, in principle, the amplification products will include the translation start site. Accordingly, for example, when the 5′-end primer is designed based on the nucleotide sequence of 5′ untranslated region (5′UTR), any part of the 5′-end, which ensures the specificity to the cDNA of interest, can be selected as the primer.
When synthesizing a full-length cDNA, the target nucleotide sequence to be amplified can extend to several thousand bp in some cDNA. However, it is possible to amplify such a long nucleotides by using such as LA PCR (Long and Accurate PCR). It is advantageous to use LA PCR when synthesizing long DNA. In LA PCR, in which a special DNA polymerase having 3′->5′ exonuclease activity is used, misincorporated nucleotides can be removed. Accordingly, accurate synthesis of the complementary strand can be achieved even with a long nucleotide sequence. By using LA PCR, it is reported that amplification of a nucleotide with 20 kb longer can be achieved under desirable conditions (Takeshi Hayashi (1996) Jikken-Igaku Bessatsu, “Advanced Technologies in PCR” Youdo-sha).
A template DNA for synthesizing the full-length cDNA of the present invention can be obtained by using cDNA libraries that are prepared by various methods. The full-length cDNA clones of the present invention are clones with high probability of completeness in length, which were obtained by the method comprising the steps of [1] preparing libraries containing cDNAs with the very high fullness ratio by oligo-capping, and [2] assembling the 5′-end sequences and selecting one with the highest probability of completeness in length in the cluster formed (there are many clones longer in the 5′-end direction).
However, the uses of primers designed based on the full-length nucleotide sequences provided by the present invention enable easily obtaining full-length cDNAs without such a special technique.
The problem with the cDNA libraries prepared by the known methods or commercially available is that mRNA contained in the libraries has very low fullness ratio. Thus, it is difficult to screen full-length cDNA clone directly from the library using ordinary cloning methods. The present invention has revealed a nucleotide sequence of novel full-length cDNA. If a full-length nucleotide sequence is provided, it is possible to synthesize a target full-length cDNA by using enzymatic reactions such as PCR. In particular, a full-length-enriched cDNA library, synthesized by methods such as oligo-capping, is desirable to synthesize a full-length cDNA with more reliability.
The 5′-end sequence of the full-length cDNA clones of the invention can be used to isolate the regulatory element of transcription including the promoter on the genome. A rough draft of the human genome (analysis of human genomic sequence with lower accuracy), which covers 90% of the genome, has been reported (Nature, Vol. 409, 814-823, 2001), and by the year 2003, analysis of the entire human genomic sequence is going to be finished. However, it is hard to analyze with software the transcription start sites on the human genome, in which long introns exist. By contrast, it is easy to specify the transcription start site on the genomic sequence using the nucleotide sequence which includes the 5′-end of the full-length cDNA clone of the present invention, and thus it is easy to obtain the genomic region involved in transcription regulation, which includes the promoter that is contained in the upstream of the transcription start site.
The polypeptide encoded by the full-length cDNA of the invention can be prepared as a recombinant polypeptide or as a natural polypeptide. For example, the recombinant polypeptide can be prepared by inserting the polynucleotide encoding the polypeptide of the invention into a vector, introducing the vector into an appropriate host cell and purifying the polypeptide expressed within the transformed host cell, as described below. In contrast, the natural polypeptide can be prepared, for example, by utilizing an affinity column to which an antibody against the polypeptide of the invention (Current Protocols in Molecular Biology (1987) Ausubel et al. edit, John Wiley & Sons, Section 16.1-16.19) is attached. The antibody used for affinity purification may be either a polyclonal antibody, or a monoclonal antibody. Alternatively, in vitro translation (See, for example, “On the fidelity of mRNA translation in the nuclease-treated rabbit reticulocyte lysate system.” Dasso M. C., and Jackson R. J. (1989) Nucleic Acids Res. 17: 3129-3144) may be used for preparing the polypeptide of the invention.
Polypeptides functionally equivalent to the polypeptides of the present invention can be prepared based on the activities, which were clarified in the above-mentioned manner, of the polypeptides of the present invention. Using the biological activity possessed by the polypeptide of the invention as an index, it is possible to verify whether or not a particular polypeptide is functionally equivalent to the polypeptide of the invention by examining whether or not the polypeptide has said activity.
Polypeptides functionally equivalent to the polypeptides of the present invention can be prepared by those skilled in the art, for example, by using a method for introducing mutations into an amino acid sequence of a polypeptide (for example, site-directed mutagenesis (Current Protocols in Molecular Biology, edit, Ausubel et al., (1987) John Wiley & Sons, Section 8.1-8.5) Besides, such polypeptides can be generated by spontaneous mutations. The present invention also includes a polypeptide comprising the amino acid sequence shown in Table 1 in which one or more amino acids are substituted, deleted, inserted, and/or added, as long as the polypeptides have the equivalent functions to those of the polypeptides identified in the present Examples described later.
There are no limitations on the number and sites of amino acid mutations, as long as the polypeptides maintain the functions thereof. The number of mutations typically corresponds to 30% or less, or 20% or less, or 10% or less, preferably 5% or less, or 3% or less of the total amino acids, more preferably 2% or less or 1% or less of the total amino acids. Alternatively, herein, substitution of one or more amino acids includes substitution of several amino acids. As used herein, the term “several amino acids” means, for example, 5 amino acids, preferably 4 or 3 amino acids, more preferably 2 amino acids, and further preferably 1 amino acid.
From the viewpoint of maintaining the polypeptide function, it is preferable that a substituted amino acid has a similar property to that of the original amino acid. For example, Ala, Val, Leu, Ile, Pro, Met, Phe and Trp are assumed to have similar properties to one another because they are all classified into a group of non-polar amino acids. Similarly, substitution can be performed among non-charged amino acid such as Gly, Ser, Thr, Cys, Tyr, Asn, and Gln, acidic amino acids such as Asp and Glu, and basic amino acids such as Lys, Arg, and His.
In addition, polypeptides functionally equivalent to the polypeptides of the present invention can be isolated by using techniques of hybridization or gene amplification known to those skilled in the art. Specifically, using the hybridization technique (Current Protocols in Molecular Biology, edit, Ausubel et al., (1987) John Wiley & Sons, Section 6.3-6.4)), those skilled in the art can usually isolate a polynucleotide highly homologous to the polynucleotide encoding the polypeptide identified in the present Example based on the identified nucleotide sequence (Table 1) or a portion thereof and obtain the functionally equivalent polypeptide from the isolated polynucleotide. The present invention include polypeptides encoded by the polynucleotides hybridizing with the polynucleotides encoding the polypeptides identified in the present Example, as long as the polypeptides are functionally equivalent to the polypeptides identified in the present Example. Organisms from which the functionally equivalent polypeptides are isolated are illustrated by vertebrates such as human, mouse, rat, rabbit, pig and bovine, but are not limited to these animals.
Washing conditions of hybridization for the isolation of polynucleotides encoding the functionally equivalent polypeptides are usually “1×SSC, 0.1% SDS, 37° C.”; more stringent conditions are “0.5×SSC, 0.1% SDS, 42° C.”; and still more stringent conditions are “0.1×SSC, 0.1% SDS, 65° C.”. Alternatively, the following conditions can be given as hybridization conditions of the present invention. Namely, conditions in which the hybridization is done at “6×SSC, 40% Formamide, 25° C.”, and the washing at “1×SSC, 55° C.” can be given. More preferable conditions are those in which the hybridization is done at “6×SSC, 40% Formamide, 37° C.”, and the washing at “0.2×SSC, 55° C.”. Even more preferable are those in which the hybridization is done at “6×SSC, 50% Formamide, 37° C.”, and the washing at “0.1×SSC, 62° C.”. The more stringent the conditions of hybridization are, the more frequently the polynucleotides highly homologous to the probe sequence are isolated. Therefore, it is preferable to conduct hybridization under stringent conditions. Examples of stringent conditions in the present invention are, washing conditions of “0.5×SSC, 0.1% SDS, 42° C.”, or alternatively, hybridization conditions of “6×SSC, 40% Formamide, 37° C.”, and the washing at “0.2×SSC, 55° C.”.
One skilled in the art can suitably select various conditions, such as dilution ratios of SSC, formamide concentrations, and temperatures to accomplish a similar stringency.
However, the above-mentioned combinations of SSC, SDS and temperature conditions are indicated just as examples. Those skilled in the art can select the hybridization conditions with similar stringency to those mentioned above by properly combining the above-mentioned or other factors (for example, probe concentration, probe length and duration of hybridization reaction) that determines the stringency of hybridization.
The amino acid sequences of polypeptides isolated by using the hybridization techniques usually have high identity to those of the polypeptides of the present invention, which are shown in Table 1. The present invention encompasses a polynucleotide comprising a nucleotide sequence that has a high identity to the nucleotide sequence of claim 1 (a). Furthermore, the present invention encompasses a peptide, or polypeptide comprising an amino acid sequence that has a high identity to the amino acid sequence encoded by the polynucleotide of claim 1 (b). The term “high identity” indicates sequence identity of at least 40% or more; preferably 60% or more; and more preferably 70% or more. Alternatively, more preferable is identity of 90% or more, or 93% or more, or 95% or more, furthermore, 97% or more, or 99% or more. The identity can be determined by using the BLAST search algorithm.
As used herein, “percent identity” of amino acid sequences or nucleic acids is determined using the algorithm BLAST of Karlin and Altschul (Proc. Natl. Acad. Sci. USA 90:5873-5877, 1993). Such an algorithm is incorporated into the BLASTN and BLASTX programs of Altschul et al. (J. Mol. Biol. 215:403-410, 1990). BLAST nucleotide searches are performed with the BLASTN program, for example, score=100, wordlength=12. BLAST protein searches are performed with the BLASTX program, for example, score=50, wordlength=3. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs are used. See http://www.ncbi.nlm.nih.gov.
With the gene amplification technique (PCR) (Current Protocols in Molecular Biology, edit, Ausubel et al., (1987) John Wiley & Sons, Section 6.1-6.4)) using primers designed based on the nucleotide sequence (Table 1) or a portion thereof identified in the present Example, it is possible to isolate a polynucleotide fragment highly homologous to the polynucleotide sequence or a portion thereof and to obtain functionally equivalent polypeptide to a particular polypeptide identified in the present Example based on the isolated polynucleotide fragment.
The present invention also provides a polynucleotide containing at least 15 nucleotides complementary to a polynucleotide comprising a nucleotide sequence of SEQ ID NOs shown in Table 1 or the complementary strand thereof. Herein, the term “complementary strand” is defined as one strand of a double strand DNA composed of A:T and G:C base pair to the other strand. Also, “complementary” is defined as not only those completely matching within a continuous region of at least 15 nucleotides, but also having a identity of at least 70%, favorably 80% or higher, more favorably 90% or higher, and most favorably 95% or higher within that region. The identity may be determined using the algorithm described herein.
Such a polynucleotide includes probes and primers used for the detection and amplification of a polynucleotide encoding the inventive polypeptide. When used as a primer, the polynucleotide usually comprises 15 to 100 bp, and preferably of 15 to 35 bp. When used as a probe, the polynucleotide comprises the whole or a part of the sequence of a polynucleotide of the invention, and comprises at least 15 bp. When used as primers, such polynucleotides are complementary at the 3′-end, and restriction enzyme recognition sequences or tags can be added to the 5′-end.
Furthermore, polynucleotides of the present invention include an antisense polynucleotide for suppressing the expression of a polypeptide of the invention, which comprises an amino acid sequence of SEQ ID NOs shown in Table 1. To exert an antisense effect, an antisense polynucleotide has at least 15 bp or more, for example 50 bp or more, preferably 100 bp or more, and more preferably 500 bp or more, and usually has 3000 bp or less, and preferably 2000 bp or less. Antisense polynucleotides can be used in the gene therapy of diseases caused by abnormalities of the polypeptides of the invention (abnormal function or abnormal expression). An antisense polynucleotide can be prepared, for example, by the phosphorothioate method (“Physicochemical properties of phosphorothioate oligodeoxynucleotides.” Stein (1988) Nucleic Acids Res. 16: 3209-3221) based on the sequence information of polynucleotide encoding a polypeptide of the invention (for example, the nucleotide sequences of SEQ ID NO: 1 to 1970).
The polynucleotides or antisense polynucleotides of the present invention can be used in, for example, gene therapy. As target diseases, for example, cancers or various inflammatory diseases may be preferable. These molecules can be used for gene therapy, for example, by administrating them to patients by the in vivo or ex vivo method using virus vectors such as retrovirus vectors, adenovirus vectors, and adeno-related virus vectors, or non-virus vectors such as liposomes.
The present invention also includes a partial peptide of the polypeptides of the invention. The partial peptide comprises a polypeptide generated as a result that a signal peptide has been removed from a secretory protein. If the polypeptide of the present invention has an activity as a receptor or a ligand, the partial peptide may function as a competitive inhibitor of the polypeptide and may bind to the receptor (or ligand). In addition, the present invention includes an antigen peptide for raising antibodies. For the peptides to be specific for the polypeptide of the invention, the peptides comprise at least 7 amino acids, preferably 8 amino acids or more, more preferably 9 amino acids or more, and even more preferably 10 amino acids or more. The peptide can be used for preparing antibodies against the polypeptide of the invention, or competitive inhibitors of them, and also screening for a receptor that binds to the polypeptide of the invention. The partial peptides of the invention can be produced, for example, by genetic engineering methods, known methods for synthesizing peptides, or digesting the polypeptide of the invention with an appropriate peptidase.
The present invention also relates to a vector into which a polynucleotide of the invention is inserted. The vector of the invention is not limited as long as it contains the inserted polynucleotide stably. For example, if E. coli is used as a host, vectors such as pBluescript vector (Stratagene) are preferable as a cloning vector. To produce the polypeptide of the invention, expression vectors are especially useful. Any expression vector can be used as long as it is capable of expressing the polypeptide in vitro, in E. coli, in cultured cells, or in vivo. For example, pBEST vector (Promega) is preferable for in vitro expression, pET vector (Invitrogen) for E. coli, pME18S-FL3 vector (GenBank Accession No. AB009864) for cultured cells, and pME18S vector (Mol. Cell. Biol. (1988) 8: 466-472) for in vivo expression. To insert the polynucleotide of the invention, ligation utilizing restriction sites can be performed according to the standard method (Current Protocols in Molecular Biology (1987) Ausubel et al. edit, John Wiley & Sons, Section 11.4-11.11).
Recently, the technique of GATEWAY™ system (Invitrogen), which is an expression vector construction system for polypeptide expression, has been developed (Experimental Medicine, Vol. 18, No. 19 (December), p2716-2717, 2000). This system includes two types of site-specific recombinases (BP CLONASE™ and LR CLONASE™) derived from lambda phage and uses BP CLONASE™-specific recombination sites for an Entry Vector and LR CLONASE™-specific recombination sites for a Destination Vector, which may comprise a tag useful for polypeptide purification. With this system, an expression vector can be obtained by using homologous recombination.
First, a polynucleotide fragment of interest is inserted into the entry vector using the first recombination. Then, the secondary recombination is allowed to take place between the entry vector, where the polynucleotide fragment of interest has been inserted, and the destination vector. Thus, the expression vector can be prepared rapidly and highly efficiently. With the above-mentioned typical method using restriction enzyme and ligase reactions, the step of expression vector construction and expression of polypeptide of interest takes about 7 to 10 days. However, with the GATEWAY™ system, the polypeptide of interest can be expressed and prepared in only 3 to 4 days. Thus, the system ensures a high-throughput functional analysis for expressed polypeptides (http://biotech.nikkeibp.co.jp/netlink/lto/gateway/).
The present invention also relates to a transformant carrying the vector of the invention. Any cell can be used as a host into which the vector of the invention is inserted, and various kinds of host cells can be used depending on the purposes. For strong expression of the polypeptide in eukaryotic cells, COS cells or CHO cells can be used, for example.
Introduction of the vector into host cells can be performed, for example, by calcium phosphate precipitation method, electroporation method (Current Protocols in Molecular Biology (1987) Ausubel et al. edit, John Wiley & Sons, Section 9.1-9.9), lipofectamine method (GIBCO-BRL), or microinjection method, etc.
Further, a polynucleotide containing at least 15 nucleotides comprising a nucleotide sequence of any one of the polynucleotides comprising the nucleotide sequences of SEQ ID NOs shown in Table 1 or the complementary strand thereof can be used not only as a primer for synthesizing full-length cDNAs but also for testing and diagnosing the abnormalities of the polypeptide encoded by the full-length cDNA of the present invention. For example, by utilizing polymerase chain reaction (genomic DNA-PCR, or RT-PCR) using the polynucleotide of the invention as a primer, polynucleotide encoding the polypeptide of the invention can be amplified. It is also possible to obtain the regulatory region of expression in the 5′-upstream by using PCR or hybridization since the transcription start site within the genomic sequence can be easily specified based on the 5′-end sequence of the full-length cDNA. The obtained genomic region can be used for detection and/or diagnosis of the abnormality of the sequence by RFLP analysis, SSCP, or sequencing. Especially, in the case where expression of the mRNA of the present invention varies according to a specific disease, analysis of the amount of expression of the mRNA using the polynucleotide of the present invention as a probe or a primer enables detection and diagnosis of the disease.
The present invention also relates to antibodies that bind to the polypeptide of the invention. There are no limitations in the form of the antibodies of the invention. They include polyclonal antibodies, monoclonal antibodies, or their portions that can bind to an antigen. They also include antibodies of all classes. Furthermore, special antibodies such as humanized antibodies and chimeric antibodies are also included.
The polyclonal antibody of the invention can be obtained according to the standard method by synthesizing an oligopeptide corresponding to the amino acid sequence and immunizing rabbits with the peptide (Current Protocols in Molecular Biology (1987) Ausubel et al. edit, John Wiley & Sons, Section 11.12-11.13). The monoclonal antibody of the invention can be obtained according to the standard method by purifying the polypeptide expressed in E. coli, immunizing mice with the polypeptide, and producing a hybridoma cell by fusing the spleen cells and myeloma cells (Current Protocols in Molecular Biology (1987) Ausubel et al. edit, John Wiley & Sons, Section 11.4-11.11).
The antibody binding to the polypeptide of the present invention can be used for purification of the polypeptide of the invention, and also for detection and/or diagnosis of the abnormalities of the expression and structure of the polypeptide. Specifically, polypeptides can be extracted, for example, from tissues, blood, or cells, and the polypeptide of the invention is detected by Western blotting, immunoprecipitation, or ELISA, etc. for the above purpose.
Furthermore, the antibody binding to the polypeptide of the present invention can be utilized for treating the diseases that associates with the polypeptide of the invention. If the antibodies are used for treating patients, human antibodies, humanized antibodies, or chimeric antibodies are preferable in terms of their low antigenicity. The human antibodies can be prepared by immunizing a mouse whose immune system is replaced with that of human (e.g., see “Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice” Mendez, M. J. et al. (1997) Nat. Genet. 15: 146-156). The humanized antibodies can be prepared by recombination of the hypervariable region of a monoclonal antibody (Methods in Enzymology (1991) 203: 99-121).
A cDNA of the present invention encodes, for example, an amino acid sequence of a protein that is predicted to have the following function. The use of the amino acid sequences of the polypeptides encoded by the cDNAs of the present invention enables predicting that the polypeptides have the following functions. It can be predict, from the results of homology search of SwissProt, GenBank, UniGene, or nr, that these polypeptides have such functions. Specifically, for instance, as shown in Examples, searching for a known gene or polypeptide that is homologous to the partial sequence of the full-length cDNA of the invention (1970 clone) and referring the function of the gene and of the polypeptide encoded by the gene make it possible to predict the function of the polypeptide encoded by the cDNA of the invention. In this way, each of 1078 clones out of the 1970 full-length cDNA clones of the invention was predicted to encode a polypeptide that was classified into the following categories.
-
- Secretory and/or membrane protein (516 clones)
- Glycoprotein-related protein (121 clones)
- Signal transduction-related protein (88 clones)
- Transcription-related protein (143 clones)
- Disease-related protein (331 clones)
- Enzyme and/or metabolism-related protein (219 clones)
- Cell division- and/or cell proliferation-related protein (44 clones)
- Cytoskeleton-related protein (80 clones)
- Nuclear protein and/or RNA synthesis-related protein (70 clones)
- Protein synthesis- and/or transport-related protein (20 clones)
- Cellular defense-related protein (10 clones)
- Development and/or differentiation-related protein (19 clones)
- DNA- and/or RNA-binding protein (168 clones)
- ATP- and/or GTP-binding protein (93 clones)
The functions of the polypeptides encoded by the cDNAs of the present invention can be predicted by assessing the presence of signal sequence, transmembrane region, nuclear translocation signal, glycosylation signal, phosphorylation site, and zinc finger motif, SH3 domain, etc. in the amino acid sequences. The programs, PSORT (Nakai K., and Kanehisa M. (1992) Genomics 14: 897-911), SOSUI (Hirokawa T. et al. (1998) Bioinformatics 14: 378-379) (Mitsui Knowledge Industry), and MEMSAT (Jones D. T., Taylor W. R., and Thornton J. M. (1994) Biochemistry 33: 3038-3049) can be used to predict the existence of the signal sequence or transmembrane region. Alternatively, a partial amino acid sequence of the polypeptide is fused with another polypeptide such as GFP, the fusion polypeptide is transfected into cultured cells, and the localization is analyzed to predict the function of the original polypeptide.
Based on the determined nucleotide sequences of the full-length cDNAs obtained in the present invention, it is possible to predict more detailed functions of the polypeptides encoded by the cDNA clones, for example, by searching the databases such as GenBank, Swiss-Prot, UniGene, and nr for homologies of the cDNAs; or by searching the amino acid sequences deduced from the full-length cDNAs for signal sequences by using software programs such as PSORT, for transmembrane regions by using software programs such as SOSUI or for motifs by using software programs such as Pfam (http://www.sanger.ac.uk/Software/Pfam/index.shtml) and PROSITE (http://www.expasy.ch/prosite/). As a matter of course, the functions are often predictable by using partial sequence information (preferably 300 nucleotides or more) instead of the full-length nucleotide sequences. However, the result of the prediction by using partial nucleotide sequence does not always agree with the result obtained by using full-length nucleotide sequence, and thus, it is needless to say that the prediction of function is preferably performed based on the full-length nucleotide sequences.
GenBank, Swiss-Prot, UniGene and nr databases were searched for homologies of the full-length nucleotide sequences of the 1970 clones (see Example 6). The amino acid sequences deduced from the full-length nucleotide sequences were searched for functional domains by PSORT, SOSUI and Pfam. Prediction of functions of polypeptides encoded by the clones and the categorization thereof were performed based on these results obtained. The categorization was carried out by the following method.
[1] Firstly, the cDNA clones were classified into the above-mentioned 14 functional categories based on the results of annotation-based categorization (using the keywords in the case of Swiss-Prot hit data; using Definition or Reference information in the case of GenBank, UniGene, or nr hit data), and the signal sequence search of the deduced ORFs by PSORT and the transmembrane region search by SOSUI.
[2] Secondly, clones which had been unassignable to the categories by the method of [1] were searched for functional domains and/or motifs by Pfam. Based on the results, the clones were additionally classified into the above-mentioned 14 types of categories when they had a functional domain and/or motif assignable to any one of the categories.
The following 516 clones presumably belong to secretory and/or membrane proteins.
The following 121 clones presumably belong to glycoprotein-related proteins.
The following 88 clones presumably belong to signal transduction-related proteins.
The following 143-clones presumably belong to transcription-related proteins.
The following 331 clones presumably belong to disease-related proteins.
The following 219 clones presumably belong to the category of enzymes and/or metabolism-related proteins.
The following 44 clones presumably belong to the category of cell division- and/or cell proliferation-related proteins.
The following 80 clones presumably belong to the category of cytoskeleton-related proteins.
The following 70 clones presumably belong to the category of nuclear proteins and/or RNA synthesis-related proteins.
The following 20 clones presumably belong to the category of protein synthesis- and/or protein transport-related proteins.
The following 10 clones presumably belong to the category of cellular defense-related proteins.
The following 19 clones presumably belong to the category of development and/or differentiation-related proteins.
The following 168 clones presumably belong to the category of DNA- and/or RNA-binding proteins.
The following 93 clones presumably belong to the category of ATP- and/or GTP-binding proteins.
Among the clones other than the ones shown above, BNGH420036410, FCBBF30257370 are clones which were predicted to highly possibly belong to the category of secretory protein and/or membrane protein based on the result of domain search by Pfam.
SMINT20044730, TESTI20140970
The two clones shown above are clones which were predicted to highly possibly belong to the category of glycoprotein-related protein based on the result of domain search by Pfam.
The 11 clones shown above are clones which were predicted to highly possibly belong to the category of signal transduction-related protein based on the result of domain search by Pfam.
The 18 clones shown above are clones which were predicted to highly possibly belong to the category of transcription-related protein based on the result of domain search by Pfam.
The 35 clones shown above are clones which were predicted to highly possibly belong to the category of enzyme and/or metabolism-related protein based on the result of domain search by Pfam.
PLACE60054820, TESTI20197030
The two clones shown above are clones which were predicted to highly possibly belong to the category of cell division and/or cell proliferation-related protein based on the result of domain search by Pfam.
ASTRO20006530, OCBBF20016390, TRACH20058000
The three clones shown above are clones which were predicted to highly possibly belong to the category of cytoskeleton-related protein based on the result of domain search by Pfam.
BRACE20065470, PLACE60054820
The two clones shown above are clones which were predicted to highly possibly belong to the category of nuclear protein and/or RNA synthesis-related protein based on the result of domain search by Pfam.
The 21 clones shown above are clones which were predicted to highly possibly belong to the category of DNA- and/or RNA-binding protein based on the result of domain search by Pfam.
KIDNE20133880, MESAN20030350, MESAN20030370, TESTI20059480
The four clones shown above are clones which were predicted to highly possibly belong to the category of ATP- and/or GTP-binding proteins based on the result of domain search by Pfam.
The 205 clones shown below are clones which were unassignable to any of the above-mentioned categories, but have been predicted to have some functions based on homology search using their full-length nucleotide sequences and motif search in their estimated ORFs. Clone Name, Definition in the result of homology search or Motif Name in the motif search, demarcated by a double slash mark (//), are shown below.
- ADRGL20022600//DIAPHANOUS PROTEIN HOMOLOG 1 (P140MDIA).
- ADRGL20023920//ABC1 PROTEIN HOMOLOG PRECURSOR.
- ASTRO20001910//Rattus norvegicus mRNA for annexin V-binding protein (ABP-10), partial cds.
- ASTRO20009140//PUTATIVE COMPETENCE-DAMAGE PROTEIN.
- ASTRO20046280//PSU1 PROTEIN.
- ASTRO20058960//DNA damage inducible protein homolog—fission yeast (Schizosaccharomyces pombe)
- BNGH420024870//C2 domain//C2 domain//C2 domain
- BRACE20007330//RING CANAL PROTEIN (KELCH PROTEIN).
- BRACE20052430//Homo sapiens AMSH mRNA, complete cds.
- BRACE20054600//Xenopus laevis mRNA for Kielin, complete cds.
- BRACE20059810//TSC-22/dip/bun family
- BRACE20063540//MEROZOITE SURFACE PROTEIN CMZ-8 (FRAGMENT).
- BRACE20079200//Xenopus laevis mRNA for Kielin, complete cds.
- BRAMY20016780//Proprotein convertase P-domain
- BRAMY20023640//UBX domain
- BRAMY20045420//Domain found in Dishevelled, Egl-10, and Pleckstrin
- BRAMY20056840//UBE-1c2
- BRAMY20063750//Homo sapiens HRIHFB2007 mRNA, partial cds.
- BRAMY20102900//Homo sapiens RU1 (RU1) mRNA, complete cds.
- BRAMY20158550//CALMODULIN.
- BRAMY20223010//Mus musculus leucine-rich glioma-inactivated 1 protein precursor, (Lgi1) mRNA, complete cds.
- BRAMY20238630//TETRATRICOPEPTIDE REPEAT PROTEIN 4.
- BRAMY20245760//Araneus diadematus fibroin-4 mRNA, partial cds.
- BRAWH20047790//HMG (high mobility group) box
- BRSSN20005610//Mus musculus semaphorin cytoplasmic domain-associated protein 3A (Semcap3) mRNA, complete cds.
- BRSSN20005660//Bacterial type II secretion system protein
- BRSSN20093890//Homo sapiens mRNA for Kelch motif containing protein, complete cds.
- CTONG20041150//Streptomyces ansochromogenes strain 7100 SanE (sanE) gene, complete cds.
- CTONG20066110//Homo sapiens DEME-6 mRNA, partial cds.
- CTONG20069420//Ribosomal protein S14p/S29e
- CTONG20071040//BETA CRYSTALLIN B2 (BP).
- CTONG20074170//DENN (AEX-3) domain
- CTONG20083430//Nuclear transition protein 2
- CTONG20170940//MYOTROPHIN (V-1 PROTEIN) (GRANULE CELL DIFFERENTIATION PROTEIN).
- CTONG20174290//TRICHOHYALIN.
- CTONG20174580//Homo sapiens mRNA for vascular Rab-GAP/TBC-containing protein complete cds.
- CTONG20180690//Collagen triple helix repeat (20 copies)
- CTONG20186550//cca3 protein—rat
- CTONG20188080//TPR Domain
- FCBBF10004760//Homo sapiens GAP-like protein (N61) mRNA, complete cds.
- FCBBF20033360//RING CANAL PROTEIN (KELCH PROTEIN).
- FCBBF20041380//SAM domain (Sterile alpha motif)
- FCBBF20043730//UBA domain
- FCBBF20056580//Mus musculus NSD1 protein mRNA, complete cds.
- FCBBF20059660//TPR Domain
- FCBBF30019180//SERINE/THREONINE PROTEIN PHOSPHATASE 2A, 65 KDA REGULATORY SUBUNIT A, ALPHA ISOFORM (PP2A, SUBUNIT A, PR65-ALPHA ISOFORM) (PP2A, SUBUNIT A, R1-ALPHA ISOFORM).
- FCBBF30026580//Homo sapiens retinoblastoma-associated protein RAP140 mRNA, complete cds.
- FCBBF30035570//C2 domain
- FCBBF30079770//D-isomer specific 2-hydroxyacid dehydrogenases
- FCBBF30100120//Mus musculus semaphorin cytoplasmic domain-associated protein 3A (Semcap3) mRNA, complete cds.
- FCBBF30100410//Mus musculus testis-specific Y-encoded-like protein (Tspyl1) mRNA, complete cds.
- FCBBF30118890//Drosophila melanogaster La related protein (larp) mRNA, partial cds.
- FCBBF30138000//trg protein—rat
- FCBBF30157270//Rattus norvegicus PAPIN mRNA, complete cds.
- FCBBF30161780//gag gene protein p24 (core nucleocapsid protein)//Zinc knuckle
- FCBBF30198670//dof protein—fruit fly (Drosophila melanogaster)
- FCBBF30222910//Mus musculus Rap2 interacting protein 8 (RPIP8) mRNA, complete cds.
- FCBBF30255680//Rattus norvegicus brain specific cortactin-binding protein CBP90 mRNA, partial cds.
- FCBBF30260210//Drosophila melanogaster KISMET-L long isoform (kis) mRNA, complete cds.
- FCBBF30282020//cca3 protein—rat
- FCBBF40000610//late gestation lung 2 protein [Rattus norvegicus].
- FEBRA20029620//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat
- FEBRA20031150//Homo sapiens HSKM-B (HSKM-B) mRNA, complete cds.
- FEBRA20038330//Corticotropin-releasing factor family
- FEBRA20038970//Homo sapiens mRNA for stabilin-1 (stab1 gene).
- FEBRA20088610//CELLULAR RETINALDEHYDE-BINDING PROTEIN (CRALBP).
- FEBRA20150420//HYPOTHETICAL 131.5 KDA PROTEIN C02F12.7 IN CHROMOSOME X.
- FEBRA20175330//D-isomer specific 2-hydroxyacid dehydrogenases
- HEART10001420//Mus musculus skm-BOP1 (Bop) mRNA, complete cds.
- HLUNG20024050//Rubredoxin
- HLUNG20030420//Mus musculus mRNA for MAIL, complete cds.
- HLUNG20030490//Ambystoma tigrinum RPE65 protein mRNA, complete cds.
- HLUNG20033060//Homo sapiens GAP-like protein (N61) mRNA, complete cds.
- HLUNG20041590//ubiquitous tetratricopeptide containing protein RoXaN [Homo sapiens].
- HLUNG20045340//MOB2 PROTEIN (MPS1 BINDER 2).
- HLUNG20051330//FHIPEP family
- HLUNG20070410//Dihydropyridine sensitive L-type calcium channel (Beta subunit)
- HLUNG20072100//Gallus gallus Dach2 protein (Dach2) mRNA, complete cds.
- HLUNG20083480//Chicken mRNA for TSC-22 variant, complete cds, clone SLFEST52.
- KIDNE20027980//SAM domain (Sterile alpha motif)
- KIDNE20084730//Homo sapiens FH1/FH2 domain-containing protein FHOS (FHOS) mRNA, complete cds.
- KIDNE20149780//NG28 [Mus musculus]
- KIDNE20154330//Rattus norvegicus mRNA for multi PDZ domain protein.
- KIDNE20170400//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Protein kinase C terminal domain//Rubredoxin
- KIDNE20189890//Homo sapiens mRNA for KARP-1-binding protein 2 (KAB2), complete cds.
- LIVER20010760//Homo sapiens C-type lectin-like receptor-1 mRNA, complete cds.
- LIVER20040740//RETINAL-BINDING PROTEIN (RALBP).
- MESAN20009090//Homo sapiens CEGP1 protein (CEGP1), mRNA
- MESAN20026870//PAN domain//TBC domain
- MESAN20090190//CEGP1 protein [Homo sapiens].
- NT2NE20059680//Homo sapiens integrin cytoplasmic domain associated protein (Icap-1a) mRNA, complete cds.
- NT2NE20077270//Adenovirus EB1 55K protein/large t-antigen
- NT2NE20087850//ANTER-SPECIFIC PROLINE-RICH PROTEIN APG (PROTEIN CEX) (FRAGMENT).
- NT2NE20095230//Homo sapiens HSKM-B (HSKM-B) mRNA, complete cds.
- NT2NE20108420//KES1 PROTEIN.
- NT2NE20173970//Rattus norvegicus beta-catenin binding protein mRNA, complete cds.
- NT2NE20177210//Leishmania major partial ppg1 gene for proteophosphoglycan.
- NT2RP70012830//CALPHOTIN.
- NT2RP70035110//Caenorhabditis elegans UNC-89 (unc-89) gene, complete cds.
- NTONG20002230//Mus musculus RW1 protein mRNA, complete cds.
- NTONG20005310//Ribosomal protein S9/S16
- NTONG20029850//CALCYPHOSINE (R2D5 ANTIGEN).
- NTONG20035150//RING CANAL PROTEIN (KELCH PROTEIN).
- NTONG20058220//Homo sapiens phosphoprotein pp75 mRNA, partial cds.
- OCBBF20005220//Rattus norvegicus Fos-related antigen mRNA, complete cds.
- OCBBF20011860//Mus musculus epithelial protein lost in neoplasm-a (Eplin) mRNA, complete cds.
- OCBBF20016810//enhancer of polycomb [Mus musculus]
- OCBBF20147070//DNA polymerase (viral) C-terminal domain
- OCBBF20160380//liver stage antigen LSA-1—Plasmodium falciparum
- OCBBF20177910//Corticotropin-releasing factor family
- PEBLM20005020//Virion host shutoff protein
- PLACE60055460//Homo sapiens leucine-zipper protein FKSG13 (FKSG13) mRNA, complete cds.
- PLACE60068710//SUPPRESSOR PROTEIN SRP40.
- PLACE60080360//mucin [Homo sapiens]
- PLACE60082850//Pathogenesis-related protein Bet v I family
- PLACE60098350//Human hepatocellular carcinoma associated protein (JCL-1) mRNA, complete cds.
- PLACE60105680//Homo sapiens mRNA for TU12B1-TY, complete cds.
- PLACE60119700//Homo sapiens mRNA for ABP32, complete cds.
- PLACE60120280//SER/THR-RICH PROTEIN T10 IN DGCR REGION.
- PLACE60132200//TRICHOHYALIN.
- PLACE60181870//Pentaxin family
- PROST20084470//Plasmodium berghei strain NYU2 merozoite surface protein-1 mRNA, partial cds.
- PROST20087240//gag gene protein p24 (core nucleocapsid protein)
- PROST20122490//Gallus gallus syndesmos mRNA, complete cds.
- PROST20130320//S-100/ICaBP type calcium binding domain
- PROST20152870//Homo sapiens APC2 gene, exon 14.
- PUAEN10001640//Mus musculus cerebellar postnatal development protein-1 (Cpd1) mRNA, partial cds.
- PUAEN20000800//Bleomycin resistance protein
- SMINT20012220//Collagen triple helix repeat (20 copies)
- SMINT20035510//Drosophila melanogaster La related protein (larp) mRNA, partial cds.
- SMINT20036440//Drosophila melanogaster epsin-like protein mRNA, complete cds.
- SMINT20038660//Homo sapiens HNOEL-iso (HNOEL-iso) mRNA, complete cds.
- SMINT20043390//Ras association (RalGDS/AF-6) domain
- SMINT20048720//Cytochrome P450//Cytochrome P450
- SMINT20052130//Rattus norvegicus mRNA for gankyrin homologue, complete cds.
- SMINT20054050//ABC1 PROTEIN HOMOLOG PRECURSOR.
- SPLEN20024770//Rattus norvegicus (rsec6) mRNA, complete cds.
- SPLEN20040780//CORNIFIN B (SMALL PROLINE-RICH PROTEIN 1B) (SPR1B) (SPR1 B).
- SPLEN20041810//BC-2 protein [Homo sapiens]
- SPLEN20100040//258.1 KDA PROTEIN C210RF5 (KIAA0933).
- SPLEN20104150//Ribosomal protein L36
- SPLEN20116720//Homo sapiens misato mRNA, partial cds.
- SPLEN20176130//Homo sapiens mRNA for ALEX1, complete cds.
- SPLEN20181570//TRICHOHYALIN.
- TESTI20004310//TRICHOHYALIN.
- TESTI20016970//TPR Domain
- TESTI20030440//TRICHOHYALIN.
- TESTI20043180//mouse mRNA for megakaryocyte potentiating factor, complete cds.
- TESTI20043910//IQ calmodulin-binding motif//IQ calmodulin-binding motif//IQ calmodulin-binding motif//IQ calmodulin-binding motif//IQ calmodulin-binding motif
- TESTI20044900//Strongylocentrotus purpuratus radial spokehead mRNA, complete cds.
- TESTI20046110//Extracellular link domain
- TESTI20047930//Homo sapiens NY-REN-2 antigen mRNA, complete cds.
- TESTI20049410//Proprotein convertase P-domain
- TESTI20053950//IQ calmodulin-binding motif
- TESTI20054700//Streptococcus pneumoniae strain g375 surface protein PspC (pspC) gene, pspC-8.1 allele, complete cds.
- TESTI20055880//Serum amyloid A protein
- TESTI20056030//Homo sapiens 88-kDa Golgi protein (GM88) mRNA, complete cds.
- TESTI20061090//Keratin, high sulfur B2 protein
- TESTI20064370//TPR Domain//TPR Domain//TPR Domain//TPR Domain//Synaptobrevin
- TESTI20084250//OXYSTEROL-BINDING PROTEIN.
- TESTI20092170//ENV polyprotein (coat polyprotein)
- TESTI20116050//UBX domain
- TESTI20120500//Kelch motif//Kelch motif
- TESTI20126280//Mus musculus STAP mRNA for sperm tail associated protein, complete cds.
- TESTI20144390//TESTIS-SPECIFIC PROTEIN PBS13.
- TESTI20165990//Ribosomal protein L36
- TESTI20169500//HYPOTHETICAL 51.9 KDA PROTEIN C27F1.04C IN CHROMOSOME I.
- TESTI20170280//Flagellar L-ring protein
- TESTI20176450//thioredoxin interacting factor [Mus musculus].
- TESTI20179230//Dihydropyridine sensitive L-type calcium channel (Beta subunit)
- TESTI20180600//Homo sapiens HOM-TES-85 tumor antigen mRNA, complete cds.
- TESTI20209050//HYPOTHETICAL 113.1 KDA PROTEIN IN PRE5-FET4 INTERGENIC REGION.
- TESTI20210570//RETINAL-BINDING PROTEIN (RALBP).
- TESTI20215310//Homo sapiens calcyclin binding protein mRNA, complete cds.
- TESTI20247440//Human BLu protein testis isoform (BLu) mRNA, complete cds.
- TESTI20249360//Homo sapiens DEME-6 mRNA, partial cds.
- TESTI20250220//TRICHOHYALIN.
- TESTI20251440//Rattus norvegicus (rsec6) mRNA, complete cds.
- TESTI20255460//Mus musculus mRNA for MIWI (piwi), complete cds.
- THYMU20009500//TPR Domain
- THYMU20010180//MOB1 PROTEIN (MPS1 BINDER 1).
- THYMU20013810//Human SEC7 homolog Tic (TIC) mRNA, complete cds.
- THYMU20018250//TPR Domain
- THYMU20026950//Mus musculus ROSA 26 transcription AS ROSA26AS mRNA, complete cds.
- THYMU20028410//Mus musculus Pax transcription activation domain interacting protein PTIP mRNA, complete cds.
- THYMU20030460//Homo sapiens tumor endothelial marker 7 precursor (TEM7) mRNA, complete cds.
- THYMU20031330//Homo sapiens putative nucleotide binding protein mRNA, complete cds.
- THYMU20052460//PHORBOLIN I (FRAGMENTS).
- THYMU20055450//Zona pellucida-like domain
- THYMU20083830//Homo sapiens angiostatin binding protein 1 mRNA, complete cds.
- THYMU20139160//Uncharacterized protein family UPF0031
- THYMU20151610//Homo sapiens antigen NY-CO-1 (NY-CO-1) mRNA, complete cds.
- TRACH20093400//TRICHOHYALIN.
- TRACH20104510//Uncharacterized protein family UPF0005
- TRACH20122980//HYPOTHETICAL PROTEIN MJ0798.
- TRACH20139280//PX domain
- TRACH20164810//D-isomer specific 2-hydroxyacid dehydrogenases
- TRACH20165540//Human alpha-1 type I collagen gene surrounding osteogenesis imperfecta OI type II deletion.
- UTERU20051790//guanylate kinase-interacting protein 1 Maguin-1, membrane-associated—rat
- UTERU20083020//Domain of unknown function DUF71
- UTERU20121140//Rhodanese-like domain
- UTERU20128560//26.4 KDA PROTEIN IN RUVC-ASPS INTERGENIC REGION.
- UTERU20132620//AXONEME-ASSOCIATED PROTEIN MST101(2).
- UTERU20134830//pellino (Drosophila) homolog 2 [Homo sapiens]
- UTERU20181270//Zinc knuckle
Further, the reason is that a polypeptide does not always belong solely to a single category of the above-described functional categories, and therefore, a polypeptide may belong to any of the predicted functional categories. Besides, additional functions can be found for the clones classified into these functional categories by further analyses.
Since the polypeptide encoded by clones of the invention contains full-length amino acid sequence, it is possible to analyze its biological activity, and its effect on cellular conditions such as cell proliferation and differentiation by expressing the polypeptide as a recombinant polypeptide using an appropriate expression system, injecting the recombinant into the cell, or raising a specific antibody against the polypeptide.
The biological activities of respective polypeptides can be analyzed by the methods as shown below. Secretory protein, transmembrane protein:
-
- ‘Ion Channels’ (Ed., R. H. Ashley, 1995) of “The Practical Approach Series” (IRL PRESS),
- “Growth Factors” (Eds., I. McKay, I. Leigh, 1993),
- “Extracellular Matrix” (Eds., M. A. Haralson, J. R. Hassell, 1995);
Glycoprotein-Related Protein: - “Glycobiology” (Eds., M. Fukuda, A. Kobata, 1993) of “The Practical Approach Series” (IRL PRESS),
- “Glycoprotein Analysis in Biomedicine” (Ed., Elizabeth F. Hounsell, 1993) of “Method in Molecular Biology” (Humana Press) series;
Signal Transduction-Related Protein: - “Signal Transduction” (Ed., G. Milligan, 1992) of “The Practical Approach Series” (IRL PRESS),
- “Protein Phosphorylation” (Ed., D. G. Hardie, 1993), or
- “Signal Transduction Protocols” (Eds., David A. Kendall, Stephen J. Hill, 1995) of “Method in Molecular Biology” (Humana Press) series;
Transcription-Related Protein: - “Gene Transcription” (Eds., B. D. Hames, S. J. Higgins, 1993) of “The Practical Approach Series” (IRL PRESS),
- “Transcription Factors” (Ed., D. S. Latchman, 1993);
Enzyme and/or Metabolism-Related Protein: - “Enzyme Assays” (Eds., ROBERT EISENTHAL and MICHAEL J. DANSON, 1992) of “The Practical Approach Series” (IRL PRESS);
Cell Division and/or Cell Proliferation-Related Protein: - “Cell Growth, Differentiation and Senescence” (Ed., GEORGE STUDZINSKI, 2000) of “The Practical Approach Series” (IRL PRESS);
Cytoskeleton-Related Protein: - “Cytoskeleton: Signalling and Cell Regulation” (Eds., KERMIT L. CARRAWAY and CAROLIE A. CAROTHERS CARRAWAY, 2000) of “The Practical Approach Series” (IRL PRESS),
- “Cytoskeleton Methods and Protocols” (Ed., Gavin, Ray H., 2000) of “Method in Molecular Biology” (Humana Press) series;
Nuclear Protein and/or RNA Synthesis-Related Protein: - “Nuclear Receptors” (Ed., DIDIER PICARD, 1999) of “The Practical Approach Series” (IRL PRESS),
- “RNA Processing” (Eds., STEPHEN J. HIGGINS and B. DAVID HAMES, 1994);
Protein Synthesis and/or Transport-Related Protein: - “Membrane Transport” (Ed., STEPHEN A. BALDWIN, 2000) of “The Practical Approach Series” (IRL PRESS),
- “Protein Synthesis Methods and Protocols” (Eds., Martin, Robin, 1998) of “Method in Molecular Biology” (Humana Press) series;
Cellular Defense-Related Protein: - “DNA Repair Protocols” (Henderson, Daryl S., 1999) of “Method in Molecular Biology” (Humana Press) series,
- “Chaperonin Protocols” (Eds., Schneider, Christine, 2000);
Development and/or Differentiation-Related Protein: - “Developmental Biology Protocols” (Eds., ROBERT EISENTHAL and MICHAEL J. DANSON, 1992) of “Method in Molecular Biology” (Humana Press) series;
DNA- and/or RNA-Binding Protein: - “DNA-Protein Interactions Principles and Protocols” (Eds., Kneale, G. Geoff, 1994) of “Method in Molecular Biology” (Humana Press) series,
- “RNA-Protein Interaction Protocols” (Eds., Haynes, Susan R., 1999);
ATP- and/or GTP-Binding Protein: - “Signal Transduction Protocols” (Eds., David A. Kendall, Stephen J. Hill, 1995) of “Method in Molecular Biology” (Humana Press) series.
In the categorization, the clone predicted to belong to the category of secretory and/or membrane protein means a clone having hit data with some annotation, such as growth factor, cytokine, hormone, signal, transmembrane, membrane, extracellular matrix, receptor, G-protein coupled receptor, ionic channel, voltage-gated channel, calcium channel, cell adhesion, collagen, connective tissue, etc., suggesting that it was a secretory or membrane protein, or a clone in which the presence of nucleotide sequence encoding a signal sequence or transmembrane region was suggested by the results of PSORT and SOSUI analyses for deduced ORF.
The clone predicted to belong to the category of glycoprotein-related protein means a clone having hit data with some annotation, such as glycoprotein, suggesting that the clone encodes a glycoprotein-related protein.
The clone predicted to belong to the category of signal transduction-related protein means a clone having hit data with some annotation, such as serine/threonine-protein kinase, tyrosine-protein kinase, SH3 domain, SH2 domain, etc., suggesting that the clone encodes a signal transduction-related protein.
The clone predicted to belong to the category of transcription-related protein means a clone having hit data with some annotation, such as transcription regulation, zinc finger, homeobox, etc., suggesting that the clone encodes a transcription-related protein.
The clone predicted to belong to the category of disease-related protein means a clone having hit data with some annotation, such as disease mutation, syndrome, etc., suggesting that the clone encodes a disease-related protein, or a clone whose full-length nucleotide sequence has hit data for Swiss-Prot, GenBank, UniGene, or nr, where the hit data corresponds to genes or polypeptides which have been deposited in the Online Mendelian Inheritance in Man (OMIM) (http://www.ncbi.nlm.nih.gov/Omim/), which is the human gene and disease database described later.
The clone predicted to belong to the category of enzyme and/or metabolism-related protein means a clone having hit data with some annotation, such as metabolism, oxidoreductase, E. C. No. (Enzyme commission number), etc., suggesting that the clone encodes an enzyme and/or metabolism-related protein.
The clone predicted to belong to the category of cell division and/or cell proliferation-related protein means a clone having hit data with some annotation, such as cell division, cell cycle, mitosis, chromosomal protein, cell growth, apoptosis, etc., suggesting that the clone encodes a cell division and/or cell proliferation-related protein.
The clone predicted to belong to the category of cytoskeleton-related protein means a clone having hit data with some annotation, such as structural protein, cytoskeleton, actin-binding, microtubles, etc., suggesting that the clone encodes a cytoskeleton-related protein.
The clone predicted to belong to the category of nuclear protein and/or RNA synthesis-related protein means a clone having hit data with some annotation, such as nuclear protein, RNA splicing, RNA processing, RNA helicase, polyadenylation, etc., suggesting that the clone encodes a nuclear protein and/or RNA synthesis-related protein.
The clone predicted to belong to the category of protein synthesis and/or transport-related protein means a clone having hit data with some annotation, such as translation regulation, protein biosynthesis, amino-acid biosynthesis, ribosomal protein, protein transport, signal recognition particle, etc., suggesting that the clone encodes a protein synthesis and/or transport-related protein.
The clone predicted to belong to the category of cellular defense-related protein means a clone having hit data with some annotation, such as heat shock, DNA repair, DNA damage, etc., suggesting that the clone encodes a cellular defense-related protein.
The clone predicted to belong to the category of development and/or differentiation-related proteins means a clone having hit data with some annotation, such as developmental protein, etc., suggesting that the clone encodes a development and/or differentiation-related protein.
The clone predicted to belong to the category of DNA- and/or RNA-binding protein means a clone having hit data with some annotation, such as DNA-binding, RNA-binding, etc.
The clone predicted to belong to the category of ATP-and/or GTP-binding protein means a clone having hit data with some annotation, such as ATP-binding, GTP-binding, etc.
As to a protein involved in a disease, it is possible to perform a functional analysis as described above, but also possible to analyze correlation between the expression or the activity of the protein and a certain disease by using a specific antibody that is obtained by using expressed protein. Alternatively, it is possible to utilize the database OMIM, which is a database of human genes and diseases, to analyze the protein. Further, new information is constantly being deposited in the OMIM database. Therefore, it is possible for one skilled in the art to find a new relationship between a particular disease and a gene of the present invention in the most up-to-date database. The proteins involved in diseases are useful for developing a diagnostic marker or medicines for regulation of their expression and activity, or as a target of gene therapy.
Also, as for a secretory protein, membrane protein, signal transduction-related protein, glycoprotein-related protein, or transcription-related protein, etc., search of the OMIM with the following keywords resulted in the finding that the proteins are involved in many diseases (the result of the OMIM search for secrete and membrane proteins is shown below). Also, association between proteins related to signal transduction or transcription and diseases is reported in “Transcription Factor Research-1999” (Fujii, Tamura, Morohashi, Kageyama, and Satake edit, (1999) Jikken-Igaku Zoukan, Vol. 17, No. 3), and “Gene Medicine”, (1999) Vol. 3, No. 2). When cancer is used as an example, as described in “Biology of Cancer” (S. Matsubara, 1992) of Life Science series (Shokabo), many proteins are involved in cancers, which include enzyme and/or metabolism-related proteins, cytoskeleton-related proteins, cell division and/or cell proliferation-related proteins as well as secretory proteins, membrane proteins, signal transduction-related proteins, glycoprotein-related proteins, transcription-related proteins. As clearly seen by the above example, it is evident that not only disease-related proteins but also secretory proteins, membrane proteins, signal transduction-related proteins, glycoprotein-related proteins, transcription-related proteins, etc. are often involved in diseases, and thus they can be useful targets in the field of medical industry.
The result of the OMIM search for secretory and membrane proteins is shown below, in which the keywords,
-
- (1) secretion protein,
- (2) membrane protein,
- (3) channel, and
- (4) extracellular matrix were used.
Shown in the search result are only the accession numbers in the OMIM. Using the number, data showing the relationship between a disease and a gene or protein can be seen. The OMIM data has been renewed everyday.
1) Secretion Protein
354 entries found, searching for “secretion protein”
2) Membrane Protein
1489 entries found, searching for “membrane protein”
3) Channel (Member of Membrane Protein)
361 entries found, searching for “channel”
4) Extracellular Matrix
218 entries found, searching for “extracellular matrix”
In addition to these, the various keywords shown in the above-mentioned categorization or others can be used for the OMIM search and the result may suggest the involvement thereof in diseases.
Further, the use of nucleotide sequences of cDNAs of the present invention enables analyzing the expression frequency of genes corresponding to the cDNAs. In addition, functions of the genes can be predicted based on the information obtained by the expression frequency analysis.
There are several methods for analyzing the expression levels of genes involved in diseases. Differences in gene expression levels between diseased and normal tissues are studied by the analytical methods using, for example, Northern hybridization, RT-PCR, DNA microarray, etc. (Experimental Medicine, Vol. 17, No. 8, 980-1056 (1999); Cell Engineering (additional volume) DNA Microarray and Advanced PCR Methods, Muramatsu & Nawa (eds.), Shujunsya (2000)). By computer analysis, in addition to these analysis methods, the nucleotide sequences of expressed genes can be compared to analyze the expression frequency. For example, there is a database called “BODYMAP”; gene clones are extracted at random from cDNA libraries of various tissues and/or cells, and the clones homologous to one another are assigned to a single cluster based on the information of nucleotide sequence homology at the 3′-end; genes are classified into any clusters, and the numbers of clones in the respective clusters are compared to gain the information on expression frequency (http://bodymap.ims.u-tokyo.ac.jp/).
When explicit difference in the expression levels between diseased tissues and normal tissues is observed for a gene by these analytical methods, it can be conclude that the gene is closely involved in a disease or disorder. Instead of diseased tissues, when gene expression is explicitly different between normal cells and cells reproducing disease-associated specific features, it can be concluded that the gene is closely involved in a disease or disorder.
From the 1970 clones whose full-length nucleotide sequences had been revealed, genes involved in particular pathology or functions were selected by the use of databases shown below (see Example 7; “Expression frequency analysis in silico”). The database used in the analyses of the present invention contains nucleotide sequences of 770,546 clones, and the population of the database is large enough for the analysis. The sequence information in the database was obtained by selecting cDNA clones at random from cDNA libraries derived from the various tissues and cells shown in Example 1 and determining the 5′-end sequences thereof.
Then, the nucleotide sequences of respective clones in this database were categorized (clustered) based on the nucleotide sequence homology determined with a search program; the number of clones belonging to every cluster of each library was determined and normalized; thus, the ratio of a certain gene in a cDNA library was determined. This analysis provided the information of the expression frequency of a gene in a tissue or cell that is the source of the cDNA library.
Then, in order to analyze the expression of genes corresponding to the nucleotide sequences of cDNAs of the present invention in tissues and cells, the libraries from the tissues or cells, which had been used in the large-scale cDNA analyses, were taken as subjects to compare the expression levels between different tissues or cells. Namely, the expression frequency was analyzed by comparing the previously normalized values between tissues or cells from which 600 or more cDNA clones whose nucleotide sequences had been analyzed were derived. The result of this analysis showed that the cDNA clones corresponded to the genes involved in the pathology and functions, which are indicated below. Each value in Tables 3 to 39 indicated below represents a relative expression frequency; the higher the value, the higher the expression level.
Osteoporosis-Related Genes
Osteoporosis is a pathology in which bones are easily broken owing to overall decrease in components of bone. The onset correlates to the balance between the functions of osteoblast producing bone and osteoclast absorbing bone, namely bone metabolism. Thus, the genes involved in the increase of osteoclasts differentiating from precursor cells of monocyte/macrophage line (Molecular Medicine 38. 642-648. (2001)) are genes involved in osteoporosis relevant to bone metabolism.
A nucleotide sequence information-based analysis was carried out to identify the genes whose expression frequencies are higher or lower in CD34+ cell (cell expressing a glycoprotein CD34) treated with the osteoclast differentiation factor (Molecular Medicine 38. 642-648. (2001)) than in the untreated CD34+ cell, which is the precursor cell of monocyte/macrophage line. The result of comparative analysis for the frequency between the cDNA libraries prepared from the RNA of CD34+ cells (CD34C) and from the RNA of CD34+ cells treated with the osteoclast differentiation factor (D30ST, D60ST or D90ST) showed that the genes whose expression levels were different between the two were 26 clones indicated in Table 3. These clones are involved in osteoporosis.
Genes Involved in Neural Cell Differentiation
Genes involved in neural cell differentiation are useful for treating neurological diseases. Genes with varying expression levels in response to induction of cellular differentiation in neural cells are thought to be involved in neurological diseases.
A survey was performed for genes whose expression levels are varied in response to induction of differentiation (stimulation by retinoic acid (RA) or growth inhibitor treatment after RA stimulation) in cultured cells of a neural strain, NT2. The result of comparative analysis of cDNA libraries derived from undifferentiated NT2 cells (NT2RM) and the cells subjected to the differentiation treatment (NT2RP, NT2RI or NT2NE) showed that the genes whose expression levels were different between the two were 193 clones indicated in Table 4. These genes are neurological disease-related genes.
Cancer-Related Genes
It has been assumed that, distinct from normal tissues, cancer tissues express a distinct set of genes, and thus the expression thereof can contribute to the carcinogenesis in tissues and cells. Thus, genes whose expression patterns in cancer tissues are different from those in normal tissues are cancer-related genes. Search was carried out for the genes whose expression levels in cancer tissues were different from those in normal tissues.
The result of comparative analysis of cDNA libraries derived from breast tumor (TBAES) and normal breast (BEAST) showed that the genes whose expression levels were different between the two were 4 clones indicated in Table 5.
The result of comparative analysis of cDNA libraries derived cervical tumor (TCERX) and normal cervical duct (CERVX) showed that the genes whose expression levels were different between the two was one clone indicated in Table 6.
The result of comparative analysis of cDNA libraries derived from colon tumor (TCOLN) and normal colon (COLON) showed that the genes whose expression levels were different between the two was one clone indicated in Table 7.
The result of comparative analysis of cDNA libraries derived from esophageal tumor (TESOP) and normal esophagus (NESOP) showed that the genes whose expression levels were different between the two were 6 clones indicated in Table 8.
The result of comparative analysis of cDNA libraries derived from kidney tumor (TKIDN) and normal kidney (KIDNE) showed that the genes whose expression levels were different between the two were 132 clones indicated in Table 9.
The result of comparative analysis of cDNA libraries derived from liver tumor (TLIVE) and normal liver (LIVER) showed that the genes whose expression levels were different between the two were 25 clones indicated in Table 10.
The result of comparative analysis of cDNA libraries derived from lung tumor (TLUNG) and normal lung (HLUNG) showed that the genes whose expression levels were different between the two were 99 clones indicated in Table 11.
The result of comparative analysis of cDNA libraries derived from ovary tumor (TOVER) and normal ovary (NOVER) showed the genes whose expression levels were different between the two were 3 clones indicated in Table 12.
The result of comparative analysis of cDNA libraries derived from stomach tumor (TSTOM) and normal stomach (STOMA) showed that the genes whose expression levels were different between the two were 15 clones indicated in Table 13.
The result of comparative analysis of cDNA libraries derived from uterine tumor (TUTER) and normal uterus (UTERU) showed that the genes whose expression levels were different between the two were 97 clones indicated in Table 14.
The result of comparative analysis of cDNA libraries derived from tongue cancer (CTONG) and normal tongue (NTONG) showed that the genes whose expression levels were different between the two were 203 clones indicated in Table 15.
These genes are involved in cancers.
Further, there is a method to search for genes involved in development and differentiation, which is the expression frequency analysis in which the expression levels of genes are compared between developing and/or differentiating tissues and/or cells and adult tissues and/or cells. The genes involved in tissue development and/or differentiation are genes participating in tissue construction and expression of function, and thus are useful genes, which are available for regenerative medicine aiming at convenient regeneration of injured tissues.
By using the information of gene expression frequency gained from the database of 5′-end nucleotide sequences described above, genes involved in development or differentiation of particular tissues were selected from the 1970 clones whose full-length nucleotide sequence had been revealed (see Example 7).
The result of comparative analysis of cDNA libraries derived from fetal brain (FCBBF, FEBRA or OCBBF) and adult brain (BRACE, BRALZ, BRAMY, BRAWH, BRCAN, BRCOC, BRHIP, BRSSN, BRSTN or BRTHA) showed that the genes whose expression levels were different between the two were 775 clones indicated in Tables 16 to 36.
The result of comparative analysis of cDNA libraries derived from fetal heart (FEHRT) and adult heart (HEART) showed that the genes whose expression levels were different between the two were 28 clones indicated in Table 37.
The result of comparative analysis of cDNA libraries derived from fetal kidney (FEKID) and adult kidney (KIDNE) showed that the genes whose expression levels were different between the two were 95 clones indicated in Table 38.
The result of comparative analysis of cDNA libraries derived from fetal lung (FELNG) and adult lung (HLUNG) showed that the genes whose expression levels were different between the two were 99 clones indicated in Table 39. These genes are involved in regeneration of tissues and/or cells.
The expression frequency or the like can be analyzed by PCR based on the nucleotide sequences of cDNAs of the present invention. There are some known methods for comparing the quantities of amplification products obtained by PCR. For example, the band intensities can be determined by ethidium bromide staining. With R1-labeled or fluorescently labeled primers, the R1 signal or fluorescence intensity can be assayed for the quantity of labeled amplification products. Alternatively, the quantity of amplification products can also be determined by measuring the RI signal or the fluorescence intensity from the RI-labeled or fluorescently labeled probe hybridizing to the products. The assay results thus obtained are compared and then the clones exhibiting differences in the expression levels can be selected.
There are some quantitative PCR methods: a PCR method using internal standards; a competitive PCR, in which the quantification is achieved by adding, to a sample, a dilution series of a known quantity of a template RNA and by comparing the quantity of an amplification product derived from the RNA of interest with the quantity of an amplification product derived from the template RNA. These methods overcome the problems of errors in the amount of amplification products among tubes and of the plateau effect. ATAC-PCR (Adaptor-tagged competitive PCR) is a method of competitive PCR which is practiced by using multiple adapters of different sizes attached to a gene whose 3′-end nucleotide sequence has previously been determined. The ratio of expression frequency of a single mRNA species from a number of tissues (cells) can be assayed in a single step (Nucleic Acids Research 1997, 25 (22): 4694-4696; “DNA Micro-array and Advanced PCR Techniques”, Cell Technology, supplement, Eds., Muramatsu and Nawa (Shujunsha, 2000): 104-112).
If it is observed, by using these analytical methods, that the expression levels of genes are evidently varied during major cellular events (such as differentiation and apoptosis), the genes are involved in the cellular events and accordingly are candidates for disease- and/or disorder-related genes. Further, genes exhibiting tissue-specific expression are genes playing important parts in the tissue functions and, therefore, can be candidates for genes involved in diseases and/or disorders affecting the tissues.
For example, inflammation is an important biological response that is known to be involved in various diseases. The representative inflammation-inducing factors include TNF-α (Tumor Necrosis Factor-alpha). There exists a signaling cascade activated by TNF-α stimulations, wherein NF-κB is a transducing molecule (Cell 1995, 80:529-532). It has also been revealed that many inflammation-related genes, including IL-2, IL-6 and G-CSF, are varied in the expression levels thereof in response to the signal through the pathway (Trends Genet. 1999, 15 (6): 229-235). It is assumed that genes whose expression levels are varied in response to the stimulation of TNF-α also participate in inflammation.
Further, the infection of Helicobacter pylori to the gastric epithelia is known to cause gastritis and gastroduodenal ulcer (Mebio 2000, July, 17 (7): 16-33). Thus, the genes whose expression levels are altered depending on co-culturing cells with Helicobacter pylori may be involved in gastritis and gastroduodenal ulcer. A recent study has suggested that Helicobacter pylori strongly activates the NF-κB pathway (Gastroenterology 2000, 119: 97-108).
THP-1 cell, which is a human monocyte cell line, was cultured in the presence of TNF-α (Tumor Necrosis Factor-alpha). The genes whose expression levels were altered owing to the presence of TNF-α were searched for, and the result showed that the clones whose expression levels were increased owing to the presence of TNF-α were
On the other hand, the clones whose expression levels were decreased owing to the presence of TNF-α were
These clones are inflammation-related genes.
MKN45, which is a gastric cancer cell line, was co-cultured with Helicobacter pylori. The genes whose expression levels were altered owing to the presence of Helicobacter pylori were searched for, and the result showed that the clones whose expression levels were increased owing to the presence of Helicobacter pylori were
On the other hand, the clones whose expression levels were decreased owing to the presence of Helicobacter pylori were
These clones are involved in gastritis or gastroduodenal ulcer.
For example, if the polypeptide encoded by the cDNA of the present invention is a regulatory factor of cellular conditions such as growth and differentiation, it can be used for developing medicines as follows. The polypeptide or antibody provided by the invention is injected into a certain kind of cells by microinjection. Then, using the cells, it is possible to screen low molecular weight compounds, etc. by measuring the change in the cellular conditions, or the activation or inhibition of a particular gene. The screening can be performed as follows.
First, the polypeptide is expressed and purified as recombinant. The purified polypeptide is microinjected into cells such as various cell lines, or primary culture cells, and the cellular change such as growth and differentiation can be examined. Alternatively, the induction of genes whose expression is known to be involved in a particular change of cellular conditions may be detected by the amount of mRNA or polypeptide. Alternatively, the amount of intracellular molecules (low molecular weight compounds, etc.) that is changed by the function of the gene product (polypeptide) which is known to be involved in a particular change of cellular conditions may be detected.
The compounds to be screened (both low and high molecular compounds are acceptable) can be added to the culture media and assessed for their activity by measuring the change of the cellular conditions.
Instead of microinjection, cell lines introduced with the gene obtained in the invention can be used for the screening. If the gene product is turn out to be involved in a particular change in the cellular conditions, the change of the product can be used as a measurement for screening. Once a compound is screened out which can activate or inhibit the function of the polypeptide of the invention, it can be applied for developing medicines.
If the polypeptide encoded by the cDNA of the present invention is a secretory protein, membrane protein, or protein involved in signal transduction, glycoprotein, transcription, or diseases, it can be used in functional assays for developing medicines.
In case of a membrane protein, it is most likely to be a polypeptide that functions as a receptor or ligand on the cell surface. Therefore, it is possible to reveal a new relationship between a ligand and receptor by screening the membrane protein of the invention based on the binding activity with the known ligand or receptor. Screening can be performed according to the known methods.
For example, a ligand against the polypeptide of the invention can be screened in the following manner. Namely, a ligand that binds to a specific polypeptide can be screened by a method comprising the steps of: (a) contacting a test sample with the polypeptide of the invention or a partial peptide thereof, or cells expressing these, and (b) selecting a test sample that binds to said polypeptide, said partial peptide, or said cells.
On the other hand, for example, screening using cells expressing the polypeptide of the present invention that is a receptor protein can also be performed as follows. It is possible to screen receptors that is capable of binding to a specific polypeptide by using procedures (a) attaching the sample cells to the polypeptide of the invention or its partial peptide, and (b) selecting cells that can bind to the said polypeptide or its partial peptide.
In a following screening as an example, first the polypeptide of the invention is expressed, and the recombinant polypeptide is purified. Next, the purified polypeptide is labeled, binding assay is performed using a various cell lines or primary cultured cells, and cells that are expressing a receptor are selected (Growth and differentiation factors and their receptors, Shin-Seikagaku Jikken Kouza Vol. 7 (1991) Honjyo, Arai, Taniguchi, and Muramatsu edit, p203-236, Tokyo-Kagaku-Doujin). A polypeptide of the invention can be labeled with RI such as 125I, and enzyme (alkaline phosphatase etc.).
Alternatively, a polypeptide of the invention may be used without labeling and then detected by using a labeled antibody against the polypeptide. The cells that are selected by the above screening methods, which express a receptor of the polypeptide of the invention, can be used for the further screening of an agonists or antagonists of the said receptor.
Once the ligand binding to the polypeptide of the invention, the receptor of the polypeptide of the invention or the cells expressing the receptor are obtained by screening, it is possible to screen a compound that binds to the ligand and receptor. Also it is possible to screen a compound that can inhibit both bindings (agonists or antagonists of the receptor, for example) by utilizing the binding activities.
When the polypeptide of the invention is a receptor, the screening method comprises the steps of (a) contacting the polypeptide of the invention or cells expressing the polypeptide of the invention with the ligand, in the presence of a test sample, (b) detecting the binding activity between said polypeptide or cells expressing said polypeptide and the ligand, and (c) selecting a compound that reduces said binding activity when compared to the activity in the absence of the test sample. Furthermore, when the polypeptide of the invention is a ligand, the screening method comprises the steps of (a) contacting the polypeptide of the invention with its receptor or cells expressing the receptor in the presence of samples, (b) detecting the binding activity between the polypeptide and its receptor or the cells expressing the receptor, and (c) selecting a compound that can potentially reduce the binding activity compared to the activity in the absence of the sample.
Samples to screen include cell extracts, expressed products from a gene library, synthesized low molecular compound, synthesized peptide, and natural compounds, for example, but are not construed to be listed here. A compound that is isolated by the above screening using a binding activity of the polypeptide of the invention can also be used as a sample.
A compound isolated by the screening may be a candidate to be an agonist or an antagonist of the receptor of the polypeptide. By utilizing an assay that monitors a change in the intracellular signaling such as phosphorylation which results from reduction of the binding between the polypeptide and its receptor, it is possible to identify whether the obtained compound is an agonist or antagonist of the receptor. Also, the compound may be a candidate of a molecule that can inhibit the interaction between the polypeptide and its associated proteins (including a receptor) in vivo. Such compounds can be used for developing drugs for precaution or cures of a disease in which the polypeptide is involved.
Secretory proteins may regulate cellular conditions such as growth and differentiation. It is possible to find out a novel factor that regulates cellular conditions by adding the secretory protein of the invention to a certain kind of cell, and performing a screening by utilizing the cellular changes in growth or differentiation, or activation of a particular gene.
The screening can be performed, for example, as follows. First, the polypeptide of the invention is expressed and purified in a recombinant form. Then, the purified polypeptide is added to a various kind of cell lines or primary cultured cells, and the change in the cell growth and differentiation is monitored. The induction of a particular gene that is known to be involved in a certain cellular change is detected by the amounts of mRNA and polypeptide. Alternatively, the amount of an intracellular molecule (low-molecular-weight compounds, etc.) that is changed by the function of a gene product (polypeptide) that is known to function in a certain cellular change is used for the detection.
Once the screening reveals that the polypeptide of the invention can regulate cellular conditions or the functions, it is possible to apply the polypeptide as a pharmaceutical and diagnostic medicine for related diseases by itself or by altering a part of it into an appropriate composition.
As is above described for membrane proteins, the secretory protein provided by the invention may be used to explore a novel ligand-receptor interaction using a screening based on the binding activity to a known ligand or receptor. A similar method can be used to identify an agonist or antagonist. The resulting compounds obtained by the methods can be a candidate of a compound that can inhibit the interaction between the polypeptide of the invention and an interacting molecule (including a receptor). The compounds may be able to use as a preventive, therapeutic, and diagnostic medicine for the diseases, in which the polypeptide may play a certain role.
Proteins involved in signal transduction or transcription may be a factor that affects a certain polypeptide or gene in response to intracellular/extracellular stimuli. It is possible to find out a novel factor that can affect a polypeptide or gene by expressing the polypeptide provided by the invention in a certain types of cells, and performing a screening utilizing the activation of a certain intracellular polypeptide or gene.
The screening may be performed as follows. First, a transformed cell line expressing the polypeptide is obtained. Then, the transformed cell line and the untransformed original cell line are compared for the changes in the expression of a certain gene by detecting the amount of its mRNA or polypeptide. Alternatively, the amount of an intracellular molecule (low molecular weight compounds, etc.) that is changed by the function of a certain gene product (polypeptide) may be used for the detection. Furthermore, the change of the expression of a certain gene can be detected by introducing a fusion gene that comprises a regulatory region of the gene and a marker gene (luciferase, β-galactosidase, etc.) into a cell, expressing the polypeptide provided by the invention into the cell, and estimating the activity of a marker gene product (polypeptide).
If the polypeptide or gene of the invention is involved in diseases, it is possible to screen a gene or compound that can regulate its expression and/or activity either directly or indirectly by utilizing the polypeptide of the present invention.
For example, the polypeptide of the invention is expressed and purified as a recombinant polypeptide. Then, the polypeptide or gene that interacts with the polypeptide of the invention is purified, and screened based on the binding. Alternatively, the screening can be performed by adding with a compound of a candidate of the inhibitor added in advance and monitoring the change of binding activity. In another method, a transcription regulatory region locating in the 5′-upstream of the gene encoding the polypeptide of the invention that is capable of regulating the expression of other genes is obtained, and fused with a marker gene. The fusion is introduced into a cell, and the cell is added with compounds to explore a regulatory factor of the expression of the said gene.
The compound obtained by the screening can be used for developing pharmaceutical and diagnostic medicines for the diseases in which the polypeptide of the present invention is involved. Similarly, if the regulatory factor obtained in the screening is turn out to be a polypeptide, compounds that can newly affect the expression or activity of the polypeptide may be used as a medicine for the diseases in which the polypeptide of the invention is involved.
If the polypeptide of the invention has an enzymatic activity, regardless as to whether it is a secretory protein, membrane protein, or proteins involved in signal transduction, glycoprotein, transcription, or diseases, a screening may be performed by adding a compound to the polypeptide of the invention and monitoring the change of the compound. The enzymatic activity may also be utilized to screen a compound that can inhibit the activity of the polypeptide.
In a screening given as an example, the polypeptide of the invention is expressed and the recombinant polypeptide is purified. Then, compounds are contacted with the purified polypeptide, and the amount of the compound and the reaction products is examined. Alternatively, compounds that are candidates of an inhibitor are pretreated, then a compound (substrate) that can react with the purified polypeptide is added, and the amount of the substrate and the reaction products is examined.
The compounds obtained in the screening may be used as a medicine for diseases in which the polypeptide of the invention is involved. Also they can be applied for tests that examine whether the polypeptide of the invention functions normally in vivo.
Whether the secretory protein, membrane protein, signal transduction-related protein, glycoprotein-related protein, or transcription-related protein of the present invention is a novel protein involved in diseases or not is determined in another method than described above, by obtaining a specific antibody against the polypeptide of the invention, and examining the relationship between the expression or activity of the polypeptide and a certain disease. In an alternative way, it may be analyzed referred to the methods in “Molecular Diagnosis of Genetic Diseases” (Elles R. edit, (1996) in the series of “Method in Molecular Biology” (Humana Press).
Proteins involved in diseases are targets of screening as mentioned, and thus are very useful in developing drugs which regulate their expression and activity. Also, the proteins are useful in the medicinal industry as a diagnostic marker of the related disease or a target of gene therapy.
Compounds isolated as mentioned above can be administered patients as it is, or after formulated into a pharmaceutical composition according to the known methods. For example, a pharmaceutically acceptable carrier or vehicle, specifically sterilized water, saline, plant oil, emulsifier, or suspending agent can be mixed with the compounds appropriately. The pharmaceutical compositions can be administered to patients by a method known to those skilled in the art, such as intraarterial, intravenous, or subcutaneous injections. The dosage may vary depending on the weight or age of a patient, or the method of administration, but those skilled in the art can choose an appropriate dosage properly. If the compound is encoded by polynucleotide, the polynucleotide can be cloned into a vector for gene therapy, and used for gene therapy. The dosage of the polynucleotide and the method of its administration may vary depending on the weight or age of a patient, or the symptoms, but those skilled in the art can choose properly.
The present invention further relates to databases comprising at least a sequence of polynucleotide and/or polypeptide, or a medium recorded in such databases, selected from the sequence data of the nucleotide and/or the amino acids indicated in Table 1. The term “database” means a set of accumulated information as machine-searchable and readable information of nucleotide sequence. The databases of the present invention comprise at least one of the novel nucleotide sequences of polynucleotides provided by the present invention. The databases of the present invention can consist of only the sequence data of the novel polynucleotides provided by the present invention or can comprise other information on nucleotide sequences of known full-length cDNAs or ESTs. The databases of the present invention can be comprised of not only the information on the nucleotide sequences but also the information on the gene functions revealed by the present invention. Additional information such as names of DNA clones carrying the full-length cDNAs can be recorded or linked together with the sequence data in the databases.
The database of the present invention is useful for gaining complete gene sequence information from partial sequence information of a gene of interest. The database of the present invention comprises nucleotide sequence information of full-length cDNAs. Consequently, by comparing the information in this database with the nucleotide sequence of a partial gene fragment yielded by differential display method or subtraction method, the information on the full-length nucleotide sequence of interest can be gained from the sequence of the partial fragment as a starting clue.
The sequence information of the full-length cDNAs constituting the database of the present invention contains not only the information on the complete sequences but also extra information on expression frequency of the genes as well as homology of the genes to known genes and known polypeptides. Thus the extra information facilitates rapid functional analyses of partial gene fragments. Further, the information on human genes is accumulated in the database of the present invention, and therefore, the database is useful for isolating a human homologue of a gene originating from other species. The human homologue can be isolated based on the nucleotide sequence of the gene from the original species.
At present, information on a wide variety of gene fragments can be obtained by differential display method and subtraction method. In general, these gene fragments are utilized as tools for isolating the full-length sequences thereof. When the gene fragment corresponds to an already-known gene, the full-length sequence is easily obtained by comparing the partial sequence with the information in known databases. However, when there exists no information corresponding to the partial sequence of interest in the known databases, cDNA cloning should be carried out for the full-length cDNA. It is often difficult to obtain the full-length nucleotide sequence using the partial sequence information as an initial clue. If the full-length of the gene is not available, the amino acid sequence of the polypeptide encoded by the gene remains unidentified. Thus the database of the present invention can contribute to the identification of full-length cDNAs corresponding to gene fragments, which cannot be revealed by using databases of known genes.
The present invention has provided 1970 polynucleotides. As has not yet proceeded the isolation of full-length cDNA within the human, the invention has great significance. It is known that secretory proteins, membrane proteins, signal transduction-related proteins, glycoprotein-related proteins, transcription-related proteins, and so on are involved in many diseases. The genes and proteins involved in diseases are useful for developing a diagnostic marker or medicines for regulation of their expression and activity, or as a target of gene therapy.
In particular, cDNA assumed to encode secretory proteins, which were provided by this invention, are very important for the industry since the encoded proteins themselves are expected to be useful as pharmaceutical agents and many disease-related genes may be included in them. In addition, membrane proteins, signal transduction-related proteins, transcription-related proteins, disease-related proteins, and genes encoding them can be used as indicators for diseases, etc. These cDNA are also very important for the industry, which are expected to regulate the activity or expression of the encoded protein to treat diseases, etc.
Any patents, patent applications, and publications cited herein are incorporated by reference.
The invention is illustrated more specifically with reference to the following examples, but is not to be construed as being limited thereto.
EXAMPLE 1 Preparation of cDNA Library by Oligo-Capping(1) Extraction and Purchase of mRNA
Total RNAs as mRNA sources were extracted from human tissues (shown below) by the method as described in the reference (J. Sambrook, E. F. Fritsch & T. Maniatis, Molecular Cloning Second edition, Cold Spring harbor Laboratory Press, 1989). Further, by the method as described in the reference (J. Sambrook, E. F. Fritsch & T. Maniatis, Molecular Cloning Second edition, Cold Spring harbor Laboratory Press, 1989), total RNAs as mRNA sources were extracted from human culture cells and human primary culture cells (shown below) which had been cultivated by the methods described in the catalogs.
The library names and the origins are indicated below in the order of “Library name: Origin”. When a library was prepared by the subtraction method, the item is followed by a description of how to prepare the subtracted library.
<Extraction of mRNA from Human Tissues>
- NTONG: Normal tongue;
- CTONG: Tongue cancer;
- FCBBF: Fetal brain;
- OCBBF: Fetal brain;
- PLACE: Placenta;
- SYNOV: Synovial membrane tissue (from rheumatioid arthritis).
<Extraction of mRNA from Culture Cells> - BNGH4: H4 cells (ATCC #HTB-148);
- IMR32: IMR32 cells (ATCC #CCL-127);
- SKNMC: SK-N-MC cells (ATCC #HTB-10);
- 3NB69: NB69 cells (RCB #RCB0480);
- BGGI1: GI1 cells (RCB #RCB0763);
- NB9N4: NB9 cells (RCB #RCB0477);
- SKNSH: SK-N-SH cells (RCB #RCB0426);
- NT2RM: NT2 cells (STARATAGENE #204101);
- NT2RP: NT2 cells treated with retinoic acid (RA) for 5 weeks to induce the differentiation;
- NT2R1: NT2 cells treated with RA for 5 weeks to induce the differentiation, followed by the treatment with the growth inhibitor for 2 weeks;
- NT2NE: NT2 cells were treated with RA and the growth inhibitor for the neuronal differentiation, and the resultant neurons were concentrated and harvested (NT2 Neuron);
- NTISM: NT2 cells (STARATAGENE #204101) were treated with RA for 5 weeks to induce the differentiation, and then treated with the growth inhibitor for 2 weeks; mRNA was prepared from the cells and a cDNA library was constructed from the mRNA; the cDNAs of the library whose nucleotide sequences were shared by those of mRNAs from undifferentiated NT2 cells were subtracted by using a Subtract Kit (Invitrogen #K4320-01); the subtracted library (NT2R1-NT2RM) was provided by this procedure.
RCB indicates that the cell was provided by the Cell Bank, RIKEN GENE BANK, The Institute of Physical and Chemical Research; ATCC indicates that the cell was provided by American Type Culture Collection.
<Extraction of mRNA from Primary Culture Cells>
- ASTRO: Normal human astrocyte NHA5732, Takara Shuzo #CC2565;
- DFNES: Normal human dermal fibroblast (neonatal skin); NHDF-Neo NHDF2564, Takara Shuzo #CC2509;
- MESAN: Normal human mesangial cell NHMC56046-2, Takara Shuzo #CC2559;
- NHNPC: Normal human neural progenitor cell NHNP5958, Takara Shuzo #CC2599;
- PEBLM: Normal human peripheral blood mononuclear cell HPBMC5939, Takara Shuzo #CC2702;
- HSYRA: Human synoviocyte HS-RA (from rheumatioid arthritis), Toyobo #T404K-05;
- PUAEN: Normal human pulmonary artery endothelial cells, Toyobo #T302K-05;
- UMVEN: Normal human umbilical vein endothelial cell HUVEC, Toyobo #T200K-05;
- HCASM: Normal human coronary artery smooth muscle cell HCASMC, Toyobo #T305K-05;
- HCHON: Normal human chondrocyte HC, Toyobo #T402K-05;
- HHDPC: Normal human dermal papilla cell HDPC, Toyobo #THPCK-001;
- CD34C: CD34+ cells (AllCells, LLC #CB14435M);
- D30ST: CD34+ cells treated with the osteoclast differentiation factor (ODF) for 3 days to induce the differentiation;
- D60ST: CD34+ cells treated with ODF for 6 days to induce the differentiation;
- D90ST: CD34+ cells treated with ODF for 9 days to induce the differentiation.
Then, total RNAs extracted from the following human tissues were purchased and used as mRNA sources. The library names and the origins are indicated below in the order of “Library name: Origin”. When a library was prepared by the subtraction method, the item is followed by a description of how to prepare the subtracted library.
<Purchase of Total RNA Containing mRNA Extracted from Human Tissues>
- ADRGL: Adrenal gland, CLONTECH #64016-1;
- BRACE: Brain (cerebellum), CLONTECH #64035-1;
- BRAWH: Whole brain, CLONTECH #64020-1;
- FEBRA: Fetal brain, CLONTECH #64019-1;
- FELIV: Fetal liver, CLONTECH #64018-1;
- HEART: Heart, CLONTECH #64025-1;
- HLUNG: Lung, CLONTECH #64023-1;
- KIDNE: Kidney, CLONTECH #64030-1;
- LIVER: Liver, CLONTECH #64022-1;
- MAMGL: Mammary Gland, CLONTECH #64037-1;
- PANCR: Pancreas, CLONTECH #64031-1;
- PROST: Prostate, CLONTECH #64038-1;
- SALGL: Salivary Gland, CLONTECH #64026-1;
- SKMUS: Skeletal Muscle, CLONTECH #64033-1;
- SMINT: Small Intestine, CLONTECH #64039-1;
- SPLEN: Spleen, CLONTECH #64034-1;
- STOMA: Stomach, CLONTECH #64090-1;
- TBAES: Breast (Tumor), CLONTECH #64015-1;
- TCERX: Cervix (Tumor), CLONTECH #64010-1;
- TCOLN: Colon (Tumor), CLONTECH #64014-1;
- TESTI: Testis, CLONTECH #64027-1;
- THYMU: Thymus, CLONTECH #64028-1;
- TLUNG: Lung (Tumor), CLONTECH #64013-1;
- TOVAR: Ovary (Tumor), CLONTECH #64011-1;
- TRACH: Trachea, CLONTECH #64091-1;
- TUTER: Uterus (Tumor), CLONTECH #64008-1;
- UTERU: Uterus, CLONTECH #64029-1;
- ADIPS: Adipose, Invitrogen #D6005-01;
- BLADE: Bladder, Invitrogen #D6020-01;
- BRALZ: Cerebral cortex from an Alzheimer patient (Brain, cortex, Alzheimer), Invitrogen #D6830-01;
- CERVX: Cervix, Invitrogen #D6047-01;
- COLON: Colon, Invitrogen #D6050-0;
- NESOP: Esophagus, Invitrogen #D6060-01;
- PERIC: Pericardium, Invitrogen #D6105-01;
- RECTM: Rectum, Invitrogen #D6110-01;
- TESOP: Esophageal (Tumor), Invitrogen #D6860-01;
- TKIDN: Kidney (Tumor), Invitrogen #D6870-01;
- TLIVE: Liver (Tumor), Invitrogen #D6880-01;
- TSTOM: Stomach (Tumor), Invitrogen #D6920-01;
- BEAST: Adult breast, STARATAGENE #735044;
- FEHRT: Fetal heart, STARATAGENE #738012;
- FEKID: Fetal kidney, STARATAGENE #738014;
- FELNG: Fetal lung, STARATAGENE #738020;
- NOVAR: Adult ovary, STARATAGENE #735260;
- BRASW: subtracted library (BRALZ-BRAWH). A cDNA library was constructed from mRNA prepared from tissues of cerebral cortex obtained from an Alzheimer patient [BRALZ: Cerebral cortex from an Alzheimer patient (Brain, cortex, Alzheimer), Invitrogen #D6830-01]; the cDNAs of this library whose nucleotide sequences were shared by those of mRNAs from whole brain tissue [BRAWH: Whole brain, CLONTECH #64020-1] were subtracted by using a Subtract Kit (Invitrogen #K4320-01).
Further, mRNAs extracted and purified as poly A(+) RNAs from the human tissues shown below were purchased. A cDNA library was prepared from an RNA mixture in which the poly A(+) RNA from each tissue had been combined with poly A(−) RNA. The poly A(−) RNA was prepared by removing poly A(+) RNA from the total RNA of whole brain tissue (CLONTECH #64020-1) by using oligo dT cellulose. The library names and the origins are indicated below in the order of “Library name: Origin”.
<Purchase of mRNAs of Human Tissues as Poly A(+) RNAs>
- BRAMY: Brain (amygdala), CLONTECH #6574-1;
- BRCAN: Brain (caudate nucleus), CLONTECH #6575-1;
- BRCOC: Brain (corpus callosum), CLONTECH #6577-1;
- BRHIP: Brain (hippocampus), CLONTECH #6578-1;
- BRSSN: Brain (substantia nigra), CLONTECH #6580-1;
- BRSTN: Brain (subthalamic nucleus), CLONTECH #6581-1;
- BRTHA: Brain (thalamus), CLONTECH #6582-1.
(2) Preparation of cDNA Library
cDNA library was prepared from each RNA by the improved method (WO 01/04286) of oligo capping [M. Maruyama and S. Sugano, Gene, 138: 171-174 (1994)]. A series of procedures, BAP (Bacterial Alkaline Phosphatase) treatment, TAP (Tobacco Acid Pyrophosphatase) treatment, RNA ligation, first strand cDNA synthesis and RNA removal, were carried out using the oligo-cap linker (SEQ ID NO: 4093) and oligo dT primer (SEQ ID NO: 4094), as described in WO 01/04286. Then, the single-stranded cDNA was converted to a double-stranded cDNA by PCR (polymerase chain reaction) using 5′ (SEQ ID NO: 4095) and 3′ (SEQ ID NO: 4096) PCR primers, and then digested with SfiI. Then, a fraction of cDNA fragments, typically 2-kb or longer (3-kb or longer in some cases), was unidirectionally cloned into a DraIII-digested pME18SFL3 vector (
The names of cDNA libraries, which were used in the analysis of full-length cDNA sequences, and their origins are shown in Table 2.
The cDNA library with the high fullness ratio (the fullness ratio of 5′-end, which was calculated for each cDNA library by using the protein coding region found in known mRNA species as an index, was 90% in average) prepared by the improved oligo-capping method was constructed by using a eukaryotic expression vector pME18SFL3. The vector contains SRα promoter and SV40 small t intron in the upstream of the cloning site, and SV40 polyA added signal sequence site in the downstream. As the cloning site of pME18SFL3 has asymmetrical DraIII sites, and the ends of cDNA fragments contain SfiI sites complementary to the DraIII sites, the cloned cDNA fragments can be inserted into the downstream of the SRα promoter unidirectionally. Therefore, clones containing full-length cDNA can be expressed transiently by introducing the obtained plasmid directly into COS cells, etc. Thus, the clones can be analyzed very easily in terms of the proteins that are the gene products of the clones, or in terms of the biological activities of the proteins.
(3) Assessment of the 5′-end Completeness of Clones Derived from the cDNA Library Prepared by Oligo-Capping
With respect to the plasmid DNAs of clones derived from the libraries, the nucleotide sequences of cDNA 5′-ends (3′-ends as well in some cases) were determined in a DNA sequencer (ABI PRISM 3700, PE Biosystems), after sequencing reaction was conducted by using a DNA sequencing reagent (BigDye Terminator Cycle Sequencing FS Ready Reaction Kit, PE Biosystems) according to the manual. A database was constructed based on the obtained data.
The 5′-end completeness of about 770,000 clones derived from the human cDNA libraries prepared by the improved oligo-capping method was determined by the following method. The clones whose 5′-end sequences were consistent with those of known human mRNA in the public database were judged to be “full-length” if they had a longer 5′-end sequence than that of the known human mRNA; or even though the 5′-end sequence was shorter, if it contained the translation initiation codon it was judged to have the “full-length” sequence. Clones which did not contain the translation initiation codon were judged to be “not-full-length”. The fullness ratio ((the number of full-length clones)/(the number of full-length and not-full-length clones)) at the 5′-end of the cDNA clones was determined by comparing with known human mRNA. As a result, the fullness ratio of the 5′-ends was 90%. The result indicates that the fullness ratio at the 5′-end sequence was extremely high in the human cDNA clones obtained by the oligo-capping method.
EXAMPLE 2 Sequencing Analysis of cDNA Ends and Selection of Full-Length ClonesWith respect to the plasmid DNAs of clones obtained from each cDNA library, the 5′-end nucleotide sequences of the cDNAs were determined in a DNA sequencer (ABI PRISM 3700, PE Biosystems), after sequencing reaction was conducted by using a DNA sequencing reagent (Dye Terminator Cycle Sequencing FS Ready Reaction Kit, dRhodamine Terminator Cycle Sequencing FS Ready Reaction Kit or BigDye Terminator Cycle Sequencing FS Ready Reaction Kit, PE Biosystems) according to the manual. A database was constructed using the data obtained.
For the analyzed 5′-end sequences of cDNA clones, the data with the annotation of “complete cds” in the GenBank and UniGene were searched by BLAST homology search. When identical to certain human mRNA sequences, such cDNA clones were excluded. Then, clustering was carried out. When the identity was 90% or higher, and the length of consensus sequence was 50 base pairs or longer, the cDNA clones were assumed to belong to an identical cluster, and thus clustered. cDNA clones longer in the 5′ direction were selected from the members belonging to a cluster; if required, the 31-end sequences of the selected clones were determined by the same analysis method as used to determine the 5′-end sequences. The data of the end sequences obtained were analyzed, and then the clones forming a sequence contig at 5′- and 3′-ends were excluded. Further, as mentioned above, the data was analyzed again by BLAST homology search; when identical to certain human mRNA sequences (including sequences patented and applied for), the cDNA clones were excluded. Thus, the cDNAs clones to be analyzed for their nucleotide sequence were obtained.
EXAMPLE 3 Analysis of the Full-Length Nucleotide SequencesThe full-length nucleotide sequences of the selected clones were determined. The nucleotide sequence determination was mainly performed by primer walking method comprising the dideoxy terminator method using custom-made synthetic DNA primers. Namely, the nucleotide sequences of the DNAs were determined in a sequencer from PE Biosystems, after sequencing reaction was carried out with a DNA sequencing reagent from the same supplier using the custom-made synthetic DNA primers according to the manual. A part of the clones were analyzed with a DNA sequencer from Licor.
Further, the nucleotide sequences of a part of the clones were determined by the shotgun method where the plasmids containing the cDNAs were digested at random were used, instead of the use of custom-made primers, by the same method in the DNA sequencer. The full-length nucleotide sequences were finally determined by completely assembling the partial nucleotide sequences obtained by the above method.
Then, the regions translatable to proteins were deduced from the determined full-length nucleotide sequences, and thereby the amino acid sequences were determined. SEQ ID NOs corresponding to the respective sequences are shown in Table 1.
EXAMPLE 4 Functional Prediction by Homology SearchFor the determined nucleotide sequences, GenBank, SwissProt, UniGene, and nr were searched by BLAST. The clones exhibiting higher homology, which were convenient to predict their functions based on the nucleotide sequences and deduced amino acid sequences, were selected based on the BLAST search hit data whose P value or E value was 10−4 or lower and for which the length of consensus sequence×homology=30 or higher in the amino acid database search. Further, from them, representative clones were selected, which are shown as Homology Search Result Data in the last part herein. Accordingly, the data shown herein are merely the representative data, and the molecule exhibiting homology to each clone is not limited thereto. Further, with respect to a part of clones, the BLAST search hit data that did not meet the criteria as described above are not shown herein.
EXAMPLE 5 Search for Signal Sequence, Transmembrane Domain and Other Functional Domains in the Deduced Amino Acid SequencesWith respect to the amino acid sequences deduced from the full-length nucleotide sequences, the prediction was made for the presence of signal sequence at the amino terminus, the presence of transmembrane domain, and the presence of functional protein domains (motifs). The signal sequence at the amino terminus was searched for by PSORT [K. Nakai & M. Kanehisa, Genomics, 14: 897-911 (1992)]; the transmembrane domain, by SOSUI [T. Hirokawa et al., Bioinformatics, 14: 378-379 (1998)] (Mitsui Knowledge Industry); the function domain, by Pfam (http://www.sanger.ac.uk/Software/Pfam/index.shtml). The amino acid sequence in which the signal sequence at the amino terminus or transmembrane domain had been predicted to be present by PSORT or SOSUI were assumed to be a secretory or membrane protein. Further, when the amino acid sequence hit a certain functional domain by the Pfam functional domain search, the protein function can be predicted based on the hit data, for example, by referring to the function categories on the PROSITE (http://www.expasy.ch/cgi-bin/prosite-list.pl). In addition, the functional domain search can also be carried out on the PROSITE.
The search results obtained with the respective programs are shown below.
The clones whose deduced amino acid sequences were detected to have the signal sequences by PSORT are as follows.
The clones whose deduced amino acid sequences were detected to have the transmembrane domains by SOSUI are as follows. Numerals indicate the numbers of transmembrane domains detected in the deduced amino acid sequences. Of the search result, the clone name and the number of transmembrane domains are demarcated by a double slash mark (//).
The Names of clones whose deduced amino acid sequences were detected to have functional domains with Pfam, and the name of hit functional domains are as follows. The search result is indicated as “clone name//functional domain name”. When the clone has multiple hit functional domains, they are listed and demarcated by a double slash mark (//). When the clone has multiple hits of an identical functional domain, each is listed without abridgment.
- ADRGL20020290//Sodium:galactoside symporter family//Nucleoside transporter
- ADRGL20021910//Immunoglobulin domain
- ADRGL20026790//PWWP domain
- ADRGL20036840//Class I Histocompatibility antigen, domains alpha 1 and 2
- ADRGL20047770//ATP synthase (F/14-kDa) subunit
- ADRGL20059610//O-Glycosyl hydrolase family 30
- ADRGL20062330//Spectrin repeat//Spectrin repeat//Bacterial flagellin N-terminus//Spectrin repeat//Spectrin repeat//Spectrin repeat
- ADRGL20066770//Collagen triple helix repeat (20 copies)//C1q domain
- ADRGL20079060//Transglutaminase-like superfamily
- ASTRO20006530//Intermediate filament proteins//Myc leucine zipper domain
- ASTRO20010010//Photosynthetic reaction center protein
- ASTRO20010290//PHD-finger
- ASTRO20026320//Viral (Superfamily 1) RNA helicase//Heavy-metal-associated domain//Viral (Superfamily 1) RNA helicase
- ASTRO20038400//Homeobox domain//Common central domain of tyrosinase//Rhabdovirus nucleocapsid protein//Homeobox domain//Homeobox domain//Homeobox domain
- ASTRO20046280//MutT-like domain
- ASTRO20050810//FGGY family of carbohydrate kinases//FGGY family of carbohydrate kinases
- ASTRO20052420//RhoGEF domain//PH domain//SH3 domain
- ASTRO20053430//FERM domain (Band 4.1 family)//FERM domain (Band 4.1 family)//Delta-aminolevulinic acid dehydratase//Lipoprotein amino terminal region
- ASTRO20055570//Prion protein
- ASTRO20055930//Aldehyde oxidase and xanthine dehydrogenase, C terminus//Zinc finger, C3HC4 type (RING finger)
- ASTRO20085080//WD domain, G-beta repeat//Fibrillarin//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat
- ASTRO20088950//Glycosyl hydrolase family 1
- BGGI120010750//Phosphoglucose isomerase//Ribosomal protein L7Ae
- BNGH420015760//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat
- BNGH420024870//C2 domain//C2 domain//C2 domain
- BNGH420035290//Zinc finger, C3HC4 type (RING finger)//TRAF-type zinc finger//Hr1 repeat motif//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat
- BNGH420036410//Arsenical pump membrane protein
- BNGH420046790//Immunoglobulin domain
- BNGH420052350//Urotensin II
- BNGH420059680//NHL repeat//NHL repeat//NHL repeat//NHL repeat
- BNGH420070370//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- BNGH420074600//RNA polymerase beta subunit
- BNGH420077980//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain
- BNGH420086030//PH domain//RhoGAP domain
- BRACE20003310//KRAB box//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- BRACE20007330//BTB/POZ domain//Kelch motif//Kelch motif//Kelch motif//Kelch motif//Kelch motif//Kelch motif
- BRACE20014450//alpha/beta hydrolase fold
- BRACE20050870//DEAD/DEAH box helicase
- BRACE20051600//Reverse transcriptase (RNA-dependent DNA polymerase)
- BRACE20051930//MAM domain.
- BRACE20054600//von Willebrand factor type D domain
- BRACE20055560//WD domain, G-beta repeat//WD domain, G-beta repeat
- BRACE20059810//TSC-22/dip/bun family
- BRACE20061620//SPRY domain
- BRACE20065470//Ubiquitin family
- BRACE20069000//CLN3 protein
- BRACE20079200//von Willebrand factor type D domain
- BRACE20099070//FYVE zinc finger
- BRACE20196180//HMG (high mobility group) box
- BRACE20204670//Protein-tyrosine phosphatase//Dual specificity phosphatase, catalytic domain//Fatty acid desaturase//Protein-tyrosine phosphatase
- BRACE20215410//Imidazoleglycerol-phosphate dehydratase//UvrD/REP helicase
- BRAMY20001510//Zinc finger, C3HC4 type (RING finger)//PHD-finger
- BRAMY20003540//PH domain//EF hand//EF hand//Viral RNA dependent RNA polymerase//Phosphatidylinositol-specific phospholipase C, X domain//Phosphatidylinositol-specific phospholipase C, Y domain//Bleomycin resistance protein//C2 domain
- BRAMY20005080//Ubiquitin carboxyl-terminal hydrolase family 2
- BRAMY20013670//S-adenosylmethionine synthetase
- BRAMY20016780//Proprotein convertase P-domain
- BRAMY20023640//UBX domain
- BRAMY20027990//C2 domain
- BRAMY20028620//Quinolinate phosphoribosyl transferase
- BRAMY20035380//Cation efflux family
- BRAMY20035830//BTB/POZ domain//Thymidylate synthase
- BRAMY20038980//Granulocyte-macrophage colony-stimulating factor//Borrelia outer surface protein E and F
- BRAMY20040580//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- BRAMY20043630//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat
- BRAMY20044920//Ubiquitin carboxyl-terminal hydrolase family 2
- BRAMY20045420//Domain found in Dishevelled, Egl-10, and Pleckstrin
- BRAMY20051820//C2 domain
- BRAMY20056620//Carboxyl transferase domain
- BRAMY20056840//PWWP domain
- BRAMY20076100//Ligand-binding domain of nuclear hormone receptor
- BRAMY20089770//ATP P2X receptor
- BRAMY20091230//Mitochondrial carrier proteins//Mitochondrial carrier proteins
- BRAMY20094890//SURF4 family
- BRAMY20102900//Ephrin
- BRAMY20111780//Zinc finger, C2H2 type//Transcription factor S-II (TFIIS)//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C3HC4 type (RING finger)//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- BRAMY20117670//DnaJ central domain (4 repeats)//DnaJ C terminal region
- BRAMY20118410//Phospholipase D. Active site motif
- BRAMY20118490//FGGY family of carbohydrate kinases
- BRAMY20125360//Asparaginase
- BRAMY20134050//Nucleosome assembly protein (NAP)
- BRAMY20143870//Peptidyl-tRNA hydrolase
- BRAMY20152510//Protein-tyrosine phosphatase//Dual specificity phosphatase, catalytic domain
- BRAMY20158550//EF hand//EF hand
- BRAMY20206340//WD domain, G-beta repeat//Dockerin domain type I//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat
- BRAMY20227860//Insulin-like growth factor binding proteins//Spectrin repeat
- BRAMY20234820//Ribosomal L25p family
- BRAMY20238630//TPR Domain//TPR Domain//TPR Domain
- BRAMY20244490//Adenylate kinase
- BRAMY20245140//Cyclic nucleotide-binding domain
- BRAMY20251210//Ephrin receptor ligand binding domain//EB module
- BRAMY20263000//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat
- BRAMY20274510//Ribosomal protein L11
- BRAWH20014590//RNA recognition motif. (a.k.a. RRM, RBD, or RNP domain)
- BRAWH20021910//Carboxylesterases
- BRAWH20026010//Hepatitis C virus RNA dependent RNA polymerase
- BRAWH20039640//Leucine rich repeat N-terminal domain//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine rich repeat C-terminal domain//Leucine rich repeat N-terminal domain//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine rich repeat C-terminal domain
- BRAWH20040680//Zinc finger, C3HC4 type (RING finger)//DENN (AEX-3) domain
- BRAWH20047790//HMG (high mobility group) box
- BRAWH20050740//BTB/POZ domain
- BRAWH20080580//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//DnaJ central domain (4 repeats)//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- BRAWH20093040//Eukaryotic protein kinase domain
- BRAWH20094900//BNR repeat//BNR repeat//BNR repeat
- BRAWH20095900//KRAB box//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Transcription factor S-II (TFIIS)//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//PHD-finger//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- BRAWH20183170//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat
- BRAWH20185260//Troponin//Serine hydroxymethyltransferase
- BRAWH20185270//Uncharacterized protein family UPF0057
- BRAWH20188750//Glypican//ubiE/COQ5 methyltransferase family
- BRAWH20191980//Proline dehydrogenase
- BRCAN1001050//Cell division protein
- BRCAN20005410//Zinc finger, C4 type (two domains)//Zinc finger, C2HC type//SAM domain (Sterile alpha motif)//Sterile alpha motif (SAM)/Pointed domain
- BRCOC20000470//TPR Domain//TPR Domain
- BRSSN20005610//PDZ domain (Also known as DHR or GLGF).
- BRSSN20005660//Bacterial type II secretion system protein
- BRSSN20066440//SCAN domain//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- BRSSN20074640//Peptidase family M48
- BRSSN20093890//Kelch motif//Kelch motif
- CD34C20001750//Immunoglobulin domain//Immunoglobulin domain
- CTONG20004110//Ank repeat//Ank repeat//Ank repeat//Ank repeat//Ank repeat//Tropomyosins//Transient receptor//Apolipoprotein A1/A4/E family//MutS family, N-terminal putative DNA binding domain//K-box region//Outer membrane efflux protein
- CTONG20004520//SH3 domain
- CTONG20007660//Caspase recruitment domain//DNA polymerase (viral) N-terminal domain//bZIP transcription factor//K-box region
- CTONG20008190//ADP-ribosylation factor family//Ras family
- CTONG20017490//Sema domain//Sema domain//Integrins, beta chain//Plexin repeat
- CTONG20020950//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- CTONG20029030//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat
- CTONG20030280//WD domain, G-beta repeat//Gram-negative pili assembly chaperone//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat
- CTONG20032930//Armadillo/beta-catenin-like repeats
- CTONG20033610//RyR domain
- CTONG20033750//FtsK/SpoIIIE family//ATPases associated with various cellular activities (AAA)
- CTONG20036990//Immunoglobulin domain//Immunoglobulin domain
- CTONG20044230//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- CTONG20044870//PH domain//PH domain
- CTONG20045500//Translation initiation factor IF-3//HCO3-transporter family//HCO3-transporter family//Domain of unknown function DUF139
- CTONG20046690//Src homology domain 2
- CTONG20049480//bZIP transcription factor//Carbamoyl-phosphate synthase (CPSase)//tRNA synthetases class I (C)
- CTONG20060040//NusB family
- CTONG20063770//KE2 family protein//Spectrin repeat
- CTONG20063930//SH3 domain//WW domain//WW domain//PH domain//RhoGAP domain
- CTONG20066110//TPR Domain//TPR Domain
- CTONG20068360//Mitochondrial carrier proteins//Mitochondrial carrier proteins
- CTONG20069420//Ribosomal protein S14p/S29e
- CTONG20070090//Bacterial luciferase
- CTONG20070720//PH domain//RhoGAP domain//bZIP transcription factor
- CTONG20070910//PCI domain
- CTONG20071040//Beta/Gamma crystallin//Beta/Gamma crystallin//Beta/Gamma crystallin//Beta/Gamma crystallin//Similarity to lectin domain of ricin beta-chain, 3 copies.
- CTONG20071680//3′-5′ exonuclease//Cytochrome c oxidase subunit III//Ammonium Transporter Family//7 transmembrane receptor (Secretin family)
- CTONG20072930//KRAB box//Ribosomal protein L20//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Transcription factor S-II (TFIIS)//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Putative zinc finger in N-recognin//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- CTONG20074000//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- CTONG20074170//DENN (AEX-3) domain
- CTONG20076810//Ribosomal protein L16//Pheromone A receptor
- CTONG20079590//Sialyltransferase family
- CTONG20083430//Nuclear transition protein 2
- CTONG20083980//WH1 domain
- CTONG20084660//SCAN domain
- CTONG20085210//Lipase (class 3)
- CTONG20165750//G-patch domain//Double-stranded RNA binding motif
- CTONG20169040//bZIP transcription factor//Adenylate cyclase//Intermediate filament proteins
- CTONG20170940//Ank repeat//Ank repeat//Ank repeat//SAM domain (Sterile alpha motif)
- CTONG20174580//TBC domain
- CTONG20176040//ADP-ribosylation factor family//Ras family
- CTONG20180690//Collagen triple helix repeat (20 copies)
- CTONG20183430//Ank repeat//Ank repeat//Ank repeat//Ank repeat//Ank repeat//Ank repeat//Ank repeat//Ank repeat//Zinc finger, C3HC4 type (RING finger)//Zinc finger, C3HC4 type (RING finger)//Zinc finger, C3HC4 type (RING finger)
- CTONG20184830//ABC transporter
- CTONG20186290//Aldehyde dehydrogenase family
- CTONG20186370//KRAB box//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- CTONG20186520//KRAB box//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Transcription factor S-II (TFIIS)//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- CTONG20186550//BTB/POZ domain//K+ channel tetramerisation domain
- CTONG20188080//TPR Domain
- CTONG20189000//RhoGEF domain
- CTONG20190290//R3H domain//RNA dependent RNA polymerase//Uncharacterized protein family UPF0024
- DFNES20025500//Sigma-54 interaction domain//ATPases associated with various cellular activities (AAA)
- DFNES20043710//Src homology domain 2//Domain of unknown function DUF36
- DFNES20055400//Viral coat protein//Putative diphthamide synthesis protein//Influenza non-structural protein (NS1)
- DFNES20057660//Plant thionins//Mitochondrial carrier proteins//Mitochondrial carrier proteins
- DFNES20072990//Integral membrane protein DUF6//Integral membrane protein DUF6
- DFNES20073320//Zinc finger, C3HC4 type (RING finger)//PHD-finger//B-box zinc finger.
- DFNES20076340//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- DFNES20080880//Glycosyl transferases//Similarity to lectin domain of ricin beta-chain, 3 copies.
- DFNES20094820//PHD-finger//Zn-finger in ubiquitin-hydrolases and other proteins
- FCBBF10000230//Sec7 domain//PH domain
- FCBBF10004760//HMG (high mobility group) box
- FCBBF20018680//C2 domain//C2 domain
- FCBBF20020440//Urease
- FCBBF20023490//Helicases conserved C-terminal domain
- FCBBF20033360//BTB/POZ domain//Kelch motif//Kelch motif//Kelch motif//Kelch motif//Kelch motif
- FCBBF20035430//AN1-like Zinc finger//AN1-like Zinc finger
- FCBBF20035490//KH domain
- FCBBF20041380//SAM domain (Sterile alpha motif)
- FCBBF20043730//UBA domain
- FCBBF20059660//TPR Domain
- FCBBF20066340//PH domain
- FCBBF20070950//DNA binding domain with preference for A/T rich regions
- FCBBF30001100//DENN (AEX-3) domain//PPR repeat
- FCBBF30002270//linker histone H1 and H5 family
- FCBBF30003610//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Plant PEC family metallothionein//DM DNA binding domain//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//PHD-finger//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Phorbol esters/diacylglycerol binding domain (C1 domain)
- FCBBF30004340//Ribosomal protein S3, C-terminal domain.//Similarity to lectin domain of ricin beta-chain, 3 copies.
- FCBBF30005360//Sigma-54 interaction domain//ATPases associated with various cellular activities (AAA)//ATPases associated with various cellular activities (AAA)
- FCBBF30005500//PH domain//PH domain//Putative GTP-ase activating protein for Arf
- FCBBF30019140//‘chromo’ (CHRromatin Organization MOdifier) domain//‘chromo’ (CHRromatin Organization MOdifier) domain//DEAD/DEAH box helicase//SNF2 and others N-terminal domain//Helicases conserved C-terminal domain
- FCBBF30019180//Armadillo/beta-catenin-like repeats//Lipoprotein amino terminal region
- FCBBF30021900//Zinc finger, C2H2 type//Zinc finger, C2H2 type//PHD-finger//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//BolA-like protein//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Snake toxin//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- FCBBF30022680//3′-5′ exonuclease
- FCBBF30029250//SET domain
- FCBBF30035570//C2 domain
- FCBBF30048420//T-box//wnt family of developmental signaling proteins
- FCBBF30071500//Influenza RNA-dependent RNA polymerase subunit PB1//Reprolysin family propeptide//Leptin
- FCBBF30076310//Eukaryotic protein kinase domain//Eukaryotic protein kinase domain//Protein kinase C terminal domain
- FCBBF30079770//D-isomer specific 2-hydroxyacid dehydrogenases
- FCBBF30080730//RNA recognition motif. (a.k.a. RRM, RBD, or RNP domain)//Zinc knuckle
- FCBBF30085560//Pyridine nucleotide-disulphide oxidoreductase//FAD binding domain//Flavin containing amine oxidase//Phytoene dehydrogenase related enzyme
- FCBBF30093170//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- FCBBF30100080//Sec7 domain
- FCBBF30100120//PDZ domain (Also known as DHR or GLGF).
- FCBBF30100410//Nucleosome assembly protein (NAP)
- FCBBF30118670//Reprolysin (M12B) family zinc metalloprotease//Disintegrin//EB module//Hantavirus glycoprotein G2//Adenovirus E3 region protein CR2//jmjN domain
- FCBBF30125460//Zinc finger, C3HC4 type (RING finger)
- FCBBF30129010//KRAB box//Zinc finger, C2H2 type//GATA zinc finger//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Transcription factor S-II (TFIIS)//Zinc finger, C2H2 type
- FCBBF30130410//UvrB/uvrC motif
- FCBBF30132050//Galactosyltransferase//Fringe-like
- FCBBF30132660//Leucine rich repeat N-terminal domain//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat
- FCBBF30136230//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Cystatin domain//Homeobox domain//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- FCBBF30142290//PHD-finger
- FCBBF30143550//Phosphatidylinositol-4-phosphate 5-Kinase
- FCBBF30153170//Phosphofructokinase//Phosphofructokinase//Phosphofructokinase//Phosphofructokinase
- FCBBF30161780//gag gene protein p24 (core nucleocapsid protein)//Zinc knuckle FCBBF30164510//Cadherin domain//Cadherin domain//Cadherin domain//Fructose-bisphosphate aldolase class-I//Cadherin domain//Cadherin domain//Alphaherpesvirus glycoprotein E//Cadherin cytoplasmic region
- FCBBF30166220//Serine hydroxymethyltransferase
- FCBBF30169280//PHD-finger//Zinc finger, C3HC4 type (RING finger)
- FCBBF30171230//Subtilase family//Proprotein convertase P-domain
- FCBBF30173960//Beta-lactamase//TPR Domain
- FCBBF30194550//Arsenical pump membrane protein//Ank repeat//Ank repeat//Ank repeat//Ank repeat//Ank repeat//Dehydrogenase E1 component//Ank repeat//Ank repeat//Ank repeat//Ank repeat//Ank repeat//Ank repeat//Ank repeat
- FCBBF30195690//C2 domain
- FCBBF30197840//Sushi domain (SCR repeat)//CUB domain//Sushi domain (SCR repeat)//CUB domain//Sushi domain (SCR repeat)//Sushi domain (SCR repeat)//Sushi domain (SCR repeat)
- FCBBF30212210//Immunoglobulin domain
- FCBBF30215240//PH domain//FERM domain (Band 4.1 family)
- FCBBF30220050//Ligand-binding domain of nuclear hormone receptor
- FCBBF30222910//Corticotropin-releasing factor family
- FCBBF30236670//DEAD/DEAH box helicase
- FCBBF30250980//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat
- FCBBF30255680//Vesicular monoamine transporter//GGL domain//Ezrin/radixin/moesin family//Ank repeat//Ank repeat
- FCBBF30257370//Geminivirus AL1 protein//Outer membrane efflux protein
- FCBBF30259050//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger present in dystrophin, CBP/p300//Zinc finger, C2H2 type//PHD-finger//Zinc finger, C2H2 type//Zinc finger, C2H2 type//DM DNA binding domain//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Transcription factor S-II (TFIIS)//Zinc finger, C2H2 type//TRAF-type zinc finger//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- FCBBF30260210//SNF2 and others N-terminal domain//Helicases conserved C-terminal domain//Domain of unknown function DUF94
- FCBBF30263080//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- FCBBF30266510//Domain of unknown function DUF71
- FCBBF30271990//Ank repeat//Ank repeat//Ank repeat//Ank repeat//Ank repeat//Ank repeat//Ank repeat//Ank repeat//Ank repeat//Ank repeat//Ank repeat//Ank repeat
- FCBBF30275590//LIM domain containing proteins
- FCBBF30282020//Ank repeat//Ank repeat//Ank repeat//K+ channel tetramerisation domain//BTB/POZ domain
- FCBBF30285930//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- FCBBF50001650//MORN motif//MORN motif//MORN motif//MORN motif//MORN motif//MORN motif//MORN motif//MORN motif
- FCBBF50003530//Zinc finger, C3HC4 type (RING finger)
- FCBBF50004950//Putative replicase 1 (ORF2)
- FEBRA20005040//Intermediate filament proteins//Hr1 repeat motif//Troponin//GrpE
- FEBRA20007820//DNA polymerase family B
- FEBRA20018670//Viral methyltransferase//Ribosomal protein S19//Alpha-2-macroglobulin family N-terminal region
- FEBRA20026820//KRAB box//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Putative zinc finger in N-recognin//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- FEBRA20027070//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Transcription factor S-II (TFIIS)//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//TRAF-type zinc finger//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- FEBRA20029620//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat
- FEBRA20031000//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Insulin/IGF/Relaxin family//Ribosomal RNA adenine dimethylases//SAM domain (Sterile alpha motif)//TFIIE alpha subunit//Zinc finger, C3HC4 type (RING finger)
- FEBRA20031280//Protein of unknown function DUF82
- FEBRA20038330//Corticotropin-releasing factor family
- FEBRA20038970//Laminin EGF-like (Domains III and V)//Phorbol esters/diacylglycerol binding domain (C1 domain)//EGF-like domain//EGF-like domain//Trypsin Inhibitor like cysteine rich domain//Metallothionein//EGF-like domain//EGF-like domain//Extracellular link domain
- FEBRA20046200//Ank repeat//Ank repeat//Ank repeat//Ank repeat//Ank repeat//Ank repeat//Ank repeat
- FEBRA20046510//Zinc finger, C2H2 type//Zinc finger, C2H2 type//BolA-like protein//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- FEBRA20063720//KRAB box//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- FEBRA20078800//NADH ubiquinone oxidoreductase, 20 Kd subunit
- FEBRA20080860//Hantavirus glycoprotein G2
- FEBRA20087550//WD domain, G-beta repeat//WD domain, G-beta repeat
- FEBRA20088610//CRAL/TR10 domain.
- FEBRA20088810//Fibroblast growth factor
- FEBRA20090160//Nuclear transition protein 2
- FEBRA20090220//Nucleotidyl transferase//Bacterial transferase hexapeptide (four repeats)//Bacterial transferase hexapeptide (four repeats)//Bacterial transferase hexapeptide (four repeats)//Domain of unknown function DUF29//Peptide hormone//eIF4-gamma/eIF5/eIF2-epsilon
- FEBRA20092760//LIM domain containing proteins//LIM domain containing proteins//LIM domain containing proteins
- FEBRA20115930//Divalent cation transporter//Translation initiation factor IF-3//Divalent cation transporter
- FEBRA20150420//Transient receptor//Borrelia ORF-A//Transient receptor FEBRA20170240//SCAN domain//KRAB box//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- FEBRA20172230//Phospholipase D. Active site motif//Phospholipase D. Active site motif
- FEBRA20173330//Eukaryotic protein kinase domain
- FEBRA20175330//D-isomer specific 2-hydroxyacid dehydrogenases
- FEBRA20191720//GGL domain//Regulator of G protein signaling domain
- HCHON10000150//LIM domain containing proteins//LIM domain containing proteins//LIM domain containing proteins//Zinc finger, C3HC4 type (RING finger)
- HCHON20000870//Eukaryotic protein kinase domain
- HCHON20002650//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- HCHON20002710//Ubiquitin carboxyl-terminal hydrolase family 2
- HCHON20015050//von Willebrand factor type A domain//IPT/TIG domain//Sm protein
- HEART10001420//MYND finger//SET domain
- HEART10001490//FAD binding domain
- HEART20009590//Peptidase family M41
- HEART20019310//Zinc finger, C3HC4 type (RING finger)//PHD-finger//B-box zinc finger.
- HEART20022200//Influenza Matrix protein (M1)//metallopeptidase family M24
- HEART20047640//3′ 5′-cyclic nucleotide phosphodiesterase//Formin Homology 2 Domain
- HEART20082570//C-5 cytosine-specific DNA methylase//Glycine cleavage T-protein (aminomethyl transferase)
- HHDPC20081230//RNA recognition motif. (a.k.a. RRM, RBD, or RNP domain)//RNA recognition motif. (a.k.a. RRM, RBD, or RNP domain)//RNA recognition motif. (a.k.a. RRM, RBD, or RNP domain)//RNA recognition motif. (a.k.a. RRM, RBD, or RNP domain)
- HHDPC20088160//PDZ domain (Also known as DHR or GLGF).
- HLUNG20008460//bZIP transcription factor
- HLUNG20011260//Eukaryotic protein kinase domain
- HLUNG20011460//RNA recognition motif. (a.k.a. RRM, RBD, or RNP domain)//RNA recognition motif. (a.k.a. RRM, RBD, or RNP domain)
- HLUNG20014590//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Putative zinc finger in N-recognin//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Transcription factor S-II (TFIIS)//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- HLUNG20015070//Leucine rich repeat N-terminal domain//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine rich repeat C-terminal domain//Immunoglobulin domain
- HLUNG20024050//Rubredoxin
- HLUNG20028110//Zinc finger, C3HC4 type (RING finger)//TPR Domain//TPR Domain//TPR Domain//Zinc finger, C3HC4 type (RING finger)//Aldo/keto reductase family
- HLUNG20030420//Ank repeat//Ank repeat//Ank repeat//Ank repeat//Ank repeat
- HLUNG20032460//Prolyl oligopeptidase family//Lipoate-protein ligase B//alpha/beta hydrolase fold
- HLUNG20033060//HMG (high mobility group) box
- HLUNG20041590//TPR Domain//TPR Domain//Domain of unknown function DUF27
- HLUNG20042730//Cytochrome P450
- HLUNG20051330//FHIPEP family
- HLUNG20063700//Progesterone receptor
- HLUNG20065990//bZIP transcription factor//SNAP-25 family//Syntaxin
- HLUNG20068120//Fimbrial Usher proteins
- HLUNG20069350//EF hand//EF hand//EF hand
- HLUNG20070410//Dihydropyridine sensitive L-type calcium channel (Beta subunit)
- HLUNG20081390//DnaJ domain
- HLUNG20082350//PH domain//START domain
- HLUNG20083330//DNA polymerase III beta subunit//Fibrillar collagen C-terminal domain
- HLUNG20084790//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat
- HLUNG20085210//C2 domain
- KIDNE20016360//PAS domain//PAC motif//Ion transport protein//Transmembrane region cyclic Nucleotide Gated Channel//Cyclic nucleotide-binding domain
- KIDNE20027980//SAM domain (Sterile alpha motif)
- KIDNE20080690//Glycosyl hydrolases family 18//Aminotransferases class-III pyridoxal-phosphate//Methyl-accepting chemotaxis protein (MCP) signaling domain//Aminotransferases class-III pyridoxal-phosphate
- KIDNE20081170//Kinesin motor domain//Kinesin motor domain
- KIDNE20083620//Asparaginase
- KIDNE20084030//Sugar (and other) transporter
- KIDNE20084730//Neuraxin and MAP1B proteins//Formin Homology 2 Domain
- KIDNE20086490//gag gene protein p24 (core nucleocapsid protein)
- KIDNE20087880//Reverse transcriptase (RNA-dependent DNA polymerase)
- KIDNE20088240//EF hand//EF hand//EF hand
- KIDNE20089870//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat
- KIDNE20094670//Sigma-54 interaction domain//FtsK/SpoIIIE family//ATPases associated with various cellular activities (AAA)
- KIDNE20133880//G-protein alpha subunit
- KIDNE20141700//Ribosomal family S4e
- KIDNE20142900//EGF-like domain//EB module//EGF-like domain//EGF-like domain
- KIDNE20148080//Zinc finger, C3HC4 type (RING finger)
- KIDNE20149780//Ank repeat//Ank repeat//Ank repeat
- KIDNE20152440//Trypsin//PDZ domain (Also known as DHR or GLGF).
- KIDNE20154330//PDZ domain (Also known as DHR or GLGF).//PDZ domain (Also known as DHR or GLGF).//PDZ domain (Also known as DHR or GLGF).//PDZ domain (Also known as DHR or GLGF).//PDZ domain (Also known as DHR or GLGF).//PDZ domain (Also known as DHR or GLGF).
- KIDNE20160360//Sec7 domain//PH domain
- KIDNE20169180//EGF-like domain//EB module//EGF-like domain//Trypsin Inhibitor like cysteine rich domain//EGF-like domain//TNFR/NGFR cysteine-rich region//Zona pellucida-like domain
- KIDNE20170400//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Protein kinase C terminal domain//Rubredoxin
- KIDNE20173150//Acetyltransferase (GNAT) family
- KIDNE20173430//PDZ domain (Also known as DHR or GLGF).//PDZ domain (Also known as DHR or GLGF).
- KIDNE20186170//UDP-glucoronosyl and UDP-glucosyl transferases
- KIDNE20189960//Trehalase
- LIVER20006260//KRAB box//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Plant PEC family metallothionein//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- LIVER20007750//Sugar (and other) transporter
- LIVER20010760//Lectin C-type domain
- LIVER20010990//DNA gyrase/topoisomerase IV, subunit A
- LIVER20013890//tRNA synthetases class I (C)
- LIVER20026440//Cytochrome P450
- LIVER20030650//General diffusion Gram-negative porins
- LIVER20038000//Mitochondrial carrier proteins//Mitochondrial carrier proteins//Mitochondrial carrier proteins
- LIVER20040740//CRAL/TR10 domain.
- LIVER20055270//AIR synthase related protein
- MESAN20006200//Annexin//Annexin
- MESAN20008150//IBR domain
- MESAN20009090//CUB domain
- MESAN20016270//KRAB box//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- MESAN20021130//SH3 domain//Eukaryotic protein kinase domain
- MESAN20021220//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine rich repeat C-terminal domain//Leucine rich repeat N-terminal domain//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine rich repeat C-terminal domain
- MESAN20026870//PAN domain//TBC domain
- MESAN20027240//RhoGEF domain
- MESAN20027900//von Willebrand factor type A domain//von Willebrand factor type A domain//von Willebrand factor type A domain//Protozoan/cyanobacterial globin//von Willebrand factor type A domain//von Willebrand factor type A domain
- MESAN20030350//LGN motif, putative GEF specific for G-alpha GTPase//DNA gyrase/topoisomerase IV, subunit A
- MESAN20030370//Porphobilinogen deaminase//GHMP kinases putative ATP-binding proteins//Protein of unknown function DUF113
- MESAN20034440//Viral DNA-binding protein//Uncharacterized protein family UPF0024
- MESAN20038520//Caspase recruitment domain//RNA polymerase beta subunit
- MESAN20057240//Elongation factor TS//Helix-hairpin-helix motif.
- MESAN20058110//FKBP-type peptidyl-prolyl cis-trans isomerases//Elongation factor Tu family//FKBP-type peptidyl-prolyl cis-trans isomerases//FKBP-type peptidyl-prolyl cis-trans isomerases
- MESAN20059570//EGF-like domain//SEA domain//Immunoglobulin domain
- MESAN20060430//SET domain
- MESAN20067430//Tropomyosins
- MESAN20069530//Calponin homology (CH) domain//PDZ domain (Also known as DHR or GLGF).
- MESAN20090190//EGF-like domain//EGF-like domain//EGF-like domain//EGF-like domain//EGF-like domain//EGF-like domain//Metallothionein//CUB domain
- MESAN20095220//Adaptin N terminal region
- MESAN20095800//Cyclophilin type peptidyl-prolyl cis-trans isomerase//RNA recognition motif. (a.k.a. RRM, RBD, or RNP domain)
- NT2NE20018890//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat
- NT2NE20026200//Transketolase
- NT2NE20026510//Zinc finger, C3HC4 type (RING finger)
- NT2NE20038870//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Lipoprotein
- NT2NE20042550//Viral (Superfamily 1) RNA helicase//NB-ARC domain//Adenylate kinase//Adenylate kinase
- NT2NE20053950//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- NT2NE20060750//KRAB box//Zinc finger, C2H2 type
- NT2NE20061030//SCAN domain
- NT2NE20077270//Adenovirus EB1 55K protein/large t-antigen
- NT2NE20079670//KRAB box//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Transcription factor S-II (TFIIS)//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- NT2NE20087270//Tudor domain
- NT2NE20092950//Fibronectin type III domain
- NT2NE20108420//Domain of unknown function DUF130//Oxysterol-binding protein
- NT2NE20117580//NADH ubiquinone oxidoreductase, 20 Kd subunit
- NT2NE20127900//Myo-inositol-1-phosphate synthase
- NT2NE20140130//Sema domain
- NT2NE20145250//Stathmin family
- NT2NE20153620//FERM domain (Band 4.1 family)//PH domain
- NT2RI20093010//Tetrahydrofolate dehydrogenase/cyclohydrolase
- NT2RP70001120//Ank repeat//Ank repeat//Ank repeat//Insulinase (Peptidase family M16)
- NT2RP70001730//BTB/POZ domain//Kelch motif//Kelch motif//Kelch motif//Kelch motif//Kelch motif
- NT2RP70003110//Collagen triple helix repeat (20 copies)//Heavy-metal-associated domain
- NT2RP70027790//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat
- NT2RP70029780//KRAB box//Zinc finger, C2H2 type//Zinc finger, C2H2 type//PHD-finger//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Transcription factor S-II (TFIIS)
- NT2RP70030840//Viral (Superfamily 1) RNA helicase
- NT2RP70031070//Nucleoside transporter
- NT2RP70031340//PHD-finger
- NT2RP70046410//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- NT2RP70056690//Thrombospondin type 1 domain//Domain of unknown function DUF18//Thrombospondin type 1 domain//Thrombospondin type 1 domain//Thrombospondin type 1 domain//Thrombospondin type 1 domain//Keratin, high sulfur B2 protein
- NT2RP70057500//KRAB box//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//DnaJ central domain (4 repeats)//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- NT2RP70064570//Calpain family cysteine protease//Calpain large subunit, domain III//EF hand//EF hand
- NT2RP70075300//KRAB box//Domain of unknown function DUF19//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- NT2RP70075800//recA bacterial DNA recombination proteins//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//SH3 domain
- NT2RP70090870//KRAB box//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//DM DNA binding domain//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Transcription factor S-II (TFIIS)//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- NTONG20005310//Ribosomal protein S9/S16
- NTONG20029850//EF hand//EF hand//EF hand
- NTONG20031580//Hsp20/alpha crystallin family
- NTONG20032100//Intermediate filament proteins
- NTONG20034540//GAF domain//GAF domain//3′ 5′-cyclic nucleotide phosphodiesterase
- NTONG20035150//BTB/POZ domain//Kelch motif//Kelch motif//Kelch motif//Kelch motif//Kelch motif
- NTONG20043080//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain
- NTONG20048440//PH domain//K-box region
- NTONG20053630//DNA binding domain with preference for A/T rich regions//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Progesterone receptor//Zinc finger, C2H2 type
- NTONG20053730//Ribosomal protein S2//Ubiquitin carboxyl-terminal hydrolases family 2//Ubiquitin carboxyl-terminal hydrolase family 2
- NTONG20053910//Translin family//PH domain//Putative GTP-ase activating protein for Arf//Ank repeat//Ank repeat
- NTONG20055200//Calcium channel extracellular region//Elongation factor Tu family//Elongation factor G C-terminus
- NTONG20058010//AMP-binding enzyme
- OCBBF20000740//Leucine rich repeat N-terminal domain//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine rich repeat C-terminal domain//Immunoglobulin domain
- OCBBF20011860//LIM domain containing proteins
- OCBBF20012520//Leucine rich repeat N-terminal domain//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine rich repeat C-terminal domain//Immunoglobulin domain
- OCBBF20016390//Chitin synthase//Fibronectin type II domain
- OCBBF20016810//‘Paired box’ domain
- OCBBF20110210//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain
- OCBBF20113110//AP endonuclease family 1
- OCBBF20116250//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//PHD-finger//Zinc finger, C2H2 type
- OCBBF20120010//Thrombospondin type 1 domain
- OCBBF20120950//K+ channel tetramerisation domain//BTB/POZ domain//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- OCBBF20121910//Ribosomal protein L24e
- OCBBF20147070//DNA polymerase (viral) C-terminal domain
- OCBBF20156450//KRAB box//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- OCBBF20157970//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//TRAF-type zinc finger//Zinc finger, C2H2 type//Zinc finger, C2H2 type//DM DNA binding domain//Zinc finger, C2H2 type
- OCBBF20165910//DnaB-like helicase
- OCBBF20166890//CAP-Gly domain//CAP-Gly domain
- OCBBF20166900//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Transcription factor S-II (TFIIS)//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- OCBBF20167290//haloacid dehalogenase-like hydrolase//Thioredoxin//Aminoglycoside phosphotransferase//Acyl-CoA dehydrogenase
- OCBBF20174580//Cyclin
- OCBBF20174890//Death domain
- OCBBF20175360//Zinc finger, C2H2 type
- OCBBF20177540//KRAB box//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Src homology domain 2//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- OCBBF20177910//Corticotropin-releasing factor family
- OCBBF20182060//Inward rectifier potassium channel
- OCBBF20191950//EGF-like domain//Low-density lipoprotein receptor domain class A//Low-density lipoprotein receptor domain class A//EGF-like domain//Low-density lipoprotein receptor domain class A//EGF-like domain//Low-density lipoprotein receptor domain class A//Low-density lipoprotein receptor domain class A//EGF-like domain//EGF-like domain//Low-density lipoprotein receptor repeat class B//Low-density lipoprotein receptor repeat class B//Low-density lipoprotein receptor repeat class B//Low-density lipoprotein receptor repeat class B//Low-density lipoprotein receptor repeat class B//EGF-like domain//60 Kd inner membrane protein
- PANCR10000860//Trypsin//Trypsin
- PEBLM10001470//Zinc finger, C2H2 type//Fork head domain
- PEBLM20001800//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain
- PEBLM20003260//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Transcription factor S-II (TFIIS)//Src homology domain 2//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Src homology domain 2//Zinc finger, C2H2 type
- PEBLM20005020//Virion host shutoff protein
- PLACE50001390//PHD-finger
- PLACE60004260//Cystatin domain
- PLACE60006300//Immunoglobulin domain
- PLACE60012620//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//AN1-like Zinc finger//FYVE zinc finger
- PLACE60054230//CheR methyltransferase//Formin Homology 2 Domain
- PLACE60054820//Regulator of chromosome condensation (RCC1)//Regulator of chromosome condensation (RCC1)//Regulator of chromosome condensation (RCC1)//Regulator of chromosome condensation (RCC1)
- PLACE60054870//IQ calmodulin-binding motif//IQ calmodulin-binding motif
- PLACE60055590//Zinc finger, C3HC4 type (RING finger)
- PLACE60061370//Phosphotyrosine interaction domain (PTB/PID).//Extracellular link domain
- PLACE60062660//Gamma-adaptin, C-terminus
- PLACE60064180//Lumenal portion of Cytochrome b559, alpha (gene psbE) subunit.//Viral (Superfamily 1) RNA helicase
- PLACE60066970//SCAN domain//Zinc finger, C2H2 type//PHD-finger//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- PLACE60070500//Immunoglobulin domain//Immunoglobulin domain
- PLACE60073090//Myo-inositol-1-phosphate synthase
- PLACE60074820//Adenylate kinase
- PLACE60082850//Pathogenesis-related protein Bet v I family
- PLACE60087680//Thyroglobulin type-1 repeat
- PLACE60093380//Penicillin amidase//Bacterial regulatory proteins, lacI family//Vacuolar sorting protein 9 (VPS9) domain
- PLACE60095600//DEAD/DEAH box helicase
- PLACE60098350//MAGE family
- PLACE60104630//Photosystem I reaction centre subunit VIII
- PLACE60113340//EGF-like domain//Laminin G domain//Insulin-like growth factor binding proteins//EGF-like domain//Laminin G domain
- PLACE60118810//bZIP transcription factor//TPR Domain//TPR Domain//TPR Domain//TPR Domain//PPR repeat
- PLACE60119700//EF hand
- PLACE60122970//Zinc finger, C2H2 type
- PLACE60138840//Syndecan domain//Mitochondrial carrier proteins//Mitochondrial carrier proteins//Mitochondrial carrier proteins
- PLACE60140640//Phosphoribulokinase//Shikimate kinase//Uncharacterized protein family UPF0038
- PLACE60154450//RhoGAP domain
- PLACE60177880//Immunoglobulin domain//Immunoglobulin domain
- PLACE60181870//Pentaxin family
- PLACE60184870//LBP/BPI/CETP family
- PROST10001100//Keratin, high sulfur B2 protein
- PROST20007170//KRAB box//Zinc finger, C2H2 type//Cyclopropane-fatty-acyl-phospholipid synthase//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Transcription factor S-II (TFIIS)//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- PROST20015210//Myosin tail//Borrelia lipoproteins//Myosin tail
- PROST20016760//‘chromo’ (CHRromatin Organization MOdifier) domain
- PROST20024250//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- PROST20028970//Ank repeat//Ank repeat//Glutamine amidotransferases class-II//Ank repeat//Ank repeat
- PROST20033240//Ephrin receptor ligand binding domain//EB module//TNFR/NGFR cysteine-rich region//Fibronectin type III domain
- PROST20036350//Glutathione S-transferases.//Ribosomal protein S24e//Interferon alpha/beta domain//tRNA synthetases class I (E and Q)
- PROST20045700//Keratin, high sulfur B2 protein
- PROST20050390//Cytochrome P450
- PROST20051310//DEAD/DEAH box helicase//Toprim domain//Helicases conserved C-terminal domain//Zinc knuckle
- PROST20065790//Phosphofructokinase//Phosphofructokinase//Phosphofructokinase//Phosphofructokinase
- PROST20073280//Transposase
- PROST20075280//Immunoglobulin domain//Immunoglobulin domain//Thrombospondin type 1 domain
- PROST20082430//Cyclophilin type peptidyl-prolyl cis-trans isomerase
- PROST20084720//Cytochrome P450
- PROST20087240//gag gene protein p24 (core nucleocapsid protein)
- PROST20099090//Disintegrin
- PROST20102190//EF hand//Ribosomal RNA adenine dimethylases//EF hand
- PROST20105450//Sodium/hydrogen exchanger family
- PROST20127450//TSC-22/dip/bun family
- PROST20130320//S-100/ICaBP type calcium binding domain
- PROST20152510//TPR Domain//TPR Domain//TPR Domain
- PROST20155370//SCAN domain//KRAB box//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- PROST20168600//KTN NAD-binding domain
- PUAEN10000650//TSC-22/dip/bun family
- PUAEN10001640//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat
- PUAEN20000800//Bleomycin resistance protein
- PUAEN20001520//Acetyltransferase (GNAT) family
- PUAEN20002470//FtsK/SpoIIIE family
- PUAEN20003120//Myb-like DNA-binding domain//ATP synthase ab C terminal//SET domain
- SALGL10001070//Family 4 glycosyl hydrolase
- SKMUS20006790//von Willebrand factor type D domain
- SKMUS20007260//Syndecan domain
- SKMUS20008730//Calponin homology (CH) domain
- SKMUS20017400//Hantavirus nucleocapsid protein//Tropomyosins
- SKMUS20040440//Ribosomal protein L3
- SKMUS20091900//Trypsin
- SKNMC10001230//Ank repeat//Ank repeat//Ank repeat
- SKNMC20006350//FKBP-type peptidyl-prolyl cis-trans isomerases//FKBP-type peptidyl-prolyl cis-trans isomerases//FKBP-type peptidyl-prolyl cis-trans isomerases//EF hand//EF hand
- SKNSH20009710//Tropomyosins//Tropomyosins
- SKNSH20052400//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat
- SKNSH20057920//Eukaryotic protein kinase domain
- SMINT20000070//Rabphilin-3A effector domain
- SMINT20002320//Protein phosphatase 2A regulatory B subunit (B56 family)
- SMINT20006020//PH domain//Phorbol esters/diacylglycerol binding domain (C1 domain)//FYVE zinc finger//PH domain
- SMINT20006090//Glutathione S-transferases.
- SMINT20008110//Na+/K+ ATPase C-terminus
- SMINT20011950//KRAB box//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//PHD-finger//Zinc finger, C2H2 type
- SMINT20012220//Collagen triple helix repeat (20 copies)
- SMINT20016150//gag gene protein p17 (matrix protein).//Ferritins
- SMINT20024140//Immunoglobulin domain
- SMINT20028800//Zinc finger, C2HC type//SAM domain (Sterile alpha motif)//Sterile alpha motif (SAM)/Pointed domain
- SMINT20028840//Immunoglobulin domain
- SMINT20030740//KRAB box//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- SMINT20035050//SH3 domain//WW domain//PH domain//RhoGAP domain
- SMINT20036440//ENTH domain
- SMINT20038660//Olfactomedin-like domain
- SMINT20039050//Flavivirus glycoprotein//IBR domain
- SMINT20043390//Ras association (RalGDS/AF-6) domain
- SMINT20044140//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//PHD-finger//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- SMINT20044730//Envelope glycoprotein GP120
- SMINT20048720//Cytochrome P450//Cytochrome P450
- SMINT20052130//Ank repeat//Ank repeat
- SMINT20056230//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain
- SMINT20062050//Reverse transcriptase (RNA-dependent DNA polymerase)
- SMINT20077960//Gelsolin repeat.//Gelsolin repeat.//Gelsolin repeat.//Gelsolin repeat.
- SMINT20083290//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain
- SMINT20086250//Glycine cleavage H-protein
- SMINT20086720//SCAN domain//KRAB box
- SMINT20088440//Immunoglobulin domain
- SMINT20089600//PDZ domain (Also known as DHR or GLGF).
- SMINT20091190//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain
- SPLEN20006950//Reverse transcriptase (RNA-dependent DNA polymerase)
- SPLEN20011350//Helper component proteinase
- SPLEN20015100//DHHC zinc finger domain
- SPLEN20023540//RasGEF domain//EF hand//EF hand
- SPLEN20023850//RecF protein//SMC domain N terminal domain//Tropomyosins
- SPLEN20024190//EGF-like domain//EB module//EGF-like domain//Trypsin Inhibitor like cysteine rich domain//EGF-like domain//EGF-like domain//WAP-type (Whey Acidic Protein) ‘four-disulfide core’//EGF-like domain
- SPLEN20024930//Inositol polyphosphate phosphatase family, catalytic domain
- SPLEN20039180//Fatty acid desaturase
- SPLEN20042200//Zinc finger, C3HC4 type (RING finger)//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- SPLEN20049840//Polyphosphate kinase//Myosin head (motor domain)//IQ calmodulin-binding motif//SH3 domain
- SPLEN20050090//Pyridoxamine 5′-phosphate oxidase//GRIP domain
- SPLEN20054500//Renal dipeptidase
- SPLEN20055600//K+ channel tetramerisation domain//BTB/POZ domain//Zinc finger, C2H2 type
- SPLEN20057900//Scorpion short toxins//EGF-like domain//EGF-like domain//Keratin, high sulfur B2 protein
- SPLEN20059270//Zinc finger, C3HC4 type (RING finger)//B-box zinc finger.//SPRY domain
- SPLEN20063250//Zinc finger, C2H2 type
- SPLEN20063890//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat
- SPLEN20071820//DNA polymerase X family
- SPLEN20076470//TPR Domain//TPR Domain//TPR Domain
- SPLEN20080070//Alpha-L-fucosidase
- SPLEN20085910//Double-stranded RNA binding motif
- SPLEN20090880//Immunoglobulin domain
- SPLEN20098030//Zinc finger, C3HC4 type (RING finger)//B-box zinc finger.
- SPLEN20101950//Sodium/hydrogen exchanger family
- SPLEN20104150//Ribosomal protein L36
- SPLEN20108000//short chain dehydrogenase
- SPLEN20110180//Transposase
- SPLEN20118050//Leucine rich repeat N-terminal domain//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat
- SPLEN20135030//PDZ domain (Also known as DHR or GLGF).//GATA zinc finger//LIM domain containing proteins
- SPLEN20139100//Sodium and potassium ATPases//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain
- SPLEN20139360//Bacterial regulatory proteins, lacI family//Site-specific recombinases
- SPLEN20175920//Uncharacterized protein family UPF0036
- SPLEN20180980//Glutathione S-transferases.
- SPLEN20182990//BTB/POZ domain//Kelch motif//Kelch motif//Kelch motif//Kelch motif
- SPLEN20183020//Laminin G domain
- SPLEN20191020//Src homology domain 2
- SPLEN20193790//Dynamin family//Dynamin family//Proteasome activator pa28 beta subunit//Peroxidase//Dynamin central region//Dynamin GTPase effector domain
- SPLEN20195710//TPR Domain//TPR Domain//TPR Domain
- SPLEN20197930//K-box region
- SPLEN20198390//WD domain, G-beta repeat//Fibrillarin//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat
- SPLEN20201830//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat
- TESTI10001570//KRAB box//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//PHD-finger//Zinc finger, C2H2 type//Zinc finger, C2H2 type//TRAF-type zinc finger//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Transcription factor S-II (TFIIS)//Zinc finger, C2H2 type
- TESTI20006160//Large-conductance mechanosensitive channel, MscL//CbiM
- TESTI20006830//PWWP domain
- TESTI20012080//Chitin synthase
- TESTI20016970//TPR Domain
- TESTI20030200//Double-stranded RNA binding motif//Adenosine-deaminase (editase) domain//Adenosine-deaminase (editase) domain
- TESTI20030440//Plant PEC family metallothionein//Tropomyosins
- TESTI20031310//Serpins (serine protease inhibitors)
- TESTI20038240//Peptidase family M13
- TESTI20041630//Outer membrane efflux protein//Intermediate filament proteins
- TESTI20043910//IQ calmodulin-binding motif//IQ calmodulin-binding motif//IQ calmodulin-binding motif//IQ calmodulin-binding motif//IQ calmodulin-binding motif
- TESTI20045390//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain//Immunoglobul in domain//Immunoglobul in domain//Immunoglobulin domain//Immunoglobulin domain
- TESTI20046110//Extracellular link domain
- TESTI20046490//LIM domain containing proteins//Somatomedin B domain
- TESTI20046870//CRAL/TR10 domain.//CRAL/TR10 domain.//MSP (Major sperm protein) domain
- TEST120046890//PHD-finger
- TESTI20049060//Immunoglobulin domain
- TESTI20049410//Proprotein convertase P-domain
- TESTI20050720//Coenzyme A transferase//Alpha-2-macroglobulin family N-terminal region//Coenzyme A transferase
- TESTI20051730//Glutamine amidotransferases class-II//alpha/beta hydrolase fold
- TESTI20053070//WD domain, G-beta repeat//WD domain, G-beta repeat
- TESTI20053950//IQ calmodulin-binding motif
- TESTI20055880//Serum amyloid A protein
- TESTI20056030//Myosin tail
- TESTI20057430//KRAB box//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//PHD-finger//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Transcription factor S-II (TFIIS)//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- TESTI20057590//Leucine rich repeat C-terminal domain//Immunoglobulin domain
- TESTI20057840//SAP domain//Zinc knuckle//Zinc finger, C3HC4 type (RING finger)
- TESTI20057880//Zinc finger, C3HC4 type (RING finger)
- TESTI20058350//Polyomavirus coat protein//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat
- TESTI20058920//Tubulin/FtsZ family
- TESTI20059080//Thermophilic metalloprotease (M29)//Hyaluronidase
- TESTI20059480//Cyclic nucleotide-binding domain
- TESTI20059810//KRAB box//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Transcription factor S-II (TFIIS)//Zinc finger, C2H2 type//DM DNA binding domain//Zinc finger, C2H2 type//Zinc finger, C2H2 type//BolA-like protein//Zinc finger, C2H2-type//Coronavirus M matrix/glycoprotein//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- TESTI20060350//bZIP transcription factor
- TESTI20060830//ZAP domain//Ferric uptake regulator family//Peptidase family M1//Piwi domain
- TESTI20061090//Keratin, high sulfur B2 protein
- TESTI20061200//Sugar (and other) transporter
- TESTI20064370//TPR Domain//TPR Domain//TPR Domain//TPR Domain//Synaptobrevin
- TESTI20064530//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat
- TESTI20064650//Myosin head (motor domain)
- TESTI20065650//G-protein alpha subunit
- TESTI20066150//Picornavirus 2B protein//Glutamine amidotransferase class-I//Pancreatic hormone peptides
- TESTI20066330//Fibronectin type III domain
- TESTI20066650//RasGEF domain
- TESTI20067480//KRAB box//Zinc finger, C2H2 type//TRAF-type zinc finger//Zinc finger, C2H2 type//Zinc finger, C2H2 type//PHD-finger//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//FYVE zinc finger//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- TESTI20068530//Zinc finger, C3HC4 type (RING finger)//PHD-finger
- TESTI20071130//ATP synthase Alpha chain, C terminal
- TESTI20071630//Glutamine synthetase//SCP-like extracellular protein
- TESTI20075240//KRAB box//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Putative zinc finger in N-recognin//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Transcription factor S-II (TFIIS)//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- TESTI20076570//Dual specificity phosphatase, catalytic domain
- TESTI20079220//KRAB box//Myb-like DNA-binding domain//Myb-like DNA-binding domain//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//PHD-finger//Transcription factor S-II (TFIIS)//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- TESTI20079980//PDZ domain (Also known as DHR or GLGF).//Domain found in Dishevelled, Egl-10, and Pleckstrin
- TESTI20081890//PDZ domain (Also known as DHR or GLGF).
- TESTI20084250//Oxysterol-binding protein
- TESTI20086840//von Willebrand factor type A domain
- TESTI20088840//Zinc finger, C3HC4 type (RING finger)//PHD-finger//Thymidine kinases//E7 protein, Early protein//CONSTANS family zinc finger//B-box zinc finger.//SPRY domain
- TESTI20092170//ENV polyprotein (coat polyprotein)
- TEST120095200//7TM chemoreceptor
- TESTI20095770//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat
- TESTI20095880//Domain of unknown function DUF33//Penicillin amidase//Formate/nitrite transporter//Sodium:galactoside symporter family
- TESTI20099350//GGL domain//Clusterin//Biopterin-dependent aromatic amino acid hydroxylase
- TESTI20100090//Lectin C-type domain
- TESTI20104090//TEA domain
- TESTI20105910//Notch (DSL) domain//Amiloride-sensitive sodium channel
- TESTI20106170//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat
- TESTI20106820//Protein kinase C terminal domain
- TESTI20108060//Ser/Thr protein phosphatase
- TESTI20112540//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Chorismate synthase//UvrB/uvrC motif
- TESTI20112860//Eukaryotic protein kinase domain
- TESTI20113940//Divalent cation transporter
- TEST120114480//Zinc finger, C4 type (two domains)//Zinc finger, C2HC type//SAM domain (Sterile alpha motif)//Sterile alpha motif (SAM)/Pointed domain
- TESTI20116050//UBX domain
- TESTI20120500//Kelch motif//Kelch motif
- TESTI20120900//DNA gyrase/topoisomerase IV, subunit A
- TESTI20121040//Protein phosphatase 2C//Protein phosphatase 2C
- TESTI20122070//ELM2 domain//Myb-like DNA-binding domain
- TESTI20125280//Immunoglobulin domain//Immunoglobulin domain
- TESTI20125920//PCI domain
- TESTI20126280//recA bacterial DNA recombination proteins
- TESTI20131440//Carboxypeptidase activation peptide//Zinc carboxypeptidase
- TESTI20132310//Ubiquitin carboxyl-terminal hydrolase family 2
- TESTI20134680//MYND finger//B-box zinc finger.//CONSTANS family zinc finger//Putative zinc finger in N-recognin
- TESTI20134970//Double-stranded RNA binding motif//Aldehyde oxidase and xanthine dehydrogenase, C terminus//Adenosine-deaminase (editase) domain
- TESTI20140970//Immunoglobulin domain
- TESTI20145780//Src homology domain 2
- TESTI20148380//TPR Domain//TPR Domain//TPR Domain//TPR Domain//TPR Domain//TPR Domain//PPR repeat//Neuraminidases//ATP synthase Alpha chain, C terminal//TPR Domain//TPR Domain//TPR Domain//TPR Domain//PPR repeat//TPR Domain
- TESTI20150420//RhoGAP domain
- TESTI20150920//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat
- TESTI20153310//Intermediate filament tail domain
- TESTI20162780//Divalent cation transporter
- TESTI20162980//Ubiquitin family//Retroviral aspartyl protease//Retroviral aspartyl protease
- TESTI20164210//Isocitrate and isopropylmalate dehydrogenases//Ribosomal protein S27a//TILa domain//von Willebrand factor type C domain
- TESTI20165990//Ribosomal protein L36
- TESTI20166290//Zinc finger, C2H2 type//FAD binding domain//Phosphoenolpyruvate carboxykinase//Ribosomal protein S11
- TESTI20166670//Zinc finger C-x8-C-x5-C-x3-H type (and similar).
- TESTI20169500//GGL domain
- TESTI20170280//Flagellar L-ring protein
- TESTI20173960//KRAB box//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//PHD-finger//Zinc finger, C2H2 type//Zinc finger, C2H2 type t
- TESTI20179230//Dihydropyridine sensitive L-type calcium channel (Beta subunit)
- TESTI20182760//Amiloride-sensitive sodium channel
- TESTI20183680//Gas vesicles protein GVPc repeated domain
- TESTI20184750//Laminin G domain//Thrombospondin N-terminal-like domains//Laminin G domain
- TESTI20184760//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//PHD-finger//Transcription factor S-II (TFIIS)//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- TESTI20186110//Divalent cation transporter//Translation initiation factor IF-3//Divalent cation transporter
- TESTI20193080//Growth-Arrest-Specific Protein 2 Domain
- TESTI20194880//SAP domain
- TESTI20196690//Glycine cleavage T-protein (aminomethyl transferase)
- TEST120197030//Pancreatic hormone peptides
- TESTI20197600//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- TESTI20199110//Disintegrin
- TESTI20205100//DNA gyrase/topoisomerase IV, subunit A
- TESTI20205250//MORN motif//MORN motif//MORN motif//MORN motif//MORN motif//MORN motif//MORN motif
- TESTI20207170//Nucleosome assembly protein (NAP)
- TESTI20210570//CRAL/TR10 domain.
- TESTI20212970//DEAD/DEAH box helicase//Helicases conserved C-terminal domain
- TESTI20219110//Eukaryotic protein kinase domain
- TESTI20222030//Hemagglutinin//ATP synthase Alpha chain, C terminal//AMP-binding enzyme
- TESTI20222460//Intermediate filament proteins
- TESTI20227380//DEAD/DEAH box helicase//Helicases conserved C-terminal domain
- TESTI20228120//RhoGAP domain
- TESTI20228740//Zinc finger, C2H2 type
- TESTI20244220//Cecropin family//Fes/CIP4 homology domain//Hr1 repeat motif//SH3 domain
- TESTI20244430//Ank repeat//Ank repeat//Ank repeat//SAM domain (Sterile alpha motif)
- TESTI20244460//pKID domain//Adenylate kinase//Thymidylate kinase//ATPases associated with various cellular activities (AAA)
- TESTI20246480//RNA recognition motif. (a.k.a. RRM, RBD, or RNP domain)
- TESTI20251610//Chitin synthase//von Willebrand factor type A domain
- TESTI20252690//Domain found in Dishevelled, Egl-10, and Pleckstrin
- TESTI20254030//LIM domain containing proteins//LIM domain containing proteins//Villin headpiece domain
- TESTI20254990//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- TESTI20255460//ZAP domain//Piwi domain
- TESTI20257910//Class I Histocompatibility antigen, domains alpha 1 and 2//Immunoglobulin domain
- TESTI20258720//Ank repeat//Ank repeat//Ank repeat
- TESTI20259110//Zinc finger, C3HC4 type (RING finger)//PHD-finger
- TESTI20261040//DNA polymerase (viral) C-terminal domain
- TESTI20261160//PH domain
- TESTI20261680//Hsp20/alpha crystallin family//Granulins
- TESTI20262150//Ion transport protein
- TESTI20262940//Phosphofructokinase
- TESTI20264530//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//C. elegans integral membrane protein Srb//WD domain, G-beta repeat//WD domain, G-beta repeat//SAM domain (Sterile alpha motif)//Sterile alpha motif (SAM)/Pointed domain
- TESTI20264910//Uteroglobin family
- TESTI20266050//Zinc finger, C3HC4 type (RING finger)//SPRY domain
- TESTI20274960//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Transcription factor S-II (TFIIS)//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- TESTI20278280//PMP-22/EMP/MP20/Claudin family
- TESTI20282530//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- TESTI20284260//Histone-like transcription factor (CBF/NF-Y) and archaeal histone//Core histone H2A/H2B/H3/H4
- TESTI20285230//Adenosine-deaminase (editase) domain
- THYMU10004280//NHL-repeat//NHL repeat
- THYMU20006020//Isocitrate and isopropylmalate dehydrogenases
- THYMU20009500//TPR Domain
- THYMU20013250//LIM domain containing proteins//RI01/ZK632.3/MJ0444 family//Eukaryotic protein kinase domain
- THYMU20018250//TPR Domain
- THYMU20019260//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- THYMU20021090//SAM domain (Sterile alpha motif)//Sterile alpha motif (SAM)/Pointed domain
- THYMU20028150//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain
- THYMU20028410//BRCA1 C Terminus (BRCT) domain//BRCA1 C Terminus (BRCT) domain
- THYMU20031330//4Fe-4S iron sulfur cluster binding proteins, NifH/frxC family
- THYMU20032820//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- THYMU20039320//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat
- THYMU20046350//Cytochrome C and Quinol oxidase polypeptide I
- THYMU20049060//RNA recognition motif. (a.k.a. RRM, RBD, or RNP domain)
- THYMU20052830//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain
- THYMU20055450//Zona pellucida-like domain
- THYMU20055460//Putative esterase
- THYMU20055760//Na+/K+ ATPase C-terminus//Phospholipase A2
- THYMU20062770//Zona pellucida-like domain
- THYMU20063650//Ribulose-phosphate 3 epimerase family//Indole-3-glycerol phosphate synthases
- THYMU20066660//DEAD/DEAH box helicase
- THYMU20070250//Transketolase//Dehydrogenase E1 component//Transketolase
- THYMU20071120//KRAB box//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- THYMU20077250//HMG (high mobility group) box
- THYMU20081110//LIM domain containing proteins
- THYMU20083390//11S plant seed storage protein
- THYMU20090230//RNA recognition motif. (a.k.a. RRM, RBD, or RNP domain)
- THYMU20095920//Iron hydrogenase small subunit
- THYMU20097920//PH domain//FERM domain (Band 4.1 family)
- THYMU20098350//bZIP transcription factor//bZIP transcription factor//Tubulin/FtsZ family//Intermediate filament proteins
- THYMU20099060//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain
- THYMU20100940//Protein of unknown function DUF132
- THYMU20104480//RNA recognition motif. (a.k.a. RRM, RBD, or RNP domain)
- THYMU20106990//PH domain
- THYMU20110720//Aminotransferases class-III pyridoxal-phosphate
- THYMU20112590//Acyl-CoA dehydrogenase//Adaptin N terminal region
- THYMU20120240//Ubiquitin carboxyl-terminal hydrolases family 2//Ubiquitin carboxyl-terminal hydrolase family 2
- THYMU20120730//Aldehyde dehydrogenase family
- THYMU20121040//bZIP transcription factor//EF-1 guanine nucleotide exchange domain
- THYMU20139160//Uncharacterized protein family UPF0031
- THYMU20143230//EGF-like domain//Extracellular link domain//Fasciclin domain
- THYMU20145990//SH3 domain
- THYMU20153210//7 transmembrane receptor (Secretin family)
- THYMU20170230//Glycine cleavage T-protein (aminomethyl transferase)
- THYMU20176010//WD domain, G-beta repeat//PQQ enzyme repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat
- THYMU20178440//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain
- THYMU20184550//HSF-type DNA-binding domain//bZIP transcription factor
- THYMU20191970//Cadherin domain//Cadherin domain//Cadherin domain//Cadherin domain
- TKIDN10000620//Thioredoxin
- TKIDN10001920//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- TRACH20011010//5′-nucleotidase
- TRACH20021380//Copper/zinc superoxide dismutase (SODC)//Adenylate and Guanylate cyclase catalytic domain//Adenylate and Guanylate cyclase catalytic domain
- TRACH20029880//MORN motif//MORN motif//Penicillin amidase//Bacterial regulatory proteins, lacI family//Vacuolar sorting protein 9 (VPS9) domain
- TRACH20040390//Pumilio-family RNA binding domains (aka PUM-HD, Pumilio homology domain)//Pumilio-family RNA binding domains (aka PUM-HID, Pumilio homology domain)//Pumilio-family RNA binding domains (aka PUM-HD, Pumilio homology domain)//Pumilio-family RNA binding domains (aka PUM-HD, Pumilio homology domain)//Pumilio-family RNA binding domains (aka PUM-HD, Pumilio homology domain)//Pumilio-family RNA binding domains (aka PUM-HD, Pumilio homology domain)//Pumilio-family RNA binding domains (aka PUM-HD, Pumilio homology domain)//Pumilio-family RNA binding domains (aka PUM-HD, Pumilio homology domain)
- TRACH20043360//Kinesin motor domain//Caspase recruitment domain//Ribosomal protein L35
- TRACH20058000//Fibronectin type III domain
- TRACH20090060//C2 domain
- TRACH20091070//Aldehyde dehydrogenase family
- TRACH20093400//Adaptin N terminal region
- TRACH20098510//Ribosomal L29 protein
- TRACH20104510//Uncharacterized protein family UPF0005
- TRACH20108240//RNA recognition motif. (a.k.a. RRM, RBD, or RNP domain)//RNA recognition motif. (a.k.a. RRM, RBD, or RNP domain)
- TRACH20113020//AIR synthase related protein
- TRACH20122980//TPR Domain//TPR Domain//TPR Domain//TPR Domain//TPR Domain
- TRACH20131230//PH domain//Oxysterol-binding protein
- TRACH20139280//PX domain
- TRACH20143710//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat
- TRACH20149500//Zinc finger//Plexin repeat//Cysteine rich repeat//Intermediate filament proteins
- TRACH20149740//Sodium:dicarboxylate symporter family
- TRACH20163470//Putative integral membrane protein DUF46//Sugar (and other) transporter//Sodium:galactoside symporter family
- TRACH20164100//Retroviral aspartyl protease
- TRACH20164810//D-isomer specific 2-hydroxyacid dehydrogenases
- TRACH20167090//Chitinases, family 2
- TRACH20170860//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain//Immunoglobulin domain
- TRACH20188350//Tropomyosins
- TRACH20190460//Lipase (class 3)
- UTERU20000950//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat//WD domain, G-beta repeat
- UTERU20016580//Zinc finger present in dystrophin, CBP/p300//Myb-like DNA-binding domain
- UTERU20026620//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- UTERU20041630//KRAB box//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Transcription factor S-II (TFIIS)//Zinc finger, C2H2 type//Zinc finger, C2H2 type
- UTERU20083020//Domain of unknown function DUF71
- UTERU20086530//Lipocalin/cytosolic fatty-acid binding protein family
- UTERU20087070//Sushi domain (SCR repeat)//Trypsin
- UTERU20089390//TPR Domain//TPR Domain//TPR Domain//TPR Domain//TPR Domain//TPR Domain//TPR Domain//TPR Domain
- UTERU20089620//Fringe-like
- UTERU20099040//Cation efflux family
- UTERU20099510//KRAB box//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//Zinc finger, C2H2 type//PHD-finger//Zinc finger, C2H2 type
- UTERU20104310//RNA polymerases K/14 to 18 kDa subunit
- UTERU20121140//Rhodanese-like domain
- UTERU20122520//FERM domain (Band 4.1 family)//FERM domain (Band 4.1 family)
- UTERU20127030//Xylose isomerase//ApbE family
- UTERU20127150//Translation initiation factor IF-3//Divalent cation transporter
- UTERU20128560//Domain of unknown function DUF28
- UTERU20132620//HMG14 and HMG17
- UTERU20139760//Mitochondrial carrier proteins//Mitochondrial carrier proteins
- UTERU20168960//PH domain//Methanol dehydrogenase beta subunit
- UTERU20181270//Zinc knuckle
- UTERU20185220//Bromodomain
The functional prediction and categorization of the proteins encoded by the clones were carried out based on the result of homology search of the databases of GenBank, Swiss-Prot, UniGene and nr (see the Homology Search Result Data) for the full-length nucleotide sequences and the result of domain search of the amino acid sequences deduced from the full-length nucleotide sequences (see Example 5).
The clone predicted to belong to the category of secretory protein/membrane protein means a clone having hit data with some annotation, such as growth factor, cytokine, hormone, signal, transmembrane, membrane, extracellular matrix, receptor, G-protein coupled receptor, ionic channel, voltage-gated channel, calcium channel, cell adhesion, collagen, connective tissue, etc., suggesting that it is a secretory or membrane protein, or means a clone in which the presence of nucleotide sequence encoding a signal sequence or transmembrane domain was suggested by the results of PSORT and SOSUI analyses for deduced ORF.
The clone predicted to belong to the category of glycoprotein-related protein means a clone having hit data with some annotation, such as glycoprotein, suggesting that the clone encodes a glycoprotein-related protein.
The clone predicted to belong to the category of signal transduction-related protein means a clone having hit data with some annotation, such as serine/threonine-protein kinase, tyrosine-protein kinase, SH3 domain, SH2 domain, etc., suggesting that the clone encodes a signal transduction-related protein.
The clone predicted to belong to the category of transcription-related protein means a clone having hit data with some annotation, such as transcription regulation, zinc finger, homeobox, etc., suggesting that the clone encodes a transcription-related protein.
The clone predicted to belong to the category of disease-related protein means a clone having hit data with some annotation, such as disease mutation, syndrome, etc., suggesting that the clone encodes a disease-related protein, or means a clone whose full-length nucleotide sequence has hit data for Swiss-Prot, GenBank, or UniGene, where the hit data corresponds to genes or proteins which have been deposited in the Online Mendelian Inheritance in Man (OMIM) (http://www.ncbi.nlm.nih.gov/Omim/), which is the human gene and disease database.
The clone predicted to belong to the category of enzyme and/or metabolism-related protein means a clone having hit data with some annotation, such as metabolism, oxidoreductase, E. C. No. (Enzyme commission number), etc., suggesting that the clone encodes an enzyme and/or metabolism-related protein.
The clone predicted to belong to the category of cell division and/or cell proliferation-related protein means a clone having hit data with some annotation, such as cell division, cell cycle, mitosis, chromosomal protein, cell growth, apoptosis, etc., suggesting that the clone encodes a cell division and/or cell proliferation-related protein.
The clone predicted to belong to the category of cytoskeleton-related protein means a clone having hit data with some annotation, such as structural protein, cytoskeleton, actin-binding, microtubles, etc., suggesting that the clone encodes a cytoskeleton-related protein.
The clone which is predicted to belong to the category of nuclear protein and/or RNA synthesis-related protein means a clone having hit data with some annotation, such as nuclear protein, RNA splicing, RNA processing, RNA helicase, polyadenylation, etc., suggesting that the clone encodes a nuclear protein and/or RNA synthesis-related protein.
The clone predicted to belong to the category of protein synthesis and/or transport-related protein means a clone having hit data with some annotation, such as translation regulation, protein biosynthesis, amino-acid biosynthesis, ribosomal protein, protein transport, signal recognition particle, etc., suggesting that the clone encodes a protein synthesis and/or transport-related protein.
The clone predicted to belong to the category of cellular defense-related protein means a clone having hit data with some annotation, such as heat shock, DNA repair, DNA damage, etc., suggesting that the clone encodes a cellular defense-related protein.
The clone predicted to belong to the category of development and/or differentiation-related proteins means a clone having hit data with some annotation, such as developmental protein, etc., suggesting that the clone encodes a development and/or differentiation-related protein.
The clone predicted to belong to the category of DNA-binding and/or RNA-binding protein means a clone having hit data with some annotation, such as DNA-binding, RNA-binding, etc.
The clone predicted to belong to the category of ATP-binding and/or GTP-binding protein means a clone having hit data with some annotation, such as ATP-binding, GTP-binding, etc.
In this functional categorization, when a single clone corresponded to multiple categories of those shown above, the clone was assigned to the multiple categories. However, the function of a protein is not restricted to the functional category in this classification, and there is the possibility that other functions are newly assigned to the protein.
The clones predicted to belong to the category of secretory protein and/or membrane protein are the following 516 clones.
The clones predicted to belong to the category of glycoprotein-related protein are the following 121 clones.
The clones predicted to belong to the category of signal transduction-related protein are the following 88 clones.
The clones predicted to belong to the category of transcription-related protein are the following 143 clones.
The clones predicted to belong to the category of disease-related protein are the following 331 clones.
In particular, hit data of the following 328 clones for Swiss-Prot, or GenBank, UniGene, or nr corresponded to genes or proteins which had been deposited in the Online Mendelian Inheritance in Man (OMIM), which is the human gene and disease database, (the OMIM Number is shown in the parenthesis after the Clone Name).
The clones predicted to belong to the category of enzyme and/or metabolism-related protein are the following 219 clones.
The clones predicted to belong to the category of cell division and/or cell proliferation-related protein are the following 44 clones.
The clones predicted to belong to the category of cytoskeleton-related protein are the following 80 clones.
The clones predicted to belong to the category of nuclear protein and/or RNA synthesis-related protein are the following 70 clones.
The clones predicted to belong to the category of protein synthesis and/or transport-related protein are the following 20 clones.
The clones predicted to belong to the category of cellular defense-related protein are the following 10 clones.
The clones predicted to belong to the category of development and/or differentiation-related protein are the following 19 clones.
The clones predicted to belong to the category of DNA-binding and/or RNA-binding protein are the following 168 clones.
The clones predicted to belong to the category of ATP binding and/or GTP-binding protein are the following 93 clones.
Among the clones other than the ones shown above, BNGH420036410 and FCBBF30257370 are clones which were predicted to highly possibly belong to the category of secretory protein and/or membrane protein based on the result of domain search by Pfam.
SMINT20044730, TESTI20140970
The two clones shown above are clones which were predicted to highly possibly belong to the category of glycoprotein-related protein based on the result of domain search by Pfam.
The 11 clones shown above are clones which were predicted to highly possibly belong to the category of signal transduction-related protein based on the result of domain search by Pfam.
The 18 clones shown above are clones which were predicted to highly possibly belong to the category of transcription-related protein based on the result of domain search by Pfam.
The 35 clones shown above are clones which were predicted to highly possibly belong to the category of enzyme and/or metabolism-related protein based on the result of domain search by Pfam.
PLACE60054820, TESTI20197030
The two clones shown above are clones which were predicted to highly possibly belong to the category of cell division and/or cell proliferation-related protein based on the result of domain search by Pfam.
ASTRO20006530, OCBBF20016390, TRACH20058000
The three clones shown above are clones which were predicted to highly possibly belong to the category of cytoskeleton-related protein based on the result of domain search by Pfam.
BRACE20065470, PLACE60054820
The two clones shown above are clones which were predicted to highly possibly belong to the category of nuclear protein and/or RNA synthesis-related protein based on the result of domain search by Pfam.
The 21 clones shown above are clones which were predicted to highly possibly belong to the category of DNA-binding and/or RNA-binding protein based on the result of domain search by Pfam.
KIDNE20133880, MESAN20030350, MESAN20030370, TESTI20059480
The four clones shown above are clones which were predicted to highly possibly belong to the category of ATP-binding and/or GTP-binding protein based on the result of domain search by Pfam.
The 205 clones shown below are clones which were unassignable to any of the above-mentioned categories, but have been predicted to have some functions based on homology search for their full-length nucleotide sequences and motif search in their deduced ORFs. Clone Name, Definition in the result of homology search or Motif Name in the motif search, demarcated by a double slash mark (//), are shown below.
- ADRGL20022600//DIAPHANOUS PROTEIN HOMOLOG 1 (P140MDIA).
- ADRGL20023920//ABC1 PROTEIN HOMOLOG PRECURSOR.
- ASTRO20001910//Rattus norvegicus mRNA for annexin V-binding protein (ABP-10), partial cds.
- ASTRO20009140//PUTATIVE COMPETENCE-DAMAGE PROTEIN.
- ASTRO20046280//PSU1 PROTEIN.
- ASTRO20058960//DNA damage inducible protein homolog—fission yeast (Schizosaccharomyces pombe)
- BNGH420024870//C2 domain//C2 domain//C2 domain
- BRACE20007330//RING CANAL PROTEIN (KELCH PROTEIN).
- BRACE20052430//Homo sapiens AMSH mRNA, complete cds.
- BRACE20054600//Xenopus laevis mRNA for Kielin, complete cds.
- BRACE20059810//TSC-22/dip/bun family
- BRACE20063540//MEROZOITE SURFACE PROTEIN CMZ-8 (FRAGMENT).
- BRACE20079200//Xenopus laevis mRNA for Kielin, complete cds.
- BRAMY20016780//Proprotein convertase P-domain
- BRAMY20023640//UBX domain
- BRAMY20045420//Domain found in Dishevelled, Egl-10, and Pleckstrin
- BRAMY20056840//UBE-1c2
- BRAMY20063750//Homo sapiens HRIHFB2007 mRNA, partial cds.
- BRAMY20102900//Homo sapiens RU1 (RU1) mRNA, complete cds.
- BRAMY20158550//CALMODULIN.
- BRAMY20223010//Mus musculus leucine-rich glioma-inactivated 1 protein precursor, (Lgi1) mRNA, complete cds.
- BRAMY20238630//TETRATRICOPEPTIDE REPEAT PROTEIN 4.
- BRAMY20245760//Araneus diadematus fibroin-4 mRNA, partial cds.
- BRAWH20047790//HMG (high mobility group) box
- BRSSN20005610//Mus musculus semaphorin cytoplasmic domain-associated protein 3A (Semcap3) mRNA, complete cds.
- BRSSN20005660//Bacterial type II secretion system protein
- BRSSN20093890//Homo sapiens mRNA for Kelch motif containing protein, complete cds.
- CTONG20041150//Streptomyces ansochromogenes strain 7100 SanE (sanE) gene, complete cds.
- CTONG20066110//Homo sapiens DEME-6 mRNA, partial cds.
- CTONG20069420//Ribosomal protein S14p/S29e
- CTONG20071040//BETA CRYSTALLIN B2 (BP).
- CTONG20074170//DENN (AEX-3) domain
- CTONG20083430//Nuclear transition protein 2
- CTONG20170940//MYOTROPHIN (V-1 PROTEIN) (GRANULE CELL DIFFERENTIATION PROTEIN).
- CTONG20174290//TRICHOHYALIN.
- CTONG20174580//Homo sapiens mRNA for vascular Rab-GAP/TBC-containing protein complete cds.
- CTONG20180690//Collagen triple helix repeat (20 copies)
- CTONG20186550//cca3 protein—rat
- CTONG20188080//TPR Domain
- FCBBF10004760//Homo sapiens GAP-like protein (N61) mRNA, complete cds.
- FCBBF20033360//RING CANAL PROTEIN (KELCH PROTEIN).
- FCBBF20041380//SAM domain (Sterile alpha motif)
- FCBBF20043730//UBA domain
- FCBBF20056580//Mus musculus NSD1 protein mRNA, complete cds.
- FCBBF20059660//TPR Domain
- FCBBF30019180//SERINE/THREONINE PROTEIN PHOSPHATASE 2A, 65 KDA REGULATORY SUBUNIT A, ALPHA ISOFORM (PP2A, SUBUNIT A, PR65-ALPHA ISOFORM) (PP2A, SUBUNIT A, R1-ALPHA ISOFORM).
- FCBBF30026580//Homo sapiens retinoblastoma-associated protein RAP140 mRNA, complete cds.
- FCBBF30035570//C2 domain
- FCBBF30079770//D-isomer specific 2-hydroxyacid dehydrogenases
- FCBBF30100120//Mus musculus semaphorin cytoplasmic domain-associated protein 3A (Semcap3) mRNA, complete cds.
- FCBBF30100410//Mus musculus testis-specific Y-encoded-like protein (Tspyl1) mRNA, complete cds.
- FCBBF30118890//Drosophila melanogaster La related protein (larp) mRNA, partial cds.
- FCBBF30138000//trg protein—rat
- FCBBF30157270//Rattus norvegicus PAPIN mRNA, complete cds.
- FCBBF30161780//gag gene protein p24 (core nucleocapsid protein)//Zinc knuckle
- FCBBF30198670//dof protein—fruit fly (Drosophila melanogaster)
- FCBBF30222910//Mus musculus Rap2 interacting protein 8 (RPIP8) mRNA, complete cds.
- FCBBF30255680//Rattus norvegicus brain specific cortactin-binding protein CBP90 mRNA, partial cds.
- FCBBF30260210//Drosophila melanogaster KISMET-L long isoform (kis) mRNA, complete cds.
- FCBBF30282020//cca3 protein—rat
- FCBBF40000610//late gestation lung 2 protein [Rattus norvegicus].
- FEBRA20029620//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat
- FEBRA20031150//Homo sapiens HSKM-B (HSKM-B) mRNA, complete cds.
- FEBRA20038330//Corticotropin-releasing factor family
- FEBRA20038970//Homo sapiens mRNA for stabilin-1 (stab1 gene).
- FEBRA20088610//CELLULAR RETINALDEHYDE-BINDING PROTEIN (CRALBP).
- FEBRA20150420//HYPOTHETICAL 131.5 KDA PROTEIN CO2F12.7 IN CHROMOSOME X.
- FEBRA20175330//D-isomer specific 2-hydroxyacid dehydrogenases
- HEART10001420//Mus musculus skm-BOP1 (Bop) mRNA, complete cds.
- HLUNG20024050//Rubredoxin
- HLUNG20030420//Mus musculus mRNA for MAIL, complete cds.
- HLUNG20030490//Ambystoma tigrinum RPE65 protein mRNA, complete cds.
- HLUNG20033060//Homo sapiens GAP-like protein (N61) mRNA, complete cds.
- HLUNG20041590//ubiquitous tetratricopeptide containing protein RoXaN [Homo sapiens].
- HLUNG20045340//MOB2 PROTEIN (MPS1 BINDER 2).
- HLUNG20051330//FHIPEP family
- HLUNG20070410//Dihydropyridine sensitive L-type calcium channel (Beta subunit)
- HLUNG20072100//Gallus gallus Dach2 protein (Dach2) mRNA, complete cds.
- HLUNG20083480//Chicken mRNA for TSC-22 variant, complete cds, clone SLFEST52.
- KIDNE20027980//SAM domain (Sterile alpha motif)
- KIDNE20084730//Homo sapiens FH1/FH2 domain-containing protein FHOS (FHOS) mRNA, complete cds.
- KIDNE20149780//NG28 [Mus musculus]
- KIDNE20154330//Rattus norvegicus mRNA for multi PDZ domain protein.
- KIDNE20170400//Leucine Rich Repeat//Leucine Rich Repeat//Leucine Rich Repeat//Protein kinase C terminal domain//Rubredoxin
- KIDNE20189890//Homo sapiens mRNA for KARP-1-binding protein 2 (KAB2), complete cds.
- LIVER20010760//Homo sapiens C-type lectin-like receptor-1 mRNA, complete cds.
- LIVER20040740//RETINAL-BINDING PROTEIN (RALBP).
- MESAN20009090//Homo sapiens CEGP1 protein (CEGP1), mRNA
- MESAN20026870//PAN domain//TBC domain
- MESAN20090190//CEGP1 protein [Homo sapiens].
- NT2NE20059680//Homo sapiens integrin cytoplasmic domain associated protein (Icap-1a) mRNA, complete cds.
- NT2NE20077270//Adenovirus EB1 55K protein/large t-antigen
- NT2NE20087850//ANTER-SPECIFIC PROLINE-RICH PROTEIN APG (PROTEIN CEX) (FRAGMENT).
- NT2NE20095230//Homo sapiens HSKM-B (HSKM-B) mRNA, complete cds.
- NT2NE20108420//KES1 PROTEIN.
- NT2NE20173970//Rattus norvegicus beta-catenin binding protein mRNA, complete cds.
- NT2NE20177210//Leishmania major partial ppg1 gene for proteophosphoglycan.
- NT2RP70012830//CALPHOTIN.
- NT2RP70035110//Caenorhabditis elegans UNC-89 (unc-89) gene, complete cds.
- NTONG20002230//Mus musculus RW1 protein mRNA, complete cds.
- NTONG20005310//Ribosomal protein S9/S16
- NTONG20029850//CALCYPHOSINE (R2D5 ANTIGEN).
- NTONG20035150//RING CANAL PROTEIN (KELCH PROTEIN).
- NTONG20058220//Homo sapiens phosphoprotein pp75 mRNA, partial cds.
- OCBBF20005220//Rattus norvegicus Fos-related antigen mRNA, complete cds.
- OCBBF20011860//Mus musculus epithelial protein lost in neoplasm-a (Eplin) mRNA, complete cds.
- OCBBF20016810//enhancer of polycomb [Mus musculus]
- OCBBF20147070//DNA polymerase (viral) C-terminal domain
- OCBBF20160380//liver stage antigen LSA-1—Plasmodium falciparum
- OCBBF20177910//Corticotropin-releasing factor family
- PEBLM20005020//Virion host shutoff protein
- PLACE60055460//Homo sapiens leucine-zipper protein FKSG13 (FKSG13) mRNA, complete cds.
- PLACE60068710//SUPPRESSOR PROTEIN SRP40.
- PLACE60080360//mucin [Homo sapiens]
- PLACE60082850//Pathogenesis-related protein Bet v I family
- PLACE60098350//Human hepatocellular carcinoma associated protein (JCL-1) mRNA, complete cds.
- PLACE60105680//Homo sapiens mRNA for TU12B1-TY, complete cds.
- PLACE60119700//Homo sapiens mRNA for ABP32, complete cds.
- PLACE60120280//SER/THR-RICH PROTEIN T10 IN DGCR REGION.
- PLACE60132200//TRICHOHYALIN.
- PLACE60181870//Pentaxin family
- PROST20084470//Plasmodium berghei strain NYU2 merozoite surface protein-1 mRNA, partial cds.
- PROST20087240//gag gene protein p24 (core nucleocapsid protein)
- PROST20122490//Gallus gallus syndesmos mRNA, complete cds.
- PROST20130320//S-100/ICaBP type calcium binding domain
- PROST20152870//Homo sapiens APC2 gene, exon 14.
- PUAEN10001640//Mus musculus cerebellar postnatal development protein-1 (Cpd1) mRNA, partial cds.
- PUAEN20000800//Bleomycin resistance protein
- SMINT20012220//Collagen triple helix repeat (20 copies)
- SMINT20035510//Drosophila melanogaster La related protein (larp) mRNA, partial cds.
- SMINT20036440//Drosophila melanogaster epsin-like protein mRNA, complete cds.
- SMINT20038660//Homo sapiens HNOEL-iso (HNOEL-iso) mRNA, complete cds.
- SMINT20043390//Ras association (RalGDS/AF-6) domain
- SMINT20048720//Cytochrome P450//Cytochrome P450
- SMINT20052130//Rattus norvegicus mRNA for gankyrin homologue, complete cds.
- SMINT20054050//ABC1 PROTEIN HOMOLOG PRECURSOR.
- SPLEN20024770//Rattus norvegicus (rsec6) mRNA, complete cds.
- SPLEN20040780//CORNIFIN B (SMALL PROLINE-RICH PROTEIN 1B) (SPR1B) (SPR1 B).
- SPLEN20041810//BC-2 protein [Homo sapiens]
- SPLEN20100040//258.1 KDA PROTEIN C210RF5 (KIAA0933).
- SPLEN20104150//Ribosomal protein L36
- SPLEN20116720//Homo sapiens misato mRNA, partial cds.
- SPLEN20176130//Homo sapiens mRNA for ALEX1, complete cds.
- SPLEN20181570//TRICHOHYALIN.
- TESTI20004310//TRICHOHYALIN.
- TESTI20016970//TPR Domain
- TESTI20030440//TRICHOHYALIN.
- TESTI20043180//mouse mRNA for megakaryocyte potentiating factor, complete cds.
- TESTI20043910//IQ calmodulin-binding motif//IQ calmodulin-binding motif//IQ calmodulin-binding motif//IQ calmodulin-binding motif//IQ calmodulin-binding motif
- TESTI20044900//Strongylocentrotus purpuratus radial spokehead mRNA, complete cds.
- TESTI20046110//Extracellular link domain
- TESTI20047930//Homo sapiens NY-REN-2 antigen mRNA, complete cds.
- TEST120049410//Proprotein convertase P-domain
- TESTI20053950//IQ calmodulin-binding motif
- TESTI20054700//Streptococcus pneumoniae strain g375 surface protein PspC (pspC) gene, pspC-8.1 allele, complete cds.
- TESTI20055880//Serum amyloid A protein
- TESTI20056030//Homo sapiens 88-kDa Golgi protein (GM88) mRNA, complete cds.
- TESTI20061090//Keratin, high sulfur B2 protein
- TESTI20064370//TPR Domain//TPR Domain//TPR Domain//TPR Domain//Synaptobrevin
- TESTI20084250//OXYSTEROL-BINDING PROTEIN.
- TESTI20092170//ENV polyprotein (coat polyprotein)
- TESTI20116050//UBX domain
- TESTI20120500//Kelch motif//Kelch motif
- TESTI20126280//Mus musculus STAP mRNA for sperm tail associated protein, complete cds.
- TESTI20144390//TESTIS-SPECIFIC PROTEIN PBS13.
- TESTI20165990//Ribosomal protein L36
- TESTI20169500//HYPOTHETICAL 51.9 KDA PROTEIN C27F1.04C IN CHROMOSOME I.
- TESTI20170280//Flagellar L-ring protein
- TESTI20176450//thioredoxin interacting factor [Mus musculus].
- TESTI20179230//Dihydropyridine sensitive L-type calcium channel (Beta subunit)
- TESTI20180600//Homo sapiens HOM-TES-85 tumor antigen mRNA, complete cds.
- TESTI20209050//HYPOTHETICAL 113.1 KDA PROTEIN IN PRE5-FET4 INTERGENIC REGION.
- TESTI20210570//RETINAL-BINDING PROTEIN (RALBP).
- TESTI20215310//Homo sapiens calcyclin binding protein mRNA, complete cds.
- TESTI20247440//Human BLu protein testis isoform (BLu) mRNA, complete cds.
- TESTI20249360//Homo sapiens DEME-6 mRNA, partial cds.
- TESTI20250220//TRICHOHYALIN.
- TESTI20251440//Rattus norvegicus (rsec6) mRNA, complete cds.
- TESTI20255460//Mus musculus mRNA for MIWI (piwi), complete cds.
- THYMU20009500//TPR Domain
- THYMU20010180//MOB1 PROTEIN (MPS1 BINDER 1).
- THYMU20013810//Human SEC7 homolog Tic (TIC) mRNA, complete cds.
- THYMU20018250//TPR Domain
- THYMU20026950//Mus musculus ROSA 26 transcription AS ROSA26AS mRNA, complete cds.
- THYMU20028410//Mus musculus Pax transcription activation domain interacting protein PTIP mRNA, complete cds.
- THYMU20030460//Homo sapiens tumor endothelial marker 7 precursor (TEM7) mRNA, complete cds.
- THYMU20031330//Homo sapiens putative nucleotide binding protein mRNA, complete cds.
- THYMU20052460//PHORBOLIN I (FRAGMENTS).
- THYMU20055450//Zona pellucida-like domain
- THYMU20083830//Homo sapiens angiostatin binding protein 1 mRNA, complete cds.
- THYMU20139160//Uncharacterized protein family UPF0031
- THYMU20151610//Homo sapiens antigen NY-CO-1 (NY-CO-1) mRNA, complete cds.
- TRACH20093400//TRICHOHYALIN.
- TRACH20104510//Uncharacterized protein family UPF0005
- TRACH20122980//HYPOTHETICAL PROTEIN MJ0798.
- TRACH20139280//PX domain
- TRACH20164810//D-isomer specific 2-hydroxyacid dehydrogenases
- TRACH20165540//Human alpha-1 type I collagen gene surrounding osteogenesis imperfecta OI type II deletion.
- UTERU20051790//guanylate kinase-interacting protein 1 Maguin-1, membrane-associated—rat
- UTERU20083020//Domain of unknown function DUF71
- UTERU20121140//Rhodanese-like domain
- UTERU20128560//26.4 KDA PROTEIN IN RUVC-ASPS INTERGENIC REGION.
- UTERU20132620//AXONEME-ASSOCIATED PROTEIN MST101 (2).
- UTERU20134830//pellino (Drosophila) homolog 2 [Homo sapiens]
- UTERU20181270//Zinc knuckle
With respect to the remaining 613 clones, there are so far no information available for estimating their functions. However, there is the possibility that the functions of these clones will be revealed in future. Their Clone Names are indicated below.
The cDNA libraries derived from various tissues and cells as indicated in Example 1 were prepared, and cDNA clones were selected from each library at random. The 5′-end sequences were determined and the database was constructed based on the data. The database was constructed based on the nucleotide sequences of 770,546 clones, and thus the population of the database is large enough for the analysis.
Then, clones having a homologous sequence are categorized into a single cluster (clustering) by searching the nucleotide sequences of respective clones in this database with the program of nucleotide sequence homology search; the number of clones belonging to each cluster was determined and normalized for every library; thus, the ratio of a certain gene in each cDNA library was determined. This analysis gave the information of the expression frequency of genes in tissues and cells which were sources of the cDNA libraries.
Then, in order to analyze the expression of a gene containing the nucleotide sequence of the cDNA of the present invention in tissues and cells, the library derived from a tissue or a cell used in the large-scale cDNA analysis was subjected to the comparison of the expression levels between tissues or cells. Namely, the expression frequency was analyzed by comparing the previously normalized values between tissues and/or cells for which the nucleotide sequences of 600 or more cDNA clones had been analyzed. By this analysis, some of the genes were revealed to be involved in the pathology and functions indicated below. Each value in Tables 3 to 39 shown below represents a relative expression frequency; the higher the value, the higher the expression level.
Osteoporosis-Related Genes
Osteoporosis is a pathology in which bones are easily broken owing to overall decrease in components of bone. The onset involves the balance between the functions of osteoblast producing bone and osteoclast absorbing bone, namely bone metabolism. Thus, the genes involved in the increase of osteoclasts differentiating from precursor cells of monocyte/macrophage line (Molecular Medicine 38. 642-648. (2001)) are genes involved in osteoporosis relevant to bone metabolism.
A nucleotide sequence information-based analysis was carried out to identify the genes whose expression frequencies are higher or lower in CD34+ cell (cell expressing a glycoprotein CD34) treated with the osteoclast differentiation factor (Molecular Medicine 38. 642-648. (2001)) than in the untreated CD34+ cell, which is the precursor cell of monocyte/macrophage line. The result of comparative analysis for the frequency between the two cDNA libraries prepared from the RNA of CD34+ cells (CD34C) and from the RNA of CD34+ cells treated with the osteoclast differentiation factor (D30ST, D60ST or D90ST) showed that the genes whose expression levels were different between the two were the following clones (Table 3).
These genes are involved in osteoporosis.
Genes Involved in Neural Cell Differentiation
Genes involved in neural cell differentiation are useful for treating neurological diseases. Genes with varying expression levels in response to induction of cellular differentiation in neural cells are thought to be involved in neurological diseases.
A survey was performed for genes whose expression levels are varied in response to induction of differentiation (stimulation by retinoic acid (RA) or growth inhibitor treatment after RA stimulation) in cultured cells of a neural strain, NT2. The result of comparative analysis of cDNA libraries derived from undifferentiated NT2 cells (NT2RM) and the cells subjected to the differentiation treatment (NT2RP, NT2RI or NT2NE) showed that the genes whose expression levels were different between the two were the following clones (Table 4).
These genes are neurological disease-related genes.
Cancer-Related Genes
It has been assumed that, distinct from normal tissues, cancer tissues express a distinct set of genes, and thus the expression can contribute to the carcinogenesis in tissues and cells. Thus, the genes whose expression patterns in cancer tissues are different from those in normal tissues are cancer-related genes. Search was carried out for the genes whose expression levels in cancer tissues were different from those in normal tissues.
The result of comparative analysis of cDNA libraries derived from breast tumor (TBAES) and normal breast (BEAST) showed that the genes whose expression levels were different between the two were the following clones (Table 5).
CTONG20070780, CTONG20084660, HLUNG20045340, TESTI20047370
The result of comparative analysis of cDNA libraries derived cervical tumor (TCERX) and normal cervical duct (CERVX) showed that the genes whose expression levels were different between the two were the following clones (Table 6).
SMINT20030740
The result of comparative analysis of cDNA libraries derived from colon tumor (TCOLN) and normal colon (COLON) showed that the genes whose expression levels were different between the two were the following clones (Table 7).
UTERU2004037
The result of comparative analysis of cDNA libraries derived from esophageal tumor (TESOP) and normal esophagus (NESOP) showed that the genes whose expression levels were different between the two were the following clones (Table 8).
The result of comparative analysis of cDNA libraries derived from kidney tumor (TKIDN) and normal kidney (KIDNE) showed that the genes whose expression levels were different between the two were the following clones (Table 9).
The result of comparative analysis of cDNA libraries derived from liver tumor (TLIVE) and normal liver (LIVER) showed that the genes whose expression levels were different between the two were the following clones (Table 10).
The result of comparative analysis of cDNA libraries derived from lung tumor (TLUNG) and normal lung (HLUNG) showed that the genes whose expression levels were different between the two were the following clones (Table 11).
The result of comparative analysis of cDNA libraries derived from ovary tumor (TOVER) and normal ovary (NOVER) showed the genes whose expression levels were different between the two were the following clones (Table 12).
KIDNE20089870, NT2RP70075300, TESTI20132310
The result of comparative analysis of cDNA libraries derived from stomach tumor (TSTOM) and normal stomach (STOMA) showed that the genes whose expression levels were different between the two were the following clones (Table 13).
The result of comparative analysis of cDNA libraries derived from uterine tumor (TUTER) and normal uterus (UTERU) showed that the genes whose expression levels were different between the two were the following clones (Table 14).
The result of comparative analysis of cDNA libraries derived from tongue cancer (CTONG) and normal tongue (NTONG) showed that the genes whose expression levels were different between the two were the following clones (Table 15).
These genes are involved in cancers.
Further, there is a method to search for genes involved in development and differentiation: the expression frequency analysis in which the expression levels of genes are compared between developing or differentiating tissues and/or cells and adult tissues and/or cells. The genes involved in tissue development and/or differentiation are genes participating in tissue construction and expression of function, and thus are useful genes, which are available for regenerative medicine aiming at convenient regeneration of injured tissues.
Search was carried out for the genes whose expression frequencies were different between developing and/or differentiating tissues and/or cells, and adult tissues and/or cells, by using the information of gene expression frequency based on the database of the nucleotide sequences of 770,546 clones shown above.
The result of comparative analysis of cDNA libraries derived from fetal brain (FCBBF, FEBRA or OCBBF) and adult brain (BRACE, BRALZ, BRAMY, BRAWH, BRCAN, BRCOC, BRHIP, BRSSN, BRSTN or BRTHA) showed that the genes whose expression levels were different between the two were the following clones (Tables 16 to 36).
The result of comparative analysis of cDNA libraries derived from fetal heart (FEHRT) and adult heart (HEART) showed that the genes whose expression levels were different between the two were the following clones (Table 37).
The result of comparative analysis of cDNA libraries derived from fetal kidney (FEKID) and adult kidney (KIDNE) showed that the genes whose expression levels were different between the two were the following clones (Table 38).
The result of comparative analysis of cDNA libraries derived from fetal lung (FELNG) and adult lung (HLUNG) showed that the genes whose expression levels were different between the two were the following clones (Table 39).
These genes are involved in regeneration of tissues and/or cells.
EXAMPLE 8 Expression Frequency Analysis by PCRSpecific PCR primers were prepared based on the full-length nucleotide sequences, and the expression frequency was analyzed by the ATAC-PCR method (Adaptor-tagged competitive PCR method: Nucleic Acids Research 1997, 25 (22): 4694-4696; “DNA Micro-array and Advanced PCR Techniques”, Cell Technology, supplement, Eds., Muramatsu and Nawa (Shujunsha, 2000): 104-112). Inflammation-related genes can be identified by revealing the genes whose expression levels are altered depending on the presence of an inflammation-inducing factor. Then, by using THP-1 cell line, which is a cell line of monocyte line, and TNF-α, which is an inflammation-inducing factor, suitable for this system, the genes whose expression levels are altered depending on the presence of the factor were searched for by the system.
THP-1 cell line (purchased from DAINIPPON PHARMACEUTICAL) was cultured to be confluent in RPMI1640 medium (sigma) containing 5% fetal calf serum (GIBCO BRL). Then, the medium was changed with the medium containing 10 ng/ml TNF-α (human recombinant TNF-α; Pharmacia Biotech), and the culture was continued at 37° C. under 5% CO2. After three hours, the cells were harvested, and total RNA was extracted from them by using ISOGEN reagent (Nippon Gene). The extraction was carried out according to the method in the document attached to ISOGEN reagent. In addition, total RNA was also extracted from the cells cultured without stimulation of TNF-α.
The genes involved in the onset of gastritis and gastroduodenal ulcer induced by the infection of Helicobacter pylori to the epithelia of stomach can be identified by revealing the genes whose expression levels are altered depending on co-culturing the cells with Helicobacter pylori. A recent study has suggested that various substances derived from Helicobacter pylori trigger the inflammation reaction. In particular, the members belonging to the family of genes called “cag pathogenicity island (cag PAI)” contribute to the activation of the NF-κB pathway (Gastroenterology 2000, 119: 97-108). Further, it has been found that cag PAI is involved in the onset of gastritis and the like by the study using an animal model (Journal of Experimental Medicine 2000, 192:1601-1610). Then, by using co-culture of a gastric cancer cell line with cag PAI-positive Helicobacter pylori (TN2), suitable for this system, the genes whose expression levels are altered depending on the presence of Helicobacter pylori were searched for by the system. Further, in order to study the involvement of cag PAI in the alterations of gene expression levels depending on the co-culture with Helicobacter pylori, the altered expression levels were compared between the cells co-cultured with a strain of Helicobacter pylori (TN2ΔcagE strain) having a mutation in cagE, which is one of the cag PAI genes, and the cag PAI-positive strain (TN2).
A gastric cancer cell line MKN45 (provided by the Cell Bank, RIKEN GENE BANK, The Institute of Physical and Chemical Research) was cultured to be confluent in RPMI1640 medium (sigma) containing 10% fetal calf serum (GIBCO BRL). Then, the medium was changed with the medium containing 100-fold excess (in terms of the number of cells or the number of colonies) of Helicobacter pylori (cag PAI positive strain (TN2) and cagE mutant (TN2ΔcagE): both were provided by Prof. Omata, Faculty of Medicine, The University of Tokyo), as compared with the number of the cancer cells. The culture was continued at 37° C. under 5% CO2. After three hours, the cells were harvested, and total RNA was extracted from them by using ISOGEN reagent (Nippon Gene). The extraction was carried out according to the method in the document attached to ISOGEN reagent. In addition, total RNA was also extracted from the cells cultured without Helicobacter pylori.
The analysis by the ATAC-PCR method was carried out basically according to “DNA Micro-array and Advanced PCR Techniques”, Cell Technology, supplement (Genome Science Series 1, Eds., Muramatsu and Nawa (Shujunsha, 2000): 104-112). Adapter ligation to the internal standard sample (sample to make the calibration curve for the clone of interest) and test sample was carried out in the two separate reaction systems indicated below. The combination of 6 types of adapters (AD-1, AD-2, AD-3, AD-4, AD-5 and AD-6: see the sequences indicated below) and the samples are as follows.
Reaction System A
- AD1; internal standard, 10-fold
- AD2; THP-1 cells, unstimulated
- AD3; internal standard, 3-fold
- AD4; THP-1 cells, TNF-α stimulation for one hour
- AD5; THP-1 cells, TNF-α stimulation for three hours
- AD6; internal standard, 1-fold
Reaction System B - AD1; internal standard, 1-fold
- AD2; MKN45 cells, unstimulated
- AD3; internal standard, 3-fold
- AD4; MKN45 cells, co-cultured with TN2 (Helicobacter pylori)
- AD5; internal standard, 10-fold
- AD6; MKN45 cells, co-cultured with TN2ΔcagE (cagE gene mutant)
Adapter Sequences:
The internal standard sample used for this assay was a mixture of total RNAs from tissues (or culture cells; all from UNITECH) of brain, kidney, NT2, testis, thymus, and trachea. RNA was prepared according to the standard method.
The sequences of primers specific to the genes and the names of clones of interest in the analysis are as follows. The gene specific primers were designed to produce the PCR products of 70 to 200 bp, which are derived from the adapter-containing cDNA. The sequence of adapter-specific primer (labeled with fluorescence (FAM)) used in the competitive PCR was GTACATATTGTCGTTAGAACGC (22 nucleotides; SEQ ID NO: 3953). PCR was basically carried out with a cycling profile of preheating at 94° C. for 3 minutes, and 35 or 40 cycles of denaturation at 94° C. for 30 seconds/annealing at 50° C. for 60 seconds/extension at 72° C. for 90 seconds.
The Nucleotide Sequences of Clone Specific Primers Used in the Experiments
Clone name, primer sequence and SEQ ID NO are indicated below in this order. Each is demarcated by a double slash mark (//).
The result of expression frequency analysis is shown in Table 40. The clones not shown in the table contain clones whose expression levels could not be measured because the levels were too low or the sizes of the PCR products were different from the expected. It was confirmed that the expression levels of IL-8 gene used as a positive control gene were elevated.
The result obtained by the search for the genes whose expression levels were altered depending on the presence of TNF-α in culturing THP-1 cell, which is a human monocyte cell line, showed that the clones whose expression levels were elevated by twofold or more one or three hours after the stimulation (the clones whose expression levels were 0.1 or lower both before and after the stimulation were excluded), were
On the other hand, in particular cases where the expression levels were relatively high in the unstimulated cells (the relative value was 1 or higher), the clones whose expression levels were decreased by twofold or more by the TNF-α stimulation (the clones whose expression levels were increased 1 or 3 hours after the stimulation were excluded) were
These clones were thus revealed to be involved in the inflammation reaction induced by TNF-α.
The result obtained by the search for the genes whose expression levels were altered depending on co-culturing gastric cancer cell line MKN45 with cag PAI positive Helicobacter pylori (TN2), showed that the clones whose expression levels were elevated by twofold or more (the clones whose expression levels were 0.1 or lower both before and after the stimulation were excluded), were
Of these clones, the expression levels of BRAMY20035380, SKMUS20091900, SPLEN20040780, UTERU20064120, CTONG20170940, OCBBF20142290, TESTI20030610 were not increased by the co-culture with the cagE mutant (TN2ΔcagE). There may be the possibility that the expression levels of the 7 clones are altered via the NF-κB pathway. Among them, the expression levels of OCBBF20142290, SPLEN20040780, TESTI20030610, UTERU20064120 were also increased when human monocyte cell line THP-1 was stimulated with TNF-α.
On the other hand, in particular cases where the expression levels were relatively high in the unstimulated cells (the relative value was 1 or higher), the clones whose expression levels were decreased by twofold or more in the presence of Helicobacter pylori were
These clones are involved in gastritis or gastroduodenal ulcer.
Homology Search Result Data
Data obtained by the homology search for full-length nucleotide sequences and deduced amino acid sequences.
In the result of the search shown below, both units, aa and bp, are used as length units for the sequences to be compared.
Each data includes Clone name, Definition in hit data, P value, Length of sequence to be compared, Homology, and Accession number (No.) of hit data. These items are shown in this order and separated by a double-slash mark, //.
- ADRGL20020290//Human placental equilibrative nucleoside transporter 1 (hENT1) mRNA, complete cds.//1.70E-240//456aa//100%//U81375
- ADRGL20021910//Homo sapiens transmembrane protein B7-H2 ICOS ligand mRNA, complete cds.//2.50E-88//168aa//100%//AAG01176
- ADRGL20022600//DIAPHANOUS PROTEIN HOMOLOG 1 (P140MDIA).//2.00E-07//121aa//36%//008808
- ADRGL20023920//ABC1 PROTEIN HOMOLOG PRECURSOR.//1.40E-98//467aa//45%//Q92338
- ADRGL20026790//Homo sapiens PLIC-1 mRNA, complete cds.//6.10E-05//169aa//31%//AF293384
- ADRGL20027530
- ADRGL20036380
- ADRGL20036840//HLA CLASS I HISTOCOMPATIBILITY ANTIGEN, ALPHA CHAIN H PRECURSOR (HLA-AR) (HLA-12.4).//7.30E-68//131aa//96%//P01893
- ADRGL20040310
- ADRGL20040770
- ADRGL20046760
- ADRGL20047080
- ADRGL20047770
- ADRGL20057560
- ADRGL20059610//GLUCOSYLCERAMIDASE PRECURSOR (EC 3.2.1.45) (BETA-GLUCOCEREBROSIDASE) (ACID BETA-GLUCOSIDASE) (D-GLUCOSYL-N-ACYLSPHINGOSINE GLUCOHYDROLASE) (ALGLUCERASE) (IMIGLUCERASE).//3.00E-94//188aa//93%//P04062
- ADRGL20062330//Homo sapiens trabeculin-alpha mRNA, complete cds.//1.10E-128//439aa//58%//AF141968
- ADRGL20063770
- ADRGL20066770//elastin microfibril interface located protein [Homo sapiens].//3.00E-31//210aa//44%//NP—008977
- ADRGL20067320
- ADRGL20079060//Mus musculus mRNA for Ky protein (muscle-specific protein).//3.80E-266//281aa//84%//AJ293727
- ADRGL20095330
- ASTRO20001910//Rattus norvegicus mRNA for annexin V-binding protein (ABP-10), partial cds.//2.20E-57//153aa//73%//D64062
- ASTRO20003720
- ASTRO20004820
- ASTRO20006530//Homo sapiens hook1 protein (HOOK1) mRNA, complete cds.//1.80E-94//383aa//55%//AF044923
- ASTRO20009140//PUTATIVE COMPETENCE-DAMAGE PROTEIN.//2.70E-06//167aa//29%//P46323
- ASTRO20010010
- ASTRO20010290
- ASTRO20012270
- ASTRO20020240
- ASTRO20020350
- ASTRO20022020
- ASTRO20026320//NAM7 PROTEIN (NONSENSE-MEDIATED mRNA DECAY PROTEIN 1) (UP-FRAMESHIFT SUPPRESSOR 1).//1.80E-47//432aa//33%//P30771
- ASTRO20027330
- ASTRO20038400//Homo sapiens zinc finger homeobox protein ZHX1 mRNA, complete cds.//3.40E-78//282aa//42%//AF106862
- ASTRO20045840
- ASTRO20046280//PSU1 PROTEIN.//1.30E-42//228aa//36%//P53550
- ASTRO20047510
- ASTRO20050810//L-RIBULOKINASE (EC 2.7.1.16).//1.10E-43//512aa//30%//P94524
- ASTRO20052420//PROBABLE GUANINE NUCLEOTIDE REGULATORY PROTEIN TIM (ONCOGENE TIM) (P60 TIM) (TRANSFORMING IMMORTALIZED MAMMARY ONCOGENE).//4.80E-151//408aa//76%//Q12774
- ASTRO20053430//BAND 4.1-LIKE PROTEIN 4 (NBL4 PROTEIN).//1.80E-58//307aa//38%//057457
- ASTRO20055530
- ASTRO20055570//MAJOR PRION PROTEIN PRECURSOR (PRP) (PRP27-30) (PRP33-35C) (ASCR).//5.40E-72//137aa//100%//P04156
- ASTRO20055930
- ASTRO20058960//DNA damage inducible protein homolog—fission yeast (Schizosaccharomyces pombe)//1.90E-14//205aa//31%//T39541
- ASTRO20069200
- ASTRO20075150//TNF RECEPTOR ASSOCIATED FACTOR 3 (CD40 RECEPTOR ASSOCIATED FACTOR 1) (CRAF1) (CD40 BINDING PROTEIN) (CD40BP) (LMP1 ASSOCIATED PROTEIN) (LAP1).//1.00E-25//60aa//98%//Q13114
- ASTRO20076660
- ASTRO20085080//TIPD PROTEIN.//1.80E-58//307aa//37%//015736
- ASTRO20088950//LACTASE-PHLORIZIN HYDROLASE PRECURSOR (LACTASE-GLYCOSYLCERAMIDASE) [INCLUDES: LACTASE (EC 3.2.1.108); PHLORIZIN HYDROLASE (EC 3.2.1.62)].//7.80E-85//331aa//48%//P09848
- ASTRO20089600//Mus musculus sacsin gene, complete cds.//1.10E-05//198aa//26%//AF193557
- ASTRO20090680//M. musculus mRNA for IB3/5-polypeptide.//1.60E-173//412aa//78%//X79131
- ASTRO20091180
- ASTRO20091770
- ASTRO20141740
- BGGI120000670//Rattus norvegicus myosin heavy chain Myr 8b mRNA, complete cds.//1.60E-05//86aa//36%//AY004215
- BGGI120010750//Rattus norvegicus mRNA for SECIS binding protein 2 (sbp2 gene).//7.90E-305//812aa//71%//AJ251245
- BNGH410000570
- BNGH420008150//Human SH3 domain-containing proline-rich kinase (sprk) mRNA, complete cds.//3.40E-139//326aa//82%//U07747
- BNGH420014060
- BNGH420015760//Mus musculus mRNA for JNK-binding protein JNKBP1, complete cds.//1.60E-130//381aa//60%//AB029482
- BNGH420021680
- BNGH420023870//RIBONUCLEASE INHIBITOR.//4.70E-41//314aa//34%//P10775
- BNGH420024870
- BNGH420035290//MYOSIN HEAVY CHAIN KINASE B (EC 2.7.1.129) (MHCK B).//7.60E-37//273aa//35%//P90648
- BNGH420036410
- BNGH420040760
- BNGH420042910
- BNGH420045380
- BNGH420046790//immunoglobulin lambda light chain variable region [Homo sapiens].//5.00E-47//84aa//100%//AAG24674
- BNGH420052350
- BNGH420059680//DIPZ PROTEIN.//3.00E-13//166aa//31%//Q10801
- BNGH420061350
- BNGH420062340
- BNGH420070370//ZINC FINGER PROTEIN GLI1 (GLI).//3.20E-65//165aa//59%//P47806
- BNGH420074600//DNA-DIRECTED RNA POLYMERASE III 128 KDA POLYPEPTIDE (EC 2.7.7.6) (RNA POLYMERASE III SUBUNIT 2).//5.40E-214//522aa//72%//P25167
- BNGH420075940
- BNGH420077980//Rattus norvegicus ankyrin binding cell adhesion molecule neurofascin mRNA, alternatively spliced form, partial cds.//0//588aa//98%//U81036
- BNGH420085100
- BNGH420086030//N-CHIMAERIN (NC) (N-CHIMERIN) (ALPHA CHIMERIN) (A-CHIMAERIN).//2.30E-21//130aa//40%//P15882
- BNGH420087430//Mus musculus mRNA 1 for phtf protein.//5.80E-118//237aa//57%//AJ133721
- BRACE10000510//KERATIN, ULTRA HIGH-SULFUR MATRIX PROTEIN (UHS KERATIN).//4.70E-12//132aa//37%//P26371
- BRACE20003310//ZINC FINGER PROTEIN 85 (ZINC FINGER PROTEIN HPF4) (HTF1).//1.00E-205//504aa//71%//Q03923
- BRACE20007330//RING CANAL PROTEIN (KELCH PROTEIN).//4.60E-66//562aa//31%//Q04652
- BRACE20009050
- BRACE20014450//Mus musculus mRNA for Ndr1 related protein Ndr2, complete cds.//3.20E-150//291aa//95%//AB033921
- BRACE20017790
- BRACE20018810
- BRACE20025820
- BRACE20038920
- BRACE20050870//PRE-mRNA SPLICING HELICASE BRR2 (EC 3.6.1.-).//8.40E-59//584aa//31%//P32639
- BRACE20051600
- BRACE20051930//NEUROPILIN PRECURSOR (A5 PROTEIN) (A5 ANTIGEN).//5.50E-20//179aa//30%//P28824
- BRACE20052430//Homo sapiens AMSH mRNA, complete cds.//4.30E-75//272aa//53%//U73522
- BRACE20052530
- BRACE20054080
- BRACE20054480
- BRACE20054600//Xenopus laevis mRNA for Kielin, complete cds.//4.30E-70//205aa//60%//AB026192
- BRACE20055560
- BRACE20057870
- BRACE20059110
- BRACE20059810
- BRACE20061620//ZINC-BINDING PROTEIN A33.//3.60E-30//329aa//28%//Q02084
- BRACE20062580
- BRACE20063540//MEROZOITE SURFACE PROTEIN CMZ-8 (FRAGMENT).//1.60E-10//164aa//35%//P09125
- BRACE20065470//Xenopus laevis ubiquitin-like fusion protein mRNA, complete cds.//6.70E-63//170aa//71%//L08474
- BRACE20066360
- BRACE20068710
- BRACE20069000//CLN3 PROTEIN (BATTENIN) (BATTEN'S DISEASE PROTEIN).//1.20E-147//279aa//100%//Q13286
- BRACE20069110
- BRACE20069440
- BRACE20079200//Xenopus laevis mRNA for Kielin, complete cds.//3.10E-15//63aa//58%//AB026192
- BRACE20079370//microtubule associated-protein orbit [Drosophila melanogaster].//8.00E-42//282aa//36%//BAA94248
- BRACE20097540//Homo sapiens protein serine/threonine phosphatase 4 regulatory subunit 1 (PP4R1) mRNA, complete cds.//2.80E-96//193aa//96%//AF111106
- BRACE20098860
- BRACE20099070
- BRACE20194670//UDP-GALACTOSE TRANSLOCATOR (UDP-GALACTOSE TRANSPORTER) (UGT) (UDP-GAL-TR).//1.40E-32//72aa//98%//P78381
- BRACE20196180//Homo sapiens HMG domain protein HMGX2 (HMGX2) mRNA, complete cds.//6.90E-154//235aa//91%//AF146223
- BRACE20196960
- BRACE20200770//PROTEIN MOV-10.//3.30E-24//113aa//50%//P23249
- BRACE20200970
- BRACE20204670//PROTEIN-TYROSINE PHOSPHATASE ALPHA PRECURSOR (EC 3.1.3.48) (R-PTP-ALPHA).//4.30E-237//428aa//99%//P18433
- BRACE20205840
- BRACE20207420
- BRACE20212450
- BRACE20215410//PROTEIN-TYROSINE PHOSPHATASE YVH1 (EC 3.1.3.48) (PTPASE YVH1).//2.90E-08//136aa//31%//Q02256
- BRACE20216700
- BRACE20216950//4F2 CELL-SURFACE ANTIGEN HEAVY CHAIN (4F2HC) (LYMPHOCYTE ACTIVATION ANTIGEN 4F2 LARGE SUBUNIT) (4F2 HEAVY CHAIN ANTIGEN) (CD98 ANTIGEN).//4.80E-66//94aa//90%//P08195
- BRACE20219360
- BRAMY10000980
- BRAMY10001730
- BRAMY20000210
- BRAMY20000250
- BRAMY20001510//Homo sapiens RING zinc finger protein (RZF) mRNA, complete cds.//3.80E-131//245aa//99%//AF037204
- BRAMY20003540//1-PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE PHOSPHODIESTERASE DELTA 1 (EC 3.1.4.11) (PLC-DELTA-1) (PHOSPHOLIPASE C-DELTA-1) (PLC-III).//0//745aa//99%//P51178
- BRAMY20003880
- BRAMY20005080//UBIQUITIN CARBOXYL-TERMINAL HYDROLASE 16 (EC 3.1.2.15) (UBIQUITIN THIOLESTERASE 16) (UBIQUITIN-SPECIFIC PROCESSING PROTEASE 16) (DEUBIQUITINATING ENZYME 16) (UBIQUITIN PROCESSING PROTEASE UBP-M).//2.70E-46//93aa//100%//Q9Y5T5
- BRAMY20013670//PECANEX PROTEIN.//1.80E-84//300aa//56%//P18490
- BRAMY20016780
- BRAMY20020440
- BRAMY20021580
- BRAMY20023390
- BRAMY20023640
- BRAMY20024790
- BRAMY20027390
- BRAMY20027990//Homo sapiens NEDL1 mRNA for NEDD4-like ubiquitin ligase 1, complete cds.//4.60E-158//294aa//100%//AB048365
- BRAMY20028530
- BRAMY20028620//NICOTINATE-NUCLEOTIDE PYROPHOSPHORYLASE [CARBOXYLATING] (EC 2.4.2.19) (QUINOLINATE PHOSPHORIBOSYLTRANSFERASE [DECARBOXYLATING]) (QAPRTASE).//9.70E-18//53aa//84%//Q15274
- BRAMY20035380//ZINC TRANSPORTER 1 (ZNT-1).//5.60E-40//211aa//35%//Q62720
- BRAMY20035830//Homo sapiens RCC1-like G exchanging factor RLG mRNA, complete cds.//3.60E-103//251aa//75%//AF060219
- BRAMY20036530
- BRAMY20036810
- BRAMY20038980//INTRACELLULAR PROTEIN TRANSPORT PROTEIN US01.//3.40E-17//407aa//23%//P25386
- BRAMY20039290
- BRAMY20040580//ZINC FINGER PROTEIN 135.//1.70E-29//115aa//54%//P52742
- BRAMY20043520
- BRAMY20043630//Homo sapiens Ras-binding protein SUR-8 mRNA, complete cds.//1.30E-167//364aa//88%//AF068920 BRAMY20044920//UBIQUITIN CARBOXYL-TERMINAL HYDROLASE 4 (EC 3.1.2.15) (UBIQUITIN THIOLESTERASE 4) (UBIQUITIN-SPECIFIC PROCESSING PROTEASE 4) (DEUBIQUITINATING ENZYME 4) (UBIQUITOUS NUCLEAR PROTEIN HOMOLOG).//7.60E-28//86aa//47%//Q13107
- BRAMY20045210
- BRAMY20045420
- BRAMY20047560
- BRAMY20050640
- BRAMY20050940
- BRAMY20051820//Human mRNA for Doc2 (Double C2), complete cds.//1.90E-49//102aa//99%//D31897
- BRAMY20052440
- BRAMY20053910
- BRAMY20055760//POTENTIAL PHOSPHOLIPID-TRANSPORTING ATPASE VA (EC 3.6.1.-).//5.80E-130//393aa//59%//054827
- BRAMY20056620//Homo sapiens mccb mRNA for non-biotin containing subunit of 3-methylcrotonyl-CoA carboxylase, complete cds.//3.00E-106//203aa//100%//AB050049
- BRAMY20056840//UBE-1c2//2.40E-74//261aa//53%//AB030505
- BRAMY20063750//Homo sapiens HRIHFB2007 mRNA, partial cds.//3.40E-139//253aa//99%//AB015330
- BRAMY20072440
- BRAMY20072870//ACETYL-COENZYME A SYNTHETASE (EC 6.2.1.1) (ACETATE-COA LIGASE) (ACYL-ACTIVATING ENZYME).//2.50E-15//88aa//46%//P16929
- BRAMY20073080
- BRAMY20074110
- BRAMY20074860
- BRAMY20076100//STEROIDOGENIC FACTOR 1 (STF-1) (SF-1) (STEROID HORMONE RECEPTOR AD4BP) (FUSHI TARAZU FACTOR HOMOLOG 1).//4.80E-66//132aa//94%//P50569
- BRAMY20076130
- BRAMY20076530
- BRAMY20083330//SYNAPSIN I.//4.50E-05//155aa//29%//P17599
- BRAMY20083820
- BRAMY20089770//P2X PURINOCEPTOR 7 (ATP RECEPTOR) (P2×7) (PURINERGIC RECEPTOR) (P2Z RECEPTOR).//3.30E-136//242aa//99%//Q99572
- BRAMY20091230//MITOCHONDRIAL UNCOUPLING PROTEIN 4 (UCP 4).//4.60E-121//224aa//100%//095847
- BRAMY20093490//Mus musculus ubiquitin-protein ligase E3-alpha (Ubr1) mRNA, complete cds.//7.80E-43//139aa//55%//AF061555
- BRAMY20094890//A KINASE ANCHOR PROTEIN 4 PRECURSOR (MAJOR FIBROUS SHEATH PROTEIN) (FSC1) (P82).//4.60E-06//131aa//27%//Q60662
- BRAMY20095080
- BRAMY20095570
- BRAMY20096930//Torpedo marmorata mRNA for male sterility protein 2-like protein (ms21 gene).//2.00E-63//139aa//82%//AJ272073
- BRAMY20100680
- BRAMY20102900//Homo sapiens RU1 (RU1) mRNA, complete cds.//1.20E-47//151aa//58%//AF168132
- BRAMY20107980
- BRAMY20111780//ZINC FINGER PROTEIN 135.//1.00E-139//416aa//57%//P52742
- BRAMY20117670//Mus musculus mmDNAJA4 mRNA for mmDj4, complete cds.//3.20E-118//239aa//90%//AB032401
- BRAMY20118410
- BRAMY20118490//GLYCEROL KINASE 2 (EC 2.7.1.30) (ATP:GLYCEROL 3-PHOSPHOTRANSFERASE 2) (GLYCEROKINASE 2) (GK 2).//1.80E-48//247aa//40%//Q9X1E4
- BRAMY20120170
- BRAMY20123400
- BRAMY20124970
- BRAMY20125170
- BRAMY20125360//L-ASPARAGINASE (EC 3.5.1.1) (L-ASPARAGINE AMIDOHYDROLASE).//3.30E-53//148aa//43%//Q9ZSD6
- BRAMY20125550//Homo sapiens mRNA for 28 kD interferon responsive protein (IFRG28 gene).//4.40E-16//155aa//33%//AJ251832
- BRAMY20126910
- BRAMY20127310
- BRAMY20127760
- BRAMY20134050//NUCLEOSOME ASSEMBLY PROTEIN 1-LIKE 2 (BRAIN-SPECIFIC PROTEIN, X-LINKED).//1.40E-25//109aa//56%//P51860
- BRAMY20135720
- BRAMY20137360//Homo sapiens gene for TU12B1-TY, exon 12 and complete cds.//2.10E-18//257aa//31%//AB032786
- BRAMY20139440
- BRAMY20139750
- BRAMY20143870//PEPTIDYL-TRNA HYDROLASE (EC 3.1.1.29) (PTH).//5.80E-27//182aa//35%//P96386
- BRAMY20152510//PROTEIN-TYROSINE PHOSPHATASE STRIATUM-ENRICHED (EC 3.1.3.48) (STEP) (NEURAL-SPECIFIC PROTEIN-TYROSINE PHOSPHATASE) (FRAGMENT).//4.80E-293//537aa//97%//P54829
- BRAMY20155500
- BRAMY20158550//CALMODULIN.//1.60E-15//116aa//42%//P04352
- BRAMY20159250
- BRAMY20160020
- BRAMY20173480
- BRAMY20190550//EPIDERMAL GROWTH FACTOR RECEPTOR SUBSTRATE SUBSTRATE 15 (PROTEIN EPS15) (AF-1P PROTEIN).//2.20E-226//464aa//89%//P42566
- BRAMY20194680
- BRAMY20204270
- BRAMY20206340//GUANINE NUCLEOTIDE-BINDING PROTEIN BETA SUBUNIT-LIKE PROTEIN.//4.20E-07//151aa//27%//P38011
- BRAMY20219620
- BRAMY20221600//H. sapiens mRNA for novel T-cell activation protein.//1.60E-130//245aa//99%//X94232
- BRAMY20223010//Mus musculus leucine-rich glioma-inactivated 1 protein precursor, (Lgi1) mRNA, complete cds.//2.00E-79//269aa//52%//AF246818
- BRAMY20225250
- BRAMY20225320
- BRAMY20227230
- BRAMY20227860//Homo sapiens dickkopf-3 (DKK-3) mRNA, complete cds.//2.30E-69//147aa//92%//AF177396
- BRAMY20227960
- BRAMY20231150//PUTATIVE ACID PHOSPHATASE F26C11.1 (EC 3.1.3.2).//2.30E-55//322aa//39%//Q09549
- BRAMY20234820//Homo sapiens mitotic checkpoint protein (MAD1) mRNA, complete cds.//1.30E-286//561aa//100%//AF123318
- BRAMY20237190
- BRAMY20238630//TETRATRICOPEPTIDE REPEAT PROTEIN 4.//1.20E-147//276aa//99%//095801
- BRAMY20243120
- BRAMY20244490//ADENYLATE KINASE ISOENZYME 1 (EC 2.7.4.3) (ATP-AMP TRANSPHOSPHORYLASE) (AK1) (MYOKINASE).//2.50E-19//119aa//37%//P00571
- BRAMY20245140//Rattus norvegicus potassium channel (erg2) mRNA, complete cds.//1.00E-178//427aa//81%//AF016192
- BRAMY20245350
- BRAMY20245760//Araneus diadematus fibroin-4 mRNA, partial cds.//7.90E-05//285aa//22%//U47856
- BRAMY20251210//EPHRIN TYPE-A RECEPTOR 7 PRECURSOR (EC 2.7.1.112) (TYROSINE-PROTEIN KINASE RECEPTOR EHK-3) (EPH HOMOLOGY KINASE-3) (EMBRYONIC BRAIN KINASE) (EBK) (DEVELOPMENTAL KINASE 1) (MDK-1).//3.80E-94//268aa//66%//Q61772
- BRAMY20251750//Homo sapiens BRI3 mRNA, complete cds.//2.80E-131//242aa//95%//AF272043
- BRAMY20263000//DYSTROPHIA MYOTONICA-CONTAINING WD REPEAT MOTIF PROTEIN (DMR-N9 PROTEIN).//2.60E-134//430aa//59%//Q08274
- BRAMY20267780
- BRAMY20269040
- BRAMY20271140
- BRAMY20274510//60S RIBOSOMAL PROTEIN L12.//1.10E-39//102aa//82%//P30050
- BRAMY20285650
- BRAMY20287400
- BRAWH20014590//ZAKI-4 PROTEIN.//3.10E-92//187aa//93%//Q14206
- BRAWH20020470
- BRAWH20020600
- BRAWH20021910//FATTY ACYL-COA HYDROLASE PRECURSOR, MEDIUM CHAIN (EC 3.1.2.14) (THIOESTERASE B).//1.30E-111//450aa//49%//Q04791
- BRAWH20025490
- BRAWH20026010//AD021 protein [Homo sapiens]//4.00E-55//245aa//44%//NP—057697
- BRAWH20027250
- BRAWH20030000
- BRAWH20039640//SLIT PROTEIN PRECURSOR.//6.10E-19//282aa//31%//P24014
- BRAWH20040680//PUTATIVE TRANSCRIPTION ELONGATION FACTOR S-II (TFIIS).//5.90E-06//179aa//29%//P52652
- BRAWH20047790
- BRAWH20050740//ZINC FINGER PROTEIN 151 (POLYOMAVIRUS LATE INITIATOR PROMOTER BINDING PROTEIN) (LP-1) (ZINC FINGER PROTEIN Z13).//1.60E-16//235aa//30%//Q60821
- BRAWH20055240
- BRAWH20055330
- BRAWH20055780
- BRAWH20058120
- BRAWH20063010//SPLICEOSOME ASSOCIATED PROTEIN 49 (SAP 49) (SF3B53).//2.60E-06//121aa//33%//Q15427
- BRAWH20078080
- BRAWH20078620
- BRAWH20080580//ZINC FINGER PROTEIN 84 (ZINC FINGER PROTEIN HPF2).//1.00E-116//316aa//63%//P51523
- BRAWH20082550
- BRAWH20082920//Human TFIIIC Box B-binding subunit mRNA, complete cds.//1.90E-36//72aa//100%//U02619
- BRAWH20093040//PROTEIN KINASE CLK2 (EC 2.7.1.-).//2.70E-86//162aa//96%//P49760 BRAWH20093070//SYNAPSIN.//4.80E-06//245aa//28%//Q24546
- BRAWH20094900//Mus musculus mRNA for sialidase, complete cds.//5.70E-73//310aa//50%//AB026842
- BRAWH20095900//ZINC FINGER PROTEIN 184 (FRAGMENT).//1.20E-170//631aa//48%//Q99676 BRAWH20173790
- BRAWH20174330//SPLICEOSOME ASSOCIATED PROTEIN 49 (SAP 49) (SF3B53).//4.50E-06//121aa//33%//Q15427
- BRAWH20175230
- BRAWH20175340
- BRAWH20176850//Mus musculus mRNA for nuclear protein ZAP, complete cds.//9.50E-151//619aa//53%//AB033168
- BRAWH20182670
- BRAWH20183170//GRR1 PROTEIN.//9.30E-13//218aa//28%//P24814
- BRAWH20185260
- BRAWH20185270
- BRAWH20186010
- BRAWH20188750//BIOTIN SYNTHESIS PROTEIN BIOC.//5.80E-11//190aa//27%//P36571
- BRAWH20190530//Homo sapiens BNPI mRNA for brain-specific Na-dependent inorganic phosphate cotransporter, complete cds.//2.10E-109//118aa//100%//AB032436
- BRAWH20190550//PUTATIVE SERINE/THREONINE-PROTEIN KINASE PKWA (EC 2.7.1.-).//1.30E-05//172aa//29%//P49695
- BRAWH20191980//PROLINE OXIDASE, MITOCHONDRIAL PRECURSOR (EC 1.5.3.-) (PROLINE DEHYDROGENASE).//2.10E-125//234aa//99%//043272
- BRCAN10000760//UREA TRANSPORTER, ERYTHROCYTE.//1.30E-212//389aa//100%//Q13336
- BRCAN10001050//PEANUT-LIKE PROTEIN 2 (BRAIN PROTEIN H5).//1.40E-62//122aa//98%//043236
- BRCAN10001680
- BRCAN20001480
- BRCAN20004180//alpha-1C-adrenergic receptor splice form 2—human//1.10E-22//76aa//76%//S65657
- BRCAN20005230//HEPARIN SULFATE N-DEACETYLASE/N-SULFOTRANSFERASE (EC 2.8.2.-) (N-HSST) (N-HEPARIN SULFATE SULFOTRANSFERASE) (GLUCOSAMINYL N-DEACETYLASE/N-SULFOTRANSFERASE).//8.90E-15//168aa//28%//P52849
- BRCAN20005410//Human 1(3)mbt protein homolog mRNA, complete cds.//2.00E-95//378aa//50%//U89358
- BRCOC10000400
- BRCOC20000470//Homo sapiens DEME-6 mRNA, partial cds.//7.30E-37//252aa//28%//AF007170
- BRCOC20003600//VACUOLAR ATP SYNTHASE SUBUNIT AC45 PRECURSOR (EC 3.6.1.34) (V-ATPASE AC45 SUBUNIT).//5.90E-192//418aa//85%//P40682
- BRHIP10000720
- BRHIP10001040//tweety homolog 1 (Drosophila) [Mus musculus]//1.30E-68//311aa//44%//NP—067299
- BRHIP20000210
- BRHIP20003590
- BRHIP20005060
- BRSSN20001970
- BRSSN20005610//Mus musculus semaphorin cytoplasmic domain-associated protein 3A (Semcap3) mRNA, complete cds.//6.30E-225//730aa//60%//AF127084
- BRSSN20005660
- BRSSN20066440//ZINC FINGER PROTEIN 202.//3.60E-37//169aa//37%//095125
- BRSSN20074640//HYPOTHETICAL 35.8 KDA PROTEIN IN PRP16—SRP40 INTERGENIC REGION.//4.50E-20//217aa//28%//P36163
- BRSSN20091190
- BRSSN20092440
- BRSSN20093890//Homo sapiens mRNA for Kelch motif containing protein, complete cds.//8.40E-13//203aa//30%//AB026190
- CD34C20001750//MHC CLASS INK CELL RECEPTOR PRECURSOR (NATURAL KILLER ASSOCIATED TRANSCRIPT 4) (NKAT-4).//1.10E-18//214aa//35%//P43630
- CTONG10000090
- CTONG20000340
- CTONG20002790
- CTONG20004110//Mus musculus ankycorbin mRNA, complete cds.//6.20E-55//1006aa//24%//AF202315
- CTONG20004520//development- and differentiation-enhancing factor 2; PYK2 C terminus-associated protein [Homo sapiens].//2.00E-86//310aa//81%//NP—003878
- CTONG20007660//Rattus norvegicus caspase recruitment domain protein 9 mRNA, complete cds.//7.30E-28//319aa//32%//AF311288
- CTONG20008190//YPT1-RELATED PROTEIN 2.//3.00E-30//160aa//40%//P17609
- CTONG20008460
- CTONG20015240
- CTONG20017490//SEMAPHORIN 4A PRECURSOR (SEMAPHORIN B) (SEMA B).//3.10E-273//607aa//82%//Q62178
- CTONG20020660
- CTONG20020950//ZINC FINGER PROTEIN 37 (ZFP-37) (MALE GERM CELL SPECIFIC ZINC FINGER PROTEIN).//7.40E-23//258aa//25%//P17141
- CTONG20027660
- CTONG20029030//Homo sapiens Ras-binding protein SUR-8 mRNA, complete cds.//8.30E-25//402aa//28%//AF068920
- CTONG20030280//VEGETATIBLE INCOMPATIBILITY PROTEIN HET-E-1.//2.90E-12//303aa//25%//Q00808
- CTONG20031150
- CTONG20031890
- CTONG20032930//microtubule associated-protein orbit [Drosophila melanogaster]//1.00E-79//913aa//30%//BAA94248
- CTONG20033500
- CTONG20033610//Rattus norvegicus SNIP-a mRNA, complete cds.//2.50E-145//567aa//41%//AF156981
- CTONG20033750//Drosophila melanogaster AAA family protein Bor (bor) mRNA, complete cds.//1.40E-174//492aa//66%//AF227209
- CTONG20035240
- CTONG20036800
- CTONG20036990//BASEMENT MEMBRANE-SPECIFIC HEPARAN SULFATE PROTEOGLYCAN CORE PROTEIN PRECURSOR (HSPG) (PERLECAN) (PLC).//1.10E-10//247aa//27%//Q05793
- CTONG20039370
- CTONG20041150//Streptomyces ansochromogenes strain 7100 SanE (sanE) gene, complete cds.//5.20E-05//133aa//35%//AF228524
- CTONG20041260//Mus musculus retinoic acid-responsive protein (Stra6) mRNA, complete cds.//1.30E-238//602aa//74%//AF062476
- CTONG20042640//NEUROBLAST DIFFERENTIATION ASSOCIATED PROTEIN AHNAK (DESMOYOKIN) (FRAGMENTS).//0//797aa//73%//Q09666
- CTONG20044230//Mus musculus zinc finger protein (Mtsh1) mRNA, partial cds.//1.40E-289//601aa//89%//AF191309
- CTONG20044870
- CTONG20045500//ANION EXCHANGE PROTEIN 3 (CARDIAC/BRAIN BAND 3-LIKE PROTEIN) (CAE3/BAE3).//2.00E-19//276aa//30%//P48751
- CTONG20046690
- CTONG20049480
- CTONG20050490
- CTONG20051100//PUTATIVE METHYLTRANSFERASE (EC 2.1.1.-).//3.50E-29//72aa//87%//043709
- CTONG20051450//testis development protein PRTD [Homo sapiens].//9.00E-50//140aa//85%//AAG33852
- CTONG20052780//Homo sapiens mRNA for SH3 binding protein, complete cds.//8.00E-21//125aa//42%//AB005047
- CTONG20053990//ZINC FINGER PROTEIN 195.//4.30E-08//40aa//75%//014628
- CTONG20055670
- CTONG20055850//Rattus norvegicus golgi peripheral membrane protein p65 (GRASP65) mRNA, complete cds.//1.10E-99//248aa//78%//AF015264
- CTONG20056150
- CTONG20057750
- CTONG20057950
- CTONG20059130//Mus musculus prominin-like protein mRNA, partial cds.//7.50E-103//259aa//77%//AF128113
- CTONG20060040
- CTONG20061290
- CTONG20062730
- CTONG20063770//M-PHASE PHOSPHOPROTEIN 9 (FRAGMENT).//1.80E-96//184aa//100%//Q99550
- CTONG20063930//BETA-CHIMAERIN (BETA-CHIMERIN).//3.50E-31//189aa//34%//Q03070
- CTONG20065240
- CTONG20065680
- CTONG20066110//Homo sapiens DEME-6 mRNA, partial cds.//8.70E-164//557aa//53%//AF007170
- CTONG20068360//MITOCHONDRIAL CARNITINE/ACYLCARNITINE CARRIER PROTEIN (CARNITINE/ACYLCARNITINE TRANSLOCASE) (CAC).//8.00E-30//248aa//35%//P97521
- CTONG20069320
- CTONG20069420
- CTONG20070090
- CTONG20070720//N-CHIMAERIN (NC) (N-CHIMERIN) (ALPHA CHIMERIN) (A-CHIMAERIN).//9.20E-25//180aa//33%//P30337
- CTONG20070780//SPERM-SPECIFIC ANTIGEN 2 (CLEAVAGE SIGNAL-1 PROTEIN) (CS-1).//1.90E-122//249aa//97%//P28290
- CTONG20070910//Homo sapiens mRNA for 26S proteasome subunit p55, complete cds.//7.70E-227//400aa//100%//AB003103
- CTONG20071040//BETA CRYSTALLIN B2 (BP).//6.80E-25//195aa//34%//P26775
- CTONG20071680//HYPOTHETICAL 33.6 KDA PROTEIN IN TDK-PRFA INTERGENIC REGION.//7.40E-14//328aa//23%//P45869
- CTONG20072930//ZINC FINGER PROTEIN 41 (FRAGMENT).//4.10E-216//542aa//69%//P51814
- CTONG20073990
- CTONG20074000//Mus musculus teashirt 2 (Tsh2) gene, partial cds.//0//1024aa//89%//AF207880
- CTONG20074170
- CTONG20074740
- CTONG20076230
- CTONG20076810//site-1 protease of sterol regulatory element binding proteins [Cricetulus griseus]//2.80E-245//463aa//93%//AF078105
- CTONG20077760//SYNAPSIN I.//1.70E-08//209aa//32%//P17599
- CTONG20078340//SUPPRESSOR PROTEIN SRP40.//4.10E-08//282aa//26%//P32583
- CTONG20079590//ALPHA-N-ACETYLGALACTOSAMINIDE ALPHA-2,6-SIALYLTRANSFERASE (EC 2.4.99.-) (ST6GALNACIII) (STY).//1.80E-151//305aa//85%//Q64686
- CTONG20080140//HYPOTHETICAL 60.3 KDA PROTEIN R13G10.2 IN CHROMOSOME III.//8.40E-29//179aa//40%//Q21988
- CTONG20081840
- CTONG20083430
- CTONG20083980//VASODILATOR-STIMULATED PHOSPHOPROTEIN (VASP).//4.50E-10//113aa//34%//P50552
- CTONG20084020
- CTONG20084660//ZINC FINGER PROTEIN 165.//3.30E-33//142aa//57%//P49910
- CTONG20085210//MONO- AND DIACYLGLYCEROL LIPASE PRECURSOR (EC 3.1.1.-) (MDGL).//3.60E-06//94aa//34%//P25234
- CTONG20133720
- CTONG20165590
- CTONG20165750//SON PROTEIN (SON3).//4.40E-239//427aa//99%//P18583
- CTONG20166580
- CTONG20167750
- CTONG20168240
- CTONG20168460
- CTONG20169040//KERATIN, TYPE I CYTOSKELETAL 15 (CYTOKERATIN 15) (K15) (CK 15).//6.00E-112//223aa//99%//P19012
- CTONG20169530
- CTONG20170940//MYOTROPHIN (V-1 PROTEIN) (GRANULE CELL DIFFERENTIATION PROTEIN).//4.60E-10//93aa//36%//P80144
- CTONG20174290//TRICHOHYALIN.//1.30E-07//340aa//21%//P37709
- CTONG20174440
- CTONG20174580//Homo sapiens mRNA for vascular Rab-GAP/TBC-containing protein complete cds.//1.00E-115//335aa//61%//NP—008994
- CTONG20176040//ADP-RIBOSYLATION FACTOR-LIKE PROTEIN 3 (ARD3).//1.70E-34//155aa//43%//P37996
- CTONG20179390
- CTONG20179890
- CTONG20179980
- CTONG20180620
- CTONG20180690
- CTONG20181350
- CTONG20183430//ANKYRIN 2 (BRAIN ANKYRIN) (ANKYRIN B) (ANKYRIN, NONERYTHROID).//4.60E-30//311aa//32%//Q01484
- CTONG20183830//IRLB [Homo sapiens]//1.50E-104//191aa//100%//CAA45013
- CTONG20184130
- CTONG20184830//ATP-BINDING CASSETTE, SUB-FAMILY A, MEMBER 1 (ATP-BINDING CASSETTE TRANSPORTER 1) (ATP-BINDING CASSETTE 1).//1.30E-63//271aa//47%//P41233
- CTONG20186140
- CTONG20186290//ALDEHYDE DEHYDROGENASE, DIMERIC NADP-PREFERRING (EC 1.2.1.5) (ALDH CLASS 3).//1.50E-74//144aa//100%//P30838
- CTONG20186370//ZINC FINGER PROTEIN 84 (ZINC FINGER PROTEIN HPF2).//2.60E-52//324aa//33%//P51523
- CTONG20186520//ZINC FINGER PROTEIN MFG-3.//1.40E-197//643aa//53%//P16374
- CTONG20186550//cca3 protein—rat//2.10E-37//141aa//56%//T31081
- CTONG20188080
- CTONG20189000//PROBABLE GUANINE NUCLEOTIDE REGULATORY PROTEIN TIM (ONCOGENE TIM) (P60 TIM) (TRANSFORMING IMMORTALIZED MAMMARY ONCOGENE).//1.10E-48//222aa//50%//Q12774
- CTONG20190290//39.1 KDA PROTEIN IN SURE-CYSC INTERGENIC REGION.//6.00E-15//132aa//31%//Q57261
- CTONG20190630
- DFNES20016470//Homo sapiens SDP1 protein mRNA, complete cds.//4.90E-33//95aa//37%//AF076957
- DFNES20018000//CADHERIN-RELATED TUMOR SUPPRESSOR PRECURSOR (FAT PROTEIN).//8.70E-23//306aa//30%//P33450
- DFNES20025500//Homo sapiens mRNA for paraplegin-like protein.//3.00E-29//68aa//94%//Y18314
- DFNES20028170//Mouse mRNA for RNA polymerase I associated factor (PAF53), complete cds.//1.40E-165//393aa//78%//D14336
- DFNES20029660
- DFNES20032550
- DFNES20043710
- DFNES20046840//FORKHEAD BOX PROTEIN E1 (FORKHEAD-RELATED PROTEIN FKHL15) (THYROID TRANSCRIPTION FACTOR 2) (TTF-2).//6.20E-05//151aa//32%//000358
- DFNES20055400//Homo sapiens diphthamide biosynthesis protein-2 (DPH2) mRNA, complete cds.//5.40E-203//413aa//91%//AF053003
- DFNES20057660//GRAVE'S DISEASE CARRIER PROTEIN (GDC) (MITOCHONDRIAL SOLUTE CARRIER PROTEIN HOMOLOG).//7.00E-31//247aa//33%//Q01888
- DFNES20063460//PAB-DEPENDENT POLY(A)-SPECIFIC RIBONUCLEASE SUBUNIT PAN3 (EC 3.1.13.4) (PAB1P-DEPENDENT POLY(A)-NUCLEASE).//1.90E-23//115aa//43%//P36102
- DFNES20072990//HYPOTHETICAL 46.7 KDA PROTEIN IN HOR7-COX7 INTERGENIC REGION.//1.80E-22//310aa//25%//Q04835
- DFNES20073320//Mus musculus RING-finger protein MURF mRNA, complete cds.//6.70E-118//362aa//61%//AF294790
- DFNES20076340
- DFNES20080880//POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE (EC 2.4.1.41) (PROTEIN-UDP ACETYLGALACTOSAMINYLTRANSFERASE) (UDP-GALNAC:POLYPEPTIDE, N-ACETYLGALACTOSAMINYLTRANSFERASE) (GALNAC-T1).//2.00E-104//486aa//43%//Q10472
- DFNES20088810
- DFNES20094820//coronin-like protein [Schizosaccharomyces pombe]//3.60E-20//333aa//24%//CAB11184
- FCBBF10000230//H. sapiens mRNA from TYL gene.//3.30E-155//650aa//51%//X99688
- FCBBF10002200
- FCBBF10004760//Homo sapiens GAP-like protein (N61) mRNA, complete cds.//9.10E-82//412aa//44%//AF251038
- FCBBF20018680//RABPHILIN-3A.//1.70E-16//262aa//30%//P47709
- FCBBF20020440
- FCBBF20021110
- FCBBF20023490//PUTATIVE PRE-mRNA SPLICING FACTOR ATP-DEPENDENT RNA HELICASE SPAC10F6.02C.//1.20E-90//505aa//39%//042643
- FCBBF20028980
- FCBBF20029280
- FCBBF20032930
- FCBBF20033360//RING CANAL PROTEIN (KELCH PROTEIN).//7.40E-33//234aa//32%//Q04652
- FCBBF20035430//Mus musculus arsenite inducible RNA associated protein (Airap) mRNA, complete cds.//1.50E-51//152aa//57%//AF224494
- FCBBF20035490//GAP-associated tyrosine phosphoprotein p62 (Sam68) [Homo sapiens]>pir∥A38219 GAP-associated tyrosine phosphoprotein p62//1.50E-214//415aa//93%//NP—006550
- FCBBF20036360
- FCBBF20038230
- FCBBF20038950
- FCBBF20041380
- FCBBF20043730
- FCBBF20054390
- FCBBF20056580//Mus musculus NSD1 protein mRNA, complete cds.//3.40E-304//773aa//75%//AF064553
- FCBBF20059660
- FCBBF20061310
- FCBBF20066340//Homo sapiens nuclear dual-specificity phosphatase (SBF1) mRNA, partial cds.//1.20E-68//312aa//49%//U93181
- FCBBF20070800
- FCBBF20070950//MICRONUCLEAR LINKER HISTONE POLYPROTEIN (MIC LH) [CONTAINS: LINKER HISTONE PROTEINS ALPHA, BETA, DELTA AND GAMMA].//5.00E-10//601aa//20%//P40631
- FCBBF30000010
- FCBBF30001020
- FCBBF30001100//CRAG protein [Drosophila melanogaster]//7.40E-185//800aa//46%//CAA76938
- FCBBF30001150
- FCBBF30002270//HISTONE H1′ (H1.0) (H1(0)).//4.90E-62//154aa//84%//P07305
- FCBBF30002280//THIOREDOXIN PEROXIDASE 2 (THIOREDOXIN-DEPENDENT PEROXIDE REDUCTASE 2) (PROLIFERATION-ASSOCIATED PROTEIN PAG) (NATURAL KILLER CELL ENHANCING FACTOR A) (NKEF-A).//1.20E-27//61aa//98%//Q06830
- FCBBF30002330
- FCBBF30003610//ZINC FINGER PROTEIN 91 (ZINC FINGER PROTEIN HTF10) (HPF7).//9.10E-93//313aa//53%//Q05481
- FCBBF30004340//Homo sapiens GalNAc-T9 mRNA for UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase, complete cds.//1.60E-109//299aa//63%//AB040672
- FCBBF30004730
- FCBBF30005180
- FCBBF30005360//Mus musculus spermatogenesis associated factor (SPAF) mRNA, complete cds.//0//894aa//84%//AF049099
- FCBBF30005500//HYPOTHETICAL PROTEIN KIAA0167.//5.80E-16//124aa//36%//Q99490
- FCBBF30019140//CHROMODOMAIN HELICASE-DNA-BINDING PROTEIN 3 (CHD-3) (MI-2 AUTOANTIGEN 240 KDA PROTEIN) (MI2-ALPHA).//0//725aa//82%//Q12873
- FCBBF30019180//SERINE/THREONINE PROTEIN PHOSPHATASE 2A, 65 KDA REGULATORY SUBUNIT A, ALPHA ISOFORM (PP2A, SUBUNIT A, PR65-ALPHA ISOFORM) (PP2A, SUBUNIT A, R1-ALPHA ISOFORM).//4.60E-233//451aa//98%//P54612
- FCBBF30019240
- FCBBF30021900//ZINC FINGER PROTEIN 91 (ZINC FINGER PROTEIN HTF10) (HPF7).//4.10E-161//633aa//48%//Q05481
- FCBBF30022680//putative 5′-3′ exonuclease//9.00E-12//200aa//25%//AAG29662
- FCBBF30026580//Homo sapiens retinoblastoma-associated protein RAP140 mRNA, complete cds.//7.60E-27//367aa//28%//AF180425
- FCBBF30029250//GLUCOAMYLASE S1/S2 PRECURSOR (EC 3.2.1.3) (GLUCAN 1,4-ALPHA-GLUCOSIDASE) (1,4-ALPHA-D-GLUCAN GLUCOHYDROLASE).//4.00E-18//754aa//23%//P08640
- FCBBF30035570
- FCBBF30042610//Homo sapiens CTL2 gene.//2.10E-137//393aa//60%//AJ245621
- FCBBF30048420//TBX19 PROTEIN (T-BOX PROTEIN 19).//1.40E-94//212aa//85%//060806
- FCBBF30053300//Human autoantigen pericentriol material 1 (PCM-1) mRNA, complete cds.//0//708aa//90%//L27841
- FCBBF30056980
- FCBBF30062490//Mus musculus prominin-like protein mRNA, partial cds.//7.70E-85//210aa//79%//AF128113
- FCBBF30063990
- FCBBF30068210
- FCBBF30071500//Homo sapiens dentin phosphoryn mRNA, complete cds.//2.80E-09//675aa//22%//AF094508
- FCBBF30072440//Homo sapiens SARDH mRNA, alternatively spliced, complete cds.//1.70E-14//81aa//53%//AF095737
- FCBBF30072480
- FCBBF30074530
- FCBBF30074620
- FCBBF30075970
- FCBBF30076310//CAMP-DEPENDENT PROTEIN KINASE, BETA-CATALYTIC SUBUNIT (EC 2.7.1.37) (PKA C-BETA).//8.20E-166//240aa//100%//P22694
- FCBBF30078600
- FCBBF30079770
- FCBBF30080730//SPLICING FACTOR, ARGININE/SERINE-RICH 7 (SPLICING FACTOR 9G8).//3.40E-70//136aa//95%//Q16629
- FCBBF30081000
- FCBBF30085560//HYPOTHETICAL 60.3 KDA PROTEIN R13G10.2 IN CHROMOSOME III.//1.10E-87//531aa//38%//Q21988
- FCBBF30088700
- FCBBF30089380
- FCBBF30091010
- FCBBF30091520//GLUCOAMYLASE S1/S2 PRECURSOR (EC 3.2.1.3) (GLUCAN 1,4-ALPHA-GLUCOSIDASE) (1,4-ALPHA-D-GLUCAN GLUCOHYDROLASE).//3.70E-09//631aa//21%//P08640
- FCBBF30093170//ZINC FINGER PROTEIN 84 (ZINC FINGER PROTEIN HPF2).//2.10E-63//173aa//65%//P51523
- FCBBF30095410
- FCBBF30099490
- FCBBF30100080//ARF NUCLEOTIDE-BINDING SITE OPENER (ARNO PROTEIN) (ARF EXCHANGE FACTOR).//1.10E-57//108aa//100%//Q99418
- FCBBF30100120//Mus musculus semaphorin cytoplasmic domain-associated protein 3A (Semcap3) mRNA, complete cds.//2.10E-192//769aa//50%//AF127084
- FCBBF30100410//Mus musculus testis-specific Y-encoded-like protein (Tspyl1) mRNA, complete cds.//1.90E-56//324aa//42%//AF042180
- FCBBF30101240
- FCBBF30101300
- FCBBF30105080
- FCBBF30105440//Rattus norvegicus ion transporter protein (NRITP) mRNA, partial cds.//3.40E-36//82aa//91%//AF184921
- FCBBF30105860//microtubule associated-protein orbit [Drosophila melanogaster].//1.00E-79//556aa//33%//BAA94248
- FCBBF30106950
- FCBBF30107290//MITOCHONDRIAL PROCESSING PEPTIDASE ALPHA SUBUNIT PRECURSOR (EC 3.4.24.64) (ALPHA-MPP) (P-55) (HA1523) (KIAA0123).//1.00E-91//172aa//100%//Q10713
- FCBBF30107330
- FCBBF30114180
- FCBBF30114850//Homo sapiens C2H2 (Kruppel-type) zinc finger protein mRNA, complete cds.//3.20E-24//249aa//34%//AF159567
- FCBBF30115230
- FCBBF30115920//Homo sapiens nolp mRNA, complete cds.//9.40E-220//257aa//100%//AB017800
- FCBBF30118670//Homo sapiens disintegrin and metalloproteinase domain 19 (ADAM19) mRNA, partial cds.//0//601aa//97%//AF134707
- FCBBF30118890//Drosophila melanogaster La related protein (larp) mRNA, partial cds.//6.70E-25//221aa//35%//AF221108
- FCBBF30125460
- FCBBF30125880//Homo sapiens single-strand selective monofunctional uracil DNA glycosylase mRNA, complete cds.//6.40E-81//96aa//100%//AF125182
- FCBBF30128420
- FCBBF30129010//ZINC FINGER PROTEIN 36 (ZINC FINGER PROTEIN KOX18) (FRAGMENT).//1.20E-179//322aa//100%//P17029
- FCBBF30130410//CALDESMON (CDM).//3.30E-06//170aa//32%//P12957
- FCBBF30130580
- FCBBF30132050//Homo sapiens mRNA for UDP-galactose:2-acetamido-2-deoxy-D-glucose3beta-galactosyltransferase.//2.10E-43//253aa//36%//Y15014 FCBBF30132660//Drosophila melanogaster Canton S tartan protein (trn) mRNA, complete cds.//2.00E-15//293aa//30%//U02078
- FCBBF30135890//GLUTENIN, LOW MOLECULAR WEIGHT SUBUNIT PRECURSOR.//2.60E-07//163aa//34%//P10385
- FCBBF30136230//NIL-2-A ZINC FINGER PROTEIN (NEGATIVE REGULATOR OF IL2) (TRANSCRIPTION FACTOR 8).//0//1090aa//94%//P37275
- FCBBF30138000//trg protein—rat//1.30E-82//560aa//37%//160486
- FCBBF30142290//dJ127B20.3 (novel PHD finger protein) [Homo sapiens].//1.00E-140//287aa//96%//CAB62994
- FCBBF30143550//FYVE FINGER-CONTAINING PHOSPHOINOSITIDE KINASE (EC 2.7.1.68) (1-PHOSPHATIDYLINOSITOL-4-PHOSPHATE KINASE) (PIP5K) (PTDINS(4)P-5-KINASE) (P235).//0//1027aa//91%//Q9Z1T6
- FCBBF30145670
- FCBBF30151190
- FCBBF30153170//6-PHOSPHOFRUCTOKINASE, LIVER TYPE (EC 2.7.1.11) (PHOSPHOFRUCTOKINASE 1) (PHOSPHOHEXOKINASE) (PHOSPHOFRUCTO-1-KINASE ISOZYME B).//0//670aa//99%//P17858
- FCBBF30157270//Rattus norvegicus PAPIN mRNA, complete cds.//1.20E-179//639aa//58%//AF169411
- FCBBF30161780
- FCBBF30164510//RETINAL-CADHERIN PRECURSOR(R-CADHERIN) (R-CAD).//0//794aa//98%//P55283
- FCBBF30166220//SERINE HYDROXYMETHYLTRANSFERASE, CYTOSOLIC (EC 2.1.2.1) (SERINE METHYLASE) (GLYCINE HYDROXYMETHYLTRANSFERASE) (SHMT).//2.70E-12//33aa//100%//P34896
- FCBBF30169280//Petunia x hybrida PGPD14 (PGPD14) mRNA, complete cds.//1.40E-62//261 aa//42%//AF049930
- FCBBF30169870
- FCBBF30170710
- FCBBF30171230//NEUROENDOCRINE CONVERTASE 2 PRECURSOR (EC 3.4.21.94) (NEC 2) (PC2) (PROHORMONE CONVERTASE 2) (PROPROTEIN CONVERTASE 2) (KEX2-LIKE ENDOPROTEASE 2).//1.70E-82//181aa//86%//P16519
- FCBBF30172330
- FCBBF30173960//erythroid differentiation-related factor 1 [Homo sapiens].//6.00E-32//113aa//100%//AAC0001
- FCBBF30175350//MITOGEN-ACTIVATED PROTEIN KINASE 7 (EC 2.7.1.-) (EXTRACELLULAR SIGNAL-REGULATED KINASE 5) (ERK5) (ERK4) (BMK1 KINASE).//4.60E-06//245aa//28%//Q13164
- FCBBF30177290//HYPOTHETICAL 47.6 KDA PROTEIN C16C10.5 IN CHROMOSOME III.//2.40E-28//133aa//46%//Q09251
- FCBBF30179180
- FCBBF30179740
- FCBBF30181730
- FCBBF30194370
- FCBBF30194550//ANKYRIN 1 (ERYTHROCYTE ANKYRIN) (ANKYRIN R) (ANKYRINS 2.1 AND 2.2).//9.90E-54//478aa//33%//P16157
- FCBBF30195690//SYNAPTOTAGMIN I.//1.30E-27//138aa//31%//P34693
- FCBBF30195700
- FCBBF30197840//Mouse mRNA for seizure-related gene product 6 type 2 precursor, complete cds.//0//869aa//91%//D64009
- FCBBF30198670//dof protein—fruit fly (Drosophila melanogaster)//6.60E-05//272aa//24%//T13712
- FCBBF30201630//Chlamydomonas reinhardtii dhc1 gene for 1-alpha dynein heavy chain.//1.10E-121//384aa//58%//AJ243806
- FCBBF30212210
- FCBBF30215240//mitogen inducible gene mig-2—human//2.20E-135//263aa//96%//S69890
- FCBBF30220050//OXYSTEROLS RECEPTOR LXR-BETA (LIVER X RECEPTOR BETA) (NUCLEAR ORPHAN RECEPTOR LXR-BETA) (UBIQUITOUSLY-EXPRESSED NUCLEAR RECEPTOR) (NUCLEAR RECEPTOR NER).//6.90E-96//167aa//100%//P55055
- FCBBF30222910//Mus musculus Rap2 interacting protein 8 (RPIP8) mRNA, complete cds.//4.70E-29//76aa//46%//U73941
- FCBBF30223110
- FCBBF30223210//PLEXIN 4 PRECURSOR (TRANSMEMBRANE PROTEIN SEX).//1.70E-72//179aa//76%//P51805
- FCBBF30225930
- FCBBF30228940//Homo sapiens zinc finger protein dp mRNA, complete cds.//2.60E-14//114aa//42%//AF153201
- FCBBF30230610
- FCBBF30236670//Homo sapiens DEAD-box protein abstrakt (ABS) mRNA, complete cds.//1.00E-128//276aa//91%//AF195417
- FCBBF30250980//GUANINE NUCLEOTIDE-BINDING PROTEIN BETA SUBUNIT-LIKE PROTEIN.//3.20E-06//190aa//28%//024076
- FCBBF30255680//Rattus norvegicus brain specific cortactin-binding protein CBP90 mRNA, partial cds.//1.80E-275//641aa//82%//AF053768
- FCBBF30257370//CARNITINE DEFICIENCY-ASSOCIATED PROTEIN EXPRESSED IN VENTRICLE 1 (CDV-1 PROTEIN).//2.80E-169//355aa//92%//035594
- FCBBF30259050//Mus musculus (clone pMLZ-1) zinc finger protein (Zfp) mRNA, 3′ end of cds.//1.40E-241//499aa//83%//L36315
- FCBBF30260210//Drosophila melanogaster KISMET-L long isoform (kis) mRNA, complete cds.//3.90E-178//420aa//68%//AF215703
- FCBBF30260480//Mus musculus putative E1-E2 ATPase mRNA, partial cds.//1.80E-78//154aa//95%//AF156547
- FCBBF30263080//ZINC FINGER PROTEIN 83 (ZINC FINGER PROTEIN HPF1).//4.20E-33//107aa//58%//P51522 FCBBF30266510
- FCBBF30271990//ANKYRIN 1 (ERYTHROCYTE ANKYRIN).//3.00E-43//419aa//33%//Q02357
- FCBBF30275590//dedicator of cyto-kinesis 1 [Homo sapiens].//1.00E-138//791aa//37%//NP—001371
- FCBBF30282020//cca3 protein—rat//5.50E-249//492aa//94%//T31081
- FCBBF30285930//ZINC FINGER PROTEIN ZFP-1 (MKR1 PROTEIN).//5.70E-68//125aa//97%//P08042
- FCBBF30287940
- FCBBF40000610//late gestation lung 2 protein [Rattus norvegicus].//5.00E-86//178aa//94%//AAF44721
- FCBBF40001920
- FCBBF40005000
- FCBBF50000410
- FCBBF50000610
- FCBBF50001650//Homo sapiens JP3 mRNA for junctophilin type3, complete cds.//1.20E-111//407aa//57%//AB042636
- FCBBF50003530//H. sapiens mRNA for dinG gene.//2.70E-137//181aa//100%//Y10571
- FCBBF50004950
- FEBRA20005040//MYOSIN HEAVY CHAIN, STRIATED MUSCLE.//1.90E-13//479aa//23%//P24733
- FEBRA20007820//MLN 64 PROTEIN (CAB1 PROTEIN).//7.00E-31//129aa//51%//Q14849
- FEBRA20018670
- FEBRA20026820//ZINC FINGER PROTEIN 91 (ZINC FINGER PROTEIN HTF10) (HPF7).//2.20E-135//431aa//50%//Q05481
- FEBRA20027070//ZINC FINGER PROTEIN 41 (FRAGMENT).//1.00E-139//333aa//70%//P51814
- FEBRA20029620
- FEBRA20031000//TRICHOHYALIN.//2.20E-16//360aa//26%//P37709
- FEBRA20031150//Homo sapiens HSKM-B (HSKM-B) mRNA, complete cds.//2.00E-29//63aa//100%//AF226053
- FEBRA20031280
- FEBRA20031810
- FEBRA20035200
- FEBRA20035240//SPLICEOSOME ASSOCIATED PROTEIN 49 (SAP 49) (SF3B53).//7.30E-05//108aa//31%//Q15427
- FEBRA20038220//GLUCOAMYLASE S1/S2 PRECURSOR (EC 3.2.1.3) (GLUCAN 1,4-ALPHA-GLUCOSIDASE) (1,4-ALPHA-D-GLUCAN GLUCOHYDROLASE).//7.50E-05//256aa//24%//P08640
- FEBRA20038330
- FEBRA20038970//Homo sapiens mRNA for stabilin-1 (stab1 gene).//1.30E-42//413aa//99%//AJ275213
- FEBRA20039070
- FEBRA20039260//NonF [Streptomyces griseus subsp. griseus].//2.20E-16//140aa//38%//AAD37457
- FEBRA20040230
- FEBRA20040260
- FEBRA20040290
- FEBRA20040560//Homo sapiens delta-6 fatty acid desaturase (CYB5RP) mRNA, complete cds.//1.70E-112//204aa//100%//AF134404
- FEBRA20045380//EVI-5 homolog [Homo sapiens].//7.00E-49//130aa//81%//AAC16031
- FEBRA20046200//ANKYRIN 2 (BRAIN ANKYRIN) (ANKYRIN B) (ANKYRIN, NONERYTHROID).//1.70E-25//368aa//30%//Q01484
- FEBRA20046280
- FEBRA20046510//ZINC FINGER PROTEIN 135.//1.10E-94//260aa//62%//P52742
- FEBRA20057010//ZINC FINGER PROTEIN 195.//1.30E-12//47aa//70%//014628
- FEBRA20063720//ZINC FINGER PROTEIN 85 (ZINC FINGER PROTEIN HPF4) (HTF1).//3.10E-243//586aa//73%//Q03923
- FEBRA20076200
- FEBRA20078180
- FEBRA20078800//NADH-UBIQUINONE OXIDOREDUCTASE 20 KDA SUBUNIT PRECURSOR (EC 1.6.5.3) (EC 1.6.99.3) (COMPLEX I-20 KD) (CI-20KD) (PSST SUBUNIT).//2.30E-96//192aa//96%//075251
- FEBRA20080860
- FEBRA20082660
- FEBRA20083410
- FEBRA20084750
- FEBRA20086600
- FEBRA20087550//damage-specific DNA binding protein 2 (48 kD) [Homo sapiens]//1.10E-106//119aa//94%//NP—000098
- FEBRA20088610//CELLULAR RETINALDEHYDE-BINDING PROTEIN (CRALBP).//2.40E-14//145aa//30%//P10123
- FEBRA20088810//FIBROBLAST GROWTH FACTOR-17 PRECURSOR (FGF-17).//1.00E-102//193aa//99%//060258
- FEBRA20090160//MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 10 (EC 2.7.1.-) (MIXED LINEAGE KINASE 2) (PROTEIN KINASE MST).//1.10E-15//111aa//48%//Q02779
- FEBRA20090220//TRANSLATION INITIATION FACTOR EIF-2B EPSILON SUBUNIT (EIF-2B GDP-GTP EXCHANGE FACTOR).//0//721aa//90%//P47823
- FEBRA20091620
- FEBRA20092760//PINCH PROTEIN (PARTICULARY INTERESTING NEW CYS-HIS PROTEIN).//2.50E-81//165aa//80%//P48059
- FEBRA20093270
- FEBRA20093280
- FEBRA20095410
- FEBRA20098040
- FEBRA20099860//dynactin 3 (p22); dynactin light chain [Homo sapiens]//1.70E-41//89aa//100%//NP—009165
- FEBRA20101410
- FEBRA20108020
- FEBRA20108580
- FEBRA20115930
- FEBRA20116650
- FEBRA20121200
- FEBRA20121950//X INACTIVE SPECIFIC TRANSCRIPT PROTEIN (FRAGMENT).//1.60E-07//155aa//24%//P27571
- FEBRA20141980
- FEBRA20150420//HYPOTHETICAL 131.5 KDA PROTEIN CO2F12.7 IN CHROMOSOME X.//6.90E-56//877aa//24%//Q11102
- FEBRA20151750//Mus musculus (clone E5.53) Huntington disease (hdh) gene, exon 5.//2.60E-12//88aa//43%//L34024
- FEBRA20163980
- FEBRA20170240//ZINC FINGER PROTEIN 75.//7.90E-158//278aa//99%//P51815
- FEBRA20172230//Mus musculus schwannoma-associated protein (SAM9) mRNA, complete cds.//1.70E-57//295aa//40%//AF026124
- FEBRA20173330//PROTEIN KINASE CLK3 (EC 2.7.1.-).//4.80E-277//490aa//99%//P49761
- FEBRA20175020
- FEBRA20175330
- FEBRA20177800//RNA binding motif protein 9 [Homo sapiens].//4.00E-09//75aa//95%//NP—055124
- FEBRA20180510
- FEBRA20182030
- FEBRA20187460
- FEBRA20191720//REGULATOR OF G-PROTEIN SIGNALING 11 (RGS11).//2.00E-73//104aa//100%//094810
- HCHON10000150//SKELETAL MUSCLE LIM-PROTEIN 1 (SLIM 1) (SLIM) (FOUR AND A HALF LIM DOMAINS PROTEIN 1) (FHL-1).//4.10E-74//154aa//84%//Q13642
- HCHON10001660
- HCHON20000870//SERINE/THREONINE-PROTEIN KINASE CTR1 (EC 2.7.1.37).//2.10E-21//300aa//26%//Q05609
- HCHON20002650//EARLY GROWTH RESPONSE PROTEIN 2 (EGR-2) (KROX-20 PROTEIN).//9.90E-05//166aa//26%//P51774
- HCHON20002710//UBIQUITIN CARBOXYL-TERMINAL HYDROLASE 13 (EC 3.1.2.15) (UBIQUITIN THIOLESTERASE 13) (UBIQUITIN-SPECIFIC PROCESSING PROTEASE 13) (DEUBIQUITINATING ENZYME 13).//7.40E-10//114aa//28%//P38187
- HCHON20015050//LEUKOCYTE ADHESION GLYCOPROTEIN P150, 95 ALPHA CHAIN PRECURSOR (LEUKOCYTE ADHESION RECEPTOR P150, 95) (CD11C) (LEU M5) (INTEGRIN ALPHA-X).//8.60E-06//250aa//26%//P20702
- HEART10001420//Mus musculus skm-BOP1 (Bop) mRNA, complete cds.//6.10E-259//485aa//94%//U76373
- HEART10001490//ACTIN INTERACTING PROTEIN 2.//1.80E-71//243aa//58%//P46681
- HEART20009590//Homo sapiens mRNA for paraplegin-like protein.//7.10E-47//145aa//67%//Y18314
- HEART20019310//Mus musculus RING-finger protein MURF mRNA, complete cds.//6.70E-118//362aa//61%//AF294790
- HEART20022200//METHIONINE AMINOPEPTIDASE 2 (EC 3.4.11.18) (METAP 2) (PEPTIDASE M 2) (INITIATION FACTOR 2 ASSOCIATED 67 KDA GLYCOPROTEIN) (P67).//1.50E-209//447aa//86%//P50579
- HEART20031680
- HEART20047640//CALCIUM/CALMODULIN-DEPENDENT 3′,5′-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1C (EC 3.1.4.17) (CAM-PDE 1C).//0//769aa//94%//Q63421
- HEART20063100//H. sapiens mRNA histone RNA hairpin-binding protein.//5.60E-114//212aa//100%//Z71188
- HEART20082570//AMINOMETHYLTRANSFERASE PRECURSOR (EC 2.1.2.10) (GLYCINE CLEAVAGE SYSTEM T PROTEIN).//5.50E-113//210aa//69%//P28337
- HHDPC10001140
- HHDPC20051850//STEROID RECEPTOR PROTEIN DG6.//9.50E-43//101aa//89%//015173
- HHDPC20081230//NUCLEOLIN (PROTEIN C23).//0//681aa//92%//P19338
- HHDPC20082790
- HHDPC20082970
- HHDPC20088160
- HLUNG20008460//DIAPHANOUS PROTEIN HOMOLOG 2.//7.60E-33//521aa//26%//060879
- HLUNG20009260
- HLUNG20009550
- HLUNG20010130
- HLUNG20011260//TYROSINE-PROTEIN KINASE SRC-1 (EC 2.7.1.112) (P60-SRC-1).//1.10E-46//92aa//100%//P13115
- HLUNG20011440
- HLUNG20011460//Rattus norvegicus serine-arginine-rich splicing regulatory protein SRRP86 mRNA, complete cds.//1.20E-159//398aa//79%//AF234765
- HLUNG20012140
- HLUNG20014590//ZINC FINGER PROTEIN 135.//1.20E-122//350aa//59%//P52742
- HLUNG20015070//SLIT PROTEIN PRECURSOR.//5.00E-14//167aa//33%//P24014
- HLUNG20015180//BALBIANI RING PROTEIN 3 PRECURSOR.//8.80E-08//444aa//24%//Q03376
- HLUNG20020500
- HLUNG20020850//TLM PROTEIN (TLM ONCOGENE).//5.00E-17//91aa//54%//P17408
- HLUNG20021450
- HLUNG20023030
- HLUNG20024050
- HLUNG20025620
- HLUNG20028110//zinc finger protein—fission yeast (Schizosaccharomyces pombe).//2.70E-23//140aa//38%//T39456
- HLUNG20029420
- HLUNG20029490
- HLUNG20030420//Mus musculus mRNA for MAIL, complete cds.//1.00E-164//728aa//68%//AB020974
- HLUNG20030490//Ambystoma tigrinum RPE65 protein mRNA, complete cds.//1.70E-64//335aa//42%//AF047465
- HLUNG20030610
- HLUNG20031620
- HLUNG20032460//LYSOSOMAL PRO-X CARBOXYPEPTIDASE PRECURSOR (EC 3.4.16.2) (PROLYLCARBOXYPEPTIDASE) (PRCP) (PROLINE CARBOXYPEPTIDASE) (ANGIOTENSINASE C) (LYSOSOMAL CARBOXYPEPTIDASE C).//8.60E-274//440aa//99%//P42785
- HLUNG20033060//Homo sapiens GAP-like protein (N61) mRNA, complete cds.//1.20E-81//389aa//45%//AF251038
- HLUNG20033310
- HLUNG20033350
- HLUNG20034970
- HLUNG20037140
- HLUNG20037160//RETROVIRUS-RELATED ENV POLYPROTEIN.//1.90E-131//439aa//54%//P10267
- HLUNG20037780
- HLUNG20038330
- HLUNG20041540//GLUCOAMYLASE S1/S2 PRECURSOR (EC 3.2.1.3) (GLUCAN 1,4-ALPHA-GLUCOSIDASE) (1,4-ALPHA-D-GLUCAN GLUCOHYDROLASE).//8.80E-08//286aa//24%//P08640
- HLUNG20041590//ubiquitous tetratricopeptide containing protein RoXaN [Homo sapiens].//1.00E-158//737aa//42%//AAF05541
- HLUNG20042730//CYTOCHROME P450 4A4 (EC 1.14.14.1) (CYPIVA4) (PROSTAGLANDIN OMEGA-HYDROXYLASE) (P450-P-2).//4.90E-126//442aa//49%//P10611
- HLUNG20045340//MOB2 PROTEIN (MPS1 BINDER 2).//4.60E-27//135aa//37%//P43563
- HLUNG20047070
- HLUNG20050760
- HLUNG20051330
- HLUNG20052300//AIG1 PROTEIN.//3.00E-23//216aa//30%//P54120
- HLUNG20054790//PHOSPHATIDYLINOSITOL 3-KINASE REGULATORY SUBUNIT (EC 2.7.1.137) (IB PI3-KINASE P101 SUBUNIT) (PTDINS-3-KINASE P101) (PI3K) (P101-P13K).//8.30E-22//292aa//25%//002696
- HLUNG20055240
- HLUNG20056560
- HLUNG20057380
- HLUNG20059240
- HLUNG20060670
- HLUNG20063700//H. sapiens PEBP2aC1 acute myeloid leukaemia mRNA.//3.60E-22//62aa//79%//Z35278
- HLUNG20065700
- HLUNG20065990//SYNTAXIN 4.//8.80E-127//267aa//96%//Q12846
- HLUNG20067810
- HLUNG20068120//NUCLEAR TRANSITION PROTEIN 2 (TP-2).//7.10E-06//86aa//38%//P11101
- HLUNG20069350//CALCYPHOSINE.//1.80E-13//128aa//31%//Q13938
- HLUNG20070410
- HLUNG20072100//Gallus gallus Dach2 protein (Dach2) mRNA, complete cds.//1.40E-236//404aa//79%//AF198349
- HLUNG20072190
- HLUNG20072450
- HLUNG20074330
- HLUNG20079310
- HLUNG20081390//DNAJ PROTEIN.//1.60E-17//98aa//47%//P35515
- HLUNG20081530//NEUROFILAMENT TRIPLET H PROTEIN (200 KDA NEUROFILAMENT PROTEIN) (NF-H).//1.90E-09//220aa//25%//P12036
- HLUNG20082350//Homo sapiens goodpasture antigen-binding protein (COL4A3BP) mRNA, complete cds.//0//399aa//93%//AF136450
- HLUNG20083330//alpha1 (III) collagen [Homo sapiens]//5.40E-61//113aa//99%//CAA29886
- HLUNG20083480//Chicken mRNA for TSC-22 variant, complete cds, clone SLFEST52.//9.00E-178//527aa//68%//D82364
- HLUNG20083840
- HLUNG20083960
- HLUNG20084790//HYPOTHETICAL 65.2 KDA TRP-ASP REPEATS CONTAINING PROTEIN D2030.9 IN CHROMOSOME I.//5.50E-47//161aa//53%//P90794
- HLUNG20085210//Homo sapiens intersectin 2 (SH3D1B) mRNA, complete cds.//9.60E-28//62aa//95%//AF248540
- HLUNG20088750
- HLUNG20092530
- HLUNG20093030
- HLUNG20094130
- KIDNE20011600
- KIDNE20016360//Rattus norvegicus potassium channel (erg2) mRNA, complete cds.//0//418aa//96%//AF016192
- KIDNE20024380
- KIDNE20027980
- KIDNE20080690//PROBABLE AMINOTRANSFERASE T01B11.2 (EC 2.6.1.-).//5.80E-114//445aa//48%//P91408
- KIDNE20081170//Homo sapiens microtubule-based motor (HsKIFC3) mRNA, complete cds.//6.20E-153//216aa//99%//AF004426
- KIDNE20083150
- KIDNE20083620//L-ASPARAGINASE (EC 3.5.1.1) (L-ASPARAGINE AMIDOHYDROLASE).//2.60E-53//148aa//43%//Q9ZSD6
- KIDNE20084030
- KIDNE20084040//PHOSPHOLIPASE D1 (EC 3.1.4.4) (PLD 1) (CHOLINE PHOSPHATASE 1) (PHOSPHATIDYLCHOLINE-HYDROLYZING PHOSPHOLIPASE D1).//3.30E-70//134aa//100%//Q13393
- KIDNE20084730//Homo sapiens FH1/FH2 domain-containing protein FHOS (FHOS) mRNA, complete cds.//2.60E-148//599aa//52%//AF113615
- KIDNE20084800
- KIDNE20086490
- KIDNE20086660
- KIDNE20086970
- KIDNE20087880
- KIDNE20088240//atopy related autoantigen CALC [Homo sapiens].//1.00E-26//300aa//26%//CAA76830
- KIDNE20089870//HISTONE ACETYLTRANSFERASE TYPE B SUBUNIT 2 (RETINOBLASTOMA BINDING PROTEIN P46) (RETINOBLASTOMA-BINDING PROTEIN 7).//4.30E-237//422aa//99%//Q16576
- KIDNE20091090
- KIDNE20094260
- KIDNE20094670//Drosophila melanogaster AAA family protein Bor (bor) mRNA, complete cds.//2.10E-124//399aa//59%//AF227209
- KIDNE20095530
- KIDNE20133460//Homo sapiens mRNA for sperm protein.//3.40E-146//284aa//100%//X91879
- KIDNE20133880
- KIDNE20134130
- KIDNE20134890//CENTROMERIC PROTEIN E (CENP-E PROTEIN).//7.70E-05//169aa//21%//Q02224
- KIDNE20137310
- KIDNE20138450
- KIDNE20140870//zinc finger protein 106 [Mus musculus]//2.10E-288//822aa//67%//AF060246
- KIDNE20141120
- KIDNE20141700//40S RIBOSOMAL PROTEIN S4, X ISOFORM (SINGLE COPY ABUNDANT mRNA PROTEIN) (SCR10).//2.60E-72//153aa//89%//P12750
- KIDNE20142680
- KIDNE20142900//THROMBOMODULIN PRECURSOR (FETOMODULIN) (TM) (CD141 ANTIGEN).//1.80E-71//119aa//100%//P07204
- KIDNE20143200
- KIDNE20147170//acetylglutamate synthase—fission yeast (Schizosaccharomyces pombe)//8.40E-15//143aa//37%//T40666
- KIDNE20148080
- KIDNE20149780//NG28 [Mus musculus]//3.50E-66//367aa//44%//AAC97966
- KIDNE20150730//REGULATOR OF MITOTIC SPINDLE ASSEMBLY 1 (RMSA-1).//2.40E-06//84aa//41%//P49646
- KIDNE20152440//Homo sapiens mRNA for serin protease with IGF-binding motif, complete cds.//1.80E-181//388aa//93%//D87258
- KIDNE20154330//Rattus norvegicus mRNA for multi PDZ domain protein.//0//763aa//87%//AJ001320
- KIDNE20154830
- KIDNE20155980
- KIDNE20157100
- KIDNE20160360//ARF NUCLEOTIDE-BINDING SITE OPENER (ARNO PROTEIN) (ARF EXCHANGE FACTOR).//7.10E-40//194aa//41%//Q99418
- KIDNE20160960
- KIDNE20163710
- KIDNE20165390//Homo sapiens mRNA for beta-tubulin folding cofactor D.//0//709aa//94%//AJ006417
- KIDNE20169180//UROMODULIN PRECURSOR (TAMM-HORSFALL URINARY GLYCOPROTEIN) (THP).//0//615aa//99%//P07911
- KIDNE20170400
- KIDNE20173150//Bos taurus mRNA for mitochondrial aralkyl acylCoA:amino acid N-acyltransferase.//2.90E-53//277aa//40%//AJ223301
- KIDNE20173430//Homo sapiens PDZ domain containing-protein (PDZK1) mRNA, complete cds.//7.90E-28//150aa//34%//AF012281
- KIDNE20176030
- KIDNE20181670
- KIDNE20182540
- KIDNE20186170//UDP-GLUCURONOSYLTRANSFERASE 2B13 PRECURSOR, MICROSOMAL (EC 2.4.1.17) (UDPGT) (EGT10).//4.40E-38//214aa//39%//P36512
- KIDNE20188630
- KIDNE20189890//Homo sapiens mRNA for KARP-1-binding protein 2 (KAB2), complete cds.//6.00E-30//177aa//44%//AB022658
- KIDNE20189960//TREHALASE PRECURSOR (EC 3.2.1.28) (ALPHA,ALPHA-TREHALASE) (ALPHA,ALPHA-TREHALOSE GLUCOHYDROLASE).//1.40E-224//421aa//97%//043280
- KIDNE20191870
- LIVER20006260//Mus musculus zinc finger protein ZFP113 mRNA, complete cds.//4.50E-183//385aa//85%//AF167320
- LIVER20007690
- LIVER20007750
- LIVER20010510
- LIVER20010760//Homo sapiens C-type lectin-like receptor-1 mRNA, complete cds.//3.10E-134//208aa//100%//AF200949
- LIVER20010990//Rattus norvegicus mRNA for putative integral membrane transport protein (UST1r).//7.00E-52//196aa//54%//Y09945
- LIVER20011640//Human proline rich calmodulin-dependent protein kinase mRNA, complete cds.//2.00E-116//221aa//97%//U23460
- LIVER20013890
- LIVER20026440//CYTOCHROME P450 4F3 (EC 1.14.13.30) (CYPIVF3) (LEUKOTRIENE-B4 OMEGA-HYDROXYLASE) (LEUKOTRIENE-B4 20-MONOOXYGENASE) (CYTOCHROME P450-LTB-OMEGA).//2.60E-136//295aa//84%//Q08477
- LIVER20030650//WHITE PROTEIN.//7.20E-09//229aa//25%//Q05360
- LIVER20032340
- LIVER20038000//MITOCHONDRIAL CARNITINE/ACYLCARNITINE CARRIER PROTEIN (CARNITINE/ACYLCARNITINE TRANSLOCASE) (CAC).//9.40E-40//148aa//38%//P97521
- LIVER20040740//RETINAL-BINDING PROTEIN (RALBP).//3.10E-60//337aa//37%//P49193
- LIVER20055270//SELENIDE, WATER DIKINASE 2 (EC 2.7.9.3) (SELENOPHOSPHATE SYNTHETASE 2) (SELENIUM DONOR PROTEIN 2).//2.70E-204//376aa//97%//Q99611
- MESAN20006200//ANNEXIN II (LIPOCORTIN II) (CALPACTIN I HEAVY CHAIN) (CHROMOBINDIN 8) (P36) (PROTEIN I) (PLACENTAL ANTICOAGULANT PROTEIN IV) (PAP-IV).//1.70E-84//174aa//95%//P07355
- MESAN20007110
- MESAN20008150
- MESAN20008940
- MESAN20009090//Homo sapiens CEGP1 protein (CEGP1), mRNA//1.10E-179//553aa//58%//NM—020974
- MESAN20016270//ZINC FINGER PROTEIN 37A (ZINC FINGER PROTEIN KOX21) (FRAGMENT).//1.60E-141//242aa//100%//P17032
- MESAN20021130//Human SH3 domain-containing proline-rich kinase (sprk) mRNA, complete cds.//8.20E-168//346aa//91%//U07747 MESAN20021220//INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN COMPLEX ACID LABILE CHAIN PRECURSOR (ALS).//7.40E-26//197aa//30%//002833
- MESAN20021470//SPINDLIN (30000 MR METAPHASE COMPLEX) (SSEC P).//3.50E-123//229aa//98%//Q61142
- MESAN20021860
- MESAN20026870
- MESAN20027240//Rho guanine nucleotide exchange factor (GEF) 10 [Homo sapiens].//1.00E-134//620aa//40%//NP—055444
- MESAN20027900//COLLAGEN ALPHA 3(VI) CHAIN PRECURSOR//0//1001aa//98%//P12111
- MESAN20029780
- MESAN20030350//Mus musculus diaphanous-related formin (Dia2) mRNA, complete cds.//6.60E-301//669aa//84%//AF094519
- MESAN20030370
- MESAN20030390
- MESAN20033220//ALDEHYDE DEHYDROGENASE 7 (EC 1.2.1.5).//1.60E-24//54aa//100%//P43353
- MESAN20034440//39.1 KDA PROTEIN IN SURE-CYSC INTERGENIC REGION.//2.70E-07//117aa//31%//Q57261
- MESAN20038520//DNA-DIRECTED RNA POLYMERASE III 128 KDA POLYPEPTIDE (EC 2.7.7.6) (RNA POLYMERASE III SUBUNIT 2).//0//831aa//70%//P25167
- MESAN20041380
- MESAN20045750
- MESAN20056890//SPLICING FACTOR, ARGININE/SERINE-RICH 2 (SPLICING FACTOR SC35) (SC-35) (SPLICING COMPONENT, 35 KDA) (PR264 PROTEIN).//3.30E-12//97aa//48%//Q01130
- MESAN20057240//DNA EXCISION REPAIR PROTEIN ERCC-1.//5.90E-120//195aa//98%//P07992
- MESAN20058110//65 KDA FK506-BINDING PROTEIN PRECURSOR (EC 5.2.1.8) (FKBP65) (FKBPRP) (PEPTIDYL-PROLYL CIS-TRANS ISOMERASE) (PPIASE) (ROTAMASE) (IMMUNOPHILIN FKBP65).//8.00E-117//229aa//89%//Q61576
- MESAN20059570//Rattus norvegicus mRNA for seven transmembrane receptor, complete cds.//1.00E-173//484aa//63%//BAA82518
- MESAN20060220
- MESAN20060430
- MESAN20065990//Human protein serine/threonine kinase stk2 mRNA, complete cds.//2.40E-07//65aa//50%//L20321
- MESAN20067430//TROPOMYOSIN, FIBROBLAST ISOFORM TM3.//1.80E-39//87aa//100%//P09494
- MESAN20069530//LIM domain only 7 isoform c [Homo sapiens]//2.20E-286//545aa//99%//NP—056667
- MESAN20084150//Mus musculus secretory carrier membrane protein 4 mRNA, complete cds.//2.20E-48//128aa//72%//AF224721
- MESAN20085360
- MESAN20089260
- MESAN20090190//CEGP1 protein [Homo sapiens].//0//880aa//57%//NP—066025
- MESAN20094180
- MESAN20095220
- MESAN20095800//PEPTIDYL-PROLYL CIS-TRANS ISOMERASE 10 (EC 5.2.1.8) (PPIASE) (ROTAMASE) (CYCLOPHILIN-10).//1.60E-31//150aa//46%//P52017
- NESOP20004520//LYMPHOCYTE-SPECIFIC PROTEIN LSP1 (PP52 PROTEIN) (52 KDA PHOSPHOPROTEIN) (LYMPHOCYTE-SPECIFIC ANTIGEN WP34).//3.40E-173//321aa//99%//P33241
- NESOP20005040
- NT2NE20018740
- NT2NE20018890//Homo sapiens WD-repeat protein 6 (WDR6) mRNA, complete cds.//6.60E-184//257aa//99%//AF099100
- NT2NE20021860//Lytechinus variegatus embryonic blastocoelar extracellular matrix protein precursor (ECM3) mRNA, complete cds.//9.00E-68//466aa//36%//AF287478
- NT2NE20026200//TRANSKETOLASE (EC 2.2.1.1) (TK).//1.80E-160//310aa//99%//P29401
- NT2NE20026510//basic protein, cytosolic—fruit fly (Drosophila melanogaster)//6.10E-35//202aa//41%//S47857
- NT2NE20028700
- NT2NE20033150
- NT2NE20037050//U2 SMALL NUCLEAR RIBONUCLEOPROTEIN AUXILIARY FACTOR 35 KDA SUBUNIT RELATED-PROTEIN 2.//7.20E-08//109aa//38%//Q15696
- NT2NE20038870//ZINC FINGER X-LINKED PROTEIN ZXDA (FRAGMENT).//5.90E-153//405aa//72%//P98168
- NT2NE20039210
- NT2NE20042550//ADENYLATE KINASE, CHLOROPLAST (EC 2.7.4.3) (ATP-AMP TRANSPHOSPHORYLASE).//7.80E-15//153aa//28%//P43188
- NT2NE20045190
- NT2NE20047870
- NT2NE20053230
- NT2NE20053950//ZINC FINGER PROTEIN 136.//6.40E-108//284aa//64%//P52737
- NT2NE20059210
- NT2NE20059680//Homo sapiens integrin cytoplasmic domain associated protein (Icap-1a) mRNA, complete cds.//1.80E-44//96aa//100%//AF012023
- NT2NE20060750//ZINC FINGER PROTEIN ZFP-36 (FRAGMENT).//1.20E-69//198aa//68%//P16415
- NT2NE20061030//ZINC FINGER PROTEIN 165.//3.00E-39//125aa//65%//P49910
- NT2NE20062880
- NT2NE20064780//A-AGGLUTININ ATTACHMENT SUBUNIT PRECURSOR.//4.10E-05//443aa//24%//P32323
- NT2NE20066590
- NT2NE20069580
- NT2NE20070520
- NT2NE20073650
- NT2NE20077250//Homo sapiens cell cycle progression 2 protein (CPR2) mRNA, complete cds.//1.20E-173//349aa//94%//AF011792
- NT2NE20077270
- NT2NE20077860
- NT2NE20079670//ZINC FINGER PROTEIN 84 (ZINC FINGER PROTEIN HPF2).//2.60E-98//345aa//47%//P51523
- NT2NE20080770
- NT2NE20082130
- NT2NE20082600//Homo sapiens zinc finger protein dp mRNA, complete cds.//2.10E-19//163aa//42%//AF153201
- NT2NE20086070
- NT2NE20087270//Homo sapiens putative RNA binding protein mRNA, alternatively spliced, complete cds.//4.30E-14//221aa//29%//AF119121
- NT2NE20087850//ANTER-SPECIFIC PROLINE-RICH PROTEIN APG (PROTEIN CEX) (FRAGMENT).//1.80E-08//75aa//40%//P40603
- NT2NE20088030
- NT2NE20092950
- NT2NE20095230//Homo sapiens HSKM-B (HSKM-B) mRNA, complete cds.//1.40E-09//112aa//32%//AF226053
- NT2NE20104000
- NT2NE20107810
- NT2NE20108420//KES1 PROTEIN.//4.70E-25//312aa//31%//P35844
- NT2NE20111190//C-TERMINAL BINDING PROTEIN 2.//9.00E-54//137aa//84%//P56545
- NT2NE20112210
- NT2NE20114850
- NT2NE20117580//NADH-UBIQUINONE OXIDOREDUCTASE 20 KDA SUBUNIT PRECURSOR (EC 1.6.5.3) (EC 1.6.99.3) (COMPLEX I-20 KD) (CI-20 KD) (PSST SUBUNIT).//1.20E-76//153aa//95%//075251
- NT2NE20119980//TUMOR NECROSIS FACTOR, ALPHA-INDUCED PROTEIN 1, ENDOTHELIAL (B12 PROTEIN).//6.10E-48//135aa//74%//Q13829
- NT2NE20123610
- NT2NE20124570
- NT2NE20126030
- NT2NE20127900//Homo sapiens myo-inositol 1-phosphate synthase A1 (ISYNA1) mRNA, complete cds.//1.40E-269//465aa//99%//AF220530
- NT2NE20140130//SEMAPHORIN 3B PRECURSOR (SEMAPHORIN V) (SEMA V).//1.90E-42//90aa//100%//Q13214
- NT2NE20140280
- NT2NE20141040//DOWN SYNDROME CRITICAL REGION PROTEIN 1.//1.80E-105//197aa//99%//P53805
- NT2NE20145250//SCG10 PROTEIN (SUPERIOR CERVICAL GANGLION-10 PROTEIN).//2.50E-58//141aa//88%//P55821
- NT2NE20146510//HYPOTHETICAL 104.7 KDA PROTEIN F23F12.8 IN CHROMOSOME III PRECURSOR.//6.20E-08//179aa//23%//P46504
- NT2NE20148690
- NT2NE20149500
- NT2NE20150610
- NT2NE20152620
- NT2NE20153620//mitogen inducible gene mig-2—human//7.90E-147//449aa//63%//S69890
- NT2NE20155650//RETROVIRUS-RELATED ENV POLYPROTEIN.//2.30E-29//114aa//33%//P10267
- NT2NE20157120
- NT2NE20165190
- NT2NE20167660//Mus musculus nuclear localization signal binding protein (spot-1) mRNA, complete cds.//3.50E-09//76aa//40%//S79410
- NT2NE20173970//Rattus norvegicus beta-catenin binding protein mRNA, complete cds.//1.60E-24//134aa//46%//AF169825
- NT2NE20177210//Leishmania major partial ppg1 gene for proteophosphoglycan.//1.10E-06//169aa//27%//AJ243460
- NT2NE20181760
- NT2NE20181800
- NT2NE20184720
- NT2RI20016240
- NT2RI20021200
- NT2RI20033920
- NT2RI20093010//BIFUNCTIONAL METHYLENETETRAHYDROFOLATE DEHYDROGENASE/CYCLOHYDROLASE, MITOCHONDRIAL PRECURSOR [INCLUDES: NAD-DEPENDENT METHYLENETETRAHYDROFOLATE DEHYDROGENASE (EC 1.5.1.15); METHENYLTETRAHYDROFOLATE CYCLOHYDROLASE (EC 3.5.4.9)].//5.90E-34//86aa//81%//P13995
- NT2RP70001120//GA BINDING PROTEIN BETA-1 CHAIN (GABP-BETA-1 SUBUNIT) (GABPB1).//2.50E-113//384aa//62%//Q00420
- NT2RP70001730//Mus musculus actin-binding protein (ENC-1) mRNA, complete cds.//4.30E-249//589aa//74%//U65079
- NT2RP70003110//ELASTIN PRECURSOR (TROPOELASTIN).//1.40E-165//613aa//61%//P15502
- NT2RP70012830//CALPHOTIN.//7.90E-17//445aa//28%//Q02910
- NT2RP70022820
- NT2RP70027190//RAS SUPPRESSOR PROTEIN 1 (RSU-1) (RSP-1 PROTEIN) (RSP-1).//3.80E-23//186aa//34%//Q01730
- NT2RP70029780//ZINC FINGER PROTEIN ZFP-36 (FRAGMENT).//4.30E-118//381aa//56%//P16415
- NT2RP70030840//Mus musculus schlafen3 (Slfn3) mRNA, complete cds.//3.70E-55//328aa//33%//AF099974
- NT2RP70031070//36 KDA NUCLEOLAR PROTEIN HNP36 (DELAYED-EARLY RESPONSE PROTEIN 12) (DER12).//1.20E-23//169aa//34%//Q61672
- NT2RP70031340
- NT2RP70031480
- NT2RP70035110//Caenorhabditis elegans UNC-89 (unc-89) gene, complete cds.//1.50E-07//229aa//26%//U33058
- NT2RP70046410//BASONUCLIN.//3.60E-71//318aa//43%//Q01954
- NT2RP70049610
- NT2RP70056290
- NT2RP70056690//F-SPONDIN PRECURSOR.//2.20E-15//366aa//24%//P35447
- NT2RP70057500//Hypothetical zinc finger-like protein [Homo sapiens].//0//799aa//94%//AAF88107
- NT2RP70064570//CALPAIN P94, LARGE [CATALYTIC] SUBUNIT (EC 3.4.22.17) (CALCIUM-ACTIVATED NEUTRAL PROTEINASE) (CANP) (P94 PROTEIN) (MUSCLE-SPECIFIC CALCIUM-ACTIVATED NEUTRAL PROTEASE 3 LARGE SUBUNIT).//9.40E-86//278aa//40%//Q64691
- NT2RP70074800
- NT2RP70075300//ZINC FINGER PROTEIN 211 (ZINC FINGER PROTEIN C2H2-25).//9.60E-121//333aa//63%//Q13398
- NT2RP70075800//HYPOTHETICAL 43.1 KDA TRP-ASP REPEATS CONTAINING PROTEIN K04G11.4 IN CHROMOSOME X.//1.80E-13//244aa//25%//Q93847
- NT2RP70080150
- NT2RP70084540
- NT2RP70087140//SKIN SECRETORY PROTEIN XP2 PRECURSOR (APEG PROTEIN).//1.40E-11//264aa//31%//P17437
- NT2RP70090870//ZINC FINGER PROTEIN 91 (ZINC FINGER PROTEIN HTF10) (HPF7).//4.20E-230//592aa//61%//Q05481
- NTONG20002230//Mus musculus RW1 protein mRNA, complete cds.//5.20E-97//546aa//34%//AF060565
- NTONG20005310
- NTONG20017620
- NTONG20029850//CALCYPHOSINE (R2D5 ANTIGEN).//1.60E-24//183aa//32%//P41150
- NTONG20031580//heat shock 27 kD protein family, member 7 (cardiovascular); cardiovascular heat shock protein [Homo sapiens]//6.10E-69//141aa//95%//NP—055239
- NTONG20032100//KERATIN, TYPE I CYTOSKELETAL 13 (CYTOKERATIN 13) (K13) (CK 13).//4.20E-175//351aa//96%//P13646
- NTONG20034540//CGMP-DEPENDENT 3′,5′-CYCLIC PHOSPHODIESTERASE (EC 3.1.4.17) (CYCLIC GMP STIMULATED PHOSPHODIESTERASE) (CGS-PDE).//0//713aa//99%//000408
- NTONG20035150//RING CANAL PROTEIN (KELCH PROTEIN).//9.10E-30//570aa//25%//Q04652
- NTONG20043080//MYOSIN LIGHT CHAIN KINASE, SMOOTH MUSCLE AND NON-MUSCLE ISOZYMES (EC 2.7.1.117) (MLCK) [CONTAINS: TELOKIN].//4.30E-12//226aa//28%//P11799
- NTONG20048440//P116 RHO-INTERACTING PROTEIN (P116RIP) (RIP3).//1.60E-269//588aa//87%//P97434
- NTONG20049180
- NTONG20053630//GLUCOAMYLASE S1/S2 PRECURSOR (EC 3.2.1.3) (GLUCAN 1,4-ALPHA-GLUCOSIDASE) (1,4-ALPHA-D-GLUCAN GLUCOHYDROLASE).//1.30E-12//247aa//29%//P08640
- NTONG20053730//UBIQUITIN CARBOXYL-TERMINAL HYDROLASE 64E (EC 3.1.2.15) (UBIQUITIN THIOLESTERASE 64E) (UBIQUITIN-SPECIFIC PROCESSING PROTEASE 64E) (DEUBIQUITINATING ENZYME 64E).//8.70E-104//340aa//60%//Q24574
- NTONG20053910//Bos taurus differentiation enhancing factor 1 (DEF-1) mRNA, complete cds.//2.50E-198//891aa//45%//AF112886
- NTONG20055200//ELONGATION FACTOR G, MITOCHONDRIAL PRECURSOR (MEF-G).//1.10E-269//522aa//83%//Q07803
- NTONG20058010//ACETYL-COENZYME A SYNTHETASE (EC 6.2.1.1) (ACETATE-COA LIGASE) (ACYL-ACTIVATING ENZYME).//3.90E-124//398aa//54%//068040
- NTONG20058220//Homo sapiens phosphoprotein pp75 mRNA, partial cds.//8.60E-14//349aa//25%//AF153085
- OCBBF20000740//Homo sapiens mRNA for ISLR, complete cds.//3.60E-87//287aa//59%//AB003184
- OCBBF20001780
- OCBBF20005220//Rattus norvegicus Fos-related antigen mRNA, complete cds.//3.40E-233//552aa//84%//U34932
- OCBBF20009820
- OCBBF20011860//Mus musculus epithelial protein lost in neoplasm-a (Eplin) mRNA, complete cds.//4.30E-33//98aa//66%//AF307844
- OCBBF20012520//Homo sapiens mRNA for ISLR, complete cds.//6.50E-88//287aa//59%//AB003184
- OCBBF20016390
- OCBBF20016810//enhancer of polycomb [Mus musculus]//0//743aa//92%//AF079765
- OCBBF20109450
- OCBBF20109780
- OCBBF20110210//KILON PROTEIN PRECURSOR (KINDRED OF IGLON).//4.30E-182//352aa//94%//Q9Z0J8
- OCBBF20110730
- OCBBF20111370//BCL2/ADENOVIRUS E1B 19-KDA PROTEIN-INTERACTING PROTEIN 2.//5.70E-84//324aa//52%//054940
- OCBBF20111600//69 KDA ISLET CELL AUTOANTIGEN (ICA69) (ISLET CELL AUTOANTIGEN 1).//1.30E-113//335aa//57%//Q05084
- OCBBF20112280//Mesembryanthemum crystallinum phosphoenolpyruvate/phosphate translocator precursor (PPT) mRNA, complete cds.//7.00E-09//113aa//30%//AF223359
- OCBBF20112320
- OCBBF20113110
- OCBBF20115360
- OCBBF20116250//Mus musculus C2H2-type zinc finger protein (Evi9) mRNA, complete cds.//0//592aa//99%//AF051525
- OCBBF20117220
- OCBBF20118720
- OCBBF20119810
- OCBBF20120010//Homo sapiens zinc metalloprotease ADAMTS6 (ADAMTS6) mRNA, complete cds.//1.60E-44//217aa//42%//AF140674
- OCBBF20120950//ZINC FINGER PROTEIN 151 (POLYOMAVIRUS LATE INITIATOR PROMOTER BINDING PROTEIN) (LP-1) (ZINC FINGER PROTEIN Z13).//1.00E-28//201aa//34%//Q60821
- OCBBF20121910//LAF-4 PROTEIN (LYMPHOID NUCLEAR PROTEIN).//0//740aa//98%//P51826
- OCBBF20123200
- OCBBF20142290
- OCBBF20147070
- OCBBF20152330
- OCBBF20155030
- OCBBF20156450//ZINC FINGER PROTEIN 75.//8.20E-163//289aa//99%//P51815
- OCBBF20157970//ZINC FINGER PROTEIN 135.//2.80E-98//306aa//56%//P52742
- OCBBF20160380//liver stage antigen LSA-1—Plasmodium falciparum//1.10E-21//938aa//24%//A45592
- OCBBF20165900//CELL SURFACE ANTIGEN 114/A10 PRECURSOR.//4.80E-09//145aa//31%//P19467
- OCBBF20165910//Mus musculus pecanex 1 mRNA, complete cds.//4.20E-116//407aa//53%//AF096286
- OCBBF20166890//RESTIN (CYTOPLASMIC LINKER PROTEIN-170) (CLIP-170).//4.20E-21//124aa//45%//042184
- OCBBF20166900//ZINC FINGER PROTEIN CLONE 647 (FRAGMENT).//9.00E-18//196aa//30%//P15622
- OCBBF20167290//probable acyl-CoA dehydrogenase—Deinococcus radiodurans (strain R1)//2.50E-72//222aa//60%//D75616
- OCBBF20170350//Mus musculus mRNA for GATS protein.//2.50E-56//121aa//96%//AJ296173
- OCBBF20174580//G2/MITOTIC-SPECIFIC CYCLIN S13-7 (B-LIKE CYCLIN) (FRAGMENT).//7.10E-16//240aa//25%//P25012
- OCBBF20174890//ankyrin 3, long splice form—human//1.10E-150//178aa//100%//A55575
- OCBBF20175360//Homo sapiens C2H2 (Kruppel-type) zinc finger protein mRNA, complete cds.//3.80E-11//101aa//36%//AF159567
- OCBBF20176650
- OCBBF20177540//ZINC FINGER PROTEIN MLZ-4 (ZINC FINGER PROTEIN 46).//1.40E-110//223aa//86%//Q03309
- OCBBF20177910
- OCBBF20182060//Mesocricetus auratus guanine nucleotide-binding protein beta 5 (Gnb5) mRNA, complete cds.//7.20E-82//265aa//61%//U13152
- OCBBF20185630
- OCBBF20188280
- OCBBF20191950//VERY LOW-DENSITY LIPOPROTEIN RECEPTOR PRECURSOR (VLDL RECEPTOR).//0//720aa//97%//P98155
- PANCR10000860//ELASTASE IIIB PRECURSOR (EC 3.4.21.70) (PROTEASE E).//1.10E-52//87aa//97%//P08861
- PEBLM10001470//glutamine (Q)-rich factor 1, QRF-1 [mice, B-cell leukemia, BCL1, Peptide Partial, 84 aa]//5.00E-42//84aa//98%//AAB29272
- PEBLM20001800//IG ALPHA-1 CHAIN C REGION.//7.90E-197//353aa//100%//P01876
- PEBLM20003260//ZINC FINGER PROTEIN 83 (ZINC FINGER PROTEIN HPF1).//4.90E-62//151aa//70%//P51522 PEBLM20005020
- PLACE50001290//HYPOTHETICAL 87.9 KDA PROTEIN F44G4.1 IN CHROMOSOME II PRECURSOR.//2.90E-16//102aa//43%//P54073
- PLACE50001390
- PLACE60001910
- PLACE60004260//CYSTATIN M PRECURSOR (CYSTATIN E).//1.50E-37//81aa//97%//Q15828
- PLACE60006300
- PLACE60011180
- PLACE60012620//LYSOSOMAL TRAFFICKING REGULATOR (BEIGE HOMOLOG).//8.40E-14//128aa//38%//Q99698
- PLACE60017120
- PLACE60052940//TRANSCRIPTION REGULATORY PROTEIN GAL11.//1.70E-05//445aa//23%//P32257
- PLACE60053280
- PLACE60054230//DIAPHANOUS PROTEIN HOMOLOG 2.//1.00E-35//385aa//26%//060879
- PLACE60054820//HYPOTHETICAL PROTEIN KIAA0032.//1.20E-50//180aa//61%//Q15034
- PLACE60054870//MYOSIN HEAVY CHAIN, NONMUSCLE TYPE B (CELLULAR MYOSIN HEAVY CHAIN, TYPE B) (NMMHC-B).//3.70E-11//434aa//20%//P35580
- PLACE60055350
- PLACE60055460//Homo sapiens leucine-zipper protein FKSG13 (FKSG13) mRNA, complete cds.//5.40E-164//327aa//99%//AF312393
- PLACE60055590//MYOSIN-BINDING PROTEIN H (MYBP-H) (H-PROTEIN) (86 KDA PROTEIN).//1.30E-05//124aa//35%//Q05623
- PLACE60056910
- PLACE60057860
- PLACE60061370
- PLACE60062660//ADP-ribosylation factor binding protein GGA1; ADP-ribosylation factor binding protein; Golgi-associated, gamma-adaptin ear containing, ARF-binding protein 1 [Homo sapiens].//6.00E-84//249aa//93%//NP—037497
- PLACE60062870
- PLACE60063940
- PLACE60064180//PUTATIVE PRE-mRNA SPLICING FACTOR ATP-DEPENDENT RNA HELICASE.//1.90E-51//368aa//37%//022899
- PLACE60064740//ADHESIVE PLAQUE MATRIX PROTEIN PRECURSOR (FOOT PROTEIN 1) (MCFP1).//4.80E-11//157aa//31%//Q25434
- PLACE60066970//ZINC FINGER PROTEIN 191.//1.30E-36//115aa//48%//014754
- PLACE60068710//SUPPRESSOR PROTEIN SRP40.//9.50E-43//238aa//50%//P32583
- PLACE60069880
- PLACE60070500
- PLACE60071800//CORONIN-LIKE PROTEIN P57.//3.80E-60//108aa//81%//Q92176
- PLACE60072390
- PLACE60072420
- PLACE60073090//Homo sapiens myo-inositol 1-phosphate synthase A1 (ISYNA1) mRNA, complete cds.//6.60E-219//362aa//98%//AF220530
- PLACE60074820
- PLACE60077870
- PLACE60080360//mucin [Homo sapiens]//5.50E-05//164aa//30%//CAA84032
- PLACE60081260
- PLACE60082850
- PLACE60087680//INSULIN-LIKE GROWTH. FACTOR BINDING PROTEIN 3 PRECURSOR (IGFBP-3) (IBP-3) (IGF-BINDING PROTEIN 3).//2.30E-103//255aa//79%//P17936
- PLACE60088240
- PLACE60092280
- PLACE60092370
- PLACE60093380
- PLACE60095240
- PLACE60095600//HYPOTHETICAL HELICASE C28H8.3 IN CHROMOSOME III.//2.70E-28//201aa//38%//Q09475
- PLACE60098350//Human hepatocellular carcinoma associated protein (JCL-1) mRNA, complete cds.//5.20E-285//558aa//97%//U92544
- PLACE60104630//macrophage migration inhibitory factor (glycosylation-inhibiting factor) [Homo sapiens]//9.70E-51//10aa//93%//XP—000858
- PLACE60105680//Homo sapiens mRNA for TU12B1-TY, complete cds.//1.70E-30//65aa//64%//AB032773
- PLACE60107010//SUPPRESSOR PROTEIN SRP40.//3.80E-05//117aa//29%//P32583
- PLACE60109910
- PLACE60113340//BASEMENT MEMBRANE-SPECIFIC HEPARAN SULFATE PROTEOGLYCAN CORE PROTEIN PRECURSOR(HSPG) (PERLECAN) (PLC).//5.90E-65//238aa//32%//Q05793
- PLACE60118810//Rattus norvegicus kinesin light chain KLCt mRNA, complete cds.//1.90E-230//504aa//87%//AF166267
- PLACE60119700//Homo sapiens mRNA for ABP32, complete cds.//2.30E-21//47aa//100%//AB018357
- PLACE60120280//SER/THR-RICH PROTEIN T10 IN DGCR REGION.//6.00E-99//126aa//84%//P54797
- PLACE60122970//novel C2H2 type zinc finger protein//5.60E-84//169aa//98%//CAC10457
- PLACE60132200//TRICHIOHYALIN.//3.10E-47//297aa//47%//P37709
- PLACE60132320
- PLACE60132880
- PLACE60138840//PUTATIVE MITOCHONDRIAL CARRIER PROTEIN PET8.//7.40E-59//274aa//47%//P38921
- PLACE60140640//Homo sapiens nucleotide binding protein (NBP) mRNA, complete cds.//3.90E-138//262aa//99%//AF208536
- PLACE60150510//NUCLEAR PROTEIN SNF7.//1.60E-11//189aa//25%//P39929
- PLACE60154450//PUTATIVE PREOPTIC REGULATORY FACTOR-2 PRECURSOR (PORF-2).//7.30E-36//75aa//98%//P18890
- PLACE60155910
- PLACE60157310
- PLACE60162100
- PLACE60175640
- PLACE60177880//IGSF5 [Homo sapiens].//3.60E-174//315aa//99%//CAB90447
- PLACE60177910
- PLACE60181870
- PLACE60184410//Mus musculus peroxisomal long chain acyl-CoA thioesterase Ib (Pte1b) gene, exon 3 and complete cds.//1.00E-43//126aa//69%//AF180801
- PLACE60184870//PHOSPHOLIPID TRANSFER PROTEIN PRECURSOR (LIPID TRANSFER PROTEIN II).//1.50E-227//330aa//99%//P55058
- PLACE60188630//Mus musculus mRNA for acetylglucosaminyltransferase-like protein.//7.80E-08//317aa//23%//AJ006278
- PROST10001100//Zea mays clone AGPZm1 arabinogalactan protein (agp) mRNA, partial cds.//5.80E-05//180aa//32%//AF134579
- PROST10001360
- PROST10002150
- PROST20007170//Hypothetical Kruppel-Type Zinc Finger Protein (R28830—1)//0//432aa//100%//AAC24608
- PROST20007600//PUTATIVE ENDONUCLEASE C1F12.06C (EC 3.1.-.-).//5.90E-29//134aa//44%//Q10348
- PROST20011160
- PROST20011800
- PROST20014140
- PROST20014150
- PROST20014650
- PROST20015210//MYOSIN HEAVY CHAIN, SMOOTH MUSCLE ISOFORM (SMMHC) (FRAGMENT).//3.00E-107//262aa//85%//P35749
- PROST20015400
- PROST20016760//M-PHASE PHOSPHOPROTEIN 8 (FRAGMENT).//9.00E-157//298aa//99%//Q99549
- PROST20022120
- PROST20024250//ZINC FINGER PROTEIN 136.//1.70E-45//128aa//63%//P52737
- PROST20028970//Oryctolagus cuniculus CARP mRNA, complete cds.//4.80E-44//177aa//51%//AF131883
- PROST20033240//EPHRIN TYPE-A RECEPTOR 6 PRECURSOR (EC 2.7.1.112) (TYROSINE-PROTEIN KINASE RECEPTOR EHK-2) (EPH HOMOLOGY KINASE-2).//8.40E-241//441aa//95%//Q62413
- PROST20035170//Homo sapiens zinc finger protein dp mRNA, complete cds.//3.40E-15//128aa//42%//AF153201
- PROST20035830
- PROST20036280
- PROST20036350//MULTIFUNCTIONAL AMINOACYL-TRNA SYNTHETASE [INCLUDES: GLUTAMYL-TRNA SYNTHETASE (EC 6.1.1.17) (GLUTAMATE-TRNA LIGASE); PROLYL-TRNA SYNTHETASE (EC 6.1.1.15) (PROLINE-TRNA LIGASE)].//2.20E-137//651aa//42%//P07814
- PROST20039300//Bos taurus mitochondrial mRNA for xenobiotic/medium-chain fatty acid:CoA ligase form XL-III.//1.60E-68//180aa//68%//AJ132751
- PROST20041460
- PROST20042700
- PROST20045700//Zea mays clone AGPZm1 arabinogalactan protein (agp) mRNA, partial cds.//5.80E-05//180aa//32%//AF134579
- PROST20047440
- PROST20048170
- PROST20050390//CYTOCHROME P450 2J2 (EC 1.14.14.1) (CYPIIJ2) (ARACHIDONIC ACID EPOXYGENASE).//1.40E-34//188aa//42%//P51589
- PROST20051310//Homo sapiens DEAD-box protein abstrakt (ABS) mRNA, complete cds.//8.50E-134//257aa//99%//AF195417
- PROST20052720
- PROST20052850//CYCLIN G-ASSOCIATED KINASE (EC 2.7.1.-).//2.20E-18//107aa//54%//P97874
- PROST20054660
- PROST20058860//SMALL NUCLEAR RIBONUCLEOPROTEIN ASSOCIATED PROTEINS B AND B′ (SNRNP-B) (SM PROTEIN B/B′) (SM-B/SM-B′).//8.20E-05//134aa//33%//P14678
- PROST20060200
- PROST20062820//TRANSLATION INITIATION FACTOR IF-2.//1.50E-07//102aa//41%//P71613
- PROST20063430//BCL2/ADENOVIRUS E1B 19-KDA PROTEIN-INTERACTING PROTEIN 2.//8.50E-74//305aa//46%//Q12982
- PROST20065100
- PROST20065790//6-PHOSPHOFRUCTOKINASE, TYPE C (EC 2.7.1.11) (PHOSPHOFRUCTOKINASE 1) (PHOSPHOHEXOKINASE) (PHOSPHOFRUCTO-1-KINASE ISOZYME C) (6-PHOSPHOFRUCTOKINASE, PLATELET TYPE).//0//697aa//99%//Q01813
- PROST20073280
- PROST20075280//MYOSIN LIGHT CHAIN KINASE, SMOOTH MUSCLE AND NON-MUSCLE ISOZYMES (EC 2.7.1.117) (MLCK) [CONTAINS: TELOKIN].//1.30E-08//245aa//23%//P11799
- PROST20078710
- PROST20082430
- PROST20084470//Plasmodium berghei strain NYU2 merozoite surface protein-1 mRNA, partial cds.//2.50E-08//122aa//28%//AF000413
- PROST20084680
- PROST20084720//CYTOCHROME P450 4F2 (EC 1.14.13.30) (CYPIVF2) (LEUKOTRIENE-B4 OMEGA-HYDROXYLASE) (LEUKOTRIENE-B4 20-MONOOXYGENASE) (CYTOCHROME P450-LTB-OMEGA).//1.50E-37//85aa//85%//P78329
- PROST20087240
- PROST20093470
- PROST20094000
- PROST20097310
- PROST20097360
- PROST20097840//SYNAPSIN I.//1.80E-09//193aa//34%//P17599
- PROST20099090//ADAM 12 PRECURSOR (EC 3.4.24.-) (A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 12) (MELTRIN ALPHA).//1.90E-22//73aa//60%//043184
- PROST20102190//CALMODULIN.//1.30E-20//98aa//47%//P02594
- PROST20102500
- PROST20103820
- PROST20105450//SODIUM/HYDROGEN EXCHANGER 6 (NA(+)/H(+) EXCHANGER 6) (NHE-6) (KIAA0267).//1.60E-96//214aa//75%//Q92581
- PROST20106060
- PROST20108850//MICROSOMAL SIGNAL PEPTIDASE 23 KDA SUBUNIT (EC 3.4.-.-) (SPC22/23).//1.20E-69//132aa//100%//P12280
- PROST20110120
- PROST20114100
- PROST20120070//KINESIN HEAVY CHAIN (UBIQUITOUS KINESIN HEAVY CHAIN) (UKHC).//5.00E-05//286aa//24%//P33176
- PROST20121570
- PROST20122490//Gallus gallus syndesmos mRNA, complete cds.//1.20E-63//139aa//84%//AF095446
- PROST20124000
- PROST20125420
- PROST20127450//Homo sapiens TSC-22 related protein (TSC-22R) mRNA, complete cds.//7.90E-44//95aa//98%//AF153603
- PROST20130320
- PROST20138730
- PROST20146590//MUCIN 1 PRECURSOR (POLYMORPHIC EPITHELIAL MUCIN) (PEM) (PEMT) (EPISIALIN) (TUMOR-ASSOCIATED MUCIN) (CARCINOMA-ASSOCIATED MUCIN) (TUMOR-ASSOCIATED EPITHELIAL MEMBRANE ANTIGEN) (EMA) (H23AG) (PEANUT-REACTIVE URINARY MUCIN) (PUM) (BREAST CARCINOMA-ASSOCIATED ANTIGEN DF3).//3.50E-08//556aa//23%//P15941
- PROST20151370//Human probable zinc finger protein H101 mRNA, partial cds.//1.60E-11//104aa//41%//U81557
- PROST20152510//UDP-N-ACETYLGLUCOSAMINE-PEPTIDE N-ACETYLGLUCOSAMINYLTRANSFERASE 100 KDA SUBUNIT (EC 2.4.1.-) (O-GLCNAC TRANSFERASE P100 SUBUNIT).//6.00E-17//148aa//34%//015294
- PROST20152870//Homo sapiens APC2 gene, exon 14.//1.60E-05//195aa//30%//AJ131187 PROST20155370//ZINC FINGER PROTEIN 38 (ZFP-38) (CTFIN51) (TRANSCRIPTION FACTOR RU49).//1.10E-72//140aa//55%//Q07231
- PROST20156360
- PROST20159320
- PROST20168600//Homo sapiens six transmembrane epithelial antigen of prostate (STEAP1) mRNA, complete cds.//1.20E-70//237aa//54%//AF186249
- PUAEN10000650//Homo sapiens TSC-22 related protein (TSC-22R) mRNA, complete cds.//7.90E-44//95aa//98%//AF153603
- PUAEN10000870
- PUAEN10001640//Mus musculus cerebellar postnatal development protein-1 (Cpd1) mRNA, partial cds.//2.80E-126//270aa//90%//U89345
- PUAEN20000800
- PUAEN20001520//L-A VIRUS GAG PROTEIN N-ACETYLTRANSFERASE (EC 2.3.1.-).//1.70E-34//145aa//51%//Q03503
- PUAEN20002470//PROTEIN MOV-10.//6.30E-102//405aa//44%//P23249
- PUAEN20003120//ENHANCER OF ZESTE HOMOLOG 2 (ENX-1).//0//643aa//97%//Q15910
- SALGL10001070//CH-TOG PROTEIN (COLONIC AND HEPATIC TUMOR OVER-EXPRESSED PROTEIN) (KIAA0097).//5.30E-150//297aa//96%//Q14008
- SKMUS20006790
- SKMUS20007260//MICROTUBULE-ASSOCIATED PROTEIN 1B (MAP1.2) (MAP1(X)) [CONTAINS: MAP1 LIGHT CHAIN LC1].//8.10E-05//396aa//23%//P14873
- SKMUS20008730//smoothelin large isoform L2 [Homo sapiens].//1.20E-221//217aa//98%//AAF01481
- SKMUS20017400//TROPOMYOSIN ALPHA CHAIN, SKELETAL MUSCLE TYPE.//3.20E-97//242aa//81%//P06753
- SKMUS20020770
- SKMUS20026340
- SKMUS20040440//60S RIBOSOMAL PROTEIN L3 (HIV-1 TAR RNA BINDING PROTEIN B) (TARBP-B).//3.60E-189//229aa//99%//P39023
- SKMUS20064810
- SKMUS20073150//20-HYDROXYECDYSONE PROTEIN PRECURSOR (20-HE).//1.50E-05//129aa//32%//P29681
- SKMUS20073590//tropomodulin 4 (muscle) [Homo sapiens]//3.90E-58//115aa//100%//NP—037485
- SKMUS20079150//splicing factor 3a, subunit 3, 60 kD; pre-mRNA splicing factor SF3a (60 kD), similar to S. cerevisiae PRP9 (spliceosome-associated protein 61) [Homo sapiens]//9.10E-13//65aa//60%//NP—006793
- SKMUS20091900
- SKNMC10001230//CYCLIN-DEPENDENT KINASE 4 INHIBITOR A (CDK4I) (P16-INK4) (P16-INK4A) (TUMOR SUPPRESSOR CDKN2A).//1.60E-08//105aa//38%//077617
- SKNMC20006350//65 KDA FK506-BINDING PROTEIN PRECURSOR (EC 5.2.1.8) (FKBP65) (FKBPRP) (PEPTIDYL-PROLYL CIS-TRANS ISOMERASE) (PPIASE) (ROTAMASE) (IMMUNOPHILIN FKBP65).//1.10E-185//419aa//79%//Q61576
- SKNSH10001010
- SKNSH20007160
- SKNSH20009710//TROPOMYOSIN, CYTOSKELETAL TYPE (TM30-NM).//3.20E-74//174aa//86%//P12324
- SKNSH20030640//SPLICEOSOME ASSOCIATED PROTEIN 62 (SAP 62) (SF3A66).//3.00E-06//127aa//33%//Q62203
- SKNSH20040390
- SKNSH20052400//VEGETATIBLE INCOMPATIBILITY PROTEIN HET-E-1.//3.60E-17//175aa//29%//Q00808
- SKNSH20057920//CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE I (EC 2.7.1.123) (CAM KINASE I).//5.00E-37//197aa//40%//Q14012
- SKNSH20068220
- SKNSH20094350
- SMINT20000070//Mus musculus mRNA for granuphilin-b, complete cds.//2.70E-44//128aa//41%//AB025259
- SMINT20002320//SERINE/THREONINE PROTEIN PHOSPHATASE 2A, 56 KDA REGULATORY SUBUNIT, BETA ISOFORM (PP2A, B SUBUNIT, B′ BETA ISOFORM) (PP2A, B SUBUNIT, B56 BETA ISOFORM) (PP2A, B SUBUNIT, PR61 BETA ISOFORM) (PP2A, B SUBUNIT, R5 BETA ISOFORM).//4.70E-160//299aa//100%//Q15173
- SMINT20006020//faciogenital dysplasia protein 2 [Mus musculus]//4.10E-158//327aa//87%//AF017368
- SMINT20006090//Oryctolagus cuniculus mRNA for parchorin, complete cds.//7.50E-87//175aa//93%//AB035520
- SMINT20007470//TRICHOHYALIN.//1.20E-37//492aa//28%//Q07283
- SMINT20008110//CALCIUM-TRANSPORTING ATPASE 2C1 (EC 3.6.1.38) (ATP-DEPENDENT CA2+ PUMP PMR1).//1.20E-50//165aa//63%//P98194
- SMINT20011830
- SMINT20011950//ZINC FINGER PROTEIN 202.//1.90E-67//426aa//40%//095125
- SMINT20012220
- SMINT20013970
- SMINT20014610
- SMINT20016150//FERRITIN LIGHT CHAIN (FERRITIN L SUBUNIT).//3.50E-91//174aa//100%//P02792
- SMINT20017310
- SMINT20021260
- SMINT20023110
- SMINT20024140//IG KAPPA CHAIN V-IV REGION B17 PRECURSOR.//1.20E-60//134aa//87%//P06314
- SMINT20026200//ENL PROTEIN.//1.10E-05//260aa//24%//Q03111
- SMINT20028800//tumor supressor protein—fruit fly (Drosophila melanogaster).//2.00E-78//493aa//34%//T13797
- SMINT20028840//CMRF35 ANTIGEN PRECURSOR.//8.40E-19//136aa//41%//Q08708
- SMINT20030740//ZINC FINGER PROTEIN 136.//4.50E-194//535aa//63%//P52737
- SMINT20031280
- SMINT20035050//GTPASE ACTIVATING PROTEIN BEM2/IPL2.//1.20E-07//134aa//26%//P39960
- SMINT20035510//Drosophila melanogaster La related protein (larp) mRNA, partial cds.//5.40E-39//334aa//30%//AF221108
- SMINT20036440//Drosophila melanogaster epsin-like protein mRNA, complete cds./12.90E-69//446aa//41%//AF233291
- SMINT20038660//Homo sapiens HNOEL-iso (HNOEL-iso) mRNA, complete cds.//5.60E-201//368aa//99%//AF201945
- SMINT20039050//Homo sapiens TRIAD3 mRNA, partial cds.//3.20E-86//156aa//100%//AF228527
- SMINT20043390
- SMINT20044140//ZINC FINGER PROTEIN 84 (ZINC FINGER PROTEIN HPF2).//3.50E-39//440aa//28%//P51523
- SMINT20044730//UBIQUINONE BIOSYNTHESIS PROTEIN AARF.//6.20E-22//272aa//27%//P27854
- SMINT20045470
- SMINT20045830
- SMINT20045890
- SMINT20047290
- SMINT20048720
- SMINT20049920//CYTOSOLIC PURINE 5′-NUCLEOTIDASE (EC 3.1.3.5).//4.10E-39//132aa//57%//P49902
- SMINT20052130//Rattus norvegicus mRNA for gankyrin homologue, complete cds.//9.20E-07//104aa//33%//AB022014
- SMINT20054050//ABC1 PROTEIN HOMOLOG PRECURSOR.//1.40E-98//467aa//45%//Q92338
- SMINT20056230//Ig mu chain precursor, membrane-bound (clone 201)—human//5.60E-233//422aa//78%//S14683
- SMINT20056240
- SMINT20062050//PLECTIN.//7.50E-17//436aa//25%//P30427
- SMINT20067080
- SMINT20070620
- SMINT20074330//tektin A1 [Strongylocentrotus purpuratus]//3.10E-26//125aa//45%//M97188
- SMINT20077920
- SMINT20077960//GELSOLIN PRECURSOR, PLASMA (ACTIN-DEPOLYMERIZING FACTOR) (ADF) (BREVIN) (AGEL).//3.30E-246//459aa//99%//P06396
- SMINT20081330
- SMINT20083290//IG ALPHA-1 CHAIN C REGION.//4.40E-196//352aa//99%//P01876
- SMINT20084910
- SMINT20085310
- SMINT20085450
- SMINT20086250//GLYCINE CLEAVAGE SYSTEM H PROTEIN PRECURSOR.//2.20E-40//70aa//97%//P23434
- SMINT20086720//ZINC FINGER PROTEIN 191.//1.40E-29//109aa//55%//014754
- SMINT20088440//IG KAPPA CHAIN V-II REGION RPMI 6410 PRECURSOR.//5.10E-44//117aa//78%//P06310
- SMINT20088690
- SMINT20089210
- SMINT20089600//Homo sapiens mRNA for PICK1, complete cds.//3.10E-145//278aa//100%//AB026491
- SMINT20091190//IG ALPHA-1 CHAIN C REGION.//3.70E-198//353aa//99%//P01876
- SMINT20092120
- SMINT20092160
- SMINT20093630
- SMINT20094150
- SMINT20094680//Homo sapiens mawbp mRNA for MAWD binding protein, complete cds.//2.80E-50//77aa//100%//AB049758
- SPLEN20005160
- SPLEN20005370
- SPLEN20006950
- SPLEN20011350
- SPLEN20012450
- SPLEN20015030
- SPLEN20015100//HYPOTHETICAL 72.5 KDA PROTEIN C2F7.10 IN CHROMOSOME I.//7.50E-16//121aa//36%//Q09701
- SPLEN20016500
- SPLEN20017610
- SPLEN20017810
- SPLEN20019120
- SPLEN20020530
- SPLEN20023430
- SPLEN20023540//H. sapiens mRNA for F25B3.3 kinase like protein from C. elegans.//1.50E-205//385aa//99%//Y12336
- SPLEN20023850//DNA REPAIR PROTEIN RAD18.//3.00E-56//469aa//30%//P53692
- SPLEN20024190//EGF-containing fibulin-like extracellular matrix protein 1; fibrillin-like [Homo sapiens]//3.70E-192//327aa//99%//NP—061489
- SPLEN20024510
- SPLEN20024620//Homo sapiens mRNA for acetyl LDL receptor, complete cds.//1.00E-217//401aa//100%//D86864
- SPLEN20024770//Rattus norvegicus (rsec6) mRNA, complete cds.//2.10E-88//545aa//31%//U32575
- SPLEN20024930//Rattus norvegicus PIPP mRNA for proline-rich inositol polyphosphate 5-phosphatase, complete cds.//0//639aa//91%//AB032551
- SPLEN20029170
- SPLEN20036780
- SPLEN20039180//TENSIN.//2.70E-135//341aa//65%//Q04205
- SPLEN20040780//CORNIFIN B (SMALL PROLINE-RICH PROTEIN 1B) (SPR1B) (SPR1 B).//5.10E-12//110aa//37%//Q62267
- SPLEN20041810//BC-2 protein [Homo sapiens]//4.00E-24//59aa//96%//AF042384
- SPLEN20042200//TRANSCRIPTIONAL REPRESSOR CTCF.//8.40E-22//127aa//33%//P49711
- SPLEN20043430
- SPLEN20043460
- SPLEN20043680//DNA-REPAIR PROTEIN COMPLEMENTING XP-D CELLS (XERODERMA PIGMENTOSUM GROUP D COMPLEMENTING PROTEIN) (DNA EXCISION REPAIR PROTEIN ERCC-2).//7.30E-171//325aa//99%//P18074
- SPLEN20045550
- SPLEN20048800//Homo sapiens mRNA for N-Acetylglucosamine kinase.//1.90E-51//104aa//100%//AJ242910
- SPLEN20049840//M. musculus mRNA for myosin I.//0//1093aa//89%//X97650
- SPLEN20050090//TRICHOHYALIN.//7.20E-17//554aa//23%//P37709
- SPLEN20051420
- SPLEN20054160//Dof protein [Drosophila melanogaster]//9.60E-14//222aa//29%//AJ010641
- SPLEN20054500//Homo sapiens mRNA for putative dipeptidase.//7.10E-130//244aa//100%//AJ295149
- SPLEN20055600//ZINC FINGER PROTEIN 46 (ZINC FINGER PROTEIN KUP).//3.00E-56//155aa//63%//P24278
- SPLEN20057830//REGULATOR OF MITOTIC SPINDLE ASSEMBLY 1 (RMSA-1).//1.10E-16//139aa//43%//P49646
- SPLEN20057900//Homo sapiens N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase mRNA, complete cds.//9.00E-75//130aa//93%//AF187072
- SPLEN20058180
- SPLEN20059270//ZINC-FINGER PROTEIN RFP (RET FINGER PROTEIN).//7.20E-61//497aa//31%//P14373
- SPLEN20062830
- SPLEN20063250//zinc finger protein nocA—fruit fly (Drosophila melanogaster)//9.00E-16//364aa//30%//A55929
- SPLEN20063890//FIBROMODULIN PRECURSOR (FM) (COLLAGEN-BINDING 59 KDA PROTEIN).//2.60E-118//242aa//94%//Q06828
- SPLEN20067010
- SPLEN20071820//Homo sapiens DNA polymerase mu (Pol mu) mRNA, complete cds.//4.70E-62//116aa//100%//AF176097
- SPLEN20073500//TUMOR NECROSIS FACTOR, ALPHA-INDUCED PROTEIN 2 (B94 PROTEIN).//3.50E-10//463aa//25%//Q03169
- SPLEN20073880
- SPLEN20076190
- SPLEN20076470//KINESIN LIGHT CHAIN (KLC).//2.40E-18//137aa//38%//P46825
- SPLEN20080070//TISSUE ALPHA-L-FUCOSIDASE PRECURSOR (EC 3.2.1.51) (ALPHA-L-FUCOSIDASE I) (ALPHA-L-FUCOSIDE FUCOHYDROLASE).//4.70E-253//359aa//98%//P04066
- SPLEN20081640
- SPLEN20085910//Homo sapiens protein activator of the interferon-induced protein kinase (PACT) mRNA, complete cds.//2.90E-23//52aa//100%//AF072860
- SPLEN20087370
- SPLEN20087860
- SPLEN20090880//HLA CLASS I HISTOCOMPATIBILITY ANTIGEN, A-24(A-9) ALPHA CHAIN PRECURSOR (AW-24).//1.40E-66//153aa//83%//P05534
- SPLEN20098030//TRANSCRIPTION INTERMEDIARY FACTOR 1-BETA (NUCLEAR COREPRESSOR KAP-1) (KRAB-ASSOCIATED PROTEIN 1).//4.00E-18//267aa//26%//Q13263
- SPLEN20100040//258.1 KDA PROTEIN C210RF5 (KIAA0933).//7.90E-46//223aa//43%//Q9Y3R5
- SPLEN20101950//SODIUM/HYDROGEN EXCHANGER 6 (NA(+)/H(+) EXCHANGER 6) (NHE-6) (KIAA0267).//7.70E-112//353aa//61%//Q92581
- SPLEN20104150
- SPLEN20104690
- SPLEN20105100
- SPLEN20108000//Homo sapiens steroid dehydrogenase homolog mRNA, complete cds.//9.30E-73//155aa//94%//AF078850
- SPLEN20108460
- SPLEN20110180//Homo sapiens golgi membrane protein GP73 mRNA, complete cds.//1.60E-162//347aa//91%//AF236056
- SPLEN20110210
- SPLEN20110860
- SPLEN20111450
- SPLEN20114190
- SPLEN20116720//Homo sapiens misato mRNA, partial cds.//1.00E-277//481aa//89%//AF272833
- SPLEN20117580
- SPLEN20118050//BONE/CARTILAGE PROTEOGLYCAN I PRECURSOR (BIGLYCAN) (PG-S1).//1.00E-123//240aa//97%//P21810
- SPLEN20121790
- SPLEN20125230
- SPLEN20126110
- SPLEN20135030//Homo sapiens PDZ-LIM protein mystique mRNA, complete cds.//3.30E-92//178aa//97%//AY007729
- SPLEN20136700
- SPLEN20136730//Homo sapiens RAB-like protein 2A (RABL2A) mRNA, complete cds.//9.30E-41//102aa//90%//AF095350
- SPLEN20137530
- SPLEN20138600//NUMB protein [Homo sapiens].//1.00E-97//102aa//100%//AAD01548
- SPLEN20139100//Human (hybridoma H210) anti-hepatitis A IgG variable region, constant region, complementarity-determining regions mRNA, complete cds.//2.30E-227//490aa//85%//M87789
- SPLEN20139360//MAJOR CENTROMERE AUTOANTIGEN B (CENTROMERE PROTEIN B) (CENP-B).//5.10E-35//295aa//32%//P07199
- SPLEN20175920
- SPLEN20176130//Homo sapiens mRNA for ALEX1, complete cds.//9.90E-21//161aa//32%//AB039670
- SPLEN20177400
- SPLEN20180980//METHIONYL-TRNA SYNTHETASE (EC 6.1.1.10) (METHIONINE-TRNA LIGASE) (METRS).//3.40E-57//133aa//87%//P56192
- SPLEN20181570//TRICHOHYALIN.//7.80E-45//832aa//23%//P37709
- SPLEN20182850
- SPLEN20182990//Mus musculus actin-binding protein (ENC-1) mRNA, complete cds.//1.90E-49//586aa//26%//U65079
- SPLEN20183020//BASEMENT MEMBRANE-SPECIFIC HEPARAN SULFATE PROTEOGLYCAN CORE PROTEIN PRECURSOR(HSPG) (PERLECAN) (PLC).//1.20E-24//128aa//46%//Q05793
- SPLEN20183950
- SPLEN20187490//RESTIN (CYTOPLASMIC LINKER PROTEIN-170 ALPHA-2) (CLIP-170) (REED-STERNBERG INTERMEDIATE FILAMENT ASSOCIATED PROTEIN).//5.10E-09//411aa//22%//P30622
- SPLEN20190080
- SPLEN20190430//NEURALIZED PROTEIN.//2.80E-09//181aa//27%//P29503
- SPLEN20190770
- SPLEN20191020//Homo sapiens MIST mRNA, partial cds.//1.50E-207//376aa//99%//AB032369
- SPLEN20192570
- SPLEN20193230
- SPLEN20193490
- SPLEN20193750
- SPLEN20193790//INTERFERON-REGULATED RESISTANCE GTP-BINDING PROTEIN MXA (INTERFERON-INDUCED PROTEIN P78) (IFI-78K).//0//572aa//98%//P20591
- SPLEN20195710//KINESIN LIGHT CHAIN (KLC).//5.80E-28//145aa//45%//P46824
- SPLEN20197090
- SPLEN20197740
- SPLEN20197930//Rattus norvegicus putative transcription factor LUZP (Luzp) mRNA, complete cds.//6.10E-124//275aa//90%//AF181259
- SPLEN20198390//TIPD PROTEIN.//2.80E-52//307aa//37%//015736
- SPLEN20199850
- SPLEN20200070
- SPLEN20200340
- SPLEN20201830//BONE/CARTILAGE PROTEOGLYCAN I PRECURSOR (BIGLYCAN) (PG-S1).//2.50E-152//283aa//100%//P21810
- SPLEN20203590
- SPLEN20204670
- SPLEN20205120
- TESOP10000350
- TESOP10001600
- TESTI10000190//MUCIN 1 PRECURSOR (POLYMORPHIC EPITHELIAL MUCIN) (PEM) (PEMT) (EPISIALIN) (TUMOR-ASSOCIATED MUCIN) (CARCINOMA-ASSOCIATED MUCIN) (TUMOR-ASSOCIATED EPITHELIAL MEMBRANE ANTIGEN) (EMA) (H23AG) (PEANUT-REACTIVE URINARY MUCIN) (PUM) (BREAST CARCINOMA-ASSOCIATED ANTIGEN DF3).//1.40E-23//667aa//28%//P15941
- TESTI10000850
- TESTI10001570//ZINC FINGER PROTEIN 84 (ZINC FINGER PROTEIN HPF2).//1.30E-148//598aa//46%//P51523
- TESTI20004310//TRICHOHYALIN.//1.40E-07//247aa//25%//P22793
- TESTI20005980
- TESTI20006160//CALCIUM-BINDING PROTEIN.//1.10E-11//260aa//28%//P35085
- TESTI20006830//GAR2 PROTEIN.//2.90E-05//221aa//19%//P41891
- TESTI20012080//TUBULIN-TYROSINE LIGASE (EC 6.3.2.25) (TTL).//2.20E-22//217aa//35%//P38584
- TESTI20012360
- TESTI20016970
- TESTI20019590
- TESTI20028020
- TESTI20029100//FIBROSIN (FRAGMENT).//1.60E-10//70aa//48%//Q60791
- TESTI20030200//DOUBLE-STRANDED RNA-SPECIFIC EDITASE 1 (EC 3.5.-.-) (DSRNA ADENOSINE DEAMINASE) (RNA EDITING ENZYME 1).//1.90E-30//192aa//38%//P51400
- TESTI20030440//TRICHOHYALIN.//2.80E-21//412aa//26%//P37709
- TESTI20030610
- TESTI20031310//ALPHA-1-ANTICHYMOTRYPSIN PRECURSOR (ACT).//7.80E-222//423aa//99%//P01011
- TESTI20031410//SYNAPTONEMAL COMPLEX PROTEIN 1 (SCP-1 PROTEIN).//6.10E-11//449aa//24%//Q03410
- TESTI20032770//ANTER-SPECIFIC PROLINE-RICH PROTEIN APG PRECURSOR.//1.40E-07//121aa//37%//P40602
- TESTI20034750
- TESTI20035330
- TESTI20035790//SPLICING FACTOR, ARGININE/SERINE-RICH 4 (PRE-mRNA SPLICING FACTOR SRP75).//2.30E-44//346aa//37%//Q08170
- TESTI20038240//Mus musculus neprilysin-like metallopeptidase 1 (Nl1) mRNA, complete cds.//0//770aa//77%//AF176569
- TESTI20040850
- TESTI20041630//Mus musculus mRNA for type II cytokeratin, complete cds.//1.30E-151//407aa//75%//AB033744
- TESTI20043130
- TESTI20043180//mouse mRNA for megakaryocyte potentiating factor, complete cds.//8.40E-06//392aa//24%//D86370
- TESTI20043220//ORM1 PROTEIN.//6.40E-21//138aa//37%//P53224
- TESTI20043910
- TESTI20043990//APOMUCIN (MUCIN CORE PROTEIN) (FRAGMENT).//8.70E-64//283aa//53%//P12021
- TESTI20044900//Strongylocentrotus purpuratus radial spokehead mRNA, complete cds.//2.50E-150//447aa//61%//U73123
- TESTI20045390//Homo sapiens adlican mRNA, complete cds.//1.80E-173//632aa//47%//AF245505
- TESTI20045740
- TESTI20046110
- TESTI20046490//Homo sapiens B2 gene partial cDNA, clone B2E.//4.30E-33//284aa//34%//AJ002220
- TESTI20046540
- TESTI20046870//RETINAL-BINDING PROTEIN (RALBP).//4.00E-06//244aa//23%//P49193
- TESTI20046890//Mus musculus axotrophin mRNA, complete cds.//2.30E-40//173aa//53%//AF155739
- TESTI20047370//ATROPHIN-1 (DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY PROTEIN).//1.90E-22//695aa//28%//P54258
- TESTI20047930//Homo sapiens NY-REN-2 antigen mRNA, complete cds.//1.50E-191//530aa//67%//AF155095
- TESTI20049060//H. sapiens mRNA for SIRP-beta1.//2.50E-31//172aa//45%//Y10376
- TESTI20049410
- TESTI20049990
- TESTI20050170
- TESTI20050400
- TESTI20050720//SUCCINYL-COA:3-KETOACID-COENZYME A TRANSFERASE PRECURSOR (EC 2.8.3.5) (SUCCINYL COA:3-OXOACID COA-TRANSFERASE) (OXCT).//1.40E-208//519aa//74%//P55809
- TESTI20051200//POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE (EC 2.4.1.41) (PROTEIN-UDP ACETYLGALACTOSAMINYLTRANSFERASE) (UDP-GALNAC:POLYPEPTIDE, N-ACETYLGALACTOSAMINYLTRANSFERASE) (GALNAC-T1).//6.10E-50//189aa//49%//Q10472
- TESTI20051730//MALTOSE PERMEASE.//2.20E-05//327aa//23%//Q45632
- TESTI20052670
- TESTI20053070//HYPOTHETICAL WD-REPEAT PROTEIN SLL0163.//5.00E-06//172aa//28%//Q55563
- TESTI20053260
- TESTI20053780
- TESTI20053800
- TESTI20053950
- TESTI20054700//Streptococcus pneumoniae strain g375 surface protein PspC (pspC) gene, pspC-8.1 allele, complete cds.//6.70E-11//219aa//32%//AF154015
- TESTI20055680//TRANSLATION INITIATION FACTOR IF-2.//5.90E-08//98aa//41%//060841
- TESTI20055880
- TESTI20056030//Homo sapiens 88-kDa Golgi protein (GM88) mRNA, complete cds.//3.60E-103//316aa//68%//AF204231
- TESTI20057200
- TESTI20057430//ZINC FINGER PROTEIN 8 (ZINC FINGER PROTEIN HF.18) (FRAGMENT).//3.00E-307//543aa//99%//P17098
- TESTI20057590//TYROSINE-PROTEIN KINASE-LIKE 7 PRECURSOR(COLON CARCINOMA KINASE-4) (CCK-4).//7.80E-07//152aa//27%//Q13308
- TESTI20057840//INHIBITOR OF APOPTOSIS PROTEIN (IAP) (INHIBITOR OF T CELL APOPTOSIS PROTEIN).//7.20E-08//86aa//36%//Q90660
- TESTI20057880//CALDESMON (CDM).//6.20E-08//203aa//29%//P12957
- TESTI20058350//SERINE/THREONINE PROTEIN PHOSPHATASE 2A, 55 KDA REGULATORY SUBUNIT B, GAMMA ISOFORM (PP2A, SUBUNIT B, B-GAMMA ISOFORM) (PP2A, SUBUNIT B, B55-GAMMA ISOFORM) (PP2A, SUBUNIT B, PR55-GAMMA ISOFORM) (PP2A, SUBUNIT B, R2-GAMMA ISOFORM).//2.00E-232//426aa//99%//P50410
- TESTI20058920//TUBULIN ALPHA-3/ALPHA-7 CHAIN.//3.50E-148//277aa//98%//P05214
- TESTI20059080//Homo sapiens hyaluronidase (LUCA-3) mRNA, complete cds.//2.40E-170//298aa//100%//AF040710
- TESTI20059330
- TESTI20059370
- TESTI20059480
- TESTI20059790
- TESTI20059810//ZINC FINGER PROTEIN 84 (ZINC FINGER PROTEIN HPF2).//7.50E-153//536aa//52%//P51523
- TESTI20060080//MYOSIN HEAVY CHAIN, CLONE 203 (FRAGMENT).//5.30E-09//236aa//24%//P39922
- TESTI20060150
- TESTI20060350
- TESTI20060450
- TESTI20060830//Mus musculus mRNA for MIWI (piwi), complete cds.//0//824aa//94%//AB032604
- TESTI20061090
- TESTI20061200//NITRITE EXTRUSION PROTEIN (NITRITE FACILITATOR).//4.90E-05//379aa//23%//P46907
- TESTI20062120//poly(A)-specific ribonuclease (deadenylation nuclease); deadenylation nuclease [Homo sapiens]//1.00E-38//144aa//36%//NP—002573
- TESTI20062180
- TESTI20062580
- TESTI20063330
- TESTI20063410
- TESTI20063600
- TESTI20064370
- TEST120064530//microtubule-associated protein like echinoderm EMAP [Homo sapiens].//1.00E-173//562aa//48%//XP—009139
- TESTI20064650//Rattus norvegicus myr 6 myosin heavy chain mRNA, complete cds.//0//645aa//91%//U60416
- TESTI20064990
- TESTI20065650//INNER CENTROMERE PROTEIN (INCENP).//1.00E-14//273aa//27%//P53352
- TESTI20066150
- TESTI20066170
- TESTI20066280
- TESTI20066330//FIBRONECTIN PRECURSOR.//9.10E-12//408aa//22%//Q91740
- TESTI20066590
- TESTI20066650//CELL DIVISION CONTROL PROTEIN 25.//2.20E-18//216aa//32%//P04821
- TESTI20067350
- TESTI20067440//INTRACELLULAR PROTEIN TRANSPORT PROTEIN US01.//2.90E-11//553aa//20%//P25386
- TESTI20067480//ZINC FINGER PROTEIN 184 (FRAGMENT).//8.60E-134//421 aa//50%//Q99676
- TESTI20068530
- TESTI20068790//TRANS-ACTING TRANSCRIPTIONAL PROTEIN ICP0 (P135 PROTEIN) (IER 2.9/ER2.6).//7.50E-06//240aa//28%//P29128
- TESTI20068940
- TESTI20070400//Homo sapiens CTL2 gene.//5.90E-229//694aa//55%//AJ245621
- TEST120070740
- TESTI20071130//MYOSIN HEAVY CHAIN, CARDIAC MUSCLE ALPHA ISOFORM.//6.30E-09//399aa//23%//Q02566
- TESTI20071630//GLIOMA PATHOGENESIS-RELATED PROTEIN (RTVP-1 PROTEIN).//5.10E-44//203aa//42%//P48060
- TESTI20073460
- TESTI20075240//HYPOTHETICAL ZINC FINGER PROTEIN KIAA0961.//3.20E-145//492aa//56%//Q9Y2G7
- TESTI20076570//Homo sapiens mitogen-activated protein kinase phosphatase x (MKPX) mRNA, complete cds.//7.20E-66//126aa//100%//AF165519
- TESTI20076920
- TESTI20079060
- TESTI20079220//ZINC FINGER PROTEIN 29 (ZFP-29).//2.00E-73//281aa//49%//Q07230
- TESTI20079980//SEGMENT POLARITY PROTEIN DISHEVELLED HOMOLOG DVL-1 (DISHEVELLED-1) (DSH HOMOLOG 1).//7.10E-212//413aa//93%//P51141
- TESTI20080460
- TESTI20081890//SPA-1 like protein p1294 [Rattus norvegicus]//5.80E-129//385aa//41%//AF026504
- TESTI20083890
- TESTI20084250//OXYSTEROL-BINDING PROTEIN.//3.70E-183//551aa//62%//P16258
- TESTI20085670
- TESTI20086840//CARTILAGE MATRIX PROTEIN PRECURSOR (MATRILIN-1).//3.40E-09//181aa//29%//P05099
- TESTI20088840//ZINC-FINGER PROTEIN RFP (RET FINGER PROTEIN).//2.60E-73//258aa//31%//Q62158
- TESTI20089290
- TESTI20090180
- TESTI20090970
- TESTI20091360
- TESTI20092170
- TESTI20093900
- TESTI20094620
- TESTI20095200//HYPOTHETICAL 98.3 KDA PROTEIN B0495.7 IN CHROMOSOME II.//1.30E-63//328aa//40%//Q09216
- TESTI20095440//probable membrane protein YOR240w—yeast (Saccharomyces cerevisiae)//1.00E-25//98aa//55%//S67133
- TESTI20095770//NEDD1 PROTEIN (FRAGMENT).//5.80E-297//648aa//85%//P33215
- TESTI20095880//HYPOTHETICAL SYMPORTER SLL1374.//3.80E-26//243aa//27%//P74168
- TESTI20097270
- TESTI20099350//MYOSIN HEAVY CHAIN, NONMUSCLE TYPE B (CELLULAR MYOSIN HEAVY CHAIN, TYPE B) (NMMHC-B).//1.50E-26//566aa//23%//P35580
- TESTI20100090//Homo sapiens endocytic receptor Endo180 (ENDO180) mRNA, complete cds.//5.00E-161//317aa//93%//AF134838
- TESTI20102390
- TESTI20103690//Columba livia mRNA for 5′-nucleotidase.//2.70E-114//324aa//66%//AJ131243
- TESTI20104090//TRANSCRIPTIONAL ENHANCER FACTOR TEF-4 (EMBRYONIC TEA DOMAIN-CONTAINING FACTOR) (ETF) (ETEF-1) (TEAD-2).//1.60E-228//450aa//92%//P48301
- TESTI20105130//MYOTUBULARIN.//4.30E-95//537aa//38%//Q13496
- TESTI20105910//AMILORIDE-SENSITIVE SODIUM CHANNEL DELTA-SUBUNIT (EPITHELIAL NA+ CHANNEL DELTA SUBUNIT) (DELTA ENAC) (NONVOLTAGE-GATED SODIUM CHANNEL 1 DELTA SUBUNIT) (SCNED) (DELTA NACH).//0//636aa//97%//P51172
- TESTI20106170//Mus musculus spermatid WD-repeat protein mRNA, complete cds.//2.20E-167//367aa//83%//AF274321
- TESTI20106820//PROTEIN KINASE C, ETA TYPE (EC 2.7.1.-) (NPKC-ETA) (PKC-L).//5.40E-53//97aa//100%//P24723
- TESTI20107240//EUKARYOTIC TRANSLATION INITIATION FACTOR 3 SUBUNIT 10 (EIF-3 THETA) (EUKARYOTIC TRANSLATION INITIATION FACTOR 3 LARGE SUBUNIT) (PNLA-35).//5.60E-07//428aa//22%//Q40554
- TESTI20107320//G1/S-SPECIFIC CYCLIN C-TYPE.//1.20E-05//130aa//26%//P93411
- TESTI20107340
- TESTI20108060//SERINE/THREONINE PROTEIN PHOSPHATASE PP1-BETA CATALYTIC SUBUNIT (EC 3.1.3.16) (PP-1B).//1.10E-78//145aa//100%//P37140
- TESTI20112540//CALDESMON (CDM).//9.10E-06//203aa//30%//P12957
- TESTI20112860//MYOSIN LIGHT CHAIN KINASE (EC 2.7.1.117) (MLCK).//1.60E-54//290aa//40%//P25323
- TESTI20113150
- TESTI20113940
- TESTI20114480//Human 1(3)mbt protein homolog mRNA, complete cds.//7.10E-146//582aa//49%//U89358
- TESTI20116050
- TESTI20116120//Aegilops squarrosa partial GAG56D gene for gamma-gliadin, accession CIae 24.//3.10E-07//93aa//40%//AJ389681
- TESTI20117500
- TESTI20118460
- TESTI20120500
- TESTI20120900
- TESTI20121040//PROBABLE PROTEIN PHOSPHATASE 2C T23F11.1 (EC 3.1.3.16) (PP2C).//8.60E-13//91aa//39%//P49596
- TESTI20121710//HYPOTHETICAL 57.5 KDA PROTEIN IN VMA7-RPS25A INTERGENIC REGION.//5.00E-08//292aa//26%//P53214
- TESTI20122070//Xenopus laevis ER1 mRNA, complete cds.//1.80E-78//341aa//49%//AF015454
- TESTI20122440
- TESTI20124440
- TESTI20125280//M-PROTEIN, STRIATED MUSCLE.//3.60E-68//295aa//46%//Q02173
- TESTI20125440
- TESTI20125920//G PROTEIN PATHWAY SUPPRESSOR 1 (GPS1 PROTEIN) (MFH PROTEIN).//5.20E-199//367aa//98%//Q13098
- TESTI20126280//Mus musculus STAP mRNA for sperm tail associated protein, complete cds.//4.60E-213//769aa//57%//AB029919
- TESTI20130530//INSULIN-DEGRADING ENZYME (EC 3.4.24.56) (INSULYSIN) (INSULINASE) (INSULIN PROTEASE).//1.60E-237//464aa//94%//P14735
- TESTI20131440//CARBOXYPEPTIDASE A1 PRECURSOR (EC 3.4.17.1).//2.80E-107//332aa//58%//P15085
- TESTI20132310
- TESTI20132680
- TESTI20134010
- TESTI20134270
- TESTI20134680//CENTROMERIC PROTEIN E (CENP-E PROTEIN).//2.40E-08//796aa//19%//Q02224
- TESTI20134970//M. musculus Tenr mRNA for RNA binding protein.//5.50E-265//559aa//88%//X84693
- TESTI20136010//MYOSIN HEAVY CHAIN, NONMUSCLE (CELLULAR MYOSIN HEAVY CHAIN) (NMMHC).//1.10E-11//438aa//23%//P14105
- TESTI20140970//V_segment translation product [Homo sapiens].//6.30E-51//101aa//99%//AAC80210
- TEST120142480
- TESTI20142540//MPV17 PROTEIN.//8.00E-62//116aa//98%//P39210
- TESTI20143180//CENTROMERIC PROTEIN E (CENP-E PROTEIN).//3.30E-09//507aa//22%//Q02224
- TESTI20144390//TESTIS-SPECIFIC PROTEIN PBS13.//6.40E-76//251aa//63%//Q01755
- TESTI20145780//Mus musculus mRNA for SH2-containing leukocyte protein 65.//1.20E-13//91aa//36%//Y17159
- TESTI20148380//TRANSFORMATION-SENSITIVE PROTEIN IEF SSP 3521.//2.50E-05//193aa//22%//P31948
- TESTI20149880
- TESTI20150420//RHO-GTPASE-ACTIVATING PROTEIN 1 (GTPASE-ACTIVATING PROTEIN RHOGAP) (RHO-RELATED SMALL GTPASE PROTEIN ACTIVATOR) (CDC42 GTPASE-ACTIVATING PROTEIN) (P50-RHOGAP).//4.50E-09//129aa//34%//Q07960
- TESTI20150920//PROTEIN PHOSPHATASES PP1 REGULATORY SUBUNIT SDS22.//2.60E-16//193aa//34%//P22194
- TESTI20151050
- TESTI20151800
- TESTI20152490
- TEST120153310//LAMIN B3.//6.30E-13//104aa//41%//P48680
- TESTI20154370//HYALURONAN MEDIATED MOTILITY RECEPTOR (INTRACELLULAR HYALURONIC ACID BINDING PROTEIN) (RECEPTOR FOR HYALURONAN-MEDIATED MOTILITY).//1.10E-07//300aa//21%//075330
- TESTI20159380
- TESTI20161010
- TESTI20162780//COTE1 PROTEIN.//1.00E-107//207aa//99%//P81408
- TESTI20162980//DNA-DAMAGE INDUCIBLE PROTEIN DDI1.//1.80E-39//174aa//48%//P40087
- TESTI20164210//PROTEIN KINASE C-BINDING PROTEIN NELL1 (NEL-LIKE PROTEIN 1) (FRAGMENT).//1.60E-88//163aa//92%//Q92832
- TESTI20165680
- TESTI20165990
- TESTI20166290//Homo sapiens NY-REN-50 antigen mRNA, partial cds.//3.00E-223//426aa//93%//AF155112
- TESTI20166670//HOMEOBOX PROTEIN HOX-B1 (HOX-2I).//6.70E-06//224aa//29%//P14653
- TESTI20167580
- TESTI20168880//BREAKPOINT CLUSTER REGION PROTEIN (EC 2.7.1.-).//2.10E-23//57aa//92%//P11274
- TESTI20169500//HYPOTHETICAL 51.9 KDA PROTEIN C27F1.04C IN CHROMOSOME I.//9.50E-17//428aa//25%//Q10173
- TESTI20170170//Homo sapiens mRNA for chondroitin-4-sulfotransferase (C4ST gene).//1.10E-53//277aa//40%//AJ269537
- TESTI20170280
- TESTI20170690
- TESTI20170890
- TESTI20171070//CYCLIC-AMP-DEPENDENT TRANSCRIPTION FACTOR ATF-4 (DNA-BINDING PROTEIN TAXREB67) (CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN 2) (CREB2).//2.60E-63//136aa//91%//P18848
- TESTI20173050
- TESTI20173110
- TESTI20173960//ZINC FINGER PROTEIN 91 (ZINC FINGER PROTEIN HTF10) (HPF7).//1.90E-104//335aa//48%//Q05481
- TESTI20175370//MYOSIN HEAVY CHAIN, NONMUSCLE (CELLULAR MYOSIN HEAVY CHAIN) (NMMHC).//1.00E-11//290aa//25%//P14105
- TESTI20176450//thioredoxin interacting factor [Mus musculus].//1.00E-75//300aa//46%//AAG32665
- TESTI20179230
- TESTI20179510
- TESTI20180600//Homo sapiens HOM-TES-85 tumor antigen mRNA, complete cds.//8.10E-106//202aa//99%//AF124430
- TESTI20182210
- TESTI20182760//AMILORIDE-SENSITIVE SODIUM CHANNEL DELTA-SUBUNIT (EPITHELIAL NA+ CHANNEL DELTA SUBUNIT) (DELTA ENAC) (NONVOLTAGE-GATED SODIUM CHANNEL 1 DELTA SUBUNIT) (SCNED) (DELTA NACH).//5.90E-185//336aa//99%//P51172
- TESTI20183680//EARLY NODULIN 20 PRECURSOR (N-20).//5.10E-08//127aa//37%//P93329
- TESTI20184280
- TESTI20184750//LAMININ ALPHA-1 CHAIN PRECURSOR (LAMININ A CHAIN).//2.30E-200//377aa//99%//P25391
- TESTI20184760//ZINC FINGER PROTEIN 29 (ZFP-29).//9.70E-74//281aa//49%//Q07230
- TESTI20184820
- TESTI20186110
- TESTI20192570
- TESTI20193080//GAR22 PROTEIN.//5.10E-153//313aa//92%//Q99501
- TESTI20193520
- TESTI20194880//PERIOD CIRCADIAN PROTEIN 1 (CIRCADIAN PACEMAKER PROTEIN RIGUI) (HPER).//1.50E-11//288aa//30%//05534
- TESTI20196690//Bos taurus pyruvate dehydrogenase phosphatase regulatory subunit precursor, mRNA, complete cds.//9.10E-114//224aa//92%//AF026954
- TESTI20196970//THIMET OLIGOPEPTIDASE (EC 3.4.24.15) (ENDOPEPTIDASE 24.15) (MP78).//4.00E-106//147aa//100%//P52888
- TESTI20197030
- TESTI20197290
- TESTI20197600//TRANSCRIPTIONAL REPRESSOR CTCF.//5.30E-120//271aa//82%//P49711
- TESTI20198540
- TESTI20198600
- TESTI20199110//disintegrin-like testicular metalloproteinase (EC 3.4.24.-) IVb—crab-eating macaque (fragment)//1.00E-167//331aa//84%//165253
- TESTI20199980
- TESTI20200120
- TESTI20200840
- TESTI20201760//SYNAPTONEMAL COMPLEX PROTEIN 1 (SCP-1 PROTEIN).//4.70E-09//189aa//25%//Q15431
- TESTI20202830
- TESTI20204260
- TESTI20205100//TRICHOHYALIN.//2.60E-15//343aa//24%//P37709
- TESTI20205150
- TESTI20205250//phosphatidylinositol-4-phosphate 5-kinase homolog T3K9.2—Arabidopsis thaliana//4.20E-21//194aa//33%//T02098
- TESTI20207170//Human testis-specific protein (TSPY) mRNA, complete cds.//6.60E-111//231aa//96%//U58096
- TESTI20209050//HYPOTHETICAL 113.1 KDA PROTEIN IN PRE5-FET4 INTERGENIC REGION.//1.90E-05//462aa//22%//Q04893
- TESTI20210030
- TESTI20210570//RETINAL-BINDING PROTEIN (RALBP).//5.00E-53//327aa//36%//P49193
- TESTI20211380
- TESTI20212970//PUTATIVE ATP-DEPENDENT RNA HELICASE YIR002C.//5.90E-85//458aa//32%//P40562
- TESTI20214630
- TESTI20215310//Homo sapiens calcyclin binding protein mRNA, complete cds.//6.60E-95//182aa//100%//AF057356
- TESTI20219110//TYROSINE-PROTEIN KINASE-LIKE 7 PRECURSOR(COLON CARCINOMA KINASE-4) (CCK-4).//4.00E-23//53aa//100%//Q13308
- TESTI20219390
- TESTI20220230//Bos taurus Reissner's fiber glycoprotein I mRNA, partial cds.//1.20E-10//77aa//50%//AF078930
- TESTI20221790
- TESTI20222030//Homo sapiens very long-chain acyl-CoA synthetase (BG1) mRNA, complete cds.//6.10E-172//643aa//50%//AF179481
- TESTI20222460//DYNEIN GAMMA CHAIN, FLAGELLAR OUTER ARM.//1.50E-138//589aa//46%//Q39575
- TESTI20223380
- TESTI20226520//TUBULIN-TYROSINE LIGASE (EC 6.3.2.25) (TTL).//6.70E-06//164aa//30%//P38160
- TEST120227380//DEAD BOX PROTEIN 4 (VASA HOMOLOG) (RVLG).//1.10E-263//577aa//86%//Q64060
- TESTI20228120//RHO-GTPASE-ACTIVATING PROTEIN 6 (RHO-TYPE GTPASE-ACTIVATING PROTEIN RHOGAPX-1) (FRAGMENT).//4.50E-12//164aa//34%//054834
- TESTI20228740//ZINC FINGER PROTEIN 135.//3.50E-25//132aa//43%//P52742
- TESTI20244220//MYOSIN HEAVY CHAIN IB (MYOSIN HEAVY CHAIN IL).//6.50E-11//77aa//42%//P19706
- TESTI20244430//ANKYRIN 1 (ERYTHROCYTE ANKYRIN) (ANKYRIN R) (ANKYRINS 2.1 AND 2.2).//3.70E-15//173aa//35%//P16157
- TESTI20244460//ADENYLATE KINASE, CHLOROPLAST (EC 2.7.4.3) (ATP-AMP TRANSPHOSPHORYLASE).//3.60E-34//209aa//37%//P43188
- TESTI20244730//Mus musculus alpha/beta hydrolase-1 mRNA, complete cds.//8.20E-113//266aa//81%//AF189764
- TESTI20245600//HYPOTHETICAL 118.4 KDA PROTEIN IN BAT2-DAL5 INTERGENIC REGION PRECURSOR.//4.50E-05//236aa//27%//P47179
- TESTI20245860
- TESTI20246410
- TESTI20246480//Homo sapiens germline specific RNA binding protein (DAZL1) mRNA, complete cds.//5.00E-22//86aa//55%//U66726
- TESTI20247440//Human BLu protein testis isoform (BLu) mRNA, complete cds.//5.40E-45//91aa//96%//U70880
- TESTI20248850
- TESTI20249360//Homo sapiens DEME-6 mRNA, partial cds.//4.70E-94//299aa//56%//AF007170
- TESTI20250220//TRICHOHYALIN.//5.40E-54//537aa//30%//P37709
- TESTI20250630//Columba livia mRNA for 5′-nucleotidase.//3.80E-115//328aa//66%//AJ131243
- TESTI20251440//Rattus norvegicus (rsec6) mRNA, complete cds.//3.80E-31//379aa//28%//U32575
- TESTI20251610//INTER-ALPHA-TRYPSIN INHIBITOR HEAVY CHAIN H2 PRECURSOR (ITI HEAVY CHAIN H2).//1.10E-07//182aa//26%//002668
- TESTI20251740//FYN-BINDING PROTEIN (SLP-76 ASSOCIATED PROTEIN) (SLAP-130).//6.30E-16//88aa//50%//015117
- TESTI20252690//SEGMENT POLARITY PROTEIN DISHEVELLED HOMOLOG DVL-3 (DISHEVELLED-3) (DSH HOMOLOG 3) (KIAA0208).//4.60E-137//304aa//85%//Q92997
- TESTI20254030//Homo sapiens actin-binding double-zinc-finger protein (abLIM) mRNA, complete cds.//6.70E-150//280aa//96%//AF005654
- TESTI20254090
- TESTI20254480
- TESTI20254990//ZINC FINGER PROTEIN GLI3 (NEURAL SPECIFIC DNA BINDING PROTEIN XGLI3) (XGLI-3).//6.50E-46//105aa//75%//Q91660
- TESTI20255460//Mus musculus mRNA for MIWI (piwi), complete cds.//1.50E-225//864aa//49%//AB032604
- TESTI20256560//NUF1 PROTEIN (SPINDLE POLY BODY SPACER PROTEIN SPC110).//5.70E-05//590aa//19%//P32380
- TESTI20257910//HLA CLASS I HISTOCOMPATIBILITY ANTIGEN, ALPHA CHAIN G PRECURSOR (HLA G ANTIGEN).//1.90E-122//223aa//100%//P17693
- TESTI20258720//ANKYRIN 1 (ERYTHROCYTE ANKYRIN) (ANKYRIN R) (ANKYRINS 2.1 AND 2.2).//1.20E-10//233aa//27%//P16157
- TEST120259110
- TESTI20259200
- TESTI20260140
- TESTI20260640//helicase II homolog—fruit fly (Drosophila sp.)//2.70E-27//374aa//27%//T13889
- TESTI20261040//DPY-19 PROTEIN.//2.10E-47//316aa//34%//P34413
- TESTI20261160//Mus musculus rasGAP-activating-like protein mRNA, complete cds.//1.60E-21//129aa//41%//AF086714
- TESTI20261680//HEAT SHOCK PROTEIN 30C.//1.70E-08//136aa//27%//P30218
- TESTI20262150//Rattus norvegicus mRNA for voltage-gated ca channel, complete cds.//0//822aa//87%//AB018253
- TESTI20262940//TUBULIN-TYROSINE LIGASE (EC 6.3.2.25) (TTL).//5.70E-10//218aa//25%//P38160
- TESTI20264530//PUTATIVE SERINE/THREONINE-PROTEIN KINASE PKWA (EC 2.7.1.-).//5.60E-18//219aa//34%//P49695
- TESTI20264910
- TEST120265150
- TESTI20265340
- TESTI20265890
- TESTI20266050//52 KDA RO PROTEIN (SJOGREN SYNDROME TYPE A ANTIGEN (SS-A)) (RO(SS-A)).//2.10E-77//472aa//38%//P19474
- TESTI20268240//Homo sapiens membrane-associated nucleic acid binding protein mRNA, partial cds.//1.90E-52//412aa//36%//AF255303
- TESTI20269250
- TESTI20269360
- TESTI20270130//FIBRILLARIN.//2.10E-11//97aa//43%//Q22053
- TESTI20271790//Human p76 mRNA, complete cds.//6.9e-317//496aa//99%//U81006
- TESTI20272380
- TESTI20274960//ZINC FINGER PROTEIN 83 (ZINC FINGER PROTEIN HPF1).//7.90E-126//342aa//63%//P51522
- TESTI20277300
- TESTI20278280//Mus musculus p53 apoptosis-associated target (Perp) mRNA, complete cds.//3.40E-84//155aa//88%//AF249870
- TESTI20282420//Mus musculus EPCS26 mRNA, complete cds.//2.40E-19//122aa//33%//AF250838
- TESTI20282530//ZINC FINGER PROTEIN 135.//1.60E-56//271aa//39%//P52742
- TESTI20282900
- TESTI20284260//HISTONE H2B F (H2B 291A).//2.10E-22//120aa//43%//P10853
- TESTI20285230//DOUBLE-STRANDED RNA-SPECIFIC EDITASE 1 (EC 3.5.-.-) (DSRNA ADENOSINE DEAMINASE) (RNA EDITING ENZYME 1).//2.10E-20//192aa//38%//P51400
- TESTI20286590//Human type 3 inositol 1,4,5-trisphosphate receptor (ITPR3) mRNA, complete cds.//1.00E-93//185aa//100%//U01062
- TESTI20287760
- THYMU10004280//ZINC-FINGER PROTEIN HT2A (72 KDA TAT-INTERACTING PROTEIN).//7.90E-13//87aa//42%//Q13049
- THYMU20006020//ISOCITRATE DEHYDROGENASE [NAD] SUBUNIT ALPHA, MITOCHONDRIAL PRECURSOR (EC 1.1.1.41) (ISOCITRIC DEHYDROGENASE) (NAD+-SPECIFIC ICDH).//2.60E-120//229aa//99%//P50213
- THYMU20007020
- THYMU20007750
- THYMU20008000
- THYMU20009460
- THYMU20009500
- THYMU20009710
- THYMU20010180//MOB1 PROTEIN (MPS1 BINDER 1).//2.60E-31//136aa//50%//P40484
- THYMU20010710
- THYMU20012020
- THYMU20012560
- THYMU20013250//LIM DOMAIN KINASE 2 (EC 2.7.1.-) (LIMK-2).//3.50E-213//354aa//99%//P53671
- THYMU20013810//Human SEC7 homolog Tic (TIC) mRNA, complete cds.//2.30E-88//138aa//96%//U63127
- THYMU20014430
- THYMU20017270
- THYMU20018250
- THYMU20018390
- THYMU20019000
- THYMU20019260//ZINC FINGER PROTEIN 85 (ZINC FINGER PROTEIN HPF4) (HTF1).//6.80E-49//137aa//68%//Q03923
- THYMU20020370
- THYMU20020800//LMBR1 long form [Mus musculus].//3.00E-69//198aa//55%//AAF91092
- THYMU20021090//Homo sapiens Sex comb on midleg homolog 1 isoform 1 (SCMH1) mRNA, complete cds.//4.40E-80//149aa//63%//AF149045
- THYMU20021540
- THYMU20023560//DNA BINDING PROTEIN RFX2.//6.70E-25//59aa//94%//P48378
- THYMU20024500//NEUROFILAMENT TRIPLET M PROTEIN (160 KDA NEUROFILAMENT PROTEIN) (NF-M).//6.20E-06//296aa//22%//P16053
- THYMU20025480
- THYMU20026950//Mus musculus ROSA 26 transcription AS ROSA26AS mRNA, complete cds.//2.20E-12//285aa//23%//U83176
- THYMU20028150//AXONIN-1 PRECURSOR (AXONAL GLYCOPROTEIN TAG-1) (TRANSIENT AXONAL GLYCOPROTEIN 1).//2.20E-33//301aa//31%//Q02246
- THYMU20028410//Mus musculus Pax transcription activation domain interacting protein PTIP mRNA, complete cds.//1.70E-144//345aa//81%//AF104261
- THYMU20029830
- THYMU20030460//Homo sapiens tumor endothelial marker 7 precursor (TEM7) mRNA, complete cds.//2.10E-123//230aa//99%//AF279144
- THYMU20030690
- THYMU20031330//Homo sapiens putative nucleotide binding protein mRNA, complete cds.//1.00E-18//64aa//82%//AF118394
- THYMU20032820//ZINC FINGER PROTEIN 135.//1.40E-82//258aa//55%//P52742
- THYMU20034400//26S proteasome subunit p44.5 [Homo sapiens]//8.80E-29//71aa//91%//AB003102
- THYMU20034790
- THYMU20036500
- THYMU20039320//PUTATIVE SERINE/THREONINE-PROTEIN KINASE PKWA (EC 2.7.1.-).//1.40E-09//206aa//27%//P49695
- THYMU20043440
- THYMU20043560
- THYMU20044100
- THYMU20044520
- THYMU20046350
- THYMU20046770
- THYMU20049060//SPLICING FACTOR, ARGININE/SERINE-RICH 2 (SPLICING FACTOR SC35) (SC-35) (SPLICING COMPONENT, 35 KDA) (PR264 PROTEIN).//6.00E-41//119aa//76%//P30352
- THYMU20050010
- THYMU20051340
- THYMU20052460//PHORBOLIN I (FRAGMENTS).//5.80E-20//111aa//45%//P31941
- THYMU20052830//Homo sapiens mRNA for immunoglobulin lambda heavy chain.//1.50E-237//477aa//90%//Y14737
- THYMU20054800
- THYMU20055450
- THYMU20055460//ESTERASE D (EC 3.1.1.1).//7.60E-57//107aa//100%//P10768
- THYMU20055740
- THYMU20055760//Mus musculus group IIF secreted phospholipase A2 (Pla2g2f) mRNA, complete cds.//1.70E-73//165aa//75%//AF166099
- THYMU20058550
- THYMU20060480
- THYMU20062520
- THYMU20062610//DYNEIN GAMMA CHAIN, FLAGELLAR OUTER ARM.//1.70E-156//585aa//50%//Q39575
- THYMU20062770//UROMODULIN PRECURSOR (TAMM-HORSFALL URINARY GLYCOPROTEIN) (THP).//4.20E-22//253aa//28%//P27590
- THYMU20063650//Homo sapiens mRNA for putative ribulose-5-phosphate-epimerase, partial cds.//9.30E-57//116aa//97%//AJ224326
- THYMU20064680
- THYMU20066660//Homo sapiens putative ATP-dependent RNA helicase ROK1 mRNA, complete cds.//9.20E-153//361aa//85%//AF077033
- THYMU20069130
- THYMU20069460
- THYMU20069650
- THYMU20070250//TRANSKETOLASE (EC 2.2.1.1) (TK).//4.50E-288//513aa//96%//P29401
- THYMU20071120//ZINC FINGER PROTEIN 85 (ZINC FINGER PROTEIN HPF4) (HTF1).//1.40E-229//536aa//74%//Q03923
- THYMU20071460
- THYMU20072580
- THYMU20073070
- THYMU20073080
- THYMU20077250//T-CELL-SPECIFIC TRANSCRIPTION FACTOR 1 (TCF-1) (T-CELL FACTOR 1) (TRANSCRIPTION FACTOR-7).//4.10E-90//176aa//96%//Q00417
- THYMU20078020
- THYMU20078240
- THYMU20079690
- THYMU20080490
- THYMU20081110//PINCH PROTEIN (PARTICULARY INTERESTING NEW CYS-HIS PROTEIN).//4.00E-28//60aa//86%//P48059
- THYMU20083390
- THYMU20083500
- THYMU20083830//Homo sapiens angiostatin binding protein 1 mRNA, complete cds.//2.30E-09//230aa//28%//AF286598
- THYMU20084520
- THYMU20086430
- THYMU20087270//POTENTIAL PHOSPHOLIPID-TRANSPORTING ATPASE IIB (EC 3.6.1.-).//7.20E-154//235aa//88%//P98195
- THYMU20089170
- THYMU20089900
- THYMU20090230//Homo sapiens ribonucleoprotein mRNA, complete cds.//9.30E-73//133aa//100%//L32610
- THYMU20091040
- THYMU20095920//Homo sapiens nuclear prelamin A recognition factor mRNA, complete cds.//2.90E-94//178aa//100%//AF128406
- THYMU20096580//SERYL-TRNA SYNTHETASE (EC 6.1.1.11) (SERINE-TRNA LIGASE) (SERRS).//9.90E-20//45aa//97%//P49591
- THYMU20097920//mitogen inducible gene mig-2—human//2.50E-197//477aa//55%//S69890
- THYMU20098350//KERATIN, TYPE II CYTOSKELETAL 5 (CYTOKERATIN 5) (K5) (CK 5) (58 KDA CYTOKERATIN).//3.40E-267//577aa//89%//P13647
- THYMU20099060//IG ALPHA-1 CHAIN C REGION.//1.70E-196//353aa//99%//P01876
- THYMU20100940//POTENTIAL PHOSPHOLIPID-TRANSPORTING ATPASE IR (EC 3.6.1.-) (FRAGMENT).//0//646aa//99%//Q9Y2G3
- THYMU20104480//TRICHOHYALIN.//2.90E-21//300aa//28%//P37709
- THYMU20106990//Mus musculus evectin-2 (Evt2) mRNA, complete cds.//2.20E-112//222aa//90%//AF189817
- THYMU20110720//PROBABLE AMINOTRANSFERASE T01B11.2 (EC 2.6.1.-).//6.90E-40//211aa//41%//P91408
- THYMU20112570
- THYMU20112590//Homo sapiens AP-4 adaptor complex beta4 subunit mRNA, complete cds.//3.40E-306//534aa//99%//AF092094
- THYMU20115380
- THYMU20115730
- THYMU20117850
- THYMU20120240//Arabidopsis thaliana ubiquitin-specific protease (AtUBP4) mRNA, complete cds.//4.10E-18//179aa//28%//U76846
- THYMU20120730//ALDEHYDE DEHYDROGENASE, DIMERIC NADP-PREFERRING (EC 1.2.1.5) (ALDH CLASS 3).//2.10E-203//379aa//99%//P30838
- THYMU20121040//ELONGATION FACTOR 1-DELTA (EF-1-DELTA).//5.30E-149//281 aa//99%//P29692
- THYMU20128910
- THYMU20129020
- THYMU20130470
- THYMU20134260
- THYMU20137050
- THYMU20137570
- THYMU20139160
- THYMU20140510
- THYMU20143230//Homo sapiens mRNA for stabilin-1 (stab1 gene).//1.70E-177//317aa//99%//AJ275213
- THYMU20145990//nesca protein [Homo sapiens].//1.90E-152//282aa//98%//NP—055143
- THYMU20148010
- THYMU20149230
- THYMU20150190
- THYMU20151610//Homo sapiens antigen NY-CO-1 (NY-CO-1) mRNA, complete cds.//1.40E-181//344aa//100%//AF039687
- THYMU20153210//Homo sapiens Diff33 protein homolog mRNA, complete cds.//4.00E-120//404aa//54%//AF164794
- THYMU20154790
- THYMU20157620
- THYMU20163600
- THYMU20170080//Homo sapiens SIT protein.//9.50E-48//78aa//98%//AJ010059
- THYMU20170230//Homo sapiens sarcosine dehydrogenase (SARDH) mRNA, complete cds.//1.80E-183//260aa//99%//AF095735
- THYMU20171580
- THYMU20174490
- THYMU20174790
- THYMU20175260
- THYMU20176010//VEGETATIBLE INCOMPATIBILITY PROTEIN HET-E-1.//1.80E-20//256aa//28%//Q00808
- THYMU20177070
- THYMU20178440//Homo sapiens mRNA for immunoglobulin lambda heavy chain.//2.20E-229//479aa//88%//Y14737
- THYMU20181890
- THYMU20184550
- THYMU20185470
- THYMU20185650//DIAPHANOUS PROTEIN HOMOLOG 1.//1.30E-20//85aa//44%//060610
- THYMU20187210
- THYMU20191970//Homo sapiens FLAMINGO 1 mRNA, partial cds.//1.80E-54//450aa//36%//AF234887
- TKIDN10000620//Homo sapiens Tax interaction protein 2 mRNA, partial cds.//1.20E-56//114aa//100%//AF028824
- TKIDN10001710
- TKIDN10001920//ZINC FINGER PROTEIN 85 (ZINC FINGER PROTEIN HPF4) (HTF1).//3.20E-97//226aa//73%//Q03923
- TRACH20011010//GLUCOAMYLASE S1/S2 PRECURSOR (EC 3.2.1.3) (GLUCAN 1,4-ALPHA-GLUCOSIDASE) (1,4-ALPHA-D-GLUCAN GLUCOHYDROLASE).//4.30E-17//593aa//22%//P08640
- TRACH20011540//TUMOR-ASSOCIATED ANTIGEN L6.//4.70E-57//113aa//97%//P30408
- TRACH20012490
- TRACH20021000
- TRACH20021380//ADENYLATE CYCLASE, TYPE V (EC 4.6.1.1) (ATP PYROPHOSPHATE-LYASE) (CA(2+)-INHIBITABLE ADENYLYL CYCLASE).//1.20E-276//492aa//95%//P30803
- TRACH20025370
- TRACH20026640
- TRACH20029880
- TRACH20040390//MATERNAL PUMILIO PROTEIN.//1.20E-177//812aa//47%//P25822
- TRACH20041090
- TRACH20043360//PUTATIVE KINESIN-LIKE PROTEIN C2F12.13.//2.30E-55//333aa//39%//014343
- TRACH20044990
- TRACH20049500
- TRACH20051590
- TRACH20057200
- TRACH20058000
- TRACH20073990
- TRACH20080810
- TRACH20081270
- TRACH20090060//SYNAPTOTAGMIN IV.//1.10E-12//301aa//25%//P40749
- TRACH20091070//ALDEHYDE DEHYDROGENASE, DIMERIC NADP-PREFERRING (EC 1.2.1.5) (ALDH CLASS 3).//1.00E-173//328aa//98%//P30838
- TRACH20093400//TRICHOHYALIN.//2.30E-13//701aa//20%//P37709
- TRACH20093480
- TRACH20098510//MYOSIN HEAVY CHAIN, GIZZARD SMOOTH MUSCLE.//1.10E-20//640aa//21%//P10587
- TRACH20101590
- TRACH20104510
- TRACH20108240//ribonucleoprotein—African clawed frog//4.10E-118//223aa//96%//S40774
- TRACH20113020//SELENIDE, WATER DIKINASE 2 (EC 2.7.9.3) (SELENOPHOSPHATE SYNTHETASE 2) (SELENIUM DONOR PROTEIN 2).//1.80E-207//364aa//96%//Q99611
- TRACH20122980//HYPOTHETICAL PROTEIN MJ0798.//6.80E-13//211aa//22%//Q58208
- TRACH20123870
- TRACH20124970
- TRACH20125620
- TRACH20129180
- TRACH20131230//Homo sapiens oxysterol binding protein-related protein 3 (ORP3) mRNA, complete cds.//7.50E-282//608aa//62%//AY008372
- TRACH20139280
- TRACH20140180
- TRACH20143710//RAB GERANYLGERANYLTRANSFERASE ALPHA SUBUNIT (EC 2.5.1.-) (RAB GERANYL-GERANYLTRANSFERASE ALPHA SUBUNIT) (RAB GG TRANSFERASE) (RAB GGTASE).//9.70E-07//142aa//33%//Q92696
- TRACH20149500//KERATIN, TYPE I CUTICULAR HA6 (HAIR KERATIN, TYPE I HA6).//1.10E-62//215aa//60%//076013
- TRACH20149720
- TRACH20149740//EXCITATORY AMINO ACID TRANSPORTER 5 (RETINAL GLUTAMATE TRANSPORTER).//5.00E-76//152aa//98%//000341
- TRACH20158240
- TRACH20159390
- TRACH20160800
- TRACH20163470//Mus musculus putative thymic stromal co-transporter TSCOT mRNA, complete cds.//3.20E-41//187aa//34%//AF148145
- TRACH20164100//RETROVIRUS-RELATED PROTEASE (EC 3.4.23.-).//1.40E-32//113aa//56%//P10265
- TRACH20164810
- TRACH20165330
- TRACH20165540//Human alpha-1 type I collagen gene surrounding osteogenesis imperfecta OI type II deletion.//4.00E-05//102aa//37%//M11162
- TRACH20167090
- TRACH20170860//IG DELTA CHAIN C REGION.//1.60E-212//383aa//100%//P01880
- TRACH20173680//Homo sapiens mRNA for LAK-4p, complete cds.//3.50E-80//410aa//38%//AB002405
- TRACH20174980
- TRACH20182780
- TRACH20185120
- TRACH20188350//Homo sapiens mRNA for centaurin beta2.//3.80E-60//204aa//56%//AJ238248
- TRACH20190460//MONO- AND DIACYLGLYCEROL LIPASE PRECURSOR (EC 3.1.1.-) (MDGL).//2.60E-11//195aa//28%//P25234
- UMVEN10001380
- UTERU10001060//ETS-DOMAIN PROTEIN ELK-1.//1.40E-39//88aa//93%//P19419
- UTERU10001870
- UTERU20000230
- UTERU20000950//Homo sapiens PC326 protein (PC326) mRNA, complete cds.//2.80E-55//112aa//100%//AF150734
- UTERU20011760
- UTERU20013890
- UTERU20016580//POTENTIAL TRANSCRIPTIONAL ADAPTOR.//1.90E-37//323aa//31%//Q02336
- UTERU20026620//ZINC FINGER PROTEIN 75.//7.50E-82//174aa//82%//P51815
- UTERU20027360
- UTERU20029930
- UTERU20031350
- UTERU20035770
- UTERU20040150
- UTERU20040370
- UTERU20040390
- UTERU20040730
- UTERU20041630//ZINC FINGER PROTEIN 184 (FRAGMENT).//3.30E-75//239aa//44%//Q99676
- UTERU20041970
- UTERU20045200
- UTERU20051790//guanylate kinase-interacting protein 1 Maguin-1, membrane-associated—rat//8.20E-26//267aa//33%//T18293
- UTERU20064120//MYELOID UPREGULATED PROTEIN.//1.30E-79//245aa//66%//035682
- UTERU20065470
- UTERU20079240
- UTERU20083020
- UTERU20086530//GLYCODELIN PRECURSOR (GD) (PREGNANCY-ASSOCIATED ENDOMETRIAL ALPHA-2 GLOBULIN) (PEG) (PAEG) (PLACENTAL PROTEIN 14) (PROGESTERONE-ASSOCIATED ENDOMETRIAL PROTEIN) (PROGESTAGEN-ASSOCIATED ENDOMETRIAL PROTEIN).//6.00E-73//140aa//99%//P09466
- UTERU20087070//COMPLEMENT C1R COMPONENT PRECURSOR (EC 3.4.21.41).//4.80E-206//360aa//99%//P00736
- UTERU20087850//Homo sapiens mRNA for mucolipidin (ML4 gene).//2.70E-34//184aa//42%//AJ293970
- UTERU20089300
- UTERU20089390//Plectonema boryanum kinesin light chain (KLC) gene, complete cds.//3.30E-38//216aa//43%//U78597
- UTERU20089620//Homo sapiens radical fringe (RFNG) gene, partial cds.//1.50E-31//65aa//100%//AF108139
- UTERU20090940
- UTERU20091470
- UTERU20094830//SINGLE-MINDED HOMOLOG 2 (SIM TRANSCRIPTION FACTOR) (MSIM).//8.70E-09//427aa//25%//Q61079
- UTERU20095100
- UTERU20099040//ZINC TRANSPORTER 2 (ZNT-2).//9.80E-96//242aa//76%//Q62941
- UTERU20099510//ZINC FINGER PROTEIN 135.//2.20E-107//346aa//54%//P52742
- UTERU20101150//NUCLEAR FACTOR NF-KAPPA-B P49 SUBUNIT.//2.20E-07//76aa//47%//Q04860
- UTERU20102260
- UTERU20103040
- UTERU20103200
- UTERU20104310//DNA-DIRECTED RNA POLYMERASE II 14.4 KDA POLYPEPTIDE (EC 2.7.7.6) (RPB6) (RPB14.4).//1.80E-48//97aa//100%//P41584
- UTERU20106510
- UTERU20121140
- UTERU20122520//MOESIN (MEMBRANE-ORGANIZING EXTENSION SPIKE PROTEIN).//6.00E-37//399aa//28%//P26042
- UTERU20125810
- UTERU20127030//LAMININ BETA-2 CHAIN PRECURSOR(S-LAMININ).//6.80E-175//377aa//92%//P55268
- UTERU20127150
- UTERU20128560//26.4 KDA PROTEIN IN RUVC-ASPS INTERGENIC REGION.//2.60E-17//120aa//34%//P24237
- UTERU20132620//AXONEME-ASSOCIATED PROTEIN MST101 (2).//1.40E-15//231aa//31%//Q08696
- UTERU20134830//pellino (Drosophila) homolog 2 [Homo sapiens]//1.40E-153//361aa//72%//NP—067078
- UTERU20139760//solute carrier family 25 (mitochondrial carrier; peroxisomal membrane protein, 34 kD), member 17 [Homo sapiens]//5.40E-100//203aa//97%//XP—001136
- UTERU20140010
- UTERU20167570
- UTERU20168960//Homo sapiens actin filament associated protein (AFAP) mRNA, complete cds.//2.60E-68//364aa//43%//AF188700
- UTERU20169020//HOMEOBOX PROSPERO-LIKE PROTEIN PROX1 (PROX 1).//1.30E-54//117aa//74%//Q91018
- UTERU20173030
- UTERU20176230
- UTERU20177150//Homo sapiens zinc finger protein dp mRNA, complete cds.//4.60E-10//104aa//40%//AF153201
- UTERU20181270
- UTERU20185220//Human mRNA for transcriptional activator hSNF2a, complete cds.//1.60E-125//246aa//98%//D26155
- UTERU20188670//HFM1 PROTEIN.//5.10E-19//234aa//26%//P51979
- UTERU20188840
Claims
1. (canceled)
2. A polypeptide encoded by a polynucleotide selected from the group consisting of the following (a) to (g):
- (a) a polynucleotide comprising a protein-coding region of the nucleotide sequence of any one of SEQ ID NOs: 1 to 1970:
- (b) a polynucleotide encoding a polypeptide comprising the amino acid sequence of any one of SEQ ID NOs: 1971 to 3940:
- (c) a polynucleotide comprising a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of any one of SEQ ID NOs: 1971 to 3940, wherein in said amino acid sequence, one or more amino acids have been substituted, deleted, inserted and/or added, and wherein said nucleotide sequence encodes a polypeptide functionally equivalent to a polypeptide comprising the selected amino acid sequence;
- (d) a polynucleotide hybridizing to a polynucleotide comprising the nucleotide sequence of any one of SEQ ID NOs: 1 to 1970, wherein said nucleotide sequence encodes a polypeptide functionally equivalent to a polypeptide encoded by the selected nucleotide sequence;
- (e) a polynucleotide comprising a nucleotide sequence encoding a partial amino acid sequence of a polypeptide encoded by the polynucleotide according to any one of (a) to (d);
- (f) a polynucleotide comprising a nucleotide sequence having at least 70% identity to the nucleotide sequence of any one of SEQ ID NOs: 1 to 1970; and
- (g) a polynucleotide comprising a nucleotide sequence having at least 90% identity to the nucleotide sequence of any one of SEQ ID NOs: 1 to 1970, or a partial peptide thereof.
3-7. (canceled)
8. A method for producing the polypeptide or the partial peptide of claim 2, said method comprising the steps of culturing a transformant carrying a polynucleotide selected from the group consisting of the following (a) to (g):
- (a) a polynucleotide comprising a protein-coding region of the nucleotide sequence of any one of SEQ ID NOs: 1 to 1970;
- (b) a polynucleotide encoding a polypeptide comprising the amino acid sequence of any one of SEQ ID NOs: 1971 to 3940;
- (c) a polynucleotide comprising a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of any one of SEQ ID NOs: 1971 to 3940, wherein, in said amino acid sequence, one or more amino acids have been substituted, deleted, inserted and/or added, and wherein said nucleotide sequence encodes a polypeptide functionally equivalent to a polypeptide comprising the selected amino acid sequence;
- (d) a polynucleotide hybridizing to a polynucleotide comprising the nucleotide sequence of any one of SEQ ID NOs: 1 to 1970, wherein said nucleotide sequence encodes a polypeptide functionally equivalent to a polypeptide encoded by the selected nucleotide sequence;
- (e) a polynucleotide comprising a nucleotide sequence encoding a partial amino acid sequence of a polypeptide encoded by the polynucleotide according to any one of (a) to (d);
- (f) a polynucleotide comprising a nucleotide sequence having at least 70% identity to the nucleotide sequence of any one of SEQ ID NOs: 1 to 1970; and
- (g) a polynucleotide comprising a nucleotide sequence having at least 90% identity to the nucleotide sequence of any one of SEQ ID NOs: 1 to 1970, and recovering an expression product.
9-14. (canceled)
Type: Application
Filed: Mar 7, 2005
Publication Date: Feb 9, 2006
Applicant:
Inventors: Takao Isogai (Ibaraki), Tomoyasu Sugiyama (Tokyo), Tetsuji Otsuki (Kisarazu-shi), Ai Wakamatsu (Kisarazu-shi), Hiroyuki Sato (Toyonaka-shi), Shizuko Ishii (Kisarazu-shi), Jun-ichi Yamamoto (Kisarazu-shi), Yuuko Isono (Kisarazu-shi), Yuri Hio (Kisarazu-shi), Kaoru Otsuka (Honjo-shi), Keiichi Nagai (Tokyo), Ryotaro Irie (Kisarazu-shi), Ichiro Tamechika (Hirakata-shi), Naohiko Seki (Chiba-shi), Tsutomu Yoshikawa (Kisarazu-shi), Motoyuki Otsuka (Tokyo), Kenji Nagahari (Tokyo), Yasuhiko Masuho (Tokyo)
Application Number: 11/072,512
International Classification: C12Q 1/68 (20060101); C07H 21/04 (20060101); C12P 21/06 (20060101); C07K 14/47 (20060101); C07K 16/18 (20060101);
